---
document_datetime: 2023-09-21 20:07:03
document_pages: 165
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/xenleta-epar-public-assessment-report_en.pdf
document_name: xenleta-epar-public-assessment-report_en.pdf
version: success
processing_time: 282.3157663
conversion_datetime: 2025-12-15 20:11:58.411238
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 May 2020 EMA/325848/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Xenleta

International non-proprietary name: lefamulin

Procedure No. EMEA/H/C/005048/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                  | Xenleta                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                      | Nabriva Therapeutics Ireland DAC Alexandra House Office 225/227 The Sweepstakes Ballsbridge Dublin 4 D04 C7H2 IRELAND                                                                                                                                                                                                                                |
| Active substance:                               | lefamulin acetate                                                                                                                                                                                                                                                                                                                                    |
| International Non-proprietary Name/Common Name: | lefamulin                                                                                                                                                                                                                                                                                                                                            |
| Pharmaco-therapeutic group (ATC Code):          | antibacterials for systemic use, pleuromutilins (J01XX12)                                                                                                                                                                                                                                                                                            |
| Therapeutic indication:                         | Xenleta is indicated for the treatment of community- acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
| Pharmaceutical forms:                           | Concentrate and solvent for solution for infusion; Film-coated tablet                                                                                                                                                                                                                                                                                |
| Strengths:                                      | 150 mg and 600 mg                                                                                                                                                                                                                                                                                                                                    |
| Routes of administration:                       | Intravenous use and Oral use                                                                                                                                                                                                                                                                                                                         |
| Packaging:                                      | Concentrate: vial (glass) / Solvent: bag (PP) and blister (PVC/PE/PCTFE/Alu)                                                                                                                                                                                                                                                                         |
| Package sizes:                                  | 10 tablets and 2 vials + 2 infusion bags                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 9                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................        | 9                                                                                                    |
| 1.2. Steps taken for the assessment of the product......................................................10                |                                                                                                      |
| 2. Scientific discussion..............................................................................                    | 11                                                                                                   |
| 2.1. Problem statement............................................................................................11      |                                                                                                      |
| 2.1.1. Disease or condition                                                                                               | .......................................................................................11            |
| 2.1.2. Epidemiology.................................................................................................11    |                                                                                                      |
| 2.1.3. Aetiology and pathogenesis                                                                                         | .............................................................................12                      |
| 2.1.4. Clinical presentation, diagnosis                                                                                   | ........................................................................12                           |
| 2.1.5. Management                                                                                                         | .................................................................................................13  |
| 2.2. Quality aspects.................................................................................................14   |                                                                                                      |
| 2.2.1. Introduction                                                                                                       | ..................................................................................................14 |
| 2.2.2. Active Substance............................................................................................14     |                                                                                                      |
| 2.2.3. Finished Medicinal Product (Xenleta 600 mg film-coated tablets)...........................19                       |                                                                                                      |
| 2.2.4. Finished Medicinal Product (Xenleta 150 mg/15 mL concentrate and solvent)..........22                              |                                                                                                      |
| 2.2.5. Discussion on chemical, pharmaceutical and biological aspects                                                      | .............................29                                                                      |
| 2.2.6. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................29                                                                             |
| 2.2.7. Recommendations for future quality                                                                                 | development...............................................29                                         |
| 2.3. Non-clinical aspects...........................................................................................29    |                                                                                                      |
| 2.3.1. Pharmacology................................................................................................29     |                                                                                                      |
| 2.3.2. Pharmacokinetics                                                                                                   | ...........................................................................................31        |
| 2.3.3. Toxicology.....................................................................................................32  |                                                                                                      |
| 2.3.4. Ecotoxicity/environmental risk assessment                                                                          | ........................................................37                                           |
| 2.3.5. Discussion on non-clinical aspects                                                                                 | ....................................................................39                               |
| 2.3.6. Conclusion on the non-clinical aspects...............................................................40            |                                                                                                      |
| 2.4. Clinical aspects.................................................................................................40  |                                                                                                      |
| 2.4.1. Introduction                                                                                                       | ..................................................................................................40 |
| 2.4.2. Pharmacokinetics                                                                                                   | ...........................................................................................46        |
| 2.4.3. Pharmacodynamics.........................................................................................67        |                                                                                                      |
| 2.4.4. Discussion on clinical pharmacology..................................................................86            |                                                                                                      |
| 2.4.5. Conclusions on clinical pharmacology................................................................93             |                                                                                                      |
| 2.5. Clinical efficacy.................................................................................................94 |                                                                                                      |
| 2.5.1. Dose response studies & main clinical studies.....................................................94               |                                                                                                      |
| 2.5.2. Discussion on clinical efficacy.........................................................................126        |                                                                                                      |
| 2.5.3. Conclusions on the clinical efficacy..................................................................130          |                                                                                                      |
| 2.6. Clinical safety.................................................................................................130  |                                                                                                      |
| 2.6.1. Discussion on clinical safety...........................................................................154        |                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.6.2. Conclusions on the clinical safety....................................................................156        |                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.7. Risk Management Plan.....................................................................................156       |                                                                                                       |
| Summary of safety concerns                                                                                              | ...............................................................................156                    |
| 2.8. Pharmacovigilance ..........................................................................................157    |                                                                                                       |
| 2.9. New Active Substance .....................................................................................157      |                                                                                                       |
| 2.10. Product information.......................................................................................157     |                                                                                                       |
| 2.10.1. User consultation........................................................................................157    |                                                                                                       |
| 2.10.2. Additional monitoring..................................................................................157      |                                                                                                       |
| 3. Benefit-Risk Balance ...........................................................................                     | 158                                                                                                   |
| 3.1. Therapeutic Context........................................................................................158     |                                                                                                       |
| 3.1.1. Disease or condition .....................................................................................158    |                                                                                                       |
| 3.1.2. Available therapies and unmet medical need....................................................158                |                                                                                                       |
| 3.1.3. Main clinical studies......................................................................................159   |                                                                                                       |
| 3.2. Favourable effects...........................................................................................159   |                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects ..........................................159               |                                                                                                       |
| 3.4. Unfavourable effects                                                                                               | .......................................................................................161            |
| 3.5. Uncertainties and limitations about unfavourable effects.......................................162                 |                                                                                                       |
| 3.6. Effects Table                                                                                                      | ..................................................................................................162 |
| 3.7. Benefit-risk assessment and discussion..............................................................163            |                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................163                                                        |
| 3.7.2. Balance of benefits and risks..........................................................................163       |                                                                                                       |
| 3.8. Conclusions....................................................................................................164 |                                                                                                       |
| 4. Recommendations...............................................................................                       | 164                                                                                                   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ABSSSI

Acute bacterial skin and skin structure infection

Aclar

PVC/PE/PCTFE / Aluminium

ADME

Absorption, distribution, metabolism, and excretion

ADR

Adverse drug reaction

AE

Adverse event

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

AUC

Area under the concentration-time curve

AUC0-8

Area under the mean concentration-time curve from time 0 to 8 hours

AUC0-12

Area under the mean concentration-time curve from time 0 to 12 hours

AUC0-24

Area under the mean concentration-time curve from time 0 to 24 hours

AUC0- ∞

Area under the mean concentration-time curve from time 0 to infinity

AUC0-t

Area under the mean concentration-time curve to the last observable

concentration at time t

BABE

Bioavailability Bioequivalence

BCRP

Breast cancer resistance protein

BCS

Biopharmaceutics Classification System

BID

twice daily ( bis in die )

BSEP

Bile salt export pump

CAP

Community-acquired pneumonia

CDC

Centers for Disease Control and Prevention

CE

Clinically evaluable

CE-TOC

Clinically Evaluable at Test of Cure

CFU

Colony forming units

CHMP

Committee for Medicinal Products for Human use

CI

Confidence interval

CL

Total plasma clearance

CLSI

Clinical and Laboratory Standards Institute

Cmax

Maximum (peak) plasma drug concentration

Cmin

Minimum (trough) plasma drug concentration

CNS

Central nervous system

CPP

Critical process parameter

CrCl

Creatinine clearance

CSR

Clinical Study Report

CURB-65

Confusion, BUN &gt;19 mg/dL (&gt;6.8 mmol/L), respiratory rate ≥ 30 breaths/min,

blood pressure &lt;90 mmHg systolic or ≤ 60 mmHg diastolic, age ≥ 65 years

DDI

Drug-drug interaction

DOE

Design of experiments

ECDC

European Centre for Disease Prevention and Control

ECG

Electrocardiogram

ECR

Early Clinical Response

eCRF

Electronic Case Report Forms

eGFR

Estimated glomerular filtration rate

ELF

Epithelial Lining Fluid

EMA

European Medicines Agency

EOT

End of treatment

ERS

European Respiratory Society

ESCMID

European Society for Clinical Microbiology and Infectious Diseases

EU

European Union

EUCAST

European Committee on Antimicrobial Susceptibility Testing

fAUC

Area under the plasma concentration-time curve corrected for plasma protein binding

fCmax

Maximum unbound drug concentration

FDA

United States Food and Drug Administration

FT-IR

Fourrier Transform Infrared Spectroscopy

FQAD

Fluoroquinolone-associated disability

GC

Gas Chromatography

GCP

Good Clinical Practice

GI

Gastrointestinal

GLP

Good Laboratory Practice

GMP

Good Manufacturing Practice

GTIs

Genotoxic impurities

HC

Host-cell protein

HDPE

High Density Polyethylene

hERG

Human Ether-à-go-go-Related Gene

HPLC

High performance liquid chromatography

Hr

Human recombinant

HRQL

Health-related quality of life

IACR

Investigator's Assessment of Clinical Response

IC50

Concentration giving 50% of the drug-induced inhibitory effect

ICH

International Conference on Harmonisation of Technical Requirements for

Registration of Pharmaceuticals for Human Use

ICP-MS

Inductively coupled plasma mass spectrometry

IPC

In-process control

IR

Immediate release

ITT

Intent-to-treat

IV

Intravenous(ly)

Ki

Inhibition constant

LDPE

Low density polyethylene

LFU

Late follow-up

LoD

Limit of detection

MA

Marketing authorisation

MAA

Marketing authorisation application

<div style=\"page-break-after: always\"></div>

MATE

Multidrug and toxin extrusion protein

MDR

Multidrug resistant

MedDRA

Medical Dictionary for Regulatory Activities

MIC

Minimum inhibitory concentration

MIC50

Concentration of drug required to inhibit growth of 50% of pathogens

MIC90

Concentration of drug required to inhibit growth of 90% of pathogens

microITT

Microbiological Intent-to-treat

mITT

Modified Intent-to-treat

MRSA

Methicillin-resistant Staphylococcus aureus

MSSA

Methicillin-susceptible Staphylococcus aureus

MS

Mass Spectrometry

NI

Non-inferiority

NLT

Not less than

NOAEL

No observed adverse effect level

NMR

Nuclear Magnetic Resonance

NMT

Not more than

NOR

Normal operating range

OAT1

OAT3

Organic anion transporter 1

Organic anion transporter 3

OATP1B1

Organic anion transporting polypeptide 1B1

OATP1B3

Organic anion transporting polypeptide 1B3

OCT1

Organic cation transporter 1

OCT2

Organic cation transporter 2

OECD

Organisation for Economic Co-operation and Development

OOS

Out of specification

P-gp

P-glycoprotein

PAR

Proven acceptable range

PBPK

Physiologically-based pharmacokinetic

PCR

Polymerase chain reaction

PD

Pharmacodynamic(s)

PK

Pharmacokinetic(s)

PO

Per os, oral use

PORT

Pneumonia Patient Outcomes Research Team

PP

Polypropylene

PSSP

Penicillin-susceptible Streptococcus pneumoniae

PVC

Polyvinyl chloride

Q12h

Every 12 hours

Q24h

Every 24 hours

QbD

Quality by Design

QC

Quality control

QD

Once daily

QTc

Corrected QT interval

QTcF

Corrected QT interval using Fridericia's correction

<div style=\"page-break-after: always\"></div>

RH

Relative Humidity

RI

Renal impairment

SAE

Serious adverse event

SAP

Statistical analysis plan

SAL

Sterility assurance level

SmPC

Summary of Product Characteristics

SMQ

Standardised MedDRA Query

SOC

System organ class

t1/2

Elimination half-life

TAMC

Total Aerobic Microbial Count

TEAE

Treatment-emergent adverse event

TFA

Triflouroacetyl

TK

Toxicokinetic(s)

Tmax

Time to maximum concentration

TOC

Test of cure

tRNA

Transfer ribonucleic acid

TFA

Trifluoroacetic acid

TSE

Transmissible Spongiform Encephalopathy

ULN

Upper limit of normal

US

United States of America

USP

United States Pharmacopoeia

USP/NF

United States Pharmacopoeia/National Formulary

UV

Ultraviolet

UV-VIS

Ultraviolet-visible light

Vmax

Maximum velocity

Vss

Volume of distribution at steady state

Vz

Terminal volume of distribution

XRPD

X-Ray Powder Diffraction

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Nabriva Therapeutics Ireland DAC submitted on 1 May 2019 an application for a marketing authorisation to the European Medicines Agency (EMA) for Xenleta, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 April 2018.

The applicant applied for the following indication:

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults 18 years of age and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decisions P/0066/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0066/2019 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's request for consideration

## Accelerated assessment

The  applicant  requested  accelerated  assessment  in  accordance  to  Article  14  (9)  of  Regulation  (EC)  No

<div style=\"page-break-after: always\"></div>

726/2004.

## New active Substance status

The applicant requested the active substance lefamulin contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## Scientific advice

The applicant did not seek Scientific advice from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Jayne Crowe

Co-Rapporteur:  Bjorg Bolstad

| The application was received by the EMA on                                                                              | 1 May 2019        |
|-------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                | 20 June 2019      |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                          | 9 September 2019  |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                       | 9 September 2019  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                     | 23 September 2019 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                 | 17 October 2019   |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                     | 24 January 2020   |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on | 27 February 2020  |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                | 12 March 2020     |
| The CHMP agreed on a list of outstanding issues in writing and/or in an                                                 | 26 March 2020     |

<div style=\"page-break-after: always\"></div>

| oral explanation to be sent to the applicant on                                                                                                                                         |               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 27 April 2020 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                        | 12 May 2020   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Xenleta on | 28 May 2020   |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Xenleta is proposed for the treatment of community-acquired pneumonia (CAP) in adults.

## 2.1.2. Epidemiology

Populations at risk for CAP include the elderly, patients who smoke, suffer from alcoholism, patients with underlying comorbidities (such as COPD, chronic heart failure, cardiovascular disease, and having a history of cerebrovascular disease/stroke) and those with recent hospital, healthcare or nursing home exposure. Given the increasing numbers of older patients hospitalised in the EU with CAP, it is expected that the burden of CAP will increase. Further amplifying the burden of illness, up to 33% of patients have a cardiac complication within 30 days of hospitalisation, with an increased risk persisting at 1 year and possibly even up to 10 years after the CAP event.

Despite advances in the diagnosis and treatment of CAP, it remains associated with high morbidity, mortality, and healthcare expenditures globally. Data from the Global Burden of Disease 2015 Study reported that lower respiratory tract infections, including pneumonia, were the third most common cause of death worldwide and the most common cause of infectious death globally, claiming 3 million lives annually. The impact on morbidity and mortality associated with community-acquired pneumonia is magnified in older groups, where data have shown that mortality is associated with advancing age. Approximately 90% of deaths due to pneumonia occur in people aged greater than 65 years. Annually, inpatient costs of pneumonia are estimated as €2.5 billion. Estimation of other direct and indirect costs of pneumonia/acute lower respiratory infections, including the cost of lost projected disability-adjusted life-years, are €43.5 billion.

While data are available from prospective studies and national databases, it remains difficult to determine the clinical and economic burden of CAP in the EU. Finland, Spain, and the UK remain the only countries to have precise epidemiologic data on CAP. Differences in study populations and methods for quantifying incidence

<div style=\"page-break-after: always\"></div>

pose challenges for comparisons across studies. Approximately 3,370,000 cases of pneumonia occur annually in the EU. The incidence of all-cause pneumonia in the EU ranged from 68-7000 per 100,000 persons but this varied by country, age, group, study and time-period. The incidence in hospitalised CAP of all causes ranged from 16-3581 per 100,000 persons and the incidence increased consistently with age within the EU. In Finland, the incidence of CAP increased six-fold when comparing patients aged 30-44 years and those aged &gt;75 years. The mortality rate for CAP was 9.1%, with ranges varying widely from &lt;1% to as high as 48%, especially when patients with CAP are treated in the intensive care unit. A long-term follow-up study found that elderly patients treated for CAP in both ambulatory and hospital settings had significantly higher risks of death and death related to pneumonia and cardiovascular conditions for several years following a diagnosis of pneumonia than the elderly without pneumonia.

Limited data are available on health-related quality of life (HRQL) following CAP infection and only a few studies have been published with follow-up extending beyond 6 weeks after CAP infection. In 3 published reports in which HRQL was followed from 1 to 1.5 years post CAP diagnosis, HRQL was diminished (e.g. reduced Short Form-36 Item Health Survey scores in physical function and general health; problems noted in all 5 domains of EQ-5D) throughout the duration of each study.

## 2.1.3. Aetiology and pathogenesis

Despite advances in diagnostic technology, a microbiological diagnosis is infrequently confirmed in cases of CAP although the microbiological diagnosis of CAP is necessary to ensure appropriate antimicrobial therapy. The microbial diagnosis of pneumonia is achieved in less than half of presenting cases and antimicrobial therapy should be empirically started to avoid the delay in establishing appropriate therapy, which has been associated with increased mortality. In the EU, the prevalence of S. pneumoniae ranged from 19%-34%. The primary factors that confound these conventional methods of microbial detection in patients with CAP are the low yield, long turnaround time and previous antibiotic use.

A population-based surveillance study conducted by the US CDC found that among 2259 patients with radiographic evidence of CAP and specimens available for testing, only 38% of cases yielded any pathogen and only 14% yielded a bacterial pathogen. Although a definitive microbiological diagnosis is made in the minority of patients with CAP, when a pathogen is identified, the majority are caused by one of a handful of microorganisms, mainly S. pneumoniae, H. influenzae and other Gram-negative aerobes. Additionally, there is increasing incidence with S. aureus, including methicillin-resistant S. aureus (MRSA), as a post-influenza, secondary, bacterial pathogen causing CAP.

## 2.1.4. Clinical presentation, diagnosis

Community-acquired pneumonia is characterised by acute signs and symptoms of a lower respiratory tract infection, with new pulmonary infiltrates on chest X-ray not attributable to other aetiologies. Patients typically develop fever and respiratory symptoms such as cough, increased sputum production, shortness of breath, chest pain. However, in subgroups of patients (e.g. elderly) typical signs and symptoms may be absent and atypical symptoms such as altered consciousness may be more prevalent, delaying diagnosis. As a result, the definitive diagnosis of pneumonia rests primarily on a thorough medical history, clinical evaluation and imaging studies that document the presence of lung infiltrates.

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

In 2011, a collaboration between the European Respiratory Society (ERS) and The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) published updated European guidelines for the treatment of CAP. The recommendation for outpatients was use of either amoxicillin or tetracycline as monotherapy, and for patients with hypersensitivity to amoxicillin, a tetracycline or macrolide should be prescribed; however, regional, macrolide resistance rates to S . pneumoniae need to be considered. When resistance rates are clinically relevant, a respiratory fluoroquinolone (levofloxacin or moxifloxacin) can be used.

For hospitalised patients not considered severe, penicillin G ± macrolide, an aminopenicillin (amoxicillin) ± macrolide, an aminopenicillin/beta-lactamase inhibitor (amoxicillin/clavulanic acid ± macrolide), a nonantipseudomonal, third-generation cephalosporin, such as cefotaxime or ceftriaxone ± macrolide or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) can be given. The ERS/ESCMID guidelines suggest that combination therapy should be restricted to patients with severe presentation of CAP, with combination therapy being the treatment of choice for patients with severe CAP being treated in the intensive care unit (ICU). Additional areas of concern for clinicians include lack of coverage with first line therapy options and cross resistance to community acquired (CA) MRSA strains, multi-drug-resistant S. pneumoniae and overuse of fluoroquinolones being a primary driver towards increasing resistance in gram negative bacteria.

Broadly, treatment of CAP is complicated by 3 issues: infrequent identification of causative pathogens, resistance to commonly prescribed antibiotic therapies and adverse effects of the medications. In addition, broad spectrum antibiotic therapy also can cause 'collateral damage' on enteric and other normal flora bacterial populations increasing risk of diarrhoea (including Clostridioides difficile [formerly Clostridium difficile ] related), selection of resistance in other pathogens and risk of fungal overgrowth and infections.

Macrolide resistance in M. pneumoniae is at least 15% in the European Union (EU) and the US and is approaching 100% in Asia. Increased rates of resistance have also been reported for fluoroquinolones, another commonly prescribed antibiotic therapy for CAP. Although the IDSA/ATS guidelines recommend initiating treatment of CAP with macrolides, resistance among S. pneumoniae and M. pneumoniae isolates to this class has been increasingly reported worldwide. Approximately 50% of S. pneumoniae strains are resistant to macrolides in the US with rates varying significantly by geographic region.

In addition to increasing resistance, the most frequently used CAP therapies, including β -lactams, macrolides and fluoroquinolones , are associated with clinically important adverse effects. β -lactam use (e.g. ceftriaxone) is commonly associated with adverse events (AEs) including allergic reactions and gastrointestinal, hematologic, hepatobiliary and neurological effects. Common adverse effects associated with macrolides include gastrointestinal side effects, particularly nausea and vomiting and risk of QT prolongation. Fluoroquinolone use has recently become more restricted due to the emergence of fluoroquinolone-associated disability (FQAD), which includes tiredness, concentration problems, neuropathies, tendinopathies, and other symptoms, which may persist after discontinuation of the offending fluoroquinolone.

<div style=\"page-break-after: always\"></div>

## About the product

Lefamulin has in-vitro activity against all of the most common pathogens associated with CAP (including S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila, C. pneumoniae and M. pneumoniae ). It is also active against S. aureus . The recommended duration of treatment for lefamulin is 5 to 7 days. The lefamulin clinical development programme included 24 Phase 1 studies, one Phase 2 study in ABSSSI and two Phase 3 studies in CAP.

## Type of Application and aspects on development

The CHMP did not agree to the applicant's request for an accelerated assessment as the product was not considered to be of major public health interest. This was primarily based on the lack of an unmet need with respect to available treatments for community-acquired pneumonia.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as 600 mg film-coated tablets and 150 mg/15 mL concentrate and solvent for solution for infusion containing the active substance lefamulin (as acetate).

Other ingredients in the film-coated tablets are Tablet core: mannitol (E421), povidone (K30), microcrystalline cellulose (E460), croscarmellose sodium (E468), talc, colloidal silicon dioxide, and magnesium stearate; Tablet coating: poly(vinyl alcohol) (partially hydrolysed) (E1203), titanium dioxide, macrogol/PEG, talc, and indigo carmine aluminium lake (E132); Tablet printing ink: shellac, black iron oxide (E172), and propylene glycol.

Other ingredients in the concentrate for solution for infusion are sodium chloride and water for injections. The solvent for dilution of the concentrate contains citric acid anhydrous, sodium citrate dihydrate, sodium chloride and water for injection.

The tablets are available in PVC/PE/PCTFE / Aluminium blister packs of 10 tablets.

The concentrate and solvent for solution for infusion is available as kits, each containing two Type I glass vials closed with a stopper (chlorobutyl rubber) and sealed with a flip off cap, containing 15 mL concentrate, and two polypropylene (PP) infusion bags containing 250 mL solvent.

## 2.2.2. Active Substance

## General information

The chemical name of lefamulin is acetic acid, 2-[[(1 R ,2 R ,4 R )-4-amino-2-hydroxycyclohexyl]thio](3a S ,4 R ,5 S ,6 S ,8 R ,9 R ,9a R ,10 R )-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-

<div style=\"page-break-after: always\"></div>

3aH-cyclopentacycloocten-8-yl ester corresponding to the molecular formula C28H45NO5S. It has a relative molecular mass of 507.74 (free base) g/mol. Lefamulin is available in the form of an acetic acid salt (acetate) with a molecular weight of 567.79 g/mol and the molecular formula of C30H49NO7S. Lefamulin acetate has the following structure:

## Figure 1. Active substance structure

<!-- image -->

Lefamulin acetate is a single stereoisomer semi-synthetically derived from pleuromutilin, a homochiral, natural fermentation product of known absolute stereochemistry. Lefamulin acetate is a diastereomer with R -configuration at carbons of the cyclohexane moiety. The absolute configuration of the active substance has been confirmed by single crystal structure determination.

The structure of the active substance lefamulin acetate has been elucidated by a combination of the following methods: UV-VIS, FTIR,  1 H NMR,  13 C NMR, MS, elemental analysis, XRPD and single crystal structure determination.

Lefamulin acetate is a white to off-white solid. It is a stable compound (requiring no special storage conditions) which is highly soluble in water and 0.9% sodium chloride solution (&gt;300mg/ml). The hydration level of lefamulin acetate at ambient conditions is typically below 1% w/w.

Two polymorphic forms are observed (Form A and Form B), both being crystalline. The manufacturing process yields the thermodynamically more stable Form B. FTIR is used to distinguish between Form A and B.

## Manufacture, characterisation and process controls

Lefamulin active substance is manufactured in seven main steps from well-defined starting materials with acceptable specifications. Pleuromutilin is a key intermediate in the manufacture of the active substance.

A detailed synthetic scheme and a narrative, including IPCs, were provided. Process parameters, including quantities of materials, batch size and process yields were presented for each step.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented and are considered to be acceptable.

<div style=\"page-break-after: always\"></div>

## Pleuromutilin intermediate

Pleuromutilin is a key intermediate used for manufacture of the active substance. Pleuromutilin is a homochiral product of natural fermentation manufactured in a three-stage process by fermentation, extraction and crystallisation. The fermentation process is standard. In general, the fermentation process is adequately described and includes appropriate IPCs. Suitable process parameters are assigned for temperature, pressure and aeration of the fermentation broth and culture duration.

Information with respect to the source, generation and characterisation of the starting material cell bank Clitopilus scyphoides var intermedius has been provided. The applicant provided results of the validation of the Pleuromutilin fermentation process. In process control results were provided and all complied with limits. The process has been demonstrated to be valid. The applicant provided a confirmation that there have been no significant manufacturing changes since the transfer of manufacture to the commercial site . During the procedure the dossier has been updated to include an overview and discussion of potential impurities coming from the fermentation batch. The applicant considers that all impurities would be successfully removed during the manufacturing process, either as water-soluble materials, or as insoluble extracts. Data has been presented to demonstrate that mycotoxins are not present in batches of crude and purified pleuromutilin which supports that these batches are free of aflatoxin B1.The risk of carry forward of any cell debris is low based on the numerous filtration and extraction steps at subsequent steps of the active substance manufacturing process. Discussion on the formation and purge of organic impurities in pleuromutilin has also been provided. Chemical impurities have been characterised and their origin and fate understood. All known impurities are controlled and their limits are in line with batch data.

The applicant was requested to discuss whether the change in manufacturer, from phase 3 manufacturing site to the proposed commercial manufacturing site, has an impact on the biological impurity profile, in order to ensure comparability between the pleuromutilin materials used for manufacture of phase 3 vs proposed commercial active substance batches. The applicant asserts that due to similarities in solvent properties, the impurity profiles are expected to be comparable between the different processes, however no information has been provided on how the solvents are considered to be similar with respect to ability to purge biological impurities. Nevertheless it is agreed that given the number of further processing steps, and the nature of solvents used in the manufacturing process for this semi-synthetic product of fermentation, the likelihood of proteinaceous materials remaining present in the final active substance is small. Comparative batch analysis data from the previous supplier and the current supplier indicate the chemical impurity profiles between the two suppliers is comparable and batch analysis data for the drug substance used in clinical trials and for registration is similar.

The structure of pleuromutilin intermediate has been confirmed using the following methods: elemental analysis, UV, IR, NMR and MS. Single crystal X-ray analysis was used to confirm that pleuromutilin had the desired molecular structure and stereochemistry. A satisfactory specification for pleuromutilin is applied by both the pleuromutilin manufacturer and the active substance manufacturer. The chirality of the intermediate is controlled by optical purity. Residual solvents are suitably controlled and a limit for sulphated ash ensures control of inorganic impurities. Pleuromutilin is placed in PE bags for storage.

Stability studies on 3 commercial batches have been conducted at ICH long term (25°C / 60% RH) and accelerated conditions (40°C / 75% RH). The batches remain within specification for 6 months at accelerated

<div style=\"page-break-after: always\"></div>

conditions and for 18 months at long-term. Based on the data provided a retest period of 18 months with no special storage conditions for the Pleuromutilin intermediate was accepted.

## Manufacturing process development

The commercial manufacturing process for the lefamulin active substance was developed in parallel with the clinical development program. It was confirmed that the overall synthetic strategy is unchanged since the manufacture of the Clinical Phase 3 batches. The quality of the active substance used from phase 3 of the development is considered to be comparable with that produced by the proposed commercial process. The manufacturing process has been developed using a combination of conventional univariate studies and elements of QbD such as risk assessment followed by design of experiment (DOE) studies. All process parameters in the lefamulin manufacturing process have a defined normal operating range (NOR) and some parameters also have a proven acceptable range (PAR). In the initial MAA submission, a major objection was raised as no clear information to support/justify the inclusion of these PARs was provided, and in particular, an absence of interaction studies was a concern as several PARs are listed for each step/series of steps. The applicant's response to the major objection largely supported a flexible description of the manufacturing process, i.e. the declared PARs could form the basis of a Design Space. However, the applicant clarified that since an absence of interaction effects with the other PARs have not been fully demonstrated, a Design Space is not claimed. The applicant instead confirmed they will follow the ICH Q8 definition, whereby only a single parameter may be varied within the PAR when all others are operated at the NOR. The dossier has been updated to clearly state this.

## Characterisation

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

The approach taken when setting related substance specifications for intermediates and in the active substance is acceptable. The origin, fate and control of potential impurities are discussed. Impurity profiles of active substance stability batches are consistent and no degradation products are seen at long term or accelerated conditions.

Two confirmed genotoxic impurities are routinely controlled in the intermediate at an appropriate limit (ICH M7). Potential GTIs were also discussed. In line with EMA Information on nitrosamines for MA holders (EMA/189634/2019), the applicant submitted a risk assessment and evaluation of the risk regarding potential presence of nitrosamine impurities in the active substance. No risk of nitrosamines is determined.

No elements as defined in ICH Q3D are intentionally added in the active substance manufacturing process. Analysis of active substance, in line with ICH Q3D, found the relevant elemental impurities were well below 30 % of the ICH limit. A test for residue on ignition is included in the active substance specification.

Batch analysis data demonstrates that most of the class 2 and 3 solvents used prior to the final synthetic step are 10% (or less) of their ICH limits. Two class 3 solvents, which will be routinely controlled in the active substance, are used in the final synthetic step. The control of solvents is acceptable.

<div style=\"page-break-after: always\"></div>

## Packaging

A sufficiently detailed description of the packaging materials is provided. The active substance is packaged in LDPE bags/sleeves in HDPE containers which complies with the EC directive 2002/72/EC and EC 10/2011 as amended.

## Specification

The active substance specification includes tests for: description (visual), identity (FTIR, HPLC), assay (HPLC), impurities (HPLC), acetic acid content (titration), residual solvents (GC), water content (Ph. Eur.), residue on ignition (Ph. Eur.), microbial purity (Ph. Eur.) and endotoxins (Ph. Eur.).

The tests and acceptance criteria are considered acceptable. Identification is confirmed by FTIR and HPLC. FTIR also serves to confirm the correct polymorphic form (Form B). In response to a request to tighten the assay limit  in  line  with  batch  data,  the  applicant  tightened  the  specification.  When  more  batches  are  available, narrowing further should be considered.

The proposed limit for individual unspecified impurities has been adequately justified. Impurities present at higher than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

Limits for genotoxic impurities are not included in the active substance specification as they are routinely controlled in the intermediate at appropriate limits. Supporting batch data in combination with the controls for chiral purity in the starting material and intermediate mean that routine control of the lefamulin diastereomer impurity in the active substance is not considered necessary. The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data from 9 batches of the active substance are provided (5 clinical Phase 3 batches, 3 registration batches and 1 pre-validation engineering batch). The results comply with the specifications and are consistent from batch to batch.

## Stability

Stability data from 5 batches of active substance (2 Phase 3 clinical and 3 registration batches; the latter ones from the proposed manufacturer) stored in the intended commercial package for up to 48 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The clinical batches are considered representative of the commercial product.

The parameters tested were appearance, assay, impurities, acetic acid, ID by IR, water, microbial purity and endotoxins. The analytical methods used were the same as for release and were stability indicating. Photostability testing following the ICH Q1B guideline was performed on one batch. All tested parameters were within the specifications. Impurity levels do not change and there is no evidence of any trends.

<div style=\"page-break-after: always\"></div>

Results on stress conditions (temperature, humidity (80°C / 80%RH), light (UVA &amp; cool white fluorescent), acidic (1M HCl), basic (1M NaOH), oxidising (1M H2O2)) were also provided on one batch, confirming the stability indicating nature of the HPLC impurities method.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 48 months in the proposed container with no special storage conditions.

## 2.2.3. Finished Medicinal Product (Xenleta 600 mg film-coated tablets)

## Description of the product and Pharmaceutical development

Xenleta 600 mg film-coated tablets are blue, oval, film-coated tablets with 'LEF 600' printed in black on one side. Xenleta tablets are supplied in opaque Aclar [PVC/PE/PCTFE] blisters with aluminium foil lidding containing 10 tablets. The theoretical quantity of the active substance lefamulin acetate is 671 mg. Since the oral dose of lefamulin is 600 mg free base the actual quantity of salt in the formula is calculated on the assay value of the active substance. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur or other relevant Pharmacopoeial standards (USP / USP-NF / JP). There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.2.1 of this report. While the applicant did not present a quality target product profile per se, the account of formulation development specifies the properties required throughout. While the dosage form necessitated a switch from 200 mg capsule to 600 mg tablet, and the target dissolution specification had to be modified as a result, development was consistent with respect to the size and weight required and the immediate release of the formulation. Formulation development was clear and logical and sufficient detail was given on how the process progressed. The applicant described that a number of clinical Phase I studies were carried out using the capsule formulation whilst others were conducted using the first tablet formulation (phase 1). Following tablet optimisation and upscaling, a phase 1 BA/BE study and two phase 3 studies were conducted using the tablet with the final formulation (Phase 3). Following this, the appearance and manufacturing process of the filmcoated tablet were amended again for the registration batches. The applicant discussed pharmacokinetic data of different formulations. Bioequivalence study NAB-BC-37811107 compared the phase I capsule formulation with tablets used in phase 3 clinical trials. Lefamulin exposures after oral administration were found to be similar - with similar Cmax, t max, and AUC0-24 values. The applicant also stated that the clinical efficacy of the tablets used in phase 3 was confirmed in study NAB-BC3781-3102; this has been addressed in the clinical section of this report. Dissolution data comparing the batches used in clinical phase 3 studies to the registration batches was provided at 0.1N HCl (the proposed QC release medium) and at pH 1.2, 4.5 and 6.8. The graphs show

<div style=\"page-break-after: always\"></div>

profiles at all pHs to be similar, as supported by f2 values, which are all higher than 50. This is considered sufficient to demonstrate that the batches used in pivotal clinical trials are sufficiently similar to the registration batches. Based on the provided data, the formulation used during clinical studies is considered to be representative as that intended for marketing.

Physico-chemical  properties  of  the  active  substance  which  could  potentially  affect  the  formulation  were investigated by the applicant. It was demonstrated that the polymorphic form of choice (Form B) of lefamulin is  unchanged as a result of  the  manufacturing  process.  A justification  of  the  proposed  dissolution  method parameters was provided by the applicant. The dissolution profiles of different aberrant batches were used by the applicant to demonstrate the discriminatory power of the dissolution method. Regarding manufacturing process  development,  the  choice  of  granulation  is  sufficiently  justified.  Some  details  of  improvement  or adjustment of the process were described in formulation development between the process used for the batches used in clinical phase 3 studies and that used to manufacture registration batches. The primary packaging is PVC/PE/PCTFE / Aluminium (Aclar) blisters with 10 film-coated tablets. The material complies with Ph.Eur. and EC  requirements.  The  choice  of  the  container  closure  system  has  been  validated  by  stability  data  and  is adequate for the intended use of the product.

## Manufacture of the product and process controls

The  manufacturing  process  consists  of  seven  main  steps:  granulation,  blending,  lubrication,  compression, coating, printing and packaging. The process is considered to be a standard manufacturing process. The inprocess controls and critical process parameters have been identified and are considered adequate for this type of manufacturing process and pharmaceutical form.

Data from development batches have been provided which demonstrate that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The applicant has submitted a validation protocol for commercial scale manufacture in line with Annex I of the EMA Guideline on process validation for finished products - information and data to be provided in regulatory submissions (EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1). This is considered satisfactory.

## Product specification

The finished product release and shelf life specifications include appropriate tests for this kind of dosage form; appearance (visual), identity (HPLC, FTIR), assay (HPLC), impurities (HPLC), uniformity of dosage units (Ph. Eur.), dissolution (Ph. Eur.), disintegration (Ph. Eur.), water content (Ph. Eur.), microbial purity (Ph. Eur.).

The finished product is released on the market based on the above release parameters, through traditional final product release testing. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

The maximum daily dose of the Xenleta tablets is 1200 mg. Based on this, the thresholds in line with the EU/ICH Q3B (R2) guideline for individual unknown impurity is NMT 2 mg (0.167%). During the procedure, the proposed limits for water content, total impurities and dissolution have been tightened. The applicant was asked to justify the dissolution specification limit in line with the Ph Eur monograph for immediate release

<div style=\"page-break-after: always\"></div>

tablets and EMA reflection paper on setting dissolution specifications. The dissolution specification limit has been sufficiently justified.

The potential presence of elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on 3 batches using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data, it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

In line with EMA Information on nitrosamines for MA holders (EMA/189634/2019), the applicant submitted a risk assessment and evaluation of the risk regarding potential presence of nitrosamine impurities in the finished product. No risk of nitrosamines is determined.

Batch analysis results are provided for three registration batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

Stability data from three commercial scale batches of finished product stored for up to 24 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. These batches of Xenleta are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

In addition, further supportive stability data from five batches (including four clinical Phase 3 batches and one engineering batch) stored for up to 36 months under long term conditions (25ºC / 60% RH) were provided. These batches of Xenleta are representative to those proposed for marketing, although some were packed in different primary packaging than the Aclar blisters proposed for marketing (i.e. Alu/Alu and PVC/Alu).

Samples were tested in line with the specifications. While some of the historic acceptance criteria were different to  those  finally  agreed  (i.e.  appearance,  individual  impurity,  total  impurities,  dissolution),  the  analytical procedures used were stability indicating and representative of the proposed finished product specification.

No trends of concern have been observed in the stability data and no significant changes were seen throughout the studies. There is an uptake of water throughout storage. The highest increase occurs with PVC/Alu blisters and the smallest increase occurs in Alu/Alu. The data shows that both Aclar and Alu/Alu are equally protective of the finished product with respect to water content and related substances. On long-term stability in the commercial Aclar blisters, the water content increased but stayed well below the revised specification limit.

The applicant performed a photostability study on bulk tablets and tablets in Aclar blister in line with the ICH Guideline on Photostability Testing of New Drug Substances and Products. All stability acceptance criteria were met  for  all  investigated  conditions.  The  data  confirm  that  Xenleta  tablets  are  not  prone  to  light  induced degradation.

Based on available stability data, the proposed shelf-life of 36 months with no special storage conditions as stated in the SmPC is acceptable.

<div style=\"page-break-after: always\"></div>

## Adventitious agents

## Non-Viral Adventitious Agents

Lefamulin acetate is a semi-synthetic molecule. Pleuromutilin, the key intermediate and first starting material for chemical synthesis in the lefamulin acetate active substance manufacture, is derived from the fungus Clitopilus scyphoides var intermedius by fermentation. Confirmation that there is no risk associated with adventitious agent contamination of this material is provided via TSE certification by the pleuromutilin manufacturer.

## Viral Adventitious Agents

No excipients derived from animal or human origin have been used in the manufacture of active substance or finished product.

## 2.2.4. Finished Medicinal Product (Xenleta 150 mg/15 mL concentrate and solvent)

## Description of the product and Pharmaceutical development

Xenleta concentrate and solvent is supplied as a kit, containing 2 vials of concentrate and 2 bags of solvent for solution for infusion.

Xenleta 150 mg / 15 ml concentrate for solution for infusion is a sterile, clear, colourless solution filled into a 15 mL clear, colourless glass vial with rubber stopper and flip-off aluminium seal.

For intravenous administration, the 15 mL concentrate must be diluted in a 250 mL bag of citrate-buffered normal saline.

The target fill volume of the solvent bags is 270 mL to ensure a minimum extractable volume of not less than 250 mL over the proposed shelf life. The container closure system consists of a primary bag with two ports. One port is used for injection of lefamulin concentrate solution into the citrate buffer. The other port is used for infusion (administration) of the diluted finished product. The primary bag is covered by a secondary film overwrap.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.2.1 of this report. Both concentrate and solvent contain sodium containing excipients. This corresponds to 1,055 mg sodium per dose (with respect to nominal filling volume), which is adequately addressed in the SmPC in line with the Excipients Guideline, EMA/CHMP/302620/2017.

## Xenleta concentrate for solution for infusion

The finished product (Xenleta concentrate 150 mg/15 mL) comprises a sterile, pyrogen-free solution of the active substance in 0.9 % sodium chloride solution. As the finished product is a concentrate for solution for infusion solubility of the active substance is the most critical physicochemical parameter. Lefamulin acetate is

<div style=\"page-break-after: always\"></div>

a BCS class III compound, highly soluble in water and 0.9% sodium chloride solution (&gt; 300 mg/mL). Aside from the active substance, which is highly soluble in water, only NaCl, which is freely soluble in water, has to be dissolved. Precipitation at low temperatures is not to be expected. Nevertheless, a freeze-thaw cycle test has been performed and demonstrate that the product is not significantly affected by freezing. Specified pHvalue and osmolarity of the solution for dilution are well in the physiological range. Each component is considered safe in the proposed concentration. The manufacturing process of Xenleta Injection consists of compounding, bioburden reduction filtration, sterile filtration, aseptic filling and visual inspection/packaging. Manufacturing of the bulk solution is a relatively simple process involving dissolution of lefamulin acetate and NaCl in water for injections. The mixing conditions have been evaluated during process validation studies and were considered to be acceptable. The manufacturing process remained consistent throughout development, the only differences were the increase in scale and related changes in equipment. An acceptable overview of the manufacturing process development was presented. The manufacturing process is relatively straightforward and process validation data was provided. Samples of all batches manufactured during process transfer and up-scaling were put on formal stability studies to generate stability data under long term and accelerated conditions. To evaluate and select a suitable sterilisation method, a terminal sterilisation study by autoclaving and gammairradiation was performed. The presented data demonstrated that the finished product is sensitive to elevated temperature and gamma-irradiation and that sterilisation at moist heat at standard conditions and sterilisation by gamma-irradiation are not an option due an increase in impurities. Based on this outcome the applicant concluded  that  Xenleta  Injection  should  be  manufactured  by  sterile  filtration  and  aseptic  processing.  The applicant's justification was initially found to be incomplete as alternative autoclave temperatures had not been investigated, and a major objection was raised on this point. In response, the applicant carried out further investigation using F0-concept steam sterilisation. It was evident from the results presented that under these conditions,  significant  degradation  occurs  resulting  in  out  of  specification  results  for  three  degradation products. In accordance with the EMA Guideline on the sterilisation of medicinal product, the applicant had demonstrated that a rationale stepwise approach to the development of the final method of manufacture has been thoroughly evaluated. Hence, the choice of the sterilisation process (sterile filtration followed by aseptic processing) is considered acceptable. The Xenleta Injection is supplied in 15 mL type I (Ph. Eur.) glass vials closed with chlorobutyl rubber stoppers and sealed with aluminium flip off crimps. The packaging material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. To demonstrate suitability of the primary packaging system the glass vials (testing of a different size is acceptable) have been tested for inorganic extractables and delamination. Based on the results provided both aspects can be considered as having negligible impact on quality. and leachables. As a result, from extractable studies a risk-based assessment of the identified extractables is

Furthermore, the coated chlorobutyl stoppers have been tested for extractables (at worst-case conditions) presented. Although no extractables were detected in purified water, a leachable study was initiated on six potential extractable compounds observed in isopropyl acetate. Samples of one validation batch have been stored at long-term (refrigerated conditions) and accelerated conditions (25 ± 2°C / 60% ± 5% RH) up to 48

<div style=\"page-break-after: always\"></div>

and 6 months. Leachable testing after storage at long-term conditions is on-going. However, leachable testing at accelerated conditions (25°C) are finished and test results at both storage conditions (up to 12 months at refrigerated conditions) demonstrate that each tested leachable is below LOD. Therefore, further data on leachable studies was requested during the procedure. Sorption studies are not addressed, but results from stability studies demonstrate that this not an issue. Suitable tests have been performed to demonstrate integrity of the container closure system.

## Xenleta solvent for solution for infusion

Extensive development work in formulation of the finished product (Xenleta solvent) was not necessary as the solvent is a sterile, pyrogen-free solution for infusion with common and stable excipients. It is used only for dilution of the respective concentrate of the active substance and provided as part of a kit together with the Xenleta concentrate. The excipients are very soluble or freely soluble in water. Therefore, precipitation at low temperatures is not to be expected and freeze-thaw cycle tests are not deemed necessary. No overages are employed in manufacture of the solvent solution.

Specified pH-value and osmolarity of the solution are well in the physiological acceptable range. Each component, including buffer-capacity of the citrate-buffer, is considered safe in the proposed concentration. Detailed information on testing in clinical studies and compatibility with the active substance concentrate was presented.

The manufacturing process of the bulk solution is a simple process involving dissolution of the excipients and the proposed manufacturer has a broad experience in manufacturing similar products. The bulk solution is filtered and filled into freeflex-bags. Finally, the filled bags are sterilised by moist heat. Detailed development studies on the manufacturing process of bulk solution and filling are not required. Manufacturing of the freeflex-bags is a standard process at the manufacturing site, however, due to the final sterilisation process (following F0 concept) the manufacturing process of the Xenleta solvent is considered to be a non-standard manufacturing process.

The container closure system (two-port 250 mL infusion bag (freeflex)) is standard for this dosage form and commonly used for large parenteral preparations. The applicant has discussed suitability of the freeflex bags. It is stated that the freeflex bag is a bag system for parenteral solutions and is already approved for various infusion solutions like electrolytes, glucose, and colloids. The PVC-free overwrap is peelable and adheres slightly to the primary bag to improve handling. The overwrap effectively avoids solution losses through vaporing. It ensures that the primary bag is internally and externally sterile and can be displayed and used in a completely aseptic way. The packaging material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

In compliance with CPMP/QWP/4359/03 the freeflex bags have been product specific tested on leachables which may potentially occur. Based on the presented results the maximum daily exposure of each of the leachables/migrants is below the PDE. Based on the provided data from leachable testing it can be concluded that the freeflex bags are safe for use with citrate-buffered normal saline solution.

Microbiological container integrity of the freeflex bag is tested on 100 mL bags. No growth was observed in the tested bags. It is certified that the 250 mL freeflex bags are produced with the same materials and

<div style=\"page-break-after: always\"></div>

equipment as the 100 mL bag size, therefore the 100 mL bags are considered to be representative and the integrity test results were accepted.

Compatibility of Xenleta Injection with the diluent, citrate-buffered normal saline, is evaluated in stability studies. Furthermore, to evaluate compatibility of the ready-to-use dilution with the infusion set, a study with a PVC and a PE- infusion set was performed and demonstrates compatibility up to the recommended infusion time of 1 hour.

## Manufacture of the product and process controls

## Xenleta concentrate for solution for infusion

The manufacturing process consists of six main steps: compounding, bioburden reduction filtration, sterilising filtration, filling, crimping and visual inspection / packaging. Due to the choice of sterilisation process (sterile filtration and aseptic filling) the process is considered to be a non-standard manufacturing process. All steps are carried out at one manufacturing site.

The narrative description of the manufacturing process is sufficiently well detailed. The critical steps in the process are identified. The temperatures and times for steam sterilisation of stoppers and depyrogenation of vials  are  stated.  The  in-process  controls  are  adequate  for  this  type  of  manufacturing  process  and pharmaceutical form. Major steps of the manufacturing process have been validated for three consecutive batches of full commercial scale. The batches have been manufactured at the commercial manufacturing site by the commercial manufacturing process. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

Based on the bioburden results collected during validation of manufacturing process and on results of media fill qualification, holding times are established.

## Xenleta solvent for solution for infusion

The  manufacturing  process  of  the  solvent  consists  of  five  main  steps:  compounding  /  preparation  of  bulk solution, bacterial retention filtration, filling &amp; pouching, final sterilisation and packaging. Due to the choice of sterilisation process (steam sterilisation following F0-concept) the process is considered to be a non-standard manufacturing process. All steps are carried out at one manufacturing site.

The narrative description of the manufacturing process is sufficiently well detailed. The critical steps in manufacturing of the finished product are identified. The in-process controls are adequate for this type of manufacturing process and pharmaceutical form. Major steps of the manufacturing process have been validated for three consecutive batches using different tank sizes covering the proposed commercial batch size range. The range of batch volume should ensure the flexibility within the available tanks suitable for commercial manufacture. These batches have been manufactured with the 'new' freeflex -film (with nonphthalates containing catalyst). It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

The proposed maximum holding time for the bulk solution from begin of mixing to start of the sterilisation process has been evaluated during process validation and is accepted.

<div style=\"page-break-after: always\"></div>

## Finished product specification

Xenleta concentrate for solution for infusion The finished product specifications for Xenleta concentrate include appropriate tests for this kind of dosage form; appearance of container (visual) , appearance of vial contents (Ph. Eur), identification (HPLC, HPLC-UV), assay (HPLC), impurities (HPLC), extractable volume (Ph. Eur.), pH of the solution (Ph. Eur.), osmolality (Ph. Eur.), particulate matter (Ph. Eur., USP), sterility (Ph. Eur.) and endotoxins (Ph. Eur.). The concentrate is released on the market based on the above release parameters, through traditional final product release testing. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented. The specifications set for impurities at release and shelf-life are in compliance with ICH Q3B (R2) requirements and can therefore be accepted. Considering a maximum daily dose of the finished product of 300 mg lefamulin as acetate as stated in the SmPC, the ICH Q3B requirements are as follows: Reporting threshold: 0.1%; Identification threshold: 0.2%; Qualification threshold: 0.2%. The potential presence of elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on 3 batches using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory. In line with EMA Information on nitrosamines for MA holders (EMA/189634/2019), the applicant submitted a risk assessment and evaluation of the risk regarding potential presence of nitrosamine impurities in the finished product. No risk of nitrosamines is determined. Batch analysis results are provided for seven batches (four commercial scale and three smaller scale) confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. Xenleta solvent for solution for infusion The finished product specifications for Xenleta solvent include appropriate tests for this kind of dosage form; appearance (Ph. Eur.), identity citrate (Ph. Eur.), identity sodium (Ph. Eur.), pH (Ph. Eur.), osmolality (Ph. Eur.), extractable volume (Ph. Eur.), particulate matter (Ph. Eur., USP), sterility (Ph. Eur.) and endotoxins (Ph. Eur.). The solvent is released on the market based on the above release parameters, through traditional final product release testing. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. The proposed specification for release/stability testing is in compliance with the requirements of ICH Q6A and the Ph. Eur. (general monograph Parenteral preparations). The presented tests on physical, chemical and microbiological parameters are adequate. Based on the simple composition of citrate-buffered normal saline

<div style=\"page-break-after: always\"></div>

solution and the nature of the ingredients, no impurities or degradation products are expected from this formulation.

The potential presence of elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on 3 batches using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

In line with EMA Information on nitrosamines for MA holders (EMA/189634/2019), the applicant submitted a risk assessment and evaluation of the risk regarding potential presence of nitrosamine impurities in the finished product. No risk of nitrosamines is determined.

The batch analyses data for 6 batches (including four commercial scale validation batches (2 at minimum, 1 at intermediate and 1 at maximum commercial scale) are presented confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## Stability of the product

## Xenleta concentrate for solution for infusion

Stability data from four commercial scale batches of finished product stored for up to 36 months under long term conditions (5°C ± 3°C) and under accelerated conditions (25ºC / 60% RH) and for 6 months at advanced accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches of Xenleta concentrate are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Additionally, three further clinical batches (smaller scale) have been put on stability studies. These batches have been also manufactured in compliance with the commercial process, however, instead of stainless-steel tanks disposable bags have been used in manufacturing.

Samples  were  tested  in  line  with  the  shelf  life  specifications.  The  analytical  procedures  used  are  stability indicating.

Results demonstrate that the product appears at long term (refrigerated) conditions to be chemically and physically stable. The data obtained show no noticeable degradation up to 36 months and all parameters remain within the acceptance criteria over the assessed period. No trends are observed.

Results  at  accelerated  conditions  show  signs  of  degradation  but  meet  the  acceptance  criteria  over  the investigated period up to 36 months. All results are within specified limits of the shelf-life specification.

Results at advanced accelerated storage show a significant increase in degradation products which lead to OOS results after 3 months in three stability batches.

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. Based on the obtained results the product is not sensitive to light.

<div style=\"page-break-after: always\"></div>

According  to  the  product  SmPC,  15  mL  of  lefamulin  concentrate  must  be  mixed  into  the  bag  of  solvent containing 250 mL solution of citrate buffered saline and administered by infusion over a period of 60 minutes. Therefore, in-use stability of the ready-for-infusion dilution has been tested at refrigerated and (uncontrolled) room conditions. Based on the data presented, all tested dilution batches (also the batch at end of shelf-life) remain physically and chemically stable at refrigerated as well as at room temperature up to 7 days storage time. No trend can be observed. Furthermore, in a microbial challenge study it is demonstrated that accidental contamination  of  lefamulin  infusion  bags  (after  dilution)  does  not  lead  to  growth  of  challenge  organisms including bacteria, yeasts and moulds for up to 98 hours.

Based on available stability data, the proposed shelf-life of 36 months with the storage instructions 'Store in a refrigerator (2 to 8°C). Do not freeze.' as stated in the SmPC is acceptable.

The chemical and physical in-use stability following dilution has been demonstrated for up to 24 hours at room temperature and up to 48 hours at 2 to 8°C as stated in the SmPC.

## Xenleta solvent for solution for infusion

Stability data from six production scale batches of finished product stored for up to 36 months under long term conditions (5 ± 3°C / ambient RH), 48 months under alternative long-term conditions (25ºC / 40% RH), 12 months under intermediate conditions (30°C/35% RH) and 6 months under accelerated conditions (40ºC / 25% RH) according  to  the  ICH  guidelines  were  provided.  The  batches  of  Xenleta  solvent  are  identical  to  those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples  were  tested  in  line  with  the  shelf  life  specifications.  The  analytical  procedures  used  are  stability indicating.

The obtained results, concerning the specified physical, chemical and microbiological properties demonstrate that  the  product  is  stable  during  the  investigated  time  periods.  The  medicinal  product  remains  within  the acceptance  criteria.  Except  for  loss  of  water  (max.  4.5%  after  48  storage  time  at  long-term  conditions 25°C/40% RH and max. 3.4 % after 6 months storage time at accelerated conditions), no significant change in any of the parameters tested can be observed. Due to the set point in IPC for target fill volume of the bags, it is assured that the extractable volume of not less than 250 mL is maintained throughout the shelf life with water loss of NMT 5 %.

In addition, the applicant has submitted photostability data confirming that the diluent is not sensitive to light.

Based on available stability data, the proposed shelf-life of 36 months with the storage instructions 'Store below 25°C. Do not freeze.' as stated in the SmPC is acceptable.

It should be noted that according to the Guideline on declaration of storage conditions in the product information of medicinal products, based on the data provided, no temperature labelling statement is required. However, as the diluent will be marketed as a kit together with the concentrate, a storage statement with respect to temperature should be applied.

<div style=\"page-break-after: always\"></div>

## Adventitious agents

## Non-Viral Adventitious Agents

Lefamulin acetate is a semi-synthetic molecule. Pleuromutilin, the key intermediate and first starting material for chemical synthesis in the lefamulin acetate active substance manufacture, is derived from the fungus Clitopilus scyphoides var intermedius by fermentation Confirmation that there is no risk associated with adventitious agent contamination of this material is provided via TSE certification by the pleuromutilin manufacturer.

## Viral Adventitious Agents

No excipients derived from animal or human origin have been used in the manufacture of active substance or finished product.

## 2.2.5. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.6. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.7. Recommendations for future quality development

Not applicable.

## 2.3. Non-clinical aspects

## 2.3.1. Pharmacology

Lefamulin is an antibacterial agent of the pleuromutilin class that is presented for intravenous (IV) and oral (PO) use to treat adults with CAP.

Lefamulin inhibits bacterial protein synthesis by interacting with the A- and P- sites of the peptidyl transferase centre (PTC) in the central part of domain V of the 23s rRNA of the 50S ribosomal subunit, preventing correct positioning of the tRNA.

<div style=\"page-break-after: always\"></div>

The non-clinical pharmacological aspects of lefamulin were assessed in the Clinical AR. The spectrum of antibacterial activity of lefamulin supports selection of CAP as a target indication.

No non-clinical secondary pharmacodynamics studies were submitted. The potential for target effects of lefamulin on common secondary targets including receptors, enzymes and ion channels were neither provided nor discussed. The applicant states that secondary pharmacodynamics is not applicable to lefamulin because no pharmacological effects other than the primary therapeutic activity (antimicrobial) are known. However, it is clear from the safety pharmacology studies and toxicology studies described that lefamulin does have pharmacological effects beyond those of inhibiting bacterial protein synthesis. However, the carrying out of a secondary screen may not give any additional information at this point, as toxicities are known due to in vivo work, and there is adequate clinical experience (n=1242) where safety findings of interest mirror findings in the non-clinical toxicology studies, namely administration site reactions, GI events and QT/QTc prolongation.

Effects on eukaryotic ribosomal translation were described in the clinical module, mammalian and mitochondrial protein synthesis are unaffected by lefamulin.

The IC50 for lefamulin at the hERG channel is 27 µM in CHO cells and 47 µM in HEK-293 cells. In rabbit Purkinje fibres, the potential to prolong the duration of the action potential was observed. Lefamulin showed a potential for QT/QTc interval prolongation, while displaying a pro-arrhythmic potential at 10 µg/ml, but not at 0.5 µg/ml and 3 µg/ml. In vitro , the hERG IC50 for the metabolite BC-8041 was approxim ately ≥10 -fold higher than the IC50 recorded for lefamulin in CHO cells.

In telemetered monkeys (study SNBL.289.02), dose-dependent QT/QTc interval prolongation was observed. The duration of prolongation noted at 40 mg/kg (highest dose tested) was 31 and 37 msec above baseline for QT and QTcF, respectively. The control-adjusted mean maximal QT and QTcF interval prolongation was 33 and 40 ms, respectively. Dosing at 15 mg/kg (NOAEL) caused a QTcF interval prolongation of 21 ms, however under conditions of this study QTc prolongation in excess of 25 - 30 ms (about 10%) is adverse.

The discrepancies in concentrations at which changes were observed in these studies may be due to different endpoints, test systems, and technologies, however a specific reason for the discrepancies could not be identified by the applicant. Nonetheless the non-clinical studies/assays indicated a risk of QT prolongation, and it is clinically relevant, however the applicant considers it not to be a significant risk with appropriate precautions and use.

In study SNBL.289.02 the applicant presents tabulated data (from study 36074 PAP. However, TK data were generated in study SNBL.289.02 and are described in the study report (). The extrapolated Ceoi values derived in study SNBL.289.02 are approximately half that of the Cmax measured in the non-GLP study. These values, from study 36074 PAP, were used to derive safety margins for cardiovascular and respiratory safety pharmacology. However, the use of the values obtained in study 36074 generate a more conservative safety margin than the extrapolated values in study SNBL.289.02.

There were no adverse effects of lefamulin on nervous system function (as assessed by evaluation of Irwin parameters) and no adverse effects on respiratory function.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

In order to determine the pharmacokinetic profile of lefamulin several PPE, LC-MS/MS methods were developed and validated as appropriate for plasma from rats and monkeys. The methods were of sufficient sensitivity and specificity and considered adequate to support the performed toxicokinetics analysis with a lower limit of quantification (LLOQ) of 50 ng/ml in rat plasma and in cynomolgus monkey the LLOQ is 50 ng/ml (Method SNBL.289.05) or 1 ng/ml (Method A&amp;M 11-011).

Based on the data derived from the IV and oral routes of administration, a dose-proportional systemic exposure of lefamulin was demonstrated in all species tested. Following a single IV administration of lefamulin the plasma concentration time curve is described by a multi-phasic decline, with a rapid initial distribution phase followed by a terminal elimination phase with half-life values of 2.1-2.5 h in rats and 6.57.4 h in monkeys, extending to 8.6-11.8 h in humans.

Pharmacokinetics following repeat dose administration was measured as part of toxicokinetics.

No clear differences between male and female animals were seen in ADME studies. Moderate in-vitro plasma protein binding of 73-88% in humans and 61-81% in animals was observed.

Lefamulin displayed low binding affinity to the two major drug binding human plasma proteins (human serum albumin and alpha-1 acid glycoprotein). In-vitro antimicrobial activity is maintained in the presence of human or mouse serum. A quantitative whole-body autoradiography in rats after IV bolus administration showed a rapid distribution into tissues and organs consistent with the apparent low protein binding affinity observed in vitro . The levels of radioactivity measured in the majority of the tissues including skin, soft tissues and lungs were higher than the radioactivity measured in the circulating blood. Similar distribution was observed after oral dosing of  14 C-lefamulin. Tissue distribution in pregnant rats following IV administration showed limited transfer of radiolabelled lefamulin to the foetus, with no evidence of retention or accumulation in any foetal tissues. In lactating dams, excretion of lefamulin into maternal milk was shown, indicating an exposure to suckling pups.

The metabolite profile of lefamulin generated with primary human hepatocytes displayed mainly hydroxylated metabolites (phase I). With cynomolgus monkey, rabbit, rat and mouse hepatocytes, similar metabolite profiles were observed. In monkey, rabbit and mouse, a mono-hydroxy lefamulin glucuronide (phase II) was also observed. No unique human metabolites were identified.

The major human lefamulin metabolite, BC-8041 (2R-hydroxy-lefamulin), is present in rat and monkey, the species used in the pivotal toxicology studies. Based on the in vitro and in vivo metabolism studies, plasma levels of major human metabolite BC-8041 in animals has been evaluated and its safety profile further assessed in an in vitro IKr (hERG) assay, Ames and Mouse Lymphoma Assay genotoxicity tests, and embryofoetal development studies in rats. However, low levels of metabolite were detected in rat samples following a single administration of 37.5 mg/kg IV or 150 mg/kg oral dose of  14 C-lefamulin (study 1281-043 and study BC3-TX-01).

In line with ICH M3 (R2) the applicant conducted a comprehensive range of testing in order to fully characterise the parent and the major human metabolite BC-8041. It is acknowledged that relative to human exposure the exposure levels of this metabolite in rats and rabbits was low. However, the characterisation of the metabolite is considered adequate in the monkey (where it has been demonstrated that the animal was

<div style=\"page-break-after: always\"></div>

sufficiently exposed). Furthermore, studies conducted with a synthesised version of this specific metabolite in the rat should generally compensate for the sub-clinical exposure levels attained in this species - in line with published guidance. Considering the short duration of treatment, accepted metabolite characterisation in the NHP, and the specific studies with synthesised metabolite, the metabolite can be considered adequately characterised. Lefamulin is predominantly eliminated via the non-renal route. Recovery of radioactivity in faeces suggests excretion via the bile and/or the gut mucosa. The faecal route is the principal route of elimination for this compound, as confirmed by mass balance studies in rats and monkeys. CYP3A4 and 3A5 were identified as lefamulin metabolising enzymes using isolated recombinant CYP450 isoenzymes as well as human liver microsomes and chemical inhibitors. For enzyme induction studies, the applicant used 3-10 times the Cmax (5 µM) up to 50 µM. The guidance stipulates that 50-fold the mean unbound Cmax should be tested, which coincidentally is also ~50 µM. Treatment of cultured human hepatocytes with up to 15 μM lefamulin caused no toxicity whereas &gt; 50 µM caused concentration -dependent cytotoxicity.

No induction of CYP1A2, CYP2B6 and CYP3A4 was detected in human hepatocytes. Since lefamulin did not induce CYP3A4 it is also not expected to induce P-gp. However, lefamulin is both a P-gp substrate and an inhibitor. Since lefamulin saturated its own efflux in Caco-2 cells, it may have the potential to saturate P-gp mediated efflux in a clinical setting as well. Lefamulin is not a substrate of efflux transporters BCRP, BSEP, MATE1, MATE2-K, or uptake transporters OATP1B1 and OATP1B3, but is a substrate of the uptake transporter OCT1 and, as already mentioned above, the efflux transporter P-gp. Lefamulin as substrate was not evaluated for the transporters OCT2, OAT1 and OAT3 since lefamulin is eliminated renally to an extent below 25%. Inhibition potential was shown with BSEP, BCRP, OCT1 and MATE1 while very poor inhibition was seen with the hepatic uptake transporters OATP1B1 and OATP1B3. With regard to the renal uptake transporters, no inhibition potential was seen with OAT1, OAT3, OCT2 and MATE2-K.

The potential for drug-drug interactions, especially with CYP3A, should be accounted for in the SmPC.

## 2.3.3. Toxicology

## Single dose toxicity

Three single dose toxicity studies in rodents (mice and rats) were presented. Two were not conducted in compliance with GLP, and had shorter than ideal observation periods post dosing (7-day evaluation in first study, 1 day in second study). The third study, NAB011, was conducted in compliance with GLP and had 14 days of observation. Lefamulin was not well tolerated at higher doses with death and moribundity common occurrences. Much higher doses are tolerated by the oral route than by the IV route.

There are discrepancies in adverse events described in rat following single dose oral administration, including the MTD in two studies. In study Nabriva 2008-31 PKB, the MTD is 1500 mg/kg, while in NAB011 the MTD is 5 times lower at 300 mg/kg. In study NAB011, lefamulin was tested up to 900 mg/kg (n=10, 5/sex/group), compared to study Nabriva 2008-31 PKB where lefamulin was only tested at two concentrations 1500 mg/kg

<div style=\"page-break-after: always\"></div>

(n=2) and 2000 mg/kg (n=3). The differences in the studies can be accepted to explain the differences in MTD observed in the two studies.

Justification for carrying out study NABRIVA-2018-02 TOX was requested, as in 2010 the CHMP removed the guideline on single dose toxicity, based upon the reasoning that single dose studies are of limited value and that information on acute toxicity can be obtained in other types of toxicology studies, and removing the need for these studies is in line with the 3Rs principals (EMA/CHMP/SWP/81714/2010). This study was carried out in 2015, years after the previous single dose studies and around the time of the repeat dose toxicity study AB21052, which used the same vehicle, route of administration and similar doses. The applicant states that the study was carried out to comply with a request from the FDA to evaluate higher doses, and is viewed by the applicant as a dose range finding study carried out prior to the repeat dose study AB21052.

## Repeat dose toxicity

In repeat dose studies in both rats and monkeys, local intolerance was dose limiting by both oral and IV routes of administration. Diarrhoea and poor physical condition were noted in both rats and monkeys, which was accompanied by body weight loss, emesis in monkeys and in rats, marked distension of the small and large intestine (mostly affecting the caecum), including meteorism (bloating). The intestinal dilatation in rats is considered to be a rodent-specific effect in response to dosing with antibiotics. Dilatation is attributed to local antibacterial effects on the intestinal flora rather than a direct effect on the GI tract (Courtney, 2000).

With IV administration, tolerability was limited by local reactions at the administration site in both rats and monkeys. Animals were typically dosed twice daily with 12 hours between dose administrations. In studies of up to 13 weeks in duration, abscesses, thrombi and inflammatory changes were noted at the injection site and thrombosis and embolisms, with related inflammatory changes and necrosis, were observed in visceral organs. These effects were dose limiting, necessitated dose reductions/drug holidays, and were associated with morbidity, premature terminations, or mortality in both species. Some effects persisted 4 weeks after cessation of dosing.

In rats, local intolerance was not observed with a formulation containing 1.875 mg/mL lefamulin dissolved in 10 mM citrate-buffered saline when injected every 12 hours for 13 weeks. In a 13-week repeated dose toxicity study in monkeys, a formulation containing 6.67 mg/mL lefamulin dissolved in 10 mM citratebuffered saline was tolerated for approximately 6 weeks but thereafter a decline in clinical condition secondary to local intolerance was noted. For comparison, the clinical formulation contains approximately 0.6 mg/mL lefamulin in the same vehicle. Evidence of dose-dependent regenerative anaemia in both species indicated lefamulin was potentially haemolytic. This effect was not apparent from in-vitro evaluation of blood compatibility using human blood. The in-vitro test was performed at a lower concentration (0.6 mg/mL) than the concentrations in formulations used for animal studies.

No systemic target organ was identified in studies up to 13 weeks of administration. Dose limiting toxicities affected the exposure levels achieved. The highest systemic exposure without local signs of toxicity was achieved in a 28-day repeated dose toxicity study in cynomolgus monkeys. The steady-state exposure level at the NOAEL of 120 mg/kg/day was 79.7 µg·h/mL for AUC0-24 and 15.8 µg/mL for Cmax, 2.8 and 2.4 times the mean AUC of the clinical IV or oral dose, respectively. The IV therapeutic daily dose of lefamulin is 300

<div style=\"page-break-after: always\"></div>

mg (150 mg q12h). Arithmetic mean therapeutic exposure at steady-state in CAP patients for the 150 mg q12h IV dose was 28.4 µg·h/mL (AUC0-24) with a corresponding Cmax of 3.03 µg/mL. The oral daily dose is 1200 mg (600 mg q12h). Arithmetic mean therapeutic exposure at steady-state in CAP patients for the 600 mg q12h oral dose was 32.7 µg·h/mL (AUC0-24) with a corresponding Cmax of 2.24 µg/mL.

## Genotoxicity

Lefamulin did not exhibit genotoxic potential in a battery of standard genotoxicity assays. Cytotoxicity limited the concentrations that were used to evaluate the mutagenic potential of lefamulin in the Ames reverse mutation study. In an invivo micronucleus test in rats (≤100 mg/kg/day), there was no evidence of chromosomal damage with lefamulin (AUC0-8 ≤ 26.9 µg.h/mL). Exposure margins of 2.5 -5 can be calculated comparing exposure in rats to human lefamulin exposure. Overall, there are no data to suggest a potential for genotoxicity with lefamulin.

## Carcinogenicity

Carcinogenicity studies were not carried out by the applicant. In line with guidance, carcinogenicity studies are not required if expected clinical use is for a short duration. Lefamulin did not produce effects indicative of genotoxic potential either in vitro or in vivo , or in toxicology studies of up to 13 weeks in duration.

## Reproductive and developmental toxicity

Fertility, embryo-foetal development, pre- and post-natal development and juvenile toxicity studies were conducted in rats, and embryo-foetal development has been assessed in rabbits. In addition, the effects on rat embryo-foetal development of the metabolite BC-8041 have been assessed.

Effects on embryo-foetal development were evaluated in rats and rabbits. Overall, a reduced live pup birth index in rats indicated an effect of lefamulin on embryo-foetal survival at high doses (AUC0-24 = 24.4 μg·h/mL at 100 mg/kg/day). In the rat EFD study, there were 1 (1), 2 (2) and 2 (2) malformed foetuses (litters) in the control, 2 x 37.5 and 2 x 50 mg/kg/day groups, respectively. However, it was concluded that due to the lack of any increase in other less severe skeletal anomalies or variations affecting the mandible, palate or vertebrae, in the treated groups compared with the control, and the fact that these abnormalities were spontaneous in origin, they were not considered treatment-related. However, there was clearly an increased incidence in malformations versus the historical control groups. Increased incidence of retarded ossification in all treatment groups versus controls is also reported in the rat EFD study. Furthermore, in the rabbit EFD study the suspected adverse effects of cannulation may have compromised the validity of the study (high incidence of control group mortality), and there was increased incidence of maternal toxicity and subsequent EFD effects that could be species-specific; but a relationship to treatment remains equivocal. Taken together the association of adverse EFD with treatment remains equivocal.

The applicant has provided a comprehensive review of the EFD findings in relation to historical controls and updated the SPC accordingly. The non-clinical expert discussed the historical control data sets and the incidence levels. Incidences of malformed foetuses was concluded to be 0.3% (4/1232), and the nature of

<div style=\"page-break-after: always\"></div>

the malformations in one high-dose animal may be a procedural artefact. Moreover, the rate and nature of the incidences in line with historical control data sets. Further, the applicant explains that no dose-response can be assigned to the malformations reported. In summary, it is concluded that the weight-of-evidence suggests that reported EFD malformations were spontaneous in origin and any association with treatment could be considered unlikely. Consequently, the applicant proposes an update to the SPC, which is accepted, as it provides further clarity into the nature of the findings from the developmental toxicology programme. Further reassurance is given by the updated wording in section 4.6 of the SPC: Xenleta is not recommended during pregnancy , and the pregnancy pharmacovigilance programme.

In a prenatal and postnatal study in rats, (AB21312), the pup live birth index was markedly lower at the highest dose tested only (100 mg/kg/day), (with 33 stillborn/dead pups on PND 0 compared with 4 in the control), associated with partial or total litter death of 4/25 litters. At a dose of 100 mg/kg/day, the live birth index was 87.4 % in high-dose groups v 98.7 % in the control. It is assumed that the exposure levels were less than that reported in the clinic at the proposed NOAEL of 75 mg/kg/day. The applicant was asked to discuss and a NOAEL of 75 mg/kg/day was agreed, however the mechanism behind the increased incidence of stillbirths in animals is unknown.

The applicant proposes to update section 4.6 of the SPC to specifically reflect the findings from the Pre- and Post-natal; development study (AB21312). The text proposed is now a more accurate reflection of the data. Unknown mechanisms relating to increase in still births in animals cannot ruled out clinically, therefore the following wording is accepted:

There are no data from the use of lefamulin in pregnant women. Studies in animals have shown increased incidence of stillbirth (see section 5.3). Animal studies are insufficient with respect to embryo-foetal development (see section 5.3).

Xenleta is not recommended during pregnancy and in women of childbearing potential not using contraception.

## Juvenile toxicity

In the juvenile toxicity studies adverse effects can be attributed to exacerbated pharmacological effects. There were no adverse effects on juvenile rat growth, development or maturation of the organ systems evaluated, including CNS assessments and reproductive function.

Following IV administration there were local tolerance effects at all doses. There was clear evidence of a dose response. In rats, these inflammatory changes occurred primarily in mid- and high-dose groups in which lefamulin was infused at concentrations of 1.67 and 2.5 mg/mL (the concentration for the low dose group was 0.83 mg/mL). As with rats, the findings in monkeys suggest lefamulin-associated exacerbation of injuries caused by the presence of the indwelling catheter. In EFD studies the placement of the catheter caused mortality in rabbits.

<div style=\"page-break-after: always\"></div>

## Other toxicity studies

Local intolerance was not observed with a formulation containing 1.875 mg/mL lefamulin in 10mM citrate- buffered saline. In vitro haemolysis did not occur when lefamulin was tested at 0.6 mg/mL (the proposed clinical administration dose). Haemolysis was noted in toxicology studies, when lefamulin was dosed at concentrations greater the 0.6 mg/mL. In single dose studies in rats lefamulin at 15 mg/mL, red coloured urine was observed in surviving animals, suggesting the occurrence of item-related haemolysis. In repeat dose toxicity studies, haemolysis was also induced by test item concentrations 2.5 to 7.5 mg/mL in the administered solutions at the infusion site. Specifically, in the 91-day monkey study (SNBL.289.19), haemolysis was accompanied by evidence of a reactive response in the bone marrow resulting in the release of larger, immature erythrocytes. The clinical significance of this finding is not adequately discussed, and a clinical safety margin was not established. In the absence of a human safety margin for this finding, the applicant was asked to discuss the potential risk to humans and potential mechanism of action, and to discuss if concentrations greater than 0.6 mg/mL were tested for the occurrence of haemolysis. 2019), where they tested concentrations greater than 0.6 mg/ml and up to 8 mg/ml. Overall, lefamulin was

In response to the request, the applicant provided a study report, Nabriva 2019-15 MIB (dated December compatible with human red blood cells up to concentration of 2 mg/mL.

Lefamulin does not absorb UVA, UVB or visible (290-700 nm) light and has a molar extinction coefficient &lt; 30 Lmol -1 cm -1 . Therefore, phototoxicity studies were not performed. ICH S10 states that a molar extinction coefficient &lt;1000 Lmol -1 cm -1  is not considered to be sufficiently photoreactive to result in direct phototoxicity, therefore, the lack of further phototoxicity studies is acceptable.

## Metabolites

Analysis of metabolites following oral dosing in human showed one mono-hydroxylated metabolite (BC-8041) with exposure greater than 10% of parent drug systemic exposure level at steady-state. In monkeys dosed orally for 28 days, BC-8041 represented approximately 22% of lefamulin exposure at the NOAEL of 70 mg/kg/day (i.e. AUC0-12 = 0.924 μg·h/mL BC -8041). When dosed twice-daily IV for 28 days, BC-8041 levels were 7.9% of lefamulin exposure at the NOAEL of 120 mg/kg/day (i.e. AUC0-12 = 3.13 μg·h/mL). In addition to characterising levels of BC-8041 present in animals dosed with lefamulin, standalone studies were conducted to further assess the non-clinical safety profile of BC-8041.

BC-8041 did not demonstrate a potential for QT/QTc interval prolongation (hERG IC50 of 7 02.18 μM) and exhibited no teratogenicity in a rat embryo-foetal development toxicity study. In this latter study the daily doses of 2 x 20 mg/kg (40 mg/kg/day) exceeded BC-8041 mean steady state maximum exposures in human by more than 2-fold after oral administration of therapeutic doses of lefamulin.

## Impurities

According to ICH Q3A, the qualification threshold for impurities in a drug substance is 0.15% or 1 mg/day, whichever is lower. For the 1200 mg/day oral dose, 0.15% is 1.8 mg, therefore the lower value of 1 mg/day

<div style=\"page-break-after: always\"></div>

(0.08%) should be applicable. However, the guideline does make provisions for the use of higher thresholds taking into account the use and exposure of the drug substance/product. Considering the duration of treatment of lefamulin acetate an identification and qualification threshold of 0.15% can be accepted (See Quality AR). The applicant suggests that known impurities BC-3846 and BC-3826, which have been qualified in toxicity studies with the non-GMP batches (study C06271 and study SNBL.289.03), were set to the lowest level present in either batch. This resulted in a proposed specification of ≤ 0.20 % for BC -3846 and ≤ 0.30 % for BC-3826. However, study C06271 could not establish a NOAEL due to adverse test item related findings, and is therefore not accepted in support of impurity qualification. Study SNBL.289.03, a 14-day study in cynomolgus monkeys, established a NOAEL of 80 mg/kg/day. Batch data for the non-clinical batch (study SNBL.289.03) have not been provided in support of the proposed limits of impurities. Batch analysis data was therefore requested from the applicant in support of the proposed limits.

Batch data was provided by the applicant from the 14-day study in rats (C06271) and from the 14-day study in monkeys (SNBL.289.03).

In the rat study (study no. C06271) the derived TDI (60 kg subject) of 1.5 mg and 2.9 mg for BC-3846 and BC-3826, respectively, exceeds the calculated maximum TDI for IV administration (0.6 mg and 0.9 mg, respectively), but is slightly below the calculated maximum TDI for oral administration (2.4 mg and 3.6 mg, respectively). This study could not establish a NOAEL. The batch used in this study was also used in genotoxicity studies, and was nongenotoxic.

The monkey study (SNBL.289.03) established a NOAEL of 80 mg/kg/day, with impurity levels for BC-3846 of 0.65%, and BC-3826 of 0.30%. Calculating the derived TDI (60 kg subject) of 10.1 mg and 4.6 mg for BC3846 and BC-3826, respectively, exceeds the calculated maximum TDI for both IV administration (0.6 mg and 0.9 mg, respectively) and oral administration (2.4 mg and 3.6 mg, respectively).

Based on this study the impurities can be considered qualified, at the proposed limits.

## 2.3.4. Ecotoxicity/environmental risk assessment

The applicant provided an Environmental Risk Assessment (ERA) in accordance with the respective EMA guidance (EMEA/CHMP/SWP/4447/00, corr. 2).

Table 1. Summary of main study results

| Substance (INN/Invented Name): lefamulin   | Substance (INN/Invented Name): lefamulin   | Substance (INN/Invented Name): lefamulin   | Substance (INN/Invented Name): lefamulin   |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| CAS-number (if available):                 | CAS-number (if available):                 | CAS-number (if available):                 | CAS-number (if available):                 |
| PBT screening                              |                                            | Result                                     | Conclusion                                 |
| Bioaccumulation potential- log K ow        | OECD107                                    | pH 5 = -0.4 pH 7 = 0.06                    | Potential PBT (N)                          |
|                                            |                                            | pH 9 = 1.9                                 |                                            |

<div style=\"page-break-after: always\"></div>

| PBT-assessment                                                      | PBT-assessment                                 | PBT-assessment                                 | PBT-assessment                                 |
|---------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Parameter                                                           | Result relevant for conclusion                 |                                                | Conclusion                                     |
| Bioaccumulation                                                     | log K ow                                       | < 4.5                                          | not B                                          |
| Bioaccumulation                                                     | BCF                                            |                                                |                                                |
| Persistence                                                         | DT50 or ready biodegradability                 |                                                |                                                |
| Toxicity                                                            | NOEC or CMR                                    |                                                |                                                |
| PBT-statement :                                                     | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB |
| Phase I                                                             | Phase I                                        | Phase I                                        | Phase I                                        |
| Calculation                                                         | Value                                          | Unit                                           | Conclusion                                     |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.112                                          | µ g/L                                          | > 0.01 threshold (Y)                           |
| Other concerns (e.g. chemical class)                                |                                                |                                                | (N)                                            |

Lefamulin is not a PBT substance, the shake flask method at pH 5, pH 7 and pH 9 was applied for the determination of the partition coefficient (Pow) of BC-3781.Ac (lefamulin acetate).

- pH 5: The mean Pow value of the test item was 3.7 x 10 -1 . It corresponds to a mean log Pow value of -0.4.
- pH 7: The mean Pow value of the test item was 1.1 x 10 0 . It corresponds to a mean log Pow value of 0.06.
- pH 9: The mean Pow value of the test item was 8.5 x 10 1 . It corresponds to a mean log Pow value of 1.9.

However, the PECsw is greater than 0.01 µg/L and the applicant has initiated a Phase II analysis. The final report is expected to be complete in September 2020.

In calculating the PECsw the applicant refined the Fpen using prevalence data and treatment regime. According to the Q&amp;A document by the European Medicines Agency (EMA) (EMA/CHMP/SWP/44609/2010) a Fpen-refinement is only acceptable if it is based on published prevalence data and/or treatment regime. The applicant provided the underlying sources of the prevalence data used in the PEC refinement.

At present, only phase I data is available for assessment. Until the results of the Phase II assessment are complete, the available data do not allow to conclude definitively on the potential risk of lefamulin to the environment. The applicant commits to complete Phase II of the Environmental Risk Assessment and provide the updated ERA including all study reports.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Discussion on non-clinical aspects

## Pharmacology

The non-clinical pharmacological aspects of lefamulin were assessed in the Clinical AR. The spectrum of antibacterial activity of lefamulin supports selection of CAP as a target indication.

No non-clinical secondary pharmacodynamics studies were submitted. The applicant states that secondary pharmacodynamics is not applicable to lefamulin because no pharmacological effects other than the primary therapeutic activity (antimicrobial) are known. However, it is clear from the safety pharmacology studies and toxicology studies described that lefamulin does have pharmacological effects beyond those of inhibiting bacterial protein synthesis. However, the carrying out of a secondary screen may not give any additional information at this point, as toxicities are known due to in vivo work, and there is adequate clinical experience (n=1242) where safety findings of interest mirror findings in the non-clinical toxicology studies, namely administration site reactions, GI events and QT/QTc prolongation. Effects on eukaryotic ribosomal translation were described in the clinical module, mammalian and mitochondrial protein synthesis are unaffected by lefamulin. The safety pharmacology studies in rats, rabbits and monkeys showed potential for QT/QTc prolongation, which correlate to a clinical risk, which according to the applicant is not a clinically significant risk with appropriate precautions and use. The CHMP considered that the provided non-clinical pharmacology package is supportive of the MAA.

## Pharmacokinetics

The pharmacokinetics package is acceptable. Based on the data derived from the IV and oral route of administration a dose-proportional systemic exposure of lefamulin was demonstrated in all species tested. Lefamulin displayed low binding affinity to the two major drug binding human plasma proteins (human serum albumin and alpha-1 acid glycoprotein) and in-vitro antimicrobial activity is maintained in the presence of human or mouse serum. No unique human metabolites were identified. The major human lefamulin metabolite, BC-8041 (2R-hydroxy-lefamulin), is present in rat and monkey, the species used in the pivotal toxicology studies. The faecal route is the principal route of elimination confirmed by mass balance studies in rats and monkeys. Lefamulin was identified as a substrate of CYP3A4, CYP3A5, P-gp and OCT1. CYP3A4 and 3A5 were identified as lefamulin metabolising enzymes. The potential for drug-drug interactions is accounted for in the SmPC.

## Toxicology

The safety studies are in line with ICH M3(R2) guidance. In repeat dose studies in both rats and monkeys, local intolerance was dose limiting by both oral and IV routes of administration. Following oral administration, diarrhoea and poor physical condition were noted in both rats and monkeys which was accompanied by body weight loss, emesis in monkeys, and in rats, marked distension of the small and large intestine. With IV administration, tolerability was limited by local reactions at the administration site in both rats and monkeys. No systemic target organ was identified in studies up to 13 weeks of administration. Dose limiting toxicities affected the exposure levels achieved. The highest systemic exposure without local signs of toxicity was

<div style=\"page-break-after: always\"></div>

achieved in a 28-day repeated dose toxicity study in cynomolgus monkeys, where 2.8 and 2.4 times the mean AUC of the clinical IV or oral dose was achieved, respectively.

Lefamulin is not genotoxic. No carcinogenicity studies have been carried out, as the expected clinical use is of short duration.

Effects on embryo-foetal development were evaluated in rats and rabbits. Overall, a reduced live pup birth index in rats indicated an effect of lefamulin on embryo-foetal survival at high doses (AUC0-24 = 24.4 μg·h/mL at 100 mg/kg/day). Foetal skeletal malformations were noted in the rat embryo-foetal development study in both control and treated animals. Unknown mechanisms relating to the increase in still births in animals cannot ruled out clinically, and this is reflected in Sections 4.6 and 5.3 of the SmPC. In juvenile animals lefamulin had no adverse effects on the juvenile rats' growth, development, and the maturation of the organ systems evaluated, including CNS assessments and reproductive function. The CHMP considered that the provided non-clinical toxicology package is supportive of the MAA.

## 2.3.6. Conclusion on the non-clinical aspects

The CHMP considered the non-clinical pharmacology, pharmacokinetics and toxicology programmes to be sufficient to support the MAA for lefamulin.

Until the results of the Phase II assessment are complete, no final conclusions on the environmental risk assessment is currently possible and the CHMP considers the following measure to be necessary to address the non-clinical issues:

The applicant commits to complete Phase II of the Environmental Risk Assessment and provide the updated ERA including all study reports.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Three sites in study 3102 (one in each of Peru, Hungary and Poland) were closed to enrolment early by the applicant following internal audits that identified some GCP compliance issues.

The Rapporteur was notified in early September of two inspections of the individual sites in Hungary and Poland that were conducted by the National Regulatory Authorities. The findings of these inspections are not considered likely to impact on the overall validity of the data.

Furthermore, the Rapporteur was notified in early September that the Austrian NRA had conducted an inspection of Nabriva and that the conclusions were satisfactory.

<div style=\"page-break-after: always\"></div>

- Tabular overview of clinical studies

Table 2. Overview of Clinical Studies that Characterized the Pharmacokinetics and Pharmacodynamics of lefamulin

| Study Number, Type of Study                                                                | Study Design                                                                                                     | Study Objective(s)                                                                                                                | Dosage Regimen Route of administration Treatment Duration                                                                                                                   |
|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Single-dose Studies Using IV and/or PO Formulations                                        | Single-dose Studies Using IV and/or PO Formulations                                                              | Single-dose Studies Using IV and/or PO Formulations                                                                               | Single-dose Studies Using IV and/or PO Formulations                                                                                                                         |
| Study 1001 Single ascending dose study in healthy subjects                                 | Phase 1, randomized, double blind, placebo-controll ed, SAD, 4-period crossover                                  | Safety and tolerability, plasma and urine PK                                                                                      | Single IV dose of lefamulin or placebo: Cohort 1 25 mg, 50 mg, 100 mg, or placebo Cohort 2 200 mg, 300 mg, 400 mg, or placebo                                               |
| Study 1003 Age/gender effect in healthy adult subjects                                     | Phase 1, randomized, double-blind, placebo- controlled, 2 period crossover                                       | Safety and tolerability, PK                                                                                                       | Single IV dose of 150 mg (0.75 mg/mL) lefamulin or placebo (over 1 h)                                                                                                       |
| Study 1101 Food-effect study in healthy subjects                                           | Phase 1, randomized, double blind, placebo-controll ed, SAD, 4- period crossover + an open-label food effect arm | Safety and tolerability, plasma and urine PK, effect of food on safety, tolerability, and PK                                      | 4-Period Crossover Single PO dose of lefamulin or placebo (fasted state): 100 mg, 200 mg, 400 mg, or placebo Food Effect Arm Single PO dose of 400 mg lefamulin (fed state) |
| Study 1013 Absorption, Distribution , Metabolism , and Excretion study in healthy subjects | Phase 1, non- randomized, open-label                                                                             | Mass balance recovery, metabolite profiling and structural identification, elimination, PK, distribution, safety and tolerability | Regimen A Single IV dose of 150 mg 14 C lefamulin over 60 min (fed state) Regimen B Single PO dose of 600 mg 14 C lefamulin (fasted state)                                  |

<div style=\"page-break-after: always\"></div>

| Study Number, Type of Study                                                                       | Study Design                                                                                      | Study Objective(s)                                                                                | Dosage Regimen Route of administration Treatment Duration                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Multiple-dose Studies Using IV and/or PO Formulations                                             | Multiple-dose Studies Using IV and/or PO Formulations                                             | Multiple-dose Studies Using IV and/or PO Formulations                                             | Multiple-dose Studies Using IV and/or PO Formulations                                                                                                                                                      |
| Study 1002 Single and multiple ascending dose study in healthy subjects                           | Phase 1, randomized, double-blind, placebo- controlled                                            | Safety and tolerability, plasma and urine PK                                                      | Single and / or repeat (q12h) IV doses of lefamulin or placebo: Cohort 1 (75 mg or placebo) Cohort 2 (150 mg or placebo) Cohort 3 (150 mg or placebo)                                                      |
| Study 1102 Food-effect study in healthy subjects                                                  | Phase 1, randomized, double-blind, placebo-controll ed, MAD                                       | Safety and tolerability, plasma and urine PK                                                      | Single and/or repeat (q12h) PO doses of lefamulin or placebo in 3 cohorts: Cohort 1 (200 mg or placebo) Cohort 2 (400 mg or placebo) Cohort 3 (600 mg or placebo)                                          |
| Penetration of Lefamulin in Blood, Soft Tissues, Muscle Tissue, and Epithelial Lining Fluid Study | Penetration of Lefamulin in Blood, Soft Tissues, Muscle Tissue, and Epithelial Lining Fluid Study | Penetration of Lefamulin in Blood, Soft Tissues, Muscle Tissue, and Epithelial Lining Fluid Study | Penetration of Lefamulin in Blood, Soft Tissues, Muscle Tissue, and Epithelial Lining Fluid Study                                                                                                          |
| Study 1005 Tissue distribution in healthy subjects                                                | Phase 1, open- label                                                                              | Distribution, safety, and tolerability                                                            | Single IV dose of 150 mg over 1 h                                                                                                                                                                          |
| Hepatic Impairment or Renal Impairment Studies                                                    | Hepatic Impairment or Renal Impairment Studies                                                    | Hepatic Impairment or Renal Impairment Studies                                                    | Hepatic Impairment or Renal Impairment Studies                                                                                                                                                             |
| Study 1010 PK in subjects with hepatic impairment                                                 | Phase 1, multicenter, open-label                                                                  | Safety and tolerability, PK                                                                       | Single IV dose of 150 mg lefamulin over 1 h                                                                                                                                                                |
| Study 1011 PK in subjects with renal impairment                                                   | Phase 1, multicenter, open-label                                                                  | Safety and tolerability, PK                                                                       | Single IV dose of 150 mg lefamulin over 1 h a                                                                                                                                                              |
| Potential Drug-Drug Interaction Studies                                                           | Potential Drug-Drug Interaction Studies                                                           | Potential Drug-Drug Interaction Studies                                                           | Potential Drug-Drug Interaction Studies                                                                                                                                                                    |
| Study 1004 DDI with midazolam                                                                     | Phase 1, randomized, open-label, 2- period crossover, DDI study                                   | PK (DDI), safety and tolerability                                                                 | Two study periods separated by 2-7 days (fasted state): Single IV dose of 150 mg lefamulin over 2 h + a single PO dose of 2 mg midazolam 1 h after the start of lefamulin Single PO dose of 2 mg midazolam |

<div style=\"page-break-after: always\"></div>

| Study Number, Type of Study       | Study Design                                                                                                 | Study Objective(s)                | Dosage Regimen Route of administration Treatment Duration                                                                                                                                                                                                                                                                                               |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 1006 DDI with ketoconazol e | Phase 1 DDI study Days 1-2 Randomized, double blind, placebo- controlled, crossover Days 4-7 Open-label      | PK (DDI), safety and tolerability | Days 1-2: Single IV dose of 150 mg lefamulin and placebo (over 1 h); or placebo (over 1 h) and single IV dose of 150 mg lefamulin Days 4-7: 200 mg ketoconazole PO q12h Day 7: Single IV dose of 150 mg lefamulin (over 1 h) starting 1 h after the morning dose of ketoconazole                                                                        |
| Study 1103 DDI with ketoconazol e | Phase 1, open- label, DDI study                                                                              | PK (DDI), safety and tolerability | Day 1: Single PO dose of 400 mg lefamulin Days 3-6: 200 mg ketoconazole PO q12h Day 6: Single PO dose of 400 mg lefamulin with the morning dose of ketoconazole                                                                                                                                                                                         |
| Study 1108 DDI with rifampin      | Phase 1, open- label, 2-part, fixed-sequence, DDI study Note: each subject participated in only 1 study part | PK (DDI), safety and tolerability | Part 1 Treatment A: Single PO dose of 600 mg lefamulin Treatment B: Multiple PO doses of 600 mg rifampin administered QD with a single PO dose of 600 mg lefamulin Part 2 Treatment C: Single IV dose of 150 mg lefamulin over 1 h Treatment D: Multiple PO doses of 600 mg rifampin administered QD with a single IV dose of 150 mg lefamulin over 1 h |
| Study 1109 DDI with digoxin       | Phase 1, open- label, multiple- dose, DDI study                                                              | PK (DDI), safety and tolerability | Treatment A Single PO dose of 0.5 mg digoxin Treatment B Multiple PO doses of 600 mg lefamulin q12h with a single PO dose of 0.5 mg digoxin                                                                                                                                                                                                             |
| Study 1110 DDI with midazolam     | Phase 1, open- label, fixed- sequence, DDI study                                                             | PK (DDI), safety and tolerability | Treatment A Single PO dose of 2 mg midazolam Treatment B Multiple PO doses of 600 mg lefamulin q12h, with a single PO dose of 2 mg midazolam                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Study Number, Type of Study   | Study Design                                                                                                          | Study Objective(s)                                                                                                | Dosage Regimen Route of administration Treatment Duration                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 1111 DDI with midazolam | Phase 1, open- label, randomized, 3- sequence, 4- period, crossover, DDI study Treatment sequences: ABCD, ACDB, ADBC. | PK (DDI), safety and tolerability                                                                                 | Treatment A Single PO dose of 2 mg midazolam Treatment B Multiple PO doses of 600 mg lefamulin q12h with a single PO dose of 2 mg midazolam co-administered with lefamulin Treatment C Multiple PO doses of 600 mg lefamulin q12h with a single PO dose of 2 mg midazolam administered 2 h after lefamulin Treatment D Multiple PO doses of 600 mg lefamulin q12h with a single PO dose of 2 mg midazolam administered 4 h after lefamulin |
| Biopharmaceutic Studies       | Biopharmaceutic Studies                                                                                               | Biopharmaceutic Studies                                                                                           | Biopharmaceutic Studies                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Study BC3- PK-01              | Phase 1, partially randomized, open-label, 5- period crossover                                                        | Bioavailability and variability, safety and tolerability                                                          | Single PO dose of lefamulin in 5 study periods separated by at least 7 days (fasted state): A: 400 mg (2×200 mg IR capsules) B: 400 mg Enterion capsule delivered to DSB C: 400 mg Enterion capsule delivered to colon D: 400 mg lipid formulation E: 400 mg lipid formulation Enterion capsule delivered to PSB                                                                                                                           |
| Study BC3- PK-02              | Phase 1, non- randomized, open-label                                                                                  | Relative bioavailability and PK variability, safety and tolerability, assess the effect of food (not implemented) | Single PO dose of 600 mg lefamulin in 4 study periods separated by at least 7 days (fasted state): A: IR tablet B: MR tablet prototype 1 (fast release) C: MR tablet prototype 2 (mid release) D: MR tablet prototype 3 (slow release)                                                                                                                                                                                                     |
| Study 1007                    | Phase 1, randomized, double-blind, placebo- controlled                                                                | Safety and tolerability (in particular, local tolerability), PK                                                   | Part A Single IV dose of 400 mg lefamulin or placebo in 3 study periods separated by at least 5 days Part B Repeat IV doses of 150 mg (Cohort 1) or 200 mg (Cohort 2) lefamulin or placebo in 2 cohorts of 12 subjects each                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Study Number, Type of Study   | Study Design                                                                                                                   | Study Objective(s)                                                         | Dosage Regimen Route of administration Treatment Duration                                                                                                                                                                     |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 1009                    | Phase 1, randomized, double-blind, placebo- controlled, parallel group                                                         | Safety and tolerability (in particular, local tolerability), PK            | Repeat IV doses of 150 mg lefamulin or placebo                                                                                                                                                                                |
| Study 1104                    | Phase 1 Part A Randomized, double blind, placebo- controlled, ascending-dose Part B Open-label                                 | PK, safety and tolerability                                                | Part A (fasted state) Single PO dose of 500 mg lefamulin (2 tablets), 750 mg lefamulin (3 tablets), or placebo in 3 study periods separated by at least 5 days Part B (fed state) Single PO dose of 500 mg lefamulin          |
| Study 1105                    | Phase 1 Part A Randomized, open-label, 2 period crossover Part B Randomized, double blind, placebo- controlled, parallel-group | PK, safety and tolerability                                                | Part A Single PO dose of 600 mg lefamulin in 2 study periods separated by at least 4 days (1 fasted state, 1 fed state) Part B Repeat PO doses of 600 mg lefamulin or placebo q12h for 6 days with a single dose on Day 7     |
| Study 1106                    | Phase 1, randomized, open-label, 3- period crossover                                                                           | PK, safety and tolerability                                                | Single PO dose of 600 mg lefamulin in 3 study periods separated by at least 4 days (1 fasted state, 1 fasted state with breakfast 1 h after dosing, 1 fed state with breakfast 1 h before dosing)                             |
| Study 1107                    | Phase 1, randomized, open-label, 4- period crossover                                                                           | Absolute and relative oral bioavailability and PK, safety and tolerability | Single dose of lefamulin in 4 study periods separated by at least 4 days: 600 mg IR tablet PO (fasted state) 600 mg (3×200 mg capsules) PO (fasted state) 150 mg (0.6 mg/mL) administered IV; 600 mg IR tablet PO (fed state) |

<div style=\"page-break-after: always\"></div>

| Study Number, Type of Study   | Study Design                                                                                     | Study Objective(s)                                                                                                | Dosage Regimen Route of administration Treatment Duration                                           |
|-------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Phase 3 CABP Studies          | Phase 3 CABP Studies                                                                             | Phase 3 CABP Studies                                                                                              | Phase 3 CABP Studies                                                                                |
| Study 3101                    | Phase 3, multicenter, randomized, double-blind, double-dummy, active- controlled, parallel group | Non-inferiority, clinical response, microbiological response, safety and tolerability, 28-day all-cause mortality | Lefamulin 150 mg IV q12h for 5 to 10 days Moxifloxacin 400 mg IV q24h for 7 to 10 days              |
| Study 3102                    | Phase 3, multicenter, randomized, double-blind, double-dummy, active- controlled, parallel group | Non-inferiority, clinical response, microbiological response, safety and tolerability, 28-day all-cause mortality | Lefamulin 600 mg PO q12h for 5 days Moxifloxacin 400 mg PO q24h for 7 days                          |
| Phase 2 ABSSSI Study          | Phase 2 ABSSSI Study                                                                             | Phase 2 ABSSSI Study                                                                                              | Phase 2 ABSSSI Study                                                                                |
| Study 2001                    | Phase 2, multicenter, randomized, double-blind, active- controlled, parallel group               | Clinical response, microbiological response, safety and tolerability, PK, time course of clinical improvement     | Lefamulin 100 mg IV q12h or 150 mg IV q12h for 5 to 14 days Vancomycin 1 g IV q12h for 5 to 14 days |

ABSSSI=acute bacterial skin and skin structure infection; CABP=community-acquired bacterial pneumonia; DDI=drug-drug interaction; DSB=distal small bowel; IR=immediate-release; IV=intravenous; MAD=multiple ascending dose; MR=modified-release; PD=pharmacodynamic(s); PK=pharmacokinetic(s); PO=by mouth (oral); PSB=proximal small bowel; QD=once daily; q12h=every 12 hours; q24h=every 24 hours; SAD=single ascending dose

a   Subjects requiring hemodialysis received a single IV dose of 150 mg lefamulin in each of 2 treatment periods (1 while on dialysis and 1 off dialysis). Doses were separated by at least 7 days.

## 2.4.2. Pharmacokinetics

Lefamulin (as acetate) for intravenous use is presented in vials containing 10 mg/ml, equivalent to 150 mg of lefamulin in 15 ml of normal saline. The content of each vial is diluted to a final concentration of 0.6 mg/ml using 250 ml of 10mM citrate buffered normal saline. Lefamulin (as acetate) for oral use is presented as immediate release (IR) coated tablets containing 600 mg lefamulin free base. The only differences between Phase 3 and commercial tablets is in their appearance.

## Absorption

## Intravenous formulation studies

Study 1001 was the FIH study for lefamulin in which fasted male subjects received single IV doses from 25 mg to 400 mg in 200 mL normal saline or placebo. The 25 mg and 50 mg doses were infused over 30 min

<div style=\"page-break-after: always\"></div>

and the higher doses over 60 min. The 300 and 400 mg doses were associated with local intolerance. AUC0-∞ increased dose-proportionally over the 25 to 400 mg range.

In study 1002 male subjects received 75 mg BID or 150 mg BID using 1h or 2h infusions. There was a 1.4fold increase in AUC0-12 after repeat vs. single dosing irrespective of the dose or duration of the infusion while mean Cmax demonstrated a 1.14- to 1.15-fold increase after repeat dosing. Based on plasma trough levels, steady state was achieved after ~2 days.

Table 3. Summary of the main PK parameters after single and repeat dosing of 1-h infusions of BC-3781 75 and 150 mg and a 2-h infusion of BC-3781 150 mg

|                            | Treatment group - BC-3781 (mg)   | Treatment group - BC-3781 (mg)   | Treatment group - BC-3781 (mg)   | Treatment group - BC-3781 (mg)   | Treatment group - BC-3781 (mg)   | Treatment group - BC-3781 (mg)                                                     |
|----------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|------------------------------------------------------------------------------------|
|                            | Single dose                      | Single dose                      | Single dose                      | Repeat dose                      | Repeat dose                      | Repeat dose                                                                        |
| Parameter                  | 75 1-h infusion                  | 150 1-h infusion                 | 150 2-h infusion                 | 75 1-h infusion                  | 150 1-h infusion                 | 150 2-h infusion                                                                   |
|                            | n=8                              | n=8                              | n=8                              | 8=u                              | n=8                              | 8=u                                                                                |
| AUC0-12, AUCo- * [ng:h/ml] | 3206.4 (517.9)                   | 5752.0 (1260.8)                  | 5340.7 (889.2)                   | 4553.8 (680.3)                   | 8247.0 (1995.0)                  | 7565.7 (2134.8)                                                                    |
| AUCo-inf [ng-h/ml]         | 3910.5 (592.9)                   | 7279.2 (1620.5)                  | 6137.7 (1163.0)                  | 6473.0 (933.3)                   | 12776.8 (3229.2)                 | 10775.2 (3681.7)                                                                   |
| Cmax [ng/ml]               | 1561.9 (217.3)                   | 2418.8 (516.1)                   | 1763.8 (253.2)                   | 1792.5 (214.3)                   | 2769.4 (516.4)                   | 2026.9 (375.6)                                                                     |
| [max [h]                   | 1.0                              | 1.0                              | 2.0                              | 1.0                              | 1.0                              | 2.0 [0.917-1.017][0.500-1.000][2.000-2.000][1.000-1.017][0.500-1.000][1.500-2.017] |
| ty[h]                      | 10.609 (1.644)                   | 10.632 (0.738)                   | 4.456 (0.400)                    | 13.548 (1.807)                   | 14.639 (1.115)                   | 9.758 (1.159)                                                                      |
| C1 [ml/min]                | 326.26 (50.21)                   | 360.52 (90.00)                   | 419.41 (73.37)                   | 279.56 (38.96)                   | 321.78 (90.46)                   | 349.95 (81.51)                                                                     |
| Vss [1]                    | 128.63 (30.29)                   | 159.53 (43.49)                   | 116.48 (17.12)                   | 136.20 (29.12)                   | 190.35 (52.19)                   | 166.07 (35.26)                                                                     |
| VD[1]                      | 304.11 (90.36)                   | 332.51 (89.79)                   | 160.26 (22.51)                   | 231.48 (49.99)                   | 263.75 (76.23)                   | 210.42 (55.53)                                                                     |
| Cum Ae [μg]                | 6.065 (0.864)                    | 14.763 (7.654)                   | 23.011 (8.017)                   | 7.329 (2.244)                    | 23.055 (3.452)                   | 16.237 (6.505)                                                                     |
| Cum % dose [%]             | 8.086 (1.152)                    |                                  | 9.842 (5.103)7.670 (2.672)       | n.c.                             | n.c.                             | n.c.                                                                               |
| ClR [ml/min]               | 26.92 (6.15)                     | 37.25 (23.38)                    | n.c.                             | 20.42 (7.70)                     |                                  | 34.07 (10.53)32.36 (15.58)                                                         |

* AUCo-12 for single dose, AUCo-t for repeat dose

<div style=\"page-break-after: always\"></div>

Due to early observations of poor tolerance of IV infusions, two studies (1007 and 1009) were conducted to investigate the use of buffered solutions.

In study 1007 dosing with 150 mg or 200 mg lefamulin in 400 mL 10 mM citrate buffered saline q12h for 5 days using 1-h infusions slightly improved local tolerance vs. using only saline as the diluent. In study 1009, 150 mg lefamulin was given q12h for 15 doses (7.5 days) using 1h infusions in saline or 10mM citrate buffered saline (pH5). The PK parameters for lefamulin were not affected by the diluent used. As in 1002, lefamulin exposures were higher after repeat dose administration (1.4-fold for AUC0-12 on day 8 vs. day 1 for both treatments).

## Oral formulation studies

In study 1101 single oral doses of 100, 200 and 400 mg lefamulin using capsules were given in the fasted state. The mean AUC0-∞ increased with dose but the dose-normalised AUC0-∞ was lower after 100 mg (6.97 ng·h/ml/mg) and similar after 200 to 400 mg (16.05 ng·h/ml/mg after 200 mg and 16.62 ng·h/ml/mg after 400 mg). In 1102, in which lefamulin was given at 200, 400 or 600 mg BID for 9 days in the fasted state, there was a bimodal plasma peak with the first at 20 minutes to 1 h after dosing and a second at 1-4 h. Steady state was reached after ~2 days.

Table 4. Summary of the main PK parameters after single and repeat oral doses of 200, 400 and 600 mg BC-3781

|                        |                | BC-3781         | BC-3781         | BC-3781         | BC-3781         | BC-3781                                                                               | BC-3781          |
|------------------------|----------------|-----------------|-----------------|-----------------|-----------------|---------------------------------------------------------------------------------------|------------------|
|                        |                | Single dose     | Single dose     | Single dose     | Repeat dose     | Repeat dose                                                                           | Repeat dose      |
| Parameter              |                | 200 mg Cohort 1 | 200 mg Cohort 2 | 600 mg Cohort 3 | 200 mg Cohort 1 | 400 mg Cohort 2                                                                       | 600 mg Cohort 3  |
|                        |                | n=6             | n=6             | n=6             | n=6             | n=6                                                                                   | n=6              |
| AUC0-12h [ng:h/ml)]    | Mean (SD)      | 1605.2 (791.6)  | 1744.6 (301.0)  | 6519.6 (2145.6) | 2975.4 (1100.3) | 5848.9 (835.0)                                                                        | 11939.5 (4044.0) |
| AUCo-inf [ng-h/ml]     | Mean (SD)      | n.c.            | n.c.            | 8394.6 (2923.9) | 4137.8 (1564.2) | 8368.0 (1473.6)                                                                       | 19942.6 (9393.0) |
| AUC/dose  [ng:h/ml/mg] | Mean (SD)      | n.c.            | n.c.            | 13.991 (4.873)  | 14.877 (5.502)  | 14.622 (2.088)                                                                        | 19.899 (6.740)   |
| C max [ng/ml]          | Mean (SD)      | 542.7 (218.9)   | 631.0 (114.5)   | 1552.7 (232.7)  | 781.0 (216.8)   | 1184.8 (234.6)                                                                        | 2081.2 (185.2)   |
| max/dose [ng/ml/mg]    | Mean (SD)      | 2.7133 (1.0943) | 3.1550 (0.5727) | 2.5878 (0.3878) | 3.9050 (1.0841) | 2.9621 (0.5865)                                                                       | 3.4686 (0.3086)  |
| [max [h]               | Median [Range] | 0.5000          | 0.7584          | 0.5000          | 0.6667          | 1.7500 [0.333-2.500][0.333-1.000][0.500-2.500][0.333-4.000][0.333-3.500][0.500-3.000] | 1.5000           |
| ty [h]                 | Mean (SD)      | n.c.            | n.c.            | 9.001 (0.679)   | 10.952 (2.759)  | 10.688 (0.547)                                                                        | 11.990 (2.825)   |

<div style=\"page-break-after: always\"></div>

In 2 studies of site of absorption (BC3-PK-01 and 02) plasma lefamulin exposure was greater when the dose was delivered via an Enterion capsule to the distal small bowel but was lower after delivery to the colon when compared to the IR capsule formulation. Direct delivery of the lipidic formulation via Enterion capsule to the PSB had no real effect of enhancement on the systemic bioavailability. It was concluded that there was no significant improvement in absorption when bypassing the stomach.

Lefamulin is a substrate for P-gp and could theoretically saturate its own efflux. The applicant proposed that the reduced AUC of the MR formulations may reflect increased P-gp efflux into the intestinal lumen due to lower luminal concentrations and thus less saturation of P-gp. In contrast, absorption from the IR formulation was rapid with a potential saturable efflux and hence possible higher availability. Following dosing of the MR formulations a few subjects had Tmax values suggesting an IR burst, which was proposed to be possibly due to increased release in acidic conditions and/or formulation breakdown. It was decided not to proceed with MR formulations.

## Absolute bioavailability

Study 1107 investigated the absolute bioavailability of oral lefamulin from the 600 mg IR tablet and bioequivalence between the 200 mg hard gelatine capsules (used in some prior Phase 1 studies) and the 600 mg IR tablet in the fasted state. The study also evaluated the effect of food on absolute bioavailability from the 600 mg tablet. The plasma profiles tended to exhibit 2 peaks, the first between 20 min and 1 or 2 h and the second between 1 to 5 h post-dose.

After dosing with one 600 mg tablet (A) or 3 x 200 mg capsules (B) in the fasted state bioequivalence was demonstrated (see A/B rows in the table below).

Table 5. Statistical Analysis - Pairwise Treatment Comparison for Relative Lefamulin Bioavailability and Food effect: PK Descriptive Population

|                    |                                             | TreatmentX   | TreatmentX               | Treatment Y   | Treatment Y              | Ratiob      |                               |             |         |
|--------------------|---------------------------------------------|--------------|--------------------------|---------------|--------------------------|-------------|-------------------------------|-------------|---------|
| Parameter          | TreatmentX/TreatmentY                       | N            | Adjusted Geometric Mean? | N             | Adjusted Geometric Mean? | (%)         | 90 % CIc (%)                  | P-valued    | CVw (%) |
| AUCo-inf (ng-h/mL) | TreatmentA/TreatmentB TreatmentD/TreatmentA | 20 19        | 8180 6680                | 20 20         | 8400 8180                | 97.40 81.57 | (90.59,104.71) (75.34,88.31)  | 0.53 <0.001 | 24.1    |
| AUClast (ng-h/mL)  | TreatmentD/TreatmentA TreatmentATreatmentB  | 20 19        | 6370 7860                | 20 20         | 8090 7860                | 81.12 97.16 | (90.37,104.46) (74.84, 87.92) | <0.001 0.50 | 23.0    |
| AUCo-12h (ng-h/mL) | TreatmentATreatmentB TreatmentD/TreatmentA  | 20 19        | 6120 4430                | 20 20         | 6340 6120                | 96.47 72.43 | (88.74,104.87) (65.74, 79.81) | <0.001 0.45 | 17.3    |
| AUCo-24h (ng-h/mL) | TreatmentATreatmentB TreatmentD/TreatmentA  | 20 19        | 7360 5870                | 20 20         | 7590 7360                | 96.98 79.74 | (90.22,104.24) (73.58, 86.42) | <0.001 0.47 | 21.8    |
| Cmax (ng/mL)       | TreatmentA/TreatmentB TreatmentD/TreatmentA | 20 19        | 1170 899                 | 20 20         | 1210 1170                | 96.09 77.11 | (85.45, 108.05) (67.72,87.80) | 0.57 0.002  | 11.8    |

aAdjustedgeometricmeanfrommodel

CVw= intra-subject variability

b Ratio of adjusted geometric means for Treatment Y/Treatment X

dP-valueforratioof adjustedgeometricmeans

Confidenceinterval forratioof adjustedgeometricmeans

TreatmentA=600mglefamulinIRtablet,administeredorallyinthefastedstate

TreatmentB=600mglefamulinAPlas3x200mgcapsules,administeredorallyinthefastedstate

Treatment C = 150 mg lefamulin in 250 mL citrate buffered saline, administered as an intravenous (i.v.) infusion over 1 h.

Treatment D = 600 mg lefamulin IR tablet, administered orally in the fed state (1 h after breakfast).

The exposure to lefamulin from a 600 mg tablet taken in the fasted state (A) was comparable with that observed following a 150 mg IV dose (C). In contrast, due to the negative effect of food on the extent of

<div style=\"page-break-after: always\"></div>

lefamulin absorption (shown in rows D/A in the table above), plasma exposures after dosing with 600 mg in the fed state (D) were lower vs. the 150 mg IV dose (C) as shown in rows D/C below.

Table 6. Statistical Analysis - Pairwise Treatment Comparison for Relative Lefamulin Bioavailability: PK Descriptive Population

|                    |                                             | TreatmentX   | TreatmentX               | TreatmentY   | TreatmentY                | Ratiob       |                               |               |         |
|--------------------|---------------------------------------------|--------------|--------------------------|--------------|---------------------------|--------------|-------------------------------|---------------|---------|
| Parameter          | TreatmentX/TreatmentY                       | N            | Adjusted Geometric Mean? | N            | Adjusted Geometr ic Mean? | (%)          | 90%CIc (%)                    | P-valued      | CVw (%) |
| AUCo-inf (ng-h/mL) | TreatmentA/TreatmentC TreatmentD/TreatmentC | 20 19        | 8180 6680                | 20 20        | 7920 7920                 | 103.36 84.31 | (94.89,112.58) (76.94, 92.37) | 0.51 0.004    | 24.1    |
| AUClast (ng-h/mL)  | TreatmentA/TreatmentC TreatmentD/TreatmentC | 20 19        | 7860 6370                | 20 20        | 7660 7660                 | 102.63 83.25 | (94.30,111.70) (76.05, 91.14) | 0.60 0.002    | 23.0    |
| AUCo-12h (ng-h/mL) | TreatmentA/TreatmentC TreatmentD/TreatmentC | 20 19        | 6120 4430                | 20 20        | 6170 6170                 | 99.18 71.84  | (91.94,106.98) (65.41,78.89)  | <0.001 0.85   | 17.3    |
| AUCo-24h (ng-h/mL) | TreatmentD/TreatmentC TreatmentA/TreatmentC | 19 20        | 5870 7360                | 20 20        | 7240 7240                 | 101.75 81.14 | (93.67,110.53) (74.25,88.67)  | <0.001 0.72   | 21.8    |
| Cmax (ng/mL)       | TreatmentD/TreatmentC TreatmentATreatmentC  | 19 20        | 1170 899                 | 20 20        | 2370 2370                 | 49.10 37.86  | (44.96,53.64) (33.85,42.35)   | <0.001 <0.001 | 11.8    |

aAdjustedgeometricmeanfrommodel

CVw=intra-subjectvariability

bRatio of adjusted geometric means for Treatment Y/Treatment X

dP-valueforratioof adjustedgeometricmeans

cConfidenceintervalforratioof adjustedgeometricmeans

TreatmentA=600mglefamulinIRtablet,administeredorallyinthefastedstate

TreatmentC=150mglefamulinin250mLcitratebufferedsaline,administeredasanintravenous(i.v.)infusionover1h.

TreatmentB=600mglefamulinAPlas3x200mgcapsules,administeredorallyinthefastedstate.

TreatmentD=600mglefamulinIRtablet,administeredorallyinthefedstate(1h afterbreakfast)

For each of the dose-corrected AUCs, reflecting the effect of food, the absolute bioavailability was ~26% when the 600 mg tablet was taken in the fasted state but ~21% when it was taken in the fed state.

## Influence of food

The definitive food effect study with the final 600 mg IR tablets was 1106, which compared exposures after single 600 mg lefamulin doses in the fasted state (A), the fasted state with breakfast (high fat/kcal) one hour after dosing (B) and one hour after breakfast had been completed (C). The highest lefamulin AUC occurred in the fasted state and the lowest with dosing one hour after breakfast had been completed. Mean Cmax was also lowest when dosing was one hour after breakfast and median Tmax was delayed. The mean terminal elimination t ½ was not affected.

<div style=\"page-break-after: always\"></div>

Table 7. Mean (SD) Summary of the Main PK Parameters of BC-3781 (PK Population)

| Parameter          | BC-3781 600 mg fasted with no breakfast N=12   | BC-3781 600 mg fastedwithbreakfast one hour after dosing N=13   | BC-3781 600 mg one hour after breakfast completed N=12   |
|--------------------|------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------|
| AUCo-t [h*ng/mL]   | 8151.2 (1780.2)                                | 7329.5 (2074.3)                                                 | 6200.3 (1977.9)                                          |
| AUCo-24h [h*ng/mL] | 7673.1 (1632.5)                                | 6877.6 (1907.6)                                                 | 5753.0 (1805.8)                                          |
| AUCo-12h [h*ng/mL] | 6424.2 (1254.5)                                | 5723.7 (1442.0)                                                 | 4593.1 (1429.7)                                          |
| AUCo-inf [h*ng/mL] | 8461.2 (1868.8)                                | 7639.1 (2183.4)                                                 | 6474.6 (2104.8)                                          |
| Cmax [ng/mL]       | 1410.6 (362.0)                                 | 1327.7 (497.4)                                                  | 912.5 (337.9)                                            |
| [max [h]           | 1.000 (0.33,4.00)                              | 0.750 (0.33,3.00)                                               | 4.500 (2.00,6.00)                                        |
| t1/2 [h]           | 8.329 (0.856)                                  | 8.638 (1.307)                                                   | 8.000 (0.647)                                            |
| CL/F [mL/min]      | 1243.0 (315.8)                                 | 1407.8 (395.2)                                                  | 1692.2 (526.2)                                           |
| MRT [h]            | 8.951 (0.979)                                  | 8.882 (1.329)                                                   | 10.857 (0.947)                                           |
| V/F [L]            | 903.0 (285.0)                                  | 1057.6 (364.4)                                                  | 1158.1 (319.7)                                           |

Table 8. Summary of Statistical Analyses of BC-3781 (N=12)

| Parameter          | Intra- individual CV [%]   | BC-3781 600 mg fasted with breakfast 1 hour after dosing / BC-3781 600 mg fasted no breakfast   | BC-3781 600 mg fasted with breakfast 1 hour after dosing / BC-3781 600 mg fasted no breakfast   | BC-3781 600 mg 1 h after breakfast / BC-3781 600 mg fasted no breakfast   | BC-3781 600 mg 1 h after breakfast / BC-3781 600 mg fasted no breakfast   |
|--------------------|----------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
|                    |                            | Geometric Mean Ratio                                                                            | 90 % CI                                                                                         | Geometric Mean Ratio                                                      | 90 % CI                                                                   |
| AUCo-24h [h*ng/mL] | 14.0                       | 0.90                                                                                            | (0.81, 0.99)                                                                                    | 0.73                                                                      | (0.67, 0.81)                                                              |
| AUCo-inf [h*ng/mL] | 13.8                       | 0.91                                                                                            | (0.82, 1.00)                                                                                    | 0.75                                                                      | (0.68, 0.82)                                                              |
| Cmax [ng/mL]       | 28.7                       | 0.91                                                                                            | (0.74, 1.10)                                                                                    | 0.63                                                                      | (0.52, 0.77)                                                              |
| t1/2 [h]           | 7.4                        | 1.05                                                                                            | (1.00, 1.11)                                                                                    | 0.96                                                                      | (0.91, 1.01)                                                              |
| MRT [h]            | 6.9                        | 1.07                                                                                            | (1.00,1.13)                                                                                     | 1.22                                                                      | (1.15,1.28)                                                               |

## Distribution

## Protein binding

In an in-vitro study using equilibrium dialysis, lefamulin binding to human plasma proteins was saturable and was estimated at 78% (range 73-88%). At typical plasma concentrations achieved with the proposed IV and oral dosing regimens, the applicant expects that lefamulin is ~ 87% bound to plasma proteins and this

<div style=\"page-break-after: always\"></div>

correction factor was applied to total drug plasma levels in study 1005 (ELF study) to estimate free drug in plasma.

Mean lefamulin protein binding was &gt; 94% at 1, 3 and 8 h in the renal impairment study and similar between the three groups. Protein binding increased ~2% to 3% as lefamulin concentrations decreased. In the hepatic impairment study, subjects with moderate hepatic impairment had mean protein binding values between 89.2% and 92.8% and subjects with severe hepatic impairment had mean values between 86.5% and 90.8%, compared to 94.8% to 97.1% in the normal controls.

## Blood to plasma distribution

In the mass balance study, the whole blood to plasma ratios suggested no preferential binding of lefamulin into RBCs.

## Lung (ELF) and tissue distribution after 150 mg IV dose

In study 1005, conducted at the Medical University of Vienna where lefamulin was assayed for this study using LC-MS-MS, lefamulin 150 mg IV (in 400 mL normal saline infused over 60 min) was administered to 12 healthy male subjects aged 18 to 55 years.

- Blood samples were obtained at frequent intervals up to 24 h.
- Epithelial lining fluid (ELF) samples were taken from 3 subjects at each of 1 h, 2 h, 4 h or 8 h after start of infusion.
- Microdialysate (MD) was collected from subcutaneous adipose tissue and muscle pre-dose (each 30 min) and then at intervals for 24 h.

ELF concentrations were corrected based on plasma and ELF urea concentrations. It was assumed that 13% lefamulin in plasma was unbound. The table below summarises the PK data, including the AUC ratios based on comparing total drug between compartments and comparing total drug in peripheral compartments with free drug in the central compartment (plasma).

<div style=\"page-break-after: always\"></div>

Table 9. Summary of the main PK parameters of BC-3781 administered as a 1-hour infusion of 150 mg BC-3781 (PK set)

|                       | Plasma n =12      | Skeletalmuscle tissue n=10   | Subcutaneous adipose tissue n=8   | ELF* (n =3)   |
|-----------------------|-------------------|------------------------------|-----------------------------------|---------------|
| AUCo-8 [ng-h/ml]      | 5268 (1166)       | 534.5 (191.0)                | 553.2 (170.8)                     | 3871          |
| AUCo-12 [ng-h/ml]     | 6022 (1365)       | 678.8 (232.5)                | 675.3 (206.9)                     |               |
| AUCo-24 [ng-h/ml]     | 6968 (1602)       | 946.8 (441.3)a               | 807.6 (264.3)b                    |               |
| AUCo.t [ng-h/ml]      | 6969 (1603)       |                              |                                   |               |
| AUCo-inr [ng.h/ml]    | 7381 (1695)       |                              |                                   |               |
| AUC/dose [ng-h/ml/mg] | 49.21 (11.30)     |                              |                                   |               |
| Cmax [ng/ml]          | 2576 (492)        | 159.8 (119.1)                | 184.7 (152.4)                     | 932           |
| Cmax/dose [ng/ml/mg]  | 17.17 (3.28)      |                              |                                   |               |
| tmax [h]              | 1.00 (0.50 -1.00) | 1.50 (1.25 -3.50)            | 1.25 (1.25 - 2.25)                | 1.00          |
| ti/z [b]              | 6.978 (1.070)     |                              |                                   |               |
| C1 [ml/min]           | 354.4 (76.4)      |                              |                                   |               |
| MRTo-inf [h]          | 6.223 (0.839)     |                              |                                   |               |
| Va [L]                | 215.1 (64.6)      |                              |                                   |               |
| Vss [L]               | 132.0 (33.5)      |                              |                                   |               |
| Accumulation ratios   |                   | Skeletalmuscle tissue/plasma | Adipose tissue/plasma             | ELF/plasma    |
| AUC0-8                |                   | 0.098                        | 0.102                             | 0.751         |
| AUC0-12               |                   | 0.109                        | 0.110                             |               |
| AUC0-24               |                   | 0.128                        | 0.113                             |               |
| Accumulation ratios** |                   | Skeletalmuscle tissue/plasma | Adipose tissue/plasma             | ELF/plasma    |
| AUC0-8                |                   | 0.751                        | 0.787                             | 5.774         |
| AUC0-12               |                   | 0.841                        | 0.842                             |               |
| AUC0-24               |                   | 0.983                        | 0.866                             |               |

The individual lefamulin concentrations in ELF approached equilibrium with total plasma levels by 2 h after start of infusion. Exposure in ELF was ~75% of that in plasma (accumulation ratio for AUC0-8 of 0.75) based on total drug but it was estimated to be 5.7-fold the unbound drug level in plasma.

Mean PK parameters in the interstitial space of skeletal muscle and subcutaneous adipose tissues were similar. When calculating the accumulation ratios in skeletal and adipose tissue vs. the free fraction in plasma, the exposure in tissues was similar to plasma exposure (98% and 87% for AUC0-24).

Equilibration occurred by 15 min post-dose and free concentration-time profiles in tissue and plasma closely resembled each other, indicating very fast exchange within the central compartment and interstitium. Elimination from ELF and adipose and skeletal muscle tissue followed the elimination of lefamulin from the

<div style=\"page-break-after: always\"></div>

central compartment (plasma) so that no clinically important accumulation was predicted following multiple doses.

## Volume of distribution at steady state (Vss)

Steady state in plasma is typically reached after 4 doses of BID oral or IV administrations. Estimates of Vss have been between 116-160L (e.g. 132 L in study 1005 described above). These estimates are 3-5-fold TBW, indicating considerable distribution of lefamulin into the extravascular space.

## Metabolism

In-vitro studies indicated that CYP3A4 and 3A5 were the major lefamulin-metabolising enzymes.

In 1013 after the IV dose of 150 mg  14 C-lefamulin the circulating BC-8041 levels were between 0.8% and 6.7% of total radioactivity (accounting for 2.7% of total based on AUC0-∞ ). After an oral dose of 600 mg  14 Clefamulin the BC-8041 levels were between 8.3% and 22.0% of total radioactivity (accounting for 12.2% of total based on AUC0-∞ and this was the only metabolite to exceed 10% of total plasma radioactivity.

Metabolites accounting for &gt;10% of the total radioactivity in excreta (faeces [IV and oral] and urine [IV]) resulted from mono- and di-hydroxylation, from phase II conjugation of mono-hydroxylated metabolites with pentose (C5-sugar) and from direct conjugation of lefamulin with pentose. Urine from subjects dosed orally contained less than 10% of the dose so that metabolite profiling was not performed on these samples.

<div style=\"page-break-after: always\"></div>

Table 10. Summary of Metabolite Profiling and Identification Results in Plasma, Faeces and Urine following a Single Intravenous Dose of 150 mg  14 C-BC-3781 (Regimen A) and a Single Oral Dose of 600 mg  14 C-BC-3781 as 3 × 200 mg Capsules (Regimen B)

| Metabolite                                                                                                      | Oral Dosea   | Oral Dosea   | Intravenous Dose   | Intravenous Dose   | Intravenous Dose   |
|-----------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------|--------------------|--------------------|
|                                                                                                                 | Plasma       | Faeces       | Plasma             | Faeces             | Urine              |
| M539: Di-hydroxy BC-3781                                                                                        | NA           | M7b          | NA                 | M7                 | NA                 |
| Co-elutingMetabolites: M523-1: Mono-hydroxyBC-3781 M655-1: Pentose Conjugate of Mono-hydroxy BC-3781            | NA NA        | M10 M10c     | NA NA              | M10 M10c           | NA NA              |
| Co-eluting Metabolites: M523-2: BC-8041: Mono-hydroxy BC-3781 M655-2: Pentose Conjugate of Mono-hydroxy BC-3781 | M13 X        | M13 M13c     | M13b X             | M13 M13c           | M13b X             |
| Co-eluting Metabolites: M639:PentoseConjugateofBC-3781 M507: Lefamulin (BC-3781)                                | X M19 (P)    | M19c M19 (P) | X M19 (P)          | M19b,c M19b (P)    | X M19 (P)          |

NA: identification not applicable in this sample; X: not present. M: the radioactive component (peak in the radiochromatogram); in some instances, this could correspond to two or more co-eluting metabolites and/or the parent compound (lefamulin [BC-3781]); P: parent.

The metabolites accounting for &gt;10% of the sample radioactivity in the AUC plasma samples or &gt;10% of the administered dose in faeces and urine are shown in bold.

u Auanbasuo pue 'sop au jo %ol ueu ssel pauieuoo (a uawbey) Aelo pasop siolans wony auun e metabolite profiling and identification work was performed on the urine samples.

b Metabolite accounts for &lt;10% of the sample radioactivity in the AUC plasma samples (or &lt;10% of the

c Not a major component of the co-eluting pair based on mass spectrometer response

Source: Pharmaron Metabolite Profiling and Identification Report (Appendix 16.1.13.2)

The proposed human biotransformation pathway is shown below.

<div style=\"page-break-after: always\"></div>

Figure 2. Proposed biotransformation pathway for BC-3781 (lefamulin)

<!-- image -->

In addition to study 1013 several studies evaluated the PK of the mono-hydroxy metabolite BC-8041. For example, study 1107 evaluated plasma concentration-time profiles of BC-8041 with results summarised below.

Whilst plasma exposures to the metabolite were very low compared to parent drug, they were very similar between the 600 mg tablet and 3 x 200 mg capsule doses administered in the fasting state (A and B). The negative effect of food on parent drug also impacted the metabolite levels after dosing with 600 mg tablets

<div style=\"page-break-after: always\"></div>

as shown by the comparison between A and D. Metabolite exposures were lower after the IV dose (C), and less than 25% of those observed with 600 mg oral doses, indicating less conversion of parent to metabolite with IV vs. oral dosing.

Table 11. Geometric Mean (Geometric CV%) Plasma Pharmacokinetic Parameters of BC-8041 Following a Single Dose of Lefamulin to Healthy Volunteers: PK Descriptive Population

| Treatment: Doseof Lefamulin: Administration: No. of Subjects: Parameter                                             | Treatment A 600 mg IRTablet,Fasted N=20                                                                             | Treatment B 600 mg Capsules, Fasted N=20                                                                            | Treatment C 150 mg i.v. Infusion N=20                                                                             | Treatment D 600 mg IR Tablet,Fed N = 19a                                                                           |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Tmax (h)b Cmax(ng/mL) AUCo-12h (ng·h/mL) AUCo-24h (ng·h/mL) AUClast (ng·h/mL) AUCo-inf (ng·h/mL) T1/2 (h) kel (1/h) | 1.50 (0.75-5.00) 228 (27.0 %) 1260 (39.2 %) 1570 (41.7 %) 1670 (43.1 %) 1740 (43.5 %) 8.16 (13.8 %) 0.0849 (13.8 %) | 2.00 (0.75-5.00) 215 (52.1 %) 1200 (44.6 %) 1510 (44.8 %) 1610 (45.0 %) 1670 (45.2 %) 8.15 (12.4 %) 0.0850 (12.4 %) | 1.25 (1.25-1.50) 29.2 (27.7 %) 160 (30.3 %) 224 (31.7 %) 247 (36.3 %) 274 (35.0 %) 10.15 (14.0 %) 0.0683 (14.0 %) | 5.00 (1.17-8.00) 181 (50.5 %) 913 (42.4 %) 1250 (37.7 %) 1350 (38.0 %) 1410 (38.5 %) 7.85 (11.0 %) 0.0883 (11.0 %) |

estimation for that subject was compromised, and the values were excluded from the PK summary statistics. b Median

## Elimination

Study 1013 was a mass balance study with single IV and PO doses in which cohorts of 5 healthy male subjects received either:

- A. 60 min IV infusion of 150 mg  14 Clefamulin containing up to 4.3 MBq [117 μCi] 14 C in the fed state (30 min after the start of a light breakfast)
- B. 600 mg  14 Clefamulin containing up to 4.1 MBq [112 μCi] 14 C as 3 × 200 mg oral capsules in the fasted state (following an overnight fast of a minimum of 10 h)

## IV dose

Cmax for lefamulin and total radioactivity occurred at either 0.75 or 1 h post-dose and then declined in parallel in a multiple-phasic manner. Plasma lefamulin was detectable for 96-120 h post-dose, whereas total radioactivity remained quantifiable for 12-48 h post-dose. The elimination half-lives ranged from 15.3 - 18.9 h for lefamulin (GM 16.3 h) and from 4.2-8.7 h for total radioactivity (GM 6.5 h). The GM Cmax and AUC values were lower for lefamulin (which accounted for 76% of circulating radioactivity) vs. total radioactivity. The GM CL, Vss and Vz for lefamulin were 305 mL/min, 157 L and 431 L, respectively, compared to 233 mL/min, 87 L and 130 L, respectively for total radioactivity.

Between 89.8% and 96.5% of the radioactivity was recovered by the end of the sampling period (192 h). The mean recovery of total radioactivity was 15.5% in urine and 77.3% in faeces. Within the first 24 h post-dose,

<div style=\"page-break-after: always\"></div>

13.8% and 0.04% of the total radioactivity was recovered in the urine and faeces, respectively. By 72 h postdose, over 65% of the total radioactivity administered had been recovered.

## Oral dose

Cmax for lefamulin and total radioactivity occurred between 0.5-2 h post-dose. Plasma lefamulin then declined in a multi-phasic manner and remained quantifiable for 96-144 h whereas total radioactivity declined in a monophasic manner and was detectable for only 8-12 h. The elimination half-lives ranged from 13.9-22.1 h for lefamulin and 3.0-4.1 h for total radioactivity with GM half-lives of 17.8 h and 3.6 h, respectively. Cmax and AUC were lower for lefamulin (which accounted for 58% of the circulating radioactivity) vs. total radioactivity. The dose-adjusted absolute bioavailability for oral lefamulin, calculated from the GM AUC0-t and AUC0-∞ , was 27.3% and 27.1%, respectively.

Table 12. Pharmacokinetic Parameters for BC-3781, BC-8041 and Total Radioactivity in Plasma following a Single Oral Dose of 600 mg  14 C-BC-3781 as 3 × 200 mg Capsules: Pharmacokinetic Population

|                  | Tiag (“)   | Tma x (n)   | Cmax (ng/mL)   | AUC(0-24) (ng.h/mL)   | AUC(0-24)/D (ng . h/mL) / (mg)   | AUC(0-1ast) (ng.h/mL)   | AUC(0-1ast)/D (ng . h/mL) / (mg)   |
|------------------|------------|-------------|----------------|-----------------------|----------------------------------|-------------------------|------------------------------------|
| BC-3781          |            |             |                |                       |                                  |                         |                                    |
| Me dian          | 0.000      | 0.500       | 1630           | 9280                  | 15.5                             | 10400                   | 17.3                               |
| Min              | 0.00       | 0.50        | 1260           | 4920                  | 8.20                             | 5490                    | 9.14                               |
| Ma x             | 0.00       | 2.00        | 1940           | 10900                 | 18.2                             | 12900                   | 21.6                               |
| n                | 5          | 5           | 5              | 5                     | 5                                | 5                       | 5                                  |
| Geometrlc Me an  | NC         | NC          | 1570           | 7760                  | 12.9                             | 8860                    | 14.8                               |
| GeometrlcCV(%)   | NC         | NC          | 17.2           | 35.9                  | 35.9                             | 37.5                    | 37.5                               |
| Geometrlc n      | NC         | NC          | 5              | 5                     | 5                                | 5                       | 5                                  |
| BC-8041          |            |             |                |                       |                                  |                         |                                    |
| Medi an          | 0.000      | 1.000       | 257            | 1990                  | NA                               | 2230                    | NA                                 |
| Min              | 0.00       | 0.50        | 182            | 978                   | NA                               | 1070                    | NA                                 |
| Ma x             | 0.00       | 6.00        | 319            | 2090                  | NA                               | 2360                    | NA                                 |
| n                | 5          | 5           | 5              | 5                     | NA                               | 5                       | NA                                 |
| Geometrlc Mean   | NC         | NC          | 244            | 1620                  | NA                               | 1810                    | NA                                 |
| CV (%)           | NC         | NC          | 27.7           | 34.1                  | NA                               | 36.1                    | NA                                 |
| Geometrlc n      | NC         | NC          | 5              | 5                     | NA                               | 5                       | NA                                 |
| Me d I an        | 0.000      | 1.000       | 2120           | 13900                 | 23.2                             | 12300                   | 20.5                               |
| Min              | 0.00       | 0.50        | 1700           | 7810                  | 13.0                             | 6260                    | 10.4                               |
| Ma x             | 0.00       | 2.00        | 2410           | 16300                 | 27.2                             | 14600                   | 24.3                               |
| n                | 5          | 5           | 5              | 5                     | 5                                | 5                       | 5                                  |
| Geometrlc Me an  | NC         | NC          | 2060           | 12200                 | 20.4                             | 10300                   | 17.2                               |
| Geometr1c CV (%) | NC         | NC          | 13.0           | 31.6                  | 31.6                             | 37.3                    | 37.3                               |
| Geometrlc n      | NC         | NC          | 5              | 5                     | 5                                | 5                       | 5                                  |

Regimen B: oral administration of 600 mg 14C-BC-3781 as 3 x 200 mg capsules (containing NMT 4.1 MBq [112 μCi] 14C), fasted

NC:notcalculated

Units for total radioactivity Cmax, AUC and AUC/D were ng eq/mL, ng eq.h/mL and ng eq.h/mL/mg.

The absolute bioavailability (F) of BC-3781 was estimated from the ratio of the geometric means of the dose adjusted AuCs in Regimens A and B

Between 89.0% and 97.2% of the radioactivity administered was recovered by the end of the sampling period (240 h) with mean recovery of 5.3% in urine and 88.5% in faeces. Within the first 24 h post-dose, 4.6% and 1.3% of the total radioactivity was recovered in the urine and faeces, respectively. By 72 h postdose, over 50% of the total radioactivity administered had been recovered.

<div style=\"page-break-after: always\"></div>

Figure 3. Arithmetic Mean ( ± Arithmetic SD) Mass Balance Recoveries of Total Radioactivity following a Single Oral Dose of 600 mg  14 C-BC-3781 as 3 × 200 mg Capsules (Regimen B): Mass Balance Population

<!-- image -->

## Pharmacokinetics in target population

## Population PK analysis 00231-1

This POPPK analysis (dated July 2011) included total lefamulin plasma concentration-time data from study 2001; a Phase 2 clinical study in patients with ABSSSI. The structural model was based on a previous POPPK model, derived using Phase 1 data [April 2010]. The final POPPK model was a three-compartment model, with zero-order input, first-order elimination and saturable protein binding. No significant covariate relationships were identified. This model was not used in PK-PD analyses.

## Population PK analysis FRX-BC3781-PMT-1

This POPPK analysis (dated July 2013) included total lefamulin plasma concentration-time data from 14 completed Phase 1 and Phase 2 clinical trials. Out of the 14 completed studies, 12 studies with a total of 311 subjects and 6949 observations were used to establish the population PK model. Two studies, with a total of 40 subjects and 1319 observations, were used for external validation of the model. Observations of lefamulin concentrations in epithelial lining fluid (ELF) (in total 12 observations from 12 different subjects) and in-vitro estimates of mean fraction unbound BC-3781 were also incorporated into the analysis.

Lefamulin pharmacokinetics was described with a 3-compartment disposition model with first order elimination of unbound drug. Unbound concentrations in the central compartment were related to the observations of total plasma concentrations via a non-linear protein binding function based on the Richard's equation. Distribution of lefamulin into ELF was better described with an equilibrium compartment approach compared to a model that assumed an instantaneous equilibrium between plasma and ELF concentrations. The oral absorption of lefamulin was characterised with a dual absorption model with a rapid and a delayed absorption path. The oral bioavailability was predicted to decrease from ~20% to 16% when the 600 mg IR

<div style=\"page-break-after: always\"></div>

tablet was administered under fed conditions. Furthermore, the rate of absorption decreased significantly when given with food.

A significant time- and dose-dependent increase in oral bioavailability of lefamulin was also identified. Overall, the developed population PK model demonstrated good predictive performance of total lefamulin plasma concentrations over time, across doses and after IV and oral administration.

## Population PK analysis 00488-1

This POPPK model (dated November 2018) refined a previous POPPK model (00429-1) by including pooled data from four Phase 1 studies (1010, 1011, 1107 and 1108), the Phase 2 study in ABSSSI (2001) and the Phase 3 studies in patients with CAP (3101 and 3102). The final PK dataset contained 6205 plasma concentrations from 849 individuals.

The previous model was a 3-compartment disposition model with linear clearance, nonlinear protein binding, first-order disposition into and out of the ELF and parallel fast and slow (delayed) first-order absorption following PO dosing. This model yielded a suboptimal fit, with a tendency to under-predict the concentrationtime data from Phase 3 patients. Thus, additional structural models were attempted. Ultimately, it was determined that the inclusion of patient factors, including study phase, would be required to successfully comodel the lefamulin PK data across studies.

The covariate analysis revealed five influential covariate effects:

- Clearance (CL) and study phase;
- CL and albumin;
- Volume of distribution for peripheral compartment 1 (Vp1) and study phase;
- Vp1 and WTKG; and
- Distributional clearance to peripheral compartment 1 (CLd1) and study phase.

Incorporation of these statistically significant relationships resulted in moderate improvement in the overall population-predicted fit, with individual-predicted fits unchanged from those obtained with the base structural model. Despite the statistical significance of these relationships, none of the covariates were associated with a clinically relevant impact on the pharmacokinetics of lefamulin.

## Pharmacokinetic Exposures and Predicted Accumulation

Semi-log scatterplots of lefamulin plasma concentrations vs. time, stratified by dose, showed that the Phase 3 and, to a lesser extent, the Phase 2 plasma concentrations were higher than those observed during Phase 1 studies at the same IV and PO doses. Further, the lefamulin plasma concentrations collected in Phase 3 CAP studies were associated with considerably larger variability than that seen in either Phase 1 or Phase 2.

The Bayesian post-hoc parameter estimates from the final model were used to generate predicted lefamulin concentration-time profiles. Summary statistics for key lefamulin Day 1 and steady state pharmacokinetic exposure parameters in ABSSSI and CABP patients enrolled in Phase 2 and Phase 3 trials are provided in

<div style=\"page-break-after: always\"></div>

Table 13. The geometric mean AUC0-24 in Phase 3 subjects receiving 150 mg IV q12h that was 1.74-fold higher than the value for the same dosing regimen administered to Phase 2 ABSSSI subjects.

Table 13. Summary of key lefamulin plasma pharmacokinetic exposure parameters for patients enrolled in Phase 2 and Phase 3 trials

|                          | Study 2001 (IV)a        | Study 2001 (IV)a        | Study 3101 (IV)         | Study 3101 (IV)         | Study 3102 (PO)         | Study 3102 (PO)                            |
|--------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|--------------------------------------------|
| Parameter                | Day 1 (n=65)            | Steady State (n=62)     | Day 1 (n=258)           | Steady State (n=252)    | Day 1 (n=364)           | Steady State (n=230)                       |
| AUCo-24 (mg-h/L)b        |                         |                         |                         |                         |                         |                                            |
| Arithmetic Mean (%CV)    | 15.3 (25.8) 14.8 (24.7) | 16.0 (27.5) 15.4 (28.0) | 27.0 (31.8) 25.8 (29.6) | 28.4 (45.1) 26.3 (38.0) | 30.7 (45.0) 28.0 (43.8) | 32.7 (49.2) 29.4 (45.3) 28.6 (7.97 - 97.9) |
| Geometric Mean (Geo %CV) |                         |                         |                         |                         |                         |                                            |
| Median (Min-Max)         | 14.7 (8.38 -33.5)       | 15.7 (7.07 -34.5)       | 25.1 (13.5 -57.5)       | 24.5 (10.3 - 84.0)      | 28.1 (7.39 -115)        |                                            |
| CL (L/h)c                |                         |                         |                         |                         |                         |                                            |
| Arithmetic Mean (%CV)    | 157 (30.8)              | 157 (29.0)              | 90.1 (36.2)             | 90.3 (36.3)             | 79.3 (40.1)             | 80.2 (38.5)                                |
| Geometric Mean (Geo %CV) | 150 (29.6)              | 151 (27.1)              | 83.2 (43.1)             | 83.3 (43.3)             | 73.1 (41.5)             | 74.4 (39.7)                                |
| Median (Min-Max)         | 154 (63.3 -354)         | 154 (63.3 -354)         | 91.8 (18.8 - 227)       | 91.9 (18.8 -227)        | 76.9 (16.1- 232)        | 77.2 (23.0 - 232)                          |
| Cmax (mg/L)d             |                         |                         |                         |                         |                         |                                            |
| Arithmetic Mean (%CV)    | 1.95 (12.5)             | 2.01 (12.8)             | 3.50 (11.7)             | 3.03 (28.9)             | 2.24 (36.4)             | 2.24 (37.1)                                |
| Geometric Mean (Geo %CV) | 1.94 (12.7)             | 1.99 (12.9)             | 3.48 (11.2)             | 2.90 (30.9)             | 2.10 (37.0)             | 2.09 (37.6)                                |
| Median (Min-Max)         | 1.94 (1.26 - 2.82)      | 1.98 (1.30 - 2.96)      | 3.42 (2.55 - 5.15)      | 3.20 (1.18 -5.56)       | 2.15 (0.616 -6.72)      | 2.15 (0.731 - 5.91)                        |
| Cmin (mg/L)e             |                         |                         |                         |                         |                         |                                            |
| Arithmetic Mean (%CV)    | 0.140 (60.1)            | 0.213 (48.6)            | 0.398 (68.1)            | 0.571 (86.2)            | 0.593 (67.3)            | 0.765 (75.7)                               |
| Geometric Mean (Geo %CV) | 0.122 (51.0)            | 0.192 (46.6)            | 0.325 (63.5)            | 0.439 (69.8)            | 0.470 (73.2)            | 0.598 (71.6)                               |
| Median (Min-Max)         | 0.118 (0.0422 - 0.613)  | 0.190(0.0505- 0.719)    | 0.330 (0.0539- 1.41)    | 0.409 (0.0595 - 2.91)   | 0.490 (0.0258 - 2.46)   | 0.623 (0.0541 - 3.16)                      |

|                          | Study 2001 (IV)a        | Study 2001 (IV)a        | Study 3101 (IV)             | Study 3101 (IV)         | Study 3102 (PO)        | Study 3102 (PO)       |
|--------------------------|-------------------------|-------------------------|-----------------------------|-------------------------|------------------------|-----------------------|
| Parameter                | Day 1 (n=65)            | SteadyState (n=62)      | Day 1 (n=258)               | Steady State (n=252)    | Day 1 (n=364)          | Steady State (n=230)  |
| t1/2,a(h)                |                         |                         |                             |                         |                        |                       |
| Arithmetic Mean (%CV)    | 0.0816 (35.9)           | 0.0813 (35.7)           | 0.0887 (23.0) 0.0864 (22.8) | 0.0886 (23.1)           | 0.0934 (11.5)          | 0.0938 (10.9)         |
| Geometric Mean (Geo %CV) | 0.0764 (37.5)           | 0.0762 (37.3)           |                             | 0.0863 (22.8)           | 0.0928 (11.9)          | 0.0933 (10.7)         |
| Median (Min-Max)         | 0.0815 (0.0349 - 0.163) | 0.0810 (0.0349 - 0.163) | 0.0856 (0.0494 - 0.168)     | 0.0856 (0.0494 - 0.168) | 0.0932 (0.0383- 0.137) | 0.0933(0.0663- 0.134) |
| t1/2. β (h)              |                         |                         |                             |                         |                        |                       |
| Arithmetic Mean (%CV)    | 1.68 (12.6)             | 1.68 (11.4)             | 1.95 (11.5)                 | 1.95 (11.6)             | 1.95 (15.2)            | 1.94 (14.7)           |
| Geometric Mean (Geo %CV) | 1.67 (12.5)             | 1.67 (11.6)             | 1.93 (11.9)                 | 1.93 (12.0)             | 1.92 (16.7)            | 1.92 (16.1)           |
| Median (Min-Max)         | 1.68 (1.26 -2.43)       | 1.76 (1.26 - 2.06)      | 1.95 (1.17 - 2.72)          | 1.94 (1.17 - 2.72)      | 1.97 (0.852 -2.61)     | 1.96 (0.945 - 2.60)   |
| t1/2.v(h)                |                         |                         |                             |                         |                        |                       |
| Arithmetic Mean (%CV)    | 11.1 (38.6)             | 11.1 (38.9)             | 8.01 (32.0)                 | 8.02 (32.1)             | 8.39 (32.1)            | 8.22 (31.9)           |
| Geometric Mean (Geo %CV) | 10.3 (41.0)             | 10.3 (41.0)             | 7.66 (29.6)                 | 7.66 (29.7)             | 7.98 (31.7)            | 7.83 (30.8)           |
| Median (Min-Max)         | 10.6 (3.36 - 23.2)      | 10.7 (3.36 -23.2)       | 7.46 (3.46 - 20.1)          | 7.46 (3.46 - 20.1)      | 8.03 (3.46 - 19.6)     | 7.87 (3.73 -19.6)     |
| Vss (L)                  |                         |                         |                             |                         |                        |                       |
| Arithmetic Mean (%CV)    | 980 (30.9)              | 987 (31.2)              | 552 (13.6)                  | 552 (13.8)              | 546 (18.9)             | 546 (19.0)            |
| Geometric Mean (Geo %CV) | 935 (31.0)              | 918 (29.8)              | 547 (13.6)                  | 547 (13.7)              | 537 (18.7)             | 536 (18.6)            |
| Median (Min-Max)         | 892 (464- 2050)         | 891 (409-2050)          | 552 (376 - 929)             | 553 (376 - 929)         | 541 (341 - 914)        | 538 (351 - 914)       |

a. Onlythosepatientsreceiving150mgIVq12hanalyzed.

Note: Abbreviationsareprovided intheAbbreviationListing.

b. AuCo-24isthetotal-drugAuCcalculatedvianumerical integrationof theconcentration-timeprofilefromthetimeof thefirstdoseuntil 24hours.

d. Cmax is the highest total-drug concentration observed in first 24 hours of therapy.

C. CL is intermsof unboundlefamulin.

e. Cmin is the lowest total-drug concentration observed in first 24 hours of therapy.

Overall, the model-based simulations indicate that lefamulin is expected to undergo limited accumulation to steady-state. Total- and free-drug plasma exposure is predicted to be 15 to 43% higher at steady-state, depending on the route of administration and concomitant food intake. ELF concentrations are expected to be subject to slightly more accumulation than plasma.

Metabolite BC-8041 exposures in patients with CAP were predicted to be about 3.5 to 10 times lower than those for parent lefamulin. In addition, BC-8041 exposures were about 1.5 to 3 times higher after oral vs. IV

<div style=\"page-break-after: always\"></div>

administration, consistent with the results of Phase 1 studies (BC-8041 was not assayed for samples obtained in Phase 2).

## Impaired renal function

Study 1011 evaluated PK after a single 150 mg IV dose in groups with: Normal function: 7 subjects with CrCLCG ≥90 mL/min were matched to those with severe renal impairment with regard to gender, age (±10 y) and weight (±10 kg) Severe impairment: 8 subjects with severe renal impairment (eGFR-MDRD &lt;30 mL/min/1.73m 2 ) 8 subjects requiring haemodialysis; these subjects also received an on-dialysis dose such

ESRD on dialysis: that dialysis began within 1 hour after the study drug infusion had completed.

Over 36 h post-dose, mean lefamulin and BC-8041 plasma Cmax concentrations were comparable between the normal and severe groups but the AUC was higher in the latter (lefamulin 12262 vs. 9004 ng.h/mL; BC-8041 695 vs. 413 ng.h/mL). Lefamulin and BC-8041 exposures were similar between the On-dialysis and Offdialysis treatment periods. Lefamulin and BC-8041 were not measurable in the dialysate, and no meaningful differences were observed in the pharmacokinetics when dialysis was performed. It was concluded that lefamulin can be administered without regard to renal function or to the timing of haemodialysis.

## Impaired hepatic function

In 1010 a single 150 mg IV dose was given to:

- Subjects with normal hepatic function (matched to subjects with hepatic impairment)
- Subjects with moderate hepatic impairment (Child-Pugh Score 7 to 9 points; Class B)
- Subjects with severe hepatic impairment (ChildPugh Score ≥10 points, Class C)

Mean lefamulin and BC-8041 plasma concentrations were mostly comparable across the 3 groups for the first 12 h, followed by slightly slower rates of elimination for subjects with hepatic impairment. Mean lefamulin Cmax decreased with decreasing hepatic function. Lefamulin and BC-8041 AUCs increased with decreasing hepatic function. Lefamulin CL decreased slightly with hepatic impairment but CLr increased &gt;2-fold in subjects with hepatic impairment, which may have helped compensate for any possible decreases in elimination due to hepatic impairment. It was proposed that some differences may be related to distribution of lefamulin into ascitic fluid. It was concluded that no dose adjustment is necessary according to hepatic function.

<div style=\"page-break-after: always\"></div>

Table 14. Summary of Lefamulin and BC-8041 Pharmacokinetic Parameters by Hepatic Function Status Group

| PK Parameter (Unit)   | Normal (N=11) Mean (SD)   | Moderate (N=8) Mean (SD)   | Severe (N=8) Mean (SD)   |
|-----------------------|---------------------------|----------------------------|--------------------------|
| Lefamulin             | Lefamulin                 | Lefamulin                  | Lefamulin                |
| Cmax (ng/mL)          | 2463 (403)                | 1746 (524)                 | 1468 (328)               |
| tmax (h)              | 1.04 (0.153)              | 1.11 (0.172)               | 1.01 (0.0124)            |
| AUC (h*ng/mL)         | 7615 (1554)               | 8233 (2286)                | 8938 (1640)              |
| CL (L/h)              | 20.5 (4.45)               | 19.6 (6.02)                | 17.4 (3.76)              |
| tyu (h)               | 11.5 (1.75)               | 13.6 (3.06)                | 17.5 (3.35)              |
| Ae (mg)               | 9.74 (2.47)               | 21.0 (6.45)                | 24.5 (6.88)              |
| BC-8041               | BC-8041                   | BC-8041                    | BC-8041                  |
| Cmax (ng/mL)          | 33.3 (9.69)               | 37.9 (41.2)                | 20.4 (12.3)              |
| tmax (h)              | 1.29 (0.104)              | 1.52 (0.314)               | 1.38 (0.134)             |
| AUC (h*ng/mL)         | 303 (116)                 | 499 (463)                  | 647 (441)                |
| tu (h)                | 14.4 (4.51)               | 24.4 (20.0)                | 33.8 (14.8)              |
| Ae (mg)               | 0.326 (0.0990)            | 0.691 (0.441)              | 0.968 (0.646)            |

Ae=amount excreted unchanged in urine; AUC=area under the plasma concentration-time curve extrapolated

through infinity; CL=systemic clearance (observed) estimated using AUC; Cmax=maximum observed concentration;

N=total number of subjects; PK=pharmacokinetic; SD=standard deviation; ty=terminal elimination half-life;

tmax=time of maximum observed concentration.

## Other special populations

The POPPK model indicated that lefamulin plasma concentrations should be very similar between male and female subjects and that none of race, BMI or age had an important effect on lefamulin plasma concentrations. The age range of subjects included in the POPPK analysis was as shown below.

Table 15. Summary statistics or counts of subject demography, pooled pharmacokinetic analysis dataset

| Variable   | Phase1 (N =98) median (Min.-Max.)   | Phase2 (N =129) median (Min.-Max.)   | Phase3 (N = 622) median (Min.-Max.)   | Total (N=849) median (Min.-Max.)   |
|------------|-------------------------------------|--------------------------------------|---------------------------------------|------------------------------------|
| Age (yr)   | 50 (19-77)                          | 41 (18-73)                           | 61 (19-97)                            | 57 (18-97)                         |

Study 1003 examined the effects of age and gender after single 150 mg IV doses. The mean plasma concentration-time profiles of lefamulin were similar between genders. Covariate analysis did not indicate any effect of body weight, height or BMI. Clearance varied little with age and Cmax and AUC demonstrated no statistically significant differences between the two age groups. The mean residence time and t½ tended to be

<div style=\"page-break-after: always\"></div>

slightly longer in the group aged ≥ 65 years and GM Vd and Vss values were greater in the group aged ≥ 65 years.

Table 16. Plasma pharmacokinetic variables of BC-3781 in subjects age 18-55 years (n=26) and age ≥ 65 years (n=12) after a single BC-3781 150 mg administered as a 60-minute intravenous infusion

|                    | C, max [μg/ml]           | AUCo-inf [μg:h/ml]       | AUC0-24 [μg:h/ml]        | t/2 [b]                  | MRT [b]                  | CL [1/h]                 | Va [凹]                   | √ss [1]                  |
|--------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                    | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years | Subjects age 18-55 years |
| Geometricmean      | 2.59                     | 7.66                     | 7.03                     | 8.88                     | 7.16                     | 19.6                     | 251                      | 140                      |
| CV% Geometric mean | 23.9                     | 24.5                     | 23.8                     | 12.2                     | 11.7                     | 24.5                     | 24.5                     | 22.3                     |
|                    | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  | Subjects age > 65 years  |
| Geometric mean     | 2.44                     | 7.50                     | 6.68                     | 10.4                     | 8.27                     | 20.0                     | 299                      | 166                      |
| CV% Geometric mean | 22.8                     | 33.6                     | 32.1                     | 15.8                     | 17.1                     | 33.6                     | 28.7                     | 26.2                     |

Table 17. Geometric mean ratios and 90% confidence intervals of CL and volume of distribution of BC-3781 in subjects age 18-55 years (n=26) and subjects age ≥ 65 years (n=12)

| Variable                               |   Lower90% confidenceinterval |   Geometricmean ratio |   Upper 90% confidenceinterval |
|----------------------------------------|-------------------------------|-----------------------|--------------------------------|
| Clearance                              |                          0.87 |                  1.02 |                           1.2  |
| Volume of distribution                 |                          1.03 |                  1.19 |                           1.39 |
| Volume of distribution at steady state |                          1.03 |                  1.18 |                           1.35 |

## Interactions

## In vitro

- o Lefamulin inhibited CYP3A4/5 (IC50=3.0 to 15 μM) using pooled HLMs. There was a very low inhibition potential against CYP3A-mediated testosterone hydroxylation (IC50 &gt; 300 μM) while midazolam hydroxylation was inhibited with an IC50 value of 5.5 μM.
- o Weak inhibition of CYP2C8 (IC50 =73 μM, Ki=41 μM) was observed in HLMs.
- o There was no inhibition of CYP1A2, 2B6, 2C9, 2C19 or 2D6 to a relevant extent.
- o No significant potential for time-dependent or metabolism-dependent inhibition was observed for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5 using pooled HLMs.
- o No induction of CYP1A2, CYP2B6 or CYP3A4/5 was detected in human hepatocytes.
- o Lefamulin is a substrate of the hepatic uptake transporter OCT1 and the efflux transporter P-gp.

<div style=\"page-break-after: always\"></div>

- o Lefamulin is not a substrate of the efflux transporters BCRP, BSEP, MATE1 or MATE2-K nor is it a substrate for the uptake transporters OATP1B1 and OATP1B3.
- o Lefamulin showed P-gp inhibitor potential (IC50=13.8 to 34.1 μM).
- o Induction of P-gp was not investigated but is unlikely due to no induction of CYP450 enzymes.
- o Lefamulin inhibited the hepatic efflux transporter BSEP, the efflux transporter BCRP, the hepatic uptake transporter OCT1 and the efflux transporter MATE1.
- o Very low inhibition was seen with hepatic uptake transporters OATP1B1 and OATP1B3.
- o There was no inhibition potential for the renal transporters OAT1, OAT3, OCT2 and MATE2-K.

## In vivo

The clinical DDI studies and their results are summarised below.

Table 18. Clinical Drug-Drug Interaction Studies conducted with lefamulin

<!-- image -->

GMIR=geomemic mean ratio; Keto=ketoconazole; LMU=lefamulin; MD=multiple doses; MID=midazolam; PO=by mouth (oral); RIF=rifampin; SD=single dose. 1.25-to 2-fold increase m the plasma AUC or50%inhibition oforal clearance,Moderate inhibitor causes a&gt;2-fold increase in theplasma AUC or50 to80%inhibition oforal

bMidkzolam co-administeredwithlefkmulin Vsmidazolam alone.

FDACYPinhibitorsareclassified asfollows:Weakinhibitor≥1.25but2-foldincresseinAUCor20-509decrease inCL,Moderate inhibitor≥2but&lt;5-foldincrenseinAUC or 50to80%decrease in CL,Strong inhibitor25-fold increase inAUC or&gt;80%6decrease inCL.CYPinducers are classified as follows:Wealk inducer 20to50%6decrease in AUC,Mfoderateinducer50to80%decrease inAUC,Stronginducer≥80%decrease inAUC(CDER,2017).EMACYPinhibitorsareclassifiedasfollows:Mfildinhibitorcauses clearance,Strong inhibitor causes a&gt;5-fold increasein the plasmaAUCvaluesor≥80%decrease in oral clearance.CYPinducers shouldbe classifiedbased on theireffect on PO midazolamclearanceorplasmaAUC.Mfild inducerS0%,Moderate inducer&gt;50 to80%,Strong inducer&gt;80%reductioninmidazolamAUC(EMA,2012)

cMidazolam edministered 2 hoursafterlefamulin Vsmidazolam alone.

d Midazolam ediministered 4 hours after lefamulin vs midazolam alone.

- o When lefamulin PO was given with midazolam PO, the midazolam AUCs were ~3-fold higher on oral coadministration and Cmax was ~2-fold higher.
- o When lefamulin PO was given with ketoconazole PO the lefamulin AUC increased by ~2.5-fold while Cmax increased ~1.5-fold. CL/F and Vd/F were reduced to about 30% on co-administration but t1/2 was unaffected. Co-administration also increased plasma exposures to the metabolite BC-8041, with

<div style=\"page-break-after: always\"></div>

reductions in CL/F and Vd/F but with an increase in t1/2 by ~ 3 h. The parent to metabolite ratio was not affected.

- o When lefamulin PO was given with rifampicin PO the lefamulin AUCs and, to a lesser extent, BC-8041 AUCs were lower. The molar metabolite to parent ratios (MR Cmax and MR AUC0-∞ ) increased when lefamulin was administered after multiple dosing with rifampicin, i.e. more metabolite was produced vs. lefamulin given alone.
- o Rifampicin had a lesser effect on IV lefamulin but a greater effect on BC-8041 compared to the effects seen with oral lefamulin. This differential effect of rifampicin on lefamulin and BC-8041 resulted in marked decreases (~84%) in the metabolite to parent ratios for Cmax and AUC0-∞ .
- o The impact of these observed effects of rifampicin on lefamulin was assessed by estimating the PTA after incorporating the data into the POPPK model (00488-2). The population mean effect of rifampicin on bioavailability was a reduction of 58.1% in absolute bioavailability and the effect on clearance was a 41% increase. Using this model and Monte Carlo simulation, co-administration of rifampicin with IV and PO lefamulin was predicted to reduce the MIC values at which PTA was &gt;90% by 1 and 2 dilution values, respectively.

## PB-PK modelling

A PB-PK model was developed and validated against clinical data as described in a separate PBPK model development report. The model was used to predict the DDI potential of IV and oral lefamulin at the final clinical doses.

## Lefamulin as victim

- o The PBPK model predicted reductions in the lefamulin Cmax and AUC of 8% and 30% (IV lefamulin) and 24% and 43% (oral lefamulin), respectively, when administered with the CYP3A inducer efavirenz.
- o No important effects on lefamulin when given IV or PO were predicted when co-administered with fluconazole (moderate inhibitor of CYP3A) 200 mg QD or fluvoxamine (weak inhibitor of CYP3A4) at 100 mg BID.

## Lefamulin as perpetrator

- o Orally administered lefamulin was predicted to result in 42% and 29% increases, respectively, in the mean AUC and Cmax of the CYP3A4/2C8 substrate repaglinide, with negligible effects (&lt;10%) predicted when lefamulin was administered IV.
- o Negligible effects on exposures to the CYP3A4 substrates ethinyl oestradiol and zolpidem were predicted when lefamulin was administered IV (&lt;10%), whereas Cmax and AUC were predicted to increase by 18% and 24% for ethinyl oestradiol and 14% and 37% for zolpidem, respectively, following oral administration of lefamulin. Neither effect was considered clinically relevant.

<div style=\"page-break-after: always\"></div>

- o Negligible effects were predicted on exposure to the OATP1B1/OATP1B3/BCRP substrate rosuvastatin following either IV or oral administration of lefamulin even after applying a 10-fold correction factor to account for uncertainty.
- o Mean increases in Cmax and AUC to the OCT2/MATEs substrate metformin of &lt;20% were predicted following IV and oral administration of lefamulin. Accounting for potential uncertainty of the in vitro assays (by applying a 20-fold correction factor), the effects on metformin Cmax and AUC were predicted to increase to 27% and 60%, respectively for IV lefamulin and 30% and 65%, respectively for oral lefamulin.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Pleuromutilins inhibit prokaryotic ribosomal protein synthesis by binding to the peptidyl transferase centre at the 50S subunit of the bacterial ribosome.

## Primary pharmacology

The CLSI-recommended MIC assay conditions produced reproducible results. Alternative assay conditions resulted in either higher MIC values (anaerobic and CO2 environments, higher inocula, pH 5, pH 6 and elevated calcium content [CoNS only]) or lower MIC values (lower inocula and pH 8). Adding polysorbate-80 at &lt;0.02% did not affect assay results but higher concentrations (0.2% and 2%) resulted in higher MICs. MIC results generated using CLSI-recommended media (CA-MHB±HLB or HTM) were similar to those generated using EUCAST recommended medium (MH-F) when testing S. pneumoniae , H. influenzae and M. catarrhalis . Addition of bovine lung surfactant at up to 4% v/v did not change the lefamulin MICs by more than one doubling dilution but increased daptomycin MICs by 160-fold. Addition of human serum (20%, 50% and 90% v/v ) reduced lefamulin activity by ≤2.5 -fold. Whilst BC-8041 plasma levels are ~10% of parent, MICs were in the range 8-&gt;256 mg/L compared to &lt;0.03 to 0.5 mg/L for lefamulin against the same panel of CAP pathogens. Therefore, this metabolite is not expected to contribute to the efficacy of lefamulin

Based on the table below, which includes isolates collected between 2011 and 2017, the spectrum of activity of lefamulin covers most Gram-positive cocci, including some anaerobic species, but not the enterococcal species. Lefamulin is active against several of the fastidious Gram-negative species (cocci and cocco-bacilli), including those associated with CAP ( H. influenzae and M. catarrhalis ). MICs of lefamulin are also low for the genera associated with atypical pneumonia. Most Gram-negative bacilli (enterobacteria and non-fermenting bacilli) are not covered by lefamulin, i.e. they are inherently insusceptible. Additional data have been collected for isolates of CAP-relevant species isolated between 2015-2017 have confirmed what is shown below. In particular, all S. pneumoniae have had lefamulin MICs ≤1 mg/L, with MIC 50 of 0.12 mg/L and MIC90 of 0.25 mg/L.

<div style=\"page-break-after: always\"></div>

Table 19. Lefamulin spectrum of activity

|                                                                 |                                                                 | Lefamulin MC (ug/mL)                                            | Lefamulin MC (ug/mL)                                            | Lefamulin MC (ug/mL)                                            |
|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Orgamism'                                                       | II                                                              | MIC50                                                           | MCgo                                                            | Range                                                           |
| Aerobic and facultative anaerobic Grain-positive microorgamisms | Aerobic and facultative anaerobic Grain-positive microorgamisms | Aerobic and facultative anaerobic Grain-positive microorgamisms | Aerobic and facultative anaerobic Grain-positive microorgamisms | Aerobic and facultative anaerobic Grain-positive microorgamisms |
| Staplylococcus aureus                                           | 11,037                                                          | 0.06                                                            | 0.12                                                            | ≤0.008 to 232                                                   |
| S. aureus, MSSA                                                 | 6,492                                                           | 0.06                                                            | 0.12                                                            | ≤0.008 to 232                                                   |
| S. aureus, MRSA                                                 | 4,545                                                           | 0.12                                                            | 0.12                                                            | ≤0.008 to 232                                                   |
| CA-MRSA (USA 300, USA400)                                       | 50                                                              | 0.12                                                            | 0.12                                                            | 0.06 to 0.12                                                    |
| VRSA, VISA, hVISA                                               | 30                                                              | 0.06                                                            | 0.25                                                            | 0.03 to 0.5                                                     |
| Coagulase-negative Staphylococcus spp.                          | 1,677                                                           | 0.06                                                            | 0.12                                                            | ≤0.008 to 232                                                   |
| S. epidermidis                                                  | 769                                                             | 0.06                                                            | 0.12                                                            | ≤0.008 to 232                                                   |
| Streptococcuspneumoniae                                         | 7.753                                                           | 0.12                                                            | 0.25                                                            | ≤0.008 to 1                                                     |
| S. pneumoniae, penicillin-resistantb                            | 29                                                              | 0.12                                                            | 0.12                                                            | 0.015 to 0.12                                                   |
| S. pneumoniae, macrolide-resistantc                             | 2,080                                                           | 0.06                                                            | 0.12                                                            | ≤0.008 to 1                                                     |
| S. pneumoniae, mmltidug-resistamtd                              | 518                                                             | 0.06                                                            | 0.12                                                            | ≤0.008 to 0.5                                                   |
| S. pyogenes (Group A Shreptococcus spp.)                        | 652                                                             | 0.03                                                            | 0.03                                                            | ≤0.008 to 0.12                                                  |
| S. agalactiae (Group B Streptococcus spp.)                      | 683                                                             | 0.03                                                            | 0.03                                                            | ≤0.008 to 232                                                   |
| Group C Streptococcus spp.                                      | 116                                                             | 0.03                                                            | 0.06                                                            | 0.015 to 0.5                                                    |
| Group G Shr'eptococcus spp.                                     | 230                                                             | 0.03                                                            | 0.06                                                            | 0.015 to 0.25                                                   |
| Viridans Group Streptococcus spp.                               | 595                                                             | 0.12                                                            | 0.5                                                             | ≤0.008 to 232                                                   |
| E.faecalis                                                      | 24                                                              | 32                                                              | 128                                                             | 16 to 128                                                       |
| E.faecium                                                       | 850                                                             | 0.12                                                            | 8                                                               | 0.015 to 232                                                    |
| E. faecium, vancomycin-susceptible                              | 361                                                             | 0.12                                                            | 232                                                             | 0.03 to 232                                                     |
| E. faecium, vancomycin-resistant                                | 389                                                             | 0.06                                                            | 0.5                                                             | 0.015 to232                                                     |

<div style=\"page-break-after: always\"></div>

|                                                                |                                                                | Lefamulin MIC (ug/mL)                                          | Lefamulin MIC (ug/mL)                                          | Lefamulin MIC (ug/mL)                                          |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Organism'                                                      |                                                                | MIC:0                                                          | MICgo                                                          | Range                                                          |
| Aerobic and Facultative Anaerobic Gram-negative Microorganisms | Aerobic and Facultative Anaerobic Gram-negative Microorganisms | Aerobic and Facultative Anaerobic Gram-negative Microorganisms | Aerobic and Facultative Anaerobic Gram-negative Microorganisms | Aerobic and Facultative Anaerobic Gram-negative Microorganisms |
| B. perhussis                                                   | 6                                                              |                                                                |                                                                | 0.03 to 0.03                                                   |
| H. influenzae                                                  | 2.198                                                          | 0.5                                                            | 2                                                              | 0.015 to 8                                                     |
| H. influenzae, B-lactamase positive                            | 400                                                            | 0.5                                                            | 1                                                              | 0.015 to 8                                                     |
| H. parainfluenzae                                              | 505                                                            | 1                                                              | 4                                                              | ≤0.008 to 8                                                    |
| H. ducrgyi                                                     | 6                                                              |                                                                |                                                                | ≤0.015 to 0.25                                                 |
| L. pneumophila                                                 | 44                                                             | 0.5                                                            | 1                                                              | 0.12 to 1                                                      |
| M. catarrhalis                                                 | 1,306                                                          | 0.06                                                           | 0.12                                                           | ≤0.008 to 1                                                    |
| N. gonorrhoede                                                 | 344                                                            | 0.25                                                           | 1                                                              | ≤0.008 to 2                                                    |
| N. gonorrhoeae, azithromycin-resistant                         | 123                                                            | 0.5                                                            | 1                                                              | 0.016 to 2                                                     |
| E. coli                                                        | 32                                                             | 16                                                             | 64                                                             | 8 to 128                                                       |
| K. pneumoniae                                                  | 24                                                             | 128                                                            | 256                                                            | ≤1 to 512                                                      |
| Anaerobic Microorganisms                                       | Anaerobic Microorganisms                                       | Anaerobic Microorganisms                                       | Anaerobic Microorganisms                                       | Anaerobic Microorganisms                                       |
| C. difficile                                                   | 43                                                             | 4                                                              | 8                                                              | 0.25 to 264                                                    |
| Clostridioides spp.                                            | 10                                                             | 1                                                              | >16                                                            | 0.06 to 232                                                    |
| Peptostreptococcus spp.                                        | 10                                                             | 0.06                                                           | 1                                                              | 0.03 to 2                                                      |
| Porphyromonas spp.                                             | 10                                                             | 0.03                                                           | 0.03                                                           | 0.03                                                           |
| B.fragilis                                                     | 11                                                             | 16                                                             | 232                                                            | 2 to232                                                        |
| B. firagilis group                                             | 11                                                             | 232                                                            | 232                                                            | 1 to232                                                        |
| Prevotella spp.                                                | 10                                                             | 0.5                                                            | 4                                                              | 0.015 to 232                                                   |
| Propionibacterium spp.                                         | 17                                                             | 0.008                                                          | 0.12                                                           | 0.008 to 0.25                                                  |
| Other Microorganisims                                          | Other Microorganisims                                          | Other Microorganisims                                          | Other Microorganisims                                          | Other Microorganisims                                          |
| C. pneumoniae                                                  | 50                                                             | 0.02                                                           | 0.04                                                           | 0.02 to 0.08                                                   |
| C.trachomatis                                                  | 15                                                             | 0.02                                                           | 0.04                                                           | 0.01 to 0.04                                                   |
| M. genitalium                                                  | 41                                                             | ≤0.08                                                          | 0.06                                                           | 0.005 to 0.06                                                  |
| M. genitalium                                                  | 5                                                              |                                                                |                                                                | 0.016 to 0.06                                                  |
| M. pneumoniaef                                                 | 61                                                             | 0.001                                                          | 0.002                                                          | ≤0.00025 to 0.008                                              |
| M. pneumoniae, macrolide-resistant                             | 7                                                              | ≤0.001                                                         | 0.008                                                          | ≤0.001 to 0.008                                                |

Lefamulin was bactericidal in vitro (≥3 log 10 reduction in CFU/mL) against S. pneumoniae , H. influenzae and M. pneumoniae at concentrations achievable in plasma and ELF. Using the checkerboard method, lefamulin did not antagonise antibacterial agents that also act at the bacterial ribosome.

<div style=\"page-break-after: always\"></div>

## Resistance

The spontaneous mutation frequencies for lefamulin in staphylococci and streptococci were low (≤10 -9 ) with no stable resistant mutants selected at 4-fold to 8-fold MIC. The intrinsic resistance of E. coli is mediated by the AcrAB-TolC efflux pump. Mechanisms of acquired resistance to lefamulin include:

Target protection by ABC-F proteins (formerly erroneously reported as putative efflux pumps):

- vga (A-E) of Staphylococcus spp.
- lsa (E) of S. agalactiae , Enterococcus spp. and S. aureus
- sal (A) (this gives intrinsic resistance in coagulase-negative Staphylococcus spp.)

## Modification of the target:

- Mutations in rplC and rplD genes encoding ribosomal proteins located outside of PTC
- Mutations in domain V of the 23S rRNA
- Cfr methyl transferase methylating A2503 in the PTC

Lefamulin binds to the pocket formed between the nucleotides G2576 with U2506 and G2505 in domain V of the 23S rRNA. G2576 is a nucleotide also critical for the activity of oxazolidinones. Linezolid MIC levels were increased 4-fold to 128-fold by G2576T and MICs of lefamulin were increased 2-fold to 16-fold when compared with the MIC90 of clinical wild-type isolates in the same study.

## Efficacy in animal infection models

Numerous studies were conducted. Some of the more important results include the following:

- In the murine thigh infection model using MSSA and MRSA in immunocompetent and neutropenic mice (MNT), lefamulin 50 mg/kg BID subcutaneously gave ~2.5 log10 kill for MSSA and MRSA and 80 mg/kg BID orally gave ~-3.5 log10 kill for MSSA but 1.3 log10 kill for MRSA.
- In the MNT model the total lefamulin AUC0-24 values after single subcutaneous doses of 20 and 80 mg/kg were 2.39 and 8.18 μg.h/mL, respectively. The dose -normalised AUC0-24 values were 0.120 and 0.102 μg.h/mL per mg/k g for respective doses. To evaluate the total lefamulin AUC for the calculated daily bacteriostatic doses, the mean dose-normalised AUC0-24 value of 0.11 μg.h/mL per mg/kg was used.
- In further MNT studies, single doses of 10, 20 or 40 mg/kg lefamulin showed maximum killing of a S. aureus and a S. pneumoniae strain at the lowest dose but higher doses delayed regrowth.

## PK-PD index

A dose fractionation study in the MNT model was conducted to determine the PK-PD index using one S. pneumoniae and one S. aureus strain. Lefamulin free drug concentrations (20.8 to 24.6% of total based on murine plasma protein binding results) were applied. The f AUC0-24/MIC ratio was considered to be the PK-PD index while f T&gt;MIC was considered less important for S. pneumoniae and S. aureus .

<div style=\"page-break-after: always\"></div>

Figure 4. Relationship of different PK/PD indices and the antimicrobial activity of lefamulin against Streptococcus pneumoniae ATCC 10813 and Staphylococcus aureus ATC 25923 in the thighs of neutropenic mice

<!-- image -->

## PDTs

In a comparative PK/PD analysis of lefamulin efficacy against various S. pneumoniae strains causing thigh and lung infections in neutropenic mice, the EC20, EC50 and the EC80 indicated 4.9-fold, 4.0-fold and 3.4-fold greater activity in murine lung vs. thigh infections caused by S. pneumoniae.

<div style=\"page-break-after: always\"></div>

Table 20. Effect of site of infection on the activity of lefamulin against Streptococcus pneumoniae

<!-- image -->

|            | Thigh              | Lung               |                   |
|------------|--------------------|--------------------|-------------------|
| Endpoint   | Plasma24hfAUC/MIIC | Plasma24hfAUC/MIIC | Enhancement Ratio |
| Stasis     | 6.40               | 0.76               | 8.4-fold          |
| -1log kill | 8.92               | 1.51               | 5.9-fold          |
| EC50       | 7.28               | 1.80               | 4.0-fold          |
| EC20       | 2.96               | 0.61               | 4.9-fold          |
| ECgo       | 17.9               | 5.25               | 3.4-fold          |

24 hfAUC/MIC=ratio of free drug AUC over 24 hours, divided by the MIC value: EC;=effective concentration for X% effect.

In the thigh infection model following 2 doses of lefamulin a mean plasma 24 h f AUC/MIC ratio of 5.23 (4.316.11) was required to achieve a mean (11 strains tested) net static effect for S. pneumonia e.

For lung infections caused by S. pneumoniae and S. aureus the median 24 h AUCELF/MIC targets to achieve a 1-log10 kill were 14.0 and 21.7, respectively. These were derived from plasma PDTs after accounting for the 2-fold higher total lefamulin concentrations in uninfected mouse ELF vs. plasma.

<div style=\"page-break-after: always\"></div>

Table 21. 24h AUC/MIC Ratio Targets for lefamulin against Streptococcus pneumoniae and Staphylococcus aureus Isolates in the Neutropenic Murine Lung Infection Model

<!-- image -->

|                            |                       |               | 1-logio CFU Reduction   | 1-logio CFU Reduction   |
|----------------------------|-----------------------|---------------|-------------------------|-------------------------|
| Species                    | Isolate               | MIIC- [μg/mL] | Plasma 24hfAUCAIICb     | 24hAUCELFAHIC           |
| S.pneunoniae               | PISP(B1378/SENTRY)    | 0.12          | 6.05                    | 61.8                    |
| Report NABRIVA 2013-04PKPD | PSSP(B1382/SENTRY)    | 0.25          | 2.73                    | 27.9                    |
| Report NABRIVA 2013-04PKPD | PRSP,MR(B1383/SENTRY) | 0.25          | 0.67                    | 6.84                    |
| Report NABRIVA 2013-04PKPD | PSSP(B1385/SENTRY)    | 0.5           | 1.34                    | 13.7                    |
| Report NABRIVA 2013-04PKPD | PISP.MR(B1386/SENTRY) | 0.5           | 1.37                    | 14.0                    |
| Report NABRIVA 2013-04PKPD | Mfean                 |               | 2.43                    | 24.9                    |
| Report NABRIVA 2013-04PKPD | Mfedian               |               | 1.37                    | 14.0                    |
| Report NABRIVA 2013-04PKPD | Range                 |               | 0.67 to 6.05            | 6.84 1o61.8             |
| S.aureus 2014-03PKPD       | MSSA(B154/ATCC25923)  | 0.12          | 1.69                    | 17.2                    |
| Report NABRIVA             | MRSA(B341/ATCC33591)  | 0.06          | 5.94                    | 60.7                    |
| Report NABRIVA             | CA-MRSA,USA300(B1118) | 0.12          | 0.76                    | 7.72                    |
| Report NABRIVA             | MRSA(B1325/SENTRY)    | 0.5           | 2.13                    | 21.7                    |
| Report NABRIVA             | MRSA(B1331/SENTRY)    | 0.5           | 4.35                    | 44.5                    |
| Report NABRIVA             | Mlean                 |               | 2.97                    | 30.4                    |
| Report NABRIVA             | Mledian               |               | 2.13                    | 21.7                    |
| Report NABRIVA             | Range                 |               | 0.76 to5.94             | 7.72 1o60.7             |

## Secondary pharmacology

## Effect on QTc

An analysis across Phase 1 data showed a significant relationship between lefamulin plasma concentrations after IV and oral dosing with change from baseline in QTcF. IV administration showed a steeper slope (0.0045 msec/ng/mL vs. 0.0034 msec/ng/mL) and an elevated intercept (1.6 msec vs. -2.54 msec) compared to oral administration, consistent with the higher Cmax for IV dosing. The model estimated that QTcF prolonging effects for an IV steady state Cmax (2770 ng/mL) as compared to oral (steady state is 1850 ng/mL) were approximately 12.5 vs. 6.3 msec. Using historical moxifloxacin data, a 200 mg dose of lefamulin gave about 33-66% of the prolongation effect of moxifloxacin. A regression analysis indicated that the maximum change in QTcF from baseline is &gt;10 msec at plasma lefamulin concentrations ≥3500 ng/mL.

<div style=\"page-break-after: always\"></div>

Figure 5. Change from Baseline Values in QTcF at T(max) by dose

<!-- image -->

Dose[mg]

T（max):time ofmaximummean change ofQTeF from baseline

The applicant did not conduct a TQT study but incorporated extensive ECG evaluations in trials in patients with a central reader and independent cardiac expert review.

## In summary:

- o Lefamulin was found to have a greater potential for QT prolongation than vancomycin (Phase 2 ABSSSI trial) but a lesser potential than moxifloxacin (Phase 3 CAP trials).
- o No Phase 2 subject had a QTcF value of &gt;480 msec or a post baseline QTcF increase of &gt;60 msec.
- o In the Phase 3 trial 3101, the mean change from baseline in QTcF interval at the steady-state assessment was 13.8 msec for IV lefamulin and 16.4 msec for moxifloxacin.
- o In the Phase 3 trial 3102 the mean change from baseline in QTcF interval at the steady-state assessment was 9.5 msec for lefamulin and 11.6 msec for moxifloxacin. There were no associated cardiac arrhythmias of concern and in several categorical analyses the degrees of QTcF change were lower for lefamulin.
- o In 3101, one lefamulin and 3 moxifloxacin patients discontinued study drug because of prolonged QTc while in 3102 one lefamulin patient discontinued for this reason.

## Relationship between plasma concentration and effect

PK-PD analysis supporting IV lefamulin dose selection for CAP trial 3101 (00353-2; 2014)

The analysis used total drug ELF and free-drug plasma AUC/MIC ratio PDTs (median and second highest among the isolates studied) as shown below. The median and second highest 1-log10 and 2-log10 kill PDTs

<div style=\"page-break-after: always\"></div>

used for estimations of plasma PTA were taken from the murine lung infection data, which gave much lower PDTs vs. the thigh model (see above). The highest PDTs observed in the neutropenic murine lung infection model were:

- S. pneumoniae - 6.05 plasma and 61.8 ELF for 1-log10 kill; 10.7 and 109 for 2-log10 kill
- S. aureus - 5.94 plasma and 60.7 ELF for 1-log10 kill; 15.3 and 157 for 2-log10 kill

Table 22. Summary of AUC:MIC ratio targets for S. pneumoniae and S. aureus

| Pathogen      | Bacterial reduction endpoint (log10 CFU reduction from baseline)   | AUC:MIC ratio target in the distribution of targets   | AUc:MlC ratio target by matrix   | AUc:MlC ratio target by matrix   |
|---------------|--------------------------------------------------------------------|-------------------------------------------------------|----------------------------------|----------------------------------|
| Pathogen      | Bacterial reduction endpoint (log10 CFU reduction from baseline)   | AUC:MIC ratio target in the distribution of targets   | ELF                              | Free-drug plasma                 |
|               | 1                                                                  | median                                                | 14.0                             | 1.37                             |
|               | 1                                                                  | second highest                                        | 27.9                             | 2.73                             |
| S. pneumoniae | 2                                                                  | median                                                | 22.0                             | 2.15                             |
| S. pneumoniae | 2                                                                  | second highest                                        | 40.5                             | 3.96                             |
|               | 1                                                                  | median                                                | 21.7                             | 2.13                             |
|               | 1                                                                  | second highest                                        | 44.5                             | 4.35                             |
|               | 2                                                                  | median                                                | 63.9                             | 6.24                             |
|               | 2                                                                  | second highest                                        | 85.7                             | 8.39                             |

The POPPK model was not the final model (00488-1; 2018). The f AUC0-24 for plasma and the AUC0-24 for ELF were simulated for 150 mg IV q12h on Day 1.

PTA based on plasma levels The PTA for the 1-log10 PDT for S. pneumoniae was 97.9% at a MIC value of 0.5 mg/L for the median and 97.9% at a MIC value of 0.25 mg/L for the second highest target. Using the median PDT for 2-log10 kill, the PTA was 99.6% at MIC 0.25 mg/L and 82.5% at 0.5 mg/L while PTA at the second highest PDT for 2-log10 kill was 99.8% at 0.12 mg/L, 87.4% at 0.25 mg/L and 32.2% at 0.5 mg/L.

PTA based on ELF levels The PTA for the median 1-log10 PDT was 97.0% at a MIC of 0.5 mg/L for S. pneumoniae and 99.4% at a MIC of 0.25 mg/L for S. aureus . At the second highest PDT, PTA was 97% and 78.8% for respective species and MICs. For the 2-log10 kill PDTs, the PTA for S. pneumoniae was 99.4% for the median PDT at MIC 0.25 mg/L and 99.7% at the second highest PDT at MIC 0.12 mg/L. Corresponding PTA for S. aureus at 2-log10 kill PDTs was 95.3% at MIC 0.12 mg/L for the median and 99.5% at MIC 0.06 mg/L for the second highest PDT.

## PK-PD analysis supporting oral lefamulin dose selection for CAP trials (00429-2; 2016)

The PDTs and approaches to generating the estimated PTA were as described above for the IV dose. The POPPK model was not the final model (00488-1; 2018). Free-drug plasma and total-drug ELF concentrationtime profiles from 0-24 h were generated for each simulated subject following 600 mg PO q12h under fed and fasted conditions.

<div style=\"page-break-after: always\"></div>

PTA based on plasma levels For the 1-log10 kill f AUC0-24/MIC PDTs for S. pneumoniae and S. aureus the PTA for the median PDT on Day 1 was ≥95.5% at a MIC value of 0.5 mg/L for S. pneumoniae and ≥99.5% at a MIC value of 0.25 mg/L for S. aureus. At the MIC90 values (0.25 and 0.12 mg/L, respectively) the PTA using median targets was 100%.

PTA based on ELF levels The report states that simulated total-drug ELF exposures did not match with those expected based upon previous analyses. Effectively, it appears that this means that the PTA was lower than expected in ELF. For example, using Day 1 PK, the PTA for S. pneumoniae 1-log kill PDTs suggested that only MICs of 0.06-0.12 mg/L might be covered by the oral dose and perhaps 0.12-0.25 mg/L on Day 5.

## PK-PD analysis of data obtained based on IV and PO Phase 3 trials (00488-2)

This report of November 2018 used the final POPPK model (00488-1), which incorporated data from the efficacy studies in CAP (3101 and 3102), to evaluate PK-PD relationship(s) for efficacy and evaluate the sufficiency of the IV and oral dose regimens. The analysis populations for this exercise included lefamulintreated patients with PK data from among the microbiologically evaluable (ME) population. PK-PD relationships for efficacy were evaluated using the f AUC0-24/MIC ratio, free-drug plasma AUC, total-drug ELF AUC/MIC ratio, total-drug ELF AUC and MIC.

Lefamulin free-drug plasma and total-drug ELF concentration-time profiles were generated for 5,000 simulated patients with CAP after administration of 150 mg q12h IV or 600 mg q12h PO in fasted and fed conditions for 5 days. Using numerical integration, the free-drug plasma and total-drug ELF AUC0-24 corresponding to Days 1 and 3 were calculated. The figures below show the plasma free drug AUCs and the total drug ELF AUCs by dose regimen for simulated patients. The lefamulin oral dosing regimen under fasted conditions gave Day 1 mean and median free-drug plasma AUCs comparable to those achieved after 150 mg BID IV but values after oral dosing in the fed state were 38.2 and 41.0% lower, respectively, than those based on the IV dosing regimen. Similarly, the Day 1 mean and median total-drug ELF AUC values were 40.7 and 43.4% lower after oral dosing in the fed state vs. IV dosing. While AUCs all increased from Day 1 to 3, oral dosing under fed conditions still gave lower AUCs compared to the other regimens.

Figure 6. Box-and-whisker plots showing distributions of free-drug plasma AUC on Days 1 and 3 among simulated patients after administration of lefamulin IV and PO dosing regimens

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7. Box-and-whisker plots showing distributions of total-drug ELF AUC on Days 1 and 3 among simulated patients after administration of lefamulin IV and PO dosing regimens

<!-- image -->

All patients with S. pneumoniae or S. aureus at baseline, irrespective of culture type, achieved the nonclinical free-drug plasma and total-drug ELF AUC/MIC ratio PDTs.

The PTA for S. pneumoniae on Day 1 exceeded 90% at 0.25 μg/mL for 150 mg IV q12h and 600 mg PO q12h administered under fasted conditions. Under fed conditions the oral regimen achieved PTA from 78.5 to 100%.

The PTA for S. aureus PDTs at 0.12 μg/mL was &gt;90% regardless of dose route and regimen.

<div style=\"page-break-after: always\"></div>

Table 23. Percent probabilities of PK-PD target attainment by MIC on Day 1 based on median or randomly assigned AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus among simulated patients after administration of lefamulin dosing regimens

|         | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   | Percentprobability of PK/PD target attainment by MIC onDay 1 by median total-drug ELF orfree-drug plasma AuC:MiCratio targetsforS.pneumoniae and S.aureus   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MIC     | Total-drug ELF                                                                                                                                              | Total-drug ELF                                                                                                                                              | Total-drug ELF                                                                                                                                              | Total-drug ELF                                                                                                                                              | Total-drug ELF                                                                                                                                              | Total-drug ELF                                                                                                                                              | Free-drug plasma                                                                                                                                            | Free-drug plasma                                                                                                                                            | Free-drug plasma                                                                                                                                            | Free-drug plasma                                                                                                                                            | Free-drug plasma                                                                                                                                            | Free-drug plasma                                                                                                                                            |
| (μg/mL) | Median                                                                                                                                                      | Median                                                                                                                                                      | Median                                                                                                                                                      | RandomlyAssigned                                                                                                                                            | RandomlyAssigned                                                                                                                                            | RandomlyAssigned                                                                                                                                            | Median                                                                                                                                                      | Median                                                                                                                                                      | Median                                                                                                                                                      | Randomly Assigned                                                                                                                                           | Randomly Assigned                                                                                                                                           | Randomly Assigned                                                                                                                                           |
|         | IV                                                                                                                                                          | PO                                                                                                                                                          | PO                                                                                                                                                          | IV                                                                                                                                                          | PO                                                                                                                                                          | PO                                                                                                                                                          | IV                                                                                                                                                          | PO                                                                                                                                                          | PO                                                                                                                                                          | IV                                                                                                                                                          | PO                                                                                                                                                          | PO                                                                                                                                                          |
|         | IV                                                                                                                                                          | Fed                                                                                                                                                         | Fasted                                                                                                                                                      | IV                                                                                                                                                          | Fed                                                                                                                                                         | Fasted                                                                                                                                                      | IV                                                                                                                                                          | Fed                                                                                                                                                         | Fasted                                                                                                                                                      | IV                                                                                                                                                          | Fed                                                                                                                                                         | Fasted                                                                                                                                                      |
| 0.12    | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.6                                                                                                                                                        | 95.2                                                                                                                                                        | 99.2                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.7                                                                                                                                                        | 100                                                                                                                                                         |
| 0.25    | 100                                                                                                                                                         | 98.3                                                                                                                                                        | 100                                                                                                                                                         | 94.1                                                                                                                                                        | 78.5                                                                                                                                                        | 91.4                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.5                                                                                                                                                        | 95.3                                                                                                                                                        | 99.1                                                                                                                                                        |
| 0.5     | 99.3                                                                                                                                                        | 76.6                                                                                                                                                        | 97.1                                                                                                                                                        | 75.0                                                                                                                                                        | 51.3                                                                                                                                                        | 72.0                                                                                                                                                        | 100                                                                                                                                                         | 98.8                                                                                                                                                        | 100                                                                                                                                                         | 94.0                                                                                                                                                        | 80.0                                                                                                                                                        | 91.5                                                                                                                                                        |
| 1       | 72.2                                                                                                                                                        | 19.1                                                                                                                                                        | 60.5                                                                                                                                                        | 44.8                                                                                                                                                        | 22.7                                                                                                                                                        | 41.8                                                                                                                                                        | 99.2                                                                                                                                                        | 79.3                                                                                                                                                        | 97.0                                                                                                                                                        | 75.1                                                                                                                                                        | 53.2                                                                                                                                                        | 72.4                                                                                                                                                        |
| Overall | 100                                                                                                                                                         | 99.6                                                                                                                                                        | 99.9                                                                                                                                                        | 99.0                                                                                                                                                        | 95.1                                                                                                                                                        | 98.5                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 99.2                                                                                                                                                        | 99.8                                                                                                                                                        |
| Pen-S   | 100                                                                                                                                                         | 99.7                                                                                                                                                        | 100                                                                                                                                                         | 99.0                                                                                                                                                        | 95.2                                                                                                                                                        | 98.5                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 99.2                                                                                                                                                        | 99.9                                                                                                                                                        |
| Pen-I   | 99.9                                                                                                                                                        | 99.3                                                                                                                                                        | 99.8                                                                                                                                                        | 98.5                                                                                                                                                        | 93.8                                                                                                                                                        | 97.9                                                                                                                                                        | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 100                                                                                                                                                         | 99.8                                                                                                                                                        | 98.8                                                                                                                                                        | 99.7                                                                                                                                                        |
| Pen-R   | 100                                                                                                                                                         | 99.8                                                                                                                                                        | 100                                                                                                                                                         | 99.3                                                                                                                                                        | 96.3                                                                                                                                                        | 99.0                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 99.5                                                                                                                                                        | 99.9                                                                                                                                                        |
| 0.12    | 100                                                                                                                                                         | 99.7                                                                                                                                                        | 100                                                                                                                                                         | 98.9                                                                                                                                                        | 91.5                                                                                                                                                        | 98.3                                                                                                                                                        | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 100                                                                                                                                                         | 99.2                                                                                                                                                        | 100                                                                                                                                                         |
| 0.25    | 99.8                                                                                                                                                        | 89.2                                                                                                                                                        | 99.3                                                                                                                                                        | 89.3                                                                                                                                                        | 70.1                                                                                                                                                        | 86.2                                                                                                                                                        | 100                                                                                                                                                         | 99.7                                                                                                                                                        | 100                                                                                                                                                         | 98.7                                                                                                                                                        | 91.6                                                                                                                                                        | 98.0                                                                                                                                                        |
| 0.5     | 90.3                                                                                                                                                        | 39.7                                                                                                                                                        | 81.7                                                                                                                                                        | 65.5                                                                                                                                                        | 39.9                                                                                                                                                        | 61.2                                                                                                                                                        | 99.8                                                                                                                                                        | 90.8                                                                                                                                                        | 99.2                                                                                                                                                        | 89.1                                                                                                                                                        | 72.0                                                                                                                                                        | 86.5                                                                                                                                                        |
| 1       | 21.2                                                                                                                                                        | 2.36                                                                                                                                                        | 20.3                                                                                                                                                        | 33.4                                                                                                                                                        | 14.0                                                                                                                                                        | 30.8                                                                                                                                                        | 89.4                                                                                                                                                        | 42.9                                                                                                                                                        | 81.8                                                                                                                                                        | 65.3                                                                                                                                                        | 41.8                                                                                                                                                        | 61.8                                                                                                                                                        |
| Overall | 99.5                                                                                                                                                        | 99.2                                                                                                                                                        | 99.5                                                                                                                                                        | 99.2                                                                                                                                                        | 96.9                                                                                                                                                        | 99.0                                                                                                                                                        | 99.8                                                                                                                                                        | 99.6                                                                                                                                                        | 99.8                                                                                                                                                        | 99.7                                                                                                                                                        | 99.3                                                                                                                                                        | 99.7                                                                                                                                                        |
| MRSA    | 98.8                                                                                                                                                        | 98.2                                                                                                                                                        | 98.7                                                                                                                                                        | 98.3                                                                                                                                                        | 95.3                                                                                                                                                        | 98.0                                                                                                                                                        | 99.4                                                                                                                                                        | 98.9                                                                                                                                                        | 99.3                                                                                                                                                        | 99.2                                                                                                                                                        | 98.5                                                                                                                                                        | 99.1                                                                                                                                                        |
| MSSA    | 99.9                                                                                                                                                        | 99.6                                                                                                                                                        | 99.9                                                                                                                                                        | 99.6                                                                                                                                                        | 97.6                                                                                                                                                        | 99.5                                                                                                                                                        | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 100                                                                                                                                                         | 99.9                                                                                                                                                        | 99.7                                                                                                                                                        | 99.9                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

Figure 8. Percent probabilities of PK-PD target attainment by MIC on Day 1 based on median AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline among simulated patients after administration of lefamulin IV and PO dosing regimens, overlaid over the MIC distribution for S. pneumoniae isolates

<!-- image -->

There were 92 lefamulin-treated patients with CAP from 3101 and 3102 who had a baseline pathogen, MIC data and were evaluable for early clinical response (ECR) at 96±24 h and investigator-assigned clinical response at EOT, TOC or LFU. After exclusion of patients with only positive NP cultures, there were 60 patients available for analysis. Of the totals (92 and 60) there were 54 and 22, respectively, considered to have CAP due to S. pneumoniae . Among the 60 patients, clinical success rates across time points were 84.3 to 95.0% overall and 73.7 to 86.4% for the subset of 22 with S. pneumoniae at baseline. The results of the PK-PD analyses for efficacy failed to demonstrate statistically significant and biologically plausible univariable relationships for the parameters tested as listed above.

The POPPK model for lefamulin was modified to include the effect of rifampicin on PK based on the DDR study findings. The resultant model demonstrated an average decrease in relative bioavailability of 58% (19.8% CV) and average increase in clearance 41% (9.27% CV).

Using this model and Monte Carlo simulation, concomitant administration of rifampicin with lefamulin 150 mg IV q12h was associated with a loss of one MIC dilution value at which PTA was ≥ 90%. Increasing the dose of lefamulin to 200 mg IV q12h resulted in PTA that was comparable to that achieved with lefamulin 150 mg IV q12h without rifampicin (≥85% at MIC ≤1 μg/mL for S. pneumoniae ; ≥90% at MIC ≤0.5 μg/mL for S. aureus based on median free-drug 1-log kill PDTs).

The effect of rifampicin was more pronounced when given with lefamulin 600 mg PO q12h under fasted conditions, such that PTA was satisfactory only at MICs 4-fold lower vs. administration without rifampicin. A lefamulin dosing regimen 1800 mg PO q12h would be required achieve similar PTA vs. 600 mg q12h under fasted conditions in the absence of rifampicin.

<div style=\"page-break-after: always\"></div>

## Additional PK-PD analyses using other PDTs

Using the final POPPK model, the applicant was asked to provide PTA estimations for the highest plasma and ELF PDTs for S. pneumoniae obtained from the lung model and at plasma PDTs derived from the mouse thigh infection model. The PTA against the lung model-derived plasma PDT on Day 1 are shown below by MIC for simulated patients after administration of lefamulin intravenous (IV) or oral (PO) dosing regimens. Percentages of observed patients from study 3101 and study 3012 with clinical success for early clinical response (ECR) and investigator assessed clinical response (IACR) by MIC, which were assessed at 96 ± 24 hours and test of cure (TOC), respectively, are also provided.

Table 24. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 1 Based on Randomly Assigned, Median, Second Highest, and Highest Free-Drug Plasma AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Lung Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|              |            |                                  |                                  | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   | Percentprobability ofPK-PDtargetattainment bylefamulindosingregimen,PK-PDtarget,andMIIC   |
|--------------|------------|----------------------------------|----------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|              |            |                                  |                                  |                                                                                           |                                                                                           |                                                                                           |                                                                                           | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      | Lefamulin600mgP0ql2h                                                                      |
|              |            | Percentageofpatients             |                                  | Lefamulin150mgIVql2h                                                                      | Lefamulin150mgIVql2h                                                                      | Lefamulin150mgIVql2h                                                                      | Lefamulin150mgIVql2h                                                                      | Fed                                                                                       | Fed                                                                                       | Fed                                                                                       | Fed                                                                                       | Fasted                                                                                    | Fasted                                                                                    | Fasted                                                                                    | Fasted                                                                                    |
|              |            | withclinicalsuccessby MIC (n/N)a | withclinicalsuccessby MIC (n/N)a |                                                                                           |                                                                                           | Second                                                                                    | Higheste                                                                                  | Randomly assignedb                                                                        | Medianc                                                                                   | Second highestd                                                                           | Higheste                                                                                  | Randomly assignedb                                                                        | Medianc                                                                                   | Second highestd                                                                           | Higheste                                                                                  |
|              | MIC (g/mL) | ECRat 96±24h                     | IACR atTOC                       | Randomly assignedb                                                                        | Medianc                                                                                   | highesrd                                                                                  |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                           |
| S.pneumoniae | 0.03       | 0                                | 0                                | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.pneumoniae | 0.06       | 0 (0/1)                          | 0 (0/1)                          | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.pneumoniae | 0.12       | 90.0 (9/10)                      | 90.0 (9/10)                      | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 99.7                                                                                      | 100                                                                                       | 100                                                                                       | 98.3                                                                                      | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.pneumoniae | 0.25       | 85.4 (35/41)                     | 82.9 (34/41)                     | 99.5                                                                                      | 100                                                                                       | 100                                                                                       | 98.5                                                                                      | 95.3                                                                                      | 100                                                                                       | 98.9                                                                                      | 73.2                                                                                      | 99.1                                                                                      | 100                                                                                       | 100                                                                                       | 95.2                                                                                      |
| S.pneumoniae | 0.5        | 77.8 (7/9)                       | 66.7 (6/9)                       | 94.0                                                                                      | 100                                                                                       | 99.2                                                                                      | 61.4                                                                                      | 80.0                                                                                      | 98.7                                                                                      | 79.6                                                                                      | 15.5                                                                                      | 91.5                                                                                      | 100                                                                                       | 97.0                                                                                      | 52.4                                                                                      |
| S.pneumoniae | 1          | 0                                | 0                                | 75.1                                                                                      | 99.0                                                                                      | 71.8                                                                                      | 2.46                                                                                      | 53.2                                                                                      | 78.0                                                                                      | 22.5                                                                                      | 0.20                                                                                      | 72.4                                                                                      | 96.7                                                                                      | 61.7                                                                                      | 4.48                                                                                      |
| S.anrels     | 0.03       | 0                                | 0                                | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.anrels     | 0.06       | 100 (1/1)                        | 100 (1/1)                        | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.anrels     | 0.12       | 100 (13/13)                      | 100 (13/13)                      | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       | 99.2                                                                                      | 100                                                                                       | 99.7                                                                                      | 98.5                                                                                      | 100                                                                                       | 100                                                                                       | 100                                                                                       | 100                                                                                       |
| S.anrels     | 0.25       | 100 (4/4)                        | 50.0 (2/4)                       | 98.7                                                                                      | 100                                                                                       | 99.7                                                                                      | 98.6                                                                                      | 91.6                                                                                      | 99.7                                                                                      | 90.1                                                                                      | 74.3                                                                                      | 98.0                                                                                      | 100                                                                                       | 99.1                                                                                      | 95.6                                                                                      |
| S.anrels     | 0.5        | 0                                | 0                                | 89.1                                                                                      | 99.8                                                                                      | 88.4                                                                                      | 63.3                                                                                      | 72.0                                                                                      | 91.1                                                                                      | 41.3                                                                                      | 16.6                                                                                      | 86.5                                                                                      | 99.3                                                                                      | 80.6                                                                                      | 54.1                                                                                      |
| S.anrels     | 1          | 0                                | 0                                | 65.3                                                                                      | 90.1                                                                                      | 19.9                                                                                      | 2.94                                                                                      | 41.8                                                                                      | 44.3                                                                                      | 2.86                                                                                      | 0.20                                                                                      | 61.8                                                                                      | 82.7                                                                                      | 19.9                                                                                      | 4.98                                                                                      |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Free-drug plasma AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of free-drug plasma AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 1.37 and 2.13, respectively.
- d) The second highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 2.73 and 4.35, respectively.

e) The highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 6.05 and 5.94, respectively.

Results of the same analyses shown above but based on assessments of percent probabilities of PK-PD target attainment by MIC on Day 3 are provided below.

<div style=\"page-break-after: always\"></div>

Table 25. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 3 Based on Randomly Assigned, Median, Second Highest, and Highest Free-Drug Plasma AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Lung Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|             |                                 |                                 | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   | Percent probability of PK-PD target attainment by lefamulin dosing regimen, PK-PD target, and MIIC   |
|-------------|---------------------------------|---------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
|             |                                 |                                 |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 | Lefamulin600mgPOql2h                                                                                 |
|             | Percentageofpatients            |                                 | Lefamulin150mgIVql2h                                                                                 | Lefamulin150mgIVql2h                                                                                 | Lefamulin150mgIVql2h                                                                                 | Lefamulin150mgIVql2h                                                                                 | Fed                                                                                                  | Fed                                                                                                  | Fed                                                                                                  | Fed                                                                                                  | Fasted                                                                                               | Fasted                                                                                               | Fasted                                                                                               | Fasted                                                                                               |
|             | withclinicalsuccessby MIC (m/N) | withclinicalsuccessby MIC (m/N) | Randomly assignedb                                                                                   | Medianc                                                                                              | Second highestd                                                                                      | Higheste                                                                                             | Randomly assignedb                                                                                   | Medianc                                                                                              | Second highestd                                                                                      | Higheste                                                                                             | Randomly assignedb                                                                                   | Medianc                                                                                              | Second highestd                                                                                      | Higheste                                                                                             |
| MIC (ug/mL) | ECRat 96±24h                    | IACR atTOC                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |                                                                                                      |
| 0.03        | 0                               | 0                               | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.06        | 0 (0/1)                         | 0 (0/1)                         | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.12        | 90.0 (9/10)                     | 90.0 (9/10)                     | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 99.9                                                                                                 | 100                                                                                                  | 100                                                                                                  | 99.7                                                                                                 | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.25        | 85.4 (35/41)                    | 82.9 (34/41)                    | 99.6                                                                                                 | 100                                                                                                  | 100                                                                                                  | 98.7                                                                                                 | 98.2                                                                                                 | 100                                                                                                  | 99.8                                                                                                 | 89.6                                                                                                 | 99.4                                                                                                 | 100                                                                                                  | 100                                                                                                  | 96.9                                                                                                 |
| 0.5         | 77.8 (7/9)                      | 66.7 (6/9)                      | 95.9                                                                                                 | 100                                                                                                  | 99.4                                                                                                 | 73.1                                                                                                 | 88.9                                                                                                 | 99.8                                                                                                 | 92.8                                                                                                 | 43.5                                                                                                 | 94.2                                                                                                 | 100                                                                                                  | 98.2                                                                                                 | 67.8                                                                                                 |
| 1           | 0                               | 0                               | 80.5                                                                                                 | 99.3                                                                                                 | 80.2                                                                                                 | 14.0                                                                                                 | 68.1                                                                                                 | 92.0                                                                                                 | 52.6                                                                                                 | 5.98                                                                                                 | 78.4                                                                                                 | 97.8                                                                                                 | 75.4                                                                                                 | 16.3                                                                                                 |
| 0.03        | 0                               | 0                               | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.06        | 100 (1/1)                       | 100 (1/1)                       | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.12        | 100 (13/13)                     | 100 (13/13)                     | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 99.8                                                                                                 | 100                                                                                                  | 100                                                                                                  | 99.7                                                                                                 | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  | 100                                                                                                  |
| 0.25        | 100 (4/4)                       | 50.0 (2/4)                      | 99.1                                                                                                 | 100                                                                                                  | 99.8                                                                                                 | 98.9                                                                                                 | 96.6                                                                                                 | 100                                                                                                  | 97.3                                                                                                 | 90.1                                                                                                 | 98.6                                                                                                 | 100                                                                                                  | 99.4                                                                                                 | 97.2                                                                                                 |
| 0.5         | 0                               | 0                               | 92.2                                                                                                 | 99.8                                                                                                 | 91.4                                                                                                 | 74.6                                                                                                 | 82.8                                                                                                 | 97.6                                                                                                 | 70.0                                                                                                 | 45.2                                                                                                 | 90.4                                                                                                 | 99.6                                                                                                 | 87.2                                                                                                 | 69.2                                                                                                 |
| 1           | 0                               | 0                               | 72.3                                                                                                 | 92.6                                                                                                 | 39.9                                                                                                 | 15.2                                                                                                 | 57.7                                                                                                 | 72.8                                                                                                 | 18.8                                                                                                 | 6.46                                                                                                 | 70.1                                                                                                 | 88.5                                                                                                 | 38.4                                                                                                 | 17.6                                                                                                 |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Free-drug plasma AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of free-drug plasma AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 1.37 and 2.13, respectively.
- d) The second highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 2.73 and 4.35, respectively.
- e) The highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 6.05 and 5.94, respectively.

Percentages of patients with clinical success by MIC and percent probabilities of PK-PD target attainment by MIC on Days 1 and 3 based on total-drug ELF AUC:MIC ratio targets for both pathogens are provided tables 33 and 34 while tables 35 and 36 show the plasma PTA against the PDTs determined in the neutropenic murine-thigh infection model.

<div style=\"page-break-after: always\"></div>

Table 26. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 1 Based on Randomly Assigned, Median, Second Highest, and Highest Total-Drug ELF AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Lung Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|          |            |                                  |                                  | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   |
|----------|------------|----------------------------------|----------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
|          |            |                                  |                                  |                                                                                        |                                                                                        |                                                                                        |                                                                                        | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   |
|          |            | Percentageofpatients             |                                  | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Fed                                                                                    | Fed                                                                                    | Fed                                                                                    | Fed                                                                                    | Fasted                                                                                 | Fasted                                                                                 | Fasted                                                                                 | Fasted                                                                                 |
|          |            | vithclinicalsuccessby MIC (m/N)a | vithclinicalsuccessby MIC (m/N)a | assignedb                                                                              | Medianc                                                                                | Second highestd                                                                        | Higheste                                                                               | Randomly assignedb                                                                     | Medianc                                                                                | Second highestd                                                                        | Higheste                                                                               | Randomly assignedb                                                                     |                                                                                        | Second highestd                                                                        | Higheste                                                                               |
|          | MIC (g/mL) | ECRat 96±24h                     | IACR at IOC                      | Randomly                                                                               |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        | Medianc                                                                                |                                                                                        |                                                                                        |
|          | 0.03       | 0                                | 0                                | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 99.9                                                                                   | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    |
|          | 0.06       | 0 (0/1)                          | 0 (0/1)                          | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 99.6                                                                                   | 100                                                                                    | 100                                                                                    | 97.8                                                                                   | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    |
|          | 0.12       | 90.0 (9/10)                      | 90.0 (9/10)                      | 99.6                                                                                   | 100                                                                                    | 100                                                                                    | 98.9                                                                                   | 95.2                                                                                   | 100                                                                                    | 98.7                                                                                   | 72.9                                                                                   | 99.2                                                                                   | 100                                                                                    | 100                                                                                    | 96.0                                                                                   |
|          | 0.25       | 85.4 (35/41)                     | 82.9 (34/41)                     | 94.1                                                                                   | 100                                                                                    | 99.3                                                                                   | 62.0                                                                                   | 78.5                                                                                   | 98.3                                                                                   | 76.8                                                                                   | 13.0                                                                                   | 91.4                                                                                   | 100                                                                                    | 97.1                                                                                   | 51.1                                                                                   |
|          | 0.5        | 77.8 (7/9)                       | 66.7 (6/9)                       | 75.0                                                                                   | 99.3                                                                                   | 72.4                                                                                   | 2.10                                                                                   | 51.3                                                                                   | 76.6                                                                                   | 19.3                                                                                   | 0.18                                                                                   | 72.0                                                                                   | 97.1                                                                                   | 60.8                                                                                   | 3.84                                                                                   |
|          | 1          | 0                                | 0                                | 44.8                                                                                   | 72.2                                                                                   | 4.62                                                                                   | 0                                                                                      | 22.7                                                                                   | 19.1                                                                                   | 0.34                                                                                   | 0                                                                                      | 41.8                                                                                   | 60.5                                                                                   | 6.90                                                                                   | 0.02                                                                                   |
| S.anrels | 0.03       | 0                                | 0                                | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 99.9                                                                                   | 100                                                                                    | 100                                                                                    | 99.9                                                                                   | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    |
| S.anrels | 0.06       | 100 (1/1)                        | 100 (1/1)                        | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 99.0                                                                                   | 100                                                                                    | 99.6                                                                                   | 98.1                                                                                   | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    |
| S.anrels | 0.12       | 100 (13/13)                      | 100 (13/13)                      | 98.9                                                                                   | 100                                                                                    | 99.8                                                                                   | 99.1                                                                                   | 91.5                                                                                   | 99.7                                                                                   | 89.8                                                                                   | 74.1                                                                                   | 98.3                                                                                   | 100                                                                                    | 99.4                                                                                   | 96.4                                                                                   |
| S.anrels | 0.25       | 100 (4/4)                        | 50.0 (2/4)                       | 89.3                                                                                   | 99.8                                                                                   | 88.9                                                                                   | 63.9                                                                                   | 70.1                                                                                   | 89.2                                                                                   | 37.3                                                                                   | 13.9                                                                                   | 86.2                                                                                   | 99.3                                                                                   | 80.0                                                                                   | 52.8                                                                                   |
| S.anrels | 0.5        | 0                                | 0                                | 65.5                                                                                   | 90.3                                                                                   | 18.9                                                                                   | 2.44                                                                                   | 39.9                                                                                   | 39.7                                                                                   | 2.00                                                                                   | 0.18                                                                                   | 61.2                                                                                   | 81.7                                                                                   | 18.4                                                                                   | 4.22                                                                                   |
| S.anrels | 1          | 0                                | 0                                | 33.4                                                                                   | 21.2                                                                                   | 0.02                                                                                   | 0                                                                                      | 14.0                                                                                   | 2.36                                                                                   | 0                                                                                      | 0                                                                                      | 30.8                                                                                   | 20.3                                                                                   | 0.14                                                                                   | 0.02                                                                                   |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Total-drug ELF AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of total-drug ELF AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 14.0 and 21.7, respectively.
- d) The second highest total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 27.9 and 44.5, respectively.

e) The highest total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 61.8 and 60.7, respectively.

<div style=\"page-break-after: always\"></div>

Table 27. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 3 Based on Randomly Assigned, Median, Second Highest, and Highest Total-Drug ELF AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Lung Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|              |            |                                  |                                  | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   |
|--------------|------------|----------------------------------|----------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|              |            |                                  |                                  |                                                                                         |                                                                                         |                                                                                         |                                                                                         | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    |
|              |            | Percentageofpatients             |                                  | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Fed                                                                                     | Fed                                                                                     | Fed                                                                                     | Fed                                                                                     | Fasted                                                                                  | Fasted                                                                                  | Fasted                                                                                  | Fasted                                                                                  |
|              |            | withclinicalsuccessby MIC (m/N)* | withclinicalsuccessby MIC (m/N)* | assignedb                                                                               | Medianc                                                                                 | Second highestd                                                                         | Higheste                                                                                | Randomly assignedb                                                                      | Medianc                                                                                 | Second highestd                                                                         | Higheste                                                                                | Randomly assignedb                                                                      | Medianc                                                                                 | Second highestd                                                                         | Higheste                                                                                |
|              | MIC (g/mL) | ECRat 96±24h                     | IACR at IOC                      | Randomly                                                                                |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| S.pneumoniae | 0.03       | 0                                | 0                                | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     |
| S.pneumoniae | 0.06       | 0 (0/1)                          | 0 (0/1)                          | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 99.7                                                                                    | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     |
| S.pneumoniae | 0.12       | 90.0 (9/10)                      | 90.0 (9/10)                      | 99.7                                                                                    | 100                                                                                     | 100                                                                                     | 99.3                                                                                    | 98.5                                                                                    | 100                                                                                     | 99.9                                                                                    | 92.1                                                                                    | 99.5                                                                                    | 100                                                                                     | 100                                                                                     | 97.8                                                                                    |
| S.pneumoniae | 0.25       | 85.4 (35/41)                     | 82.9 (34/41)                     | 96.1                                                                                    | 100                                                                                     | 99.5                                                                                    | 76.0                                                                                    | 89.5                                                                                    | 99.8                                                                                    | 93.6                                                                                    | 46.8                                                                                    | 94.8                                                                                    | 100                                                                                     | 98.5                                                                                    | 70.6                                                                                    |
| S.pneumoniae | 0.5        | 77.8 (7/9)                       | 66.7 (6/9)                       | 81.7                                                                                    | 99.5                                                                                    | 82.4                                                                                    | 16.1                                                                                    | 69.4                                                                                    | 93.5                                                                                    | 55.6                                                                                    | 6.84                                                                                    | 79.3                                                                                    | 98.4                                                                                    | 77.9                                                                                    | 18.4                                                                                    |
| S.pneumoniae | 1          | 0                                | 0                                | 54.6                                                                                    | 82.2                                                                                    | 23.3                                                                                    | 0.36                                                                                    | 41.0                                                                                    | 55.3                                                                                    | 10.2                                                                                    | 0.10                                                                                    | 52.7                                                                                    | 77.6                                                                                    | 24.6                                                                                    | 0.78                                                                                    |
|              | 0.03       | 0                                | 0                                | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     |
|              | 0.06       | 100 (1/1)                        | 100 (1/1)                        | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 99.8                                                                                    | 100                                                                                     | 100                                                                                     | 99.8                                                                                    | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     |
|              | 0.12       | 100 (13/13)                      | 100 (13/13)                      | 99.3                                                                                    | 100                                                                                     | 99.9                                                                                    | 99.4                                                                                    | 97.2                                                                                    | 100                                                                                     | 98.1                                                                                    | 92.6                                                                                    | 99.0                                                                                    | 100                                                                                     | 99.7                                                                                    | 98.1                                                                                    |
|              | 0.25       | 100 (4/4)                        | 50.0 (2/4)                       | 93.0                                                                                    | 99.9                                                                                    | 92.7                                                                                    | 77.0                                                                                    | 84.0                                                                                    | 97.9                                                                                    | 72.8                                                                                    | 48.4                                                                                    | 91.2                                                                                    | 99.7                                                                                    | 88.6                                                                                    | 71.9                                                                                    |
|              | 0.5        | 0                                | 0                                | 73.8                                                                                    | 93.7                                                                                    | 43.5                                                                                    | 17.4                                                                                    | 59.5                                                                                    | 74.5                                                                                    | 20.8                                                                                    | 7.20                                                                                    | 72.0                                                                                    | 89.5                                                                                    | 41.1                                                                                    | 19.6                                                                                    |
|              | 1          | 0                                | 0                                | 43.1                                                                                    | 46.0                                                                                    | 3.02                                                                                    | 0.38                                                                                    | 30.1                                                                                    | 22.2                                                                                    | 1.10                                                                                    | 0.10                                                                                    | 42.7                                                                                    | 42.8                                                                                    | 4.84                                                                                    | 0.88                                                                                    |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Total-drug ELF AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of total-drug ELF AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 14.0 and 21.7, respectively.
- d) The second highest total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 27.9 and 44.5, respectively.
- e) The highest total-drug ELF AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 61.8 and 60.7, respectively.

<div style=\"page-break-after: always\"></div>

Table 28. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 1 Based on Randomly Assigned, Median, Second Highest, and Highest Free-Drug Plasma AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Thigh Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|              |            |                                  |                                  | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimen,PK-PDtarget,andMIIC   |
|--------------|------------|----------------------------------|----------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|              |            |                                  |                                  |                                                                                         |                                                                                         |                                                                                         |                                                                                         | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    | Lefamulin600mgPOql2h                                                                    |
|              |            | Percentageofpatients             |                                  | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Lefamulin150mgIVql2h                                                                    | Fed                                                                                     | Fed                                                                                     | Fed                                                                                     | Fed                                                                                     | Fasted                                                                                  | Fasted                                                                                  | Fasted                                                                                  | Fasted                                                                                  |
|              |            | withclinicalsuccessby MIC (m/N)a | withclinicalsuccessby MIC (m/N)a | Randomly                                                                                |                                                                                         | Second                                                                                  |                                                                                         | Randomly assignedb                                                                      |                                                                                         | Second highesrd                                                                         |                                                                                         | Randomly                                                                                |                                                                                         | Second highestd                                                                         |                                                                                         |
|              | MIC (g/mL) | ECR at 96±24 h                   | IACR at TOC                      | assignedb                                                                               | Medianc                                                                                 | highesrd                                                                                | Higheste                                                                                |                                                                                         | Medianc                                                                                 |                                                                                         | Higheste                                                                                | assignedb                                                                               | Medianc                                                                                 |                                                                                         | Higheste                                                                                |
| S.pneumoniae | 0.03       | 0                                | 0                                | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     | 99.8                                                                                    | 99.7                                                                                    | 100                                                                                     | 100                                                                                     | 100                                                                                     | 100                                                                                     |
| S.pneumoniae | 0.06       | 0 (0/1)                          | 0 (0/1)                          | 100                                                                                     | 100                                                                                     | 100                                                                                     | 99.8                                                                                    | 98.9                                                                                    | 99.8                                                                                    | 95.3                                                                                    | 91.7                                                                                    | 100                                                                                     | 100                                                                                     | 99.7                                                                                    | 99.4                                                                                    |
| S.pneumoniae | 0.12       | 90.0 (9/10)                      | 90.0 (9/10)                      | 98.9                                                                                    | 100                                                                                     | 94.9                                                                                    | 90.8                                                                                    | 88.2                                                                                    | 94.8                                                                                    | 57.2                                                                                    | 46.0                                                                                    | 97.8                                                                                    | 99.7                                                                                    | 89.6                                                                                    | 83.5                                                                                    |
| S.pneumoniae | 0.25       | 85.4 (35/41)                     | 82.9 (34/41)                     | 83.4                                                                                    | 93.5                                                                                    | 35.6                                                                                    | 21.0                                                                                    | 52.5                                                                                    | 52.3                                                                                    | 5.94                                                                                    | 3.08                                                                                    | 78.6                                                                                    | 87.2                                                                                    | 31.8                                                                                    | 20.8                                                                                    |
| S.pneumoniae | 0.5        | 77.8 (7/9)                       | 66.7 (6/9)                       | 40.9                                                                                    | 33.6                                                                                    | 0.30                                                                                    | 0.04                                                                                    | 14.2                                                                                    | 5.50                                                                                    | 0.04                                                                                    | 0                                                                                       | 37.6                                                                                    | 30.2                                                                                    | 0.96                                                                                    | 0.24                                                                                    |
| S.pneumoniae | 1          | 0                                | 0                                | 6.82                                                                                    | 0.28                                                                                    | 0                                                                                       | 0                                                                                       | 1.34                                                                                    | 0.04                                                                                    | 0                                                                                       | 0                                                                                       | 6.72                                                                                    | 0.84                                                                                    | 0                                                                                       | 0                                                                                       |
| S.anrels     | 0.03       | 0                                | 0                                | 99.9                                                                                    | 100                                                                                     | 99.7                                                                                    | 99.6                                                                                    | 93.2                                                                                    | 96.4                                                                                    | 87.4                                                                                    | 84.0                                                                                    | 99.4                                                                                    | 99.8                                                                                    | 98.7                                                                                    | 97.8                                                                                    |
| S.anrels     | 0.06       | 100 (1/1)                        | 100 (1/1)                        | 92.5                                                                                    | 96.6                                                                                    | 84.0                                                                                    | 78.2                                                                                    | 59.6                                                                                    | 64.2                                                                                    | 35.5                                                                                    | 28.6                                                                                    | 87.0                                                                                    | 92.2                                                                                    | 75.2                                                                                    | 68.4                                                                                    |
| S.anrels     | 0.12       | 100 (13/13)                      | 100 (13/13)                      | 44.4                                                                                    | 48.8                                                                                    | 14.7                                                                                    | 9.04                                                                                    | 12.1                                                                                    | 10.1                                                                                    | 1.78                                                                                    | 1.02                                                                                    | 39.4                                                                                    | 42.2                                                                                    | 15.1                                                                                    | 11.0                                                                                    |
| S.anrels     | 0.25       | 100 (4/4)                        | 50.0 (2/4)                       | 2.52                                                                                    | 0.66                                                                                    | 0.02                                                                                    | 0                                                                                       | 0.34                                                                                    | 0.08                                                                                    | 0                                                                                       | 0                                                                                       | 3.56                                                                                    | 1.78                                                                                    | 0.10                                                                                    | 0.10                                                                                    |
| S.anrels     | 0.5        | 0                                | 0                                | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |
| S.anrels     | 1          | 0                                | 0                                | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Free-drug plasma AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of free-drug plasma AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 7.70 and 28.09, respectively.
- d) The second highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 15.12 and 38.8, respectively.
- e) The highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 17.2 and 42.2, respectively.

<div style=\"page-break-after: always\"></div>

Table 29. Comparison of Percentages of Patients with Clinical Success by MIC and Percent Probabilities of PK-PD Target Attainment by MIC on Day 3 Based on Randomly Assigned, Median, Second Highest, and Highest Free-Drug Plasma AUC:MIC Ratio Targets Associated with a 1-log10 CFU Reduction from Baseline for S. pneumoniae and S. aureus Based on Data from a Neutropenic Murine-Thigh Infection Model Among Simulated Patients After Administration of Lefamulin IV or PO Dosing Regimens

|              |            |                                            |              | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   | PercentprobabilityofPK-PDtargetattainmentbylefamulindosingregimenPK-PDtarget,andMIIC   |
|--------------|------------|--------------------------------------------|--------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
|              |            |                                            |              |                                                                                        |                                                                                        |                                                                                        |                                                                                        | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   | Lefamulin600mgPOql2h                                                                   |
|              |            | Percentageofpatients withclinicalsuccessby |              | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Lefamulin150mgIVql2h                                                                   | Fed                                                                                    | Fed                                                                                    | Fed                                                                                    | Fed                                                                                    | Fasted                                                                                 | Fasted                                                                                 | Fasted                                                                                 | Fasted                                                                                 |
|              |            | MIIC (m/N)a                                | MIIC (m/N)a  | assignedb                                                                              | Medianc                                                                                | Second highestd                                                                        | Higheste                                                                               | Randomly assignedb                                                                     | Medianc                                                                                | Second highesrd                                                                        | Higheste                                                                               | Randomly assignedb                                                                     | Medianc                                                                                | Second highestd                                                                        | Higheste                                                                               |
| Pathogen     | MIC (g/mL) | ECR at 96±24h                              | IACR atTOC   | Randomly                                                                               |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |                                                                                        |
| S.pneumoniae | 0.03       | 0                                          | 0            | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    | 100                                                                                    |
|              | 0.06       | 0 (0/1)                                    | 0 (0/1)      | 100                                                                                    | 100                                                                                    | 100                                                                                    | 99.9                                                                                   | 99.8                                                                                   | 100                                                                                    | 98.8                                                                                   | 97.8                                                                                   | 100                                                                                    | 100                                                                                    | 99.8                                                                                   | 99.6                                                                                   |
|              | 0.12       | 90.0 (9/10)                                | 90.0 (9/10)  | 99.1                                                                                   | 100                                                                                    | 96.3                                                                                   | 93.2                                                                                   | 95.5                                                                                   | 98.7                                                                                   | 81.7                                                                                   | 74.0                                                                                   | 98.4                                                                                   | 99.8                                                                                   | 93.2                                                                                   | 89.1                                                                                   |
|              | 0.25       | 85.4 (35/41)                               | 82.9 (34/41) | 87.8                                                                                   | 95.1                                                                                   | 53.9                                                                                   | 41.1                                                                                   | 72.3                                                                                   | 78.6                                                                                   | 27.4                                                                                   | 19.4                                                                                   | 84.9                                                                                   | 91.5                                                                                   | 49.5                                                                                   | 39.3                                                                                   |
|              | 0.5        | 77.8 (7/9)                                 | 66.7 (6/9)   | 51.8                                                                                   | 51.9                                                                                   | 5.10                                                                                   | 2.58                                                                                   | 33.4                                                                                   | 26.2                                                                                   | 2.10                                                                                   | 1.06                                                                                   | 50.1                                                                                   | 48.1                                                                                   | 7.44                                                                                   | 4.28                                                                                   |
|              | 1          | 0                                          | 0            | 14.0                                                                                   | 4.70                                                                                   | 0.02                                                                                   | 0                                                                                      | 6.74                                                                                   | 1.90                                                                                   | 0                                                                                      | 0                                                                                      | 14.4                                                                                   | 6.92                                                                                   | 0.10                                                                                   | 0.04                                                                                   |
| S.areus      | 0.03       | 0                                          | 0            | 99.9                                                                                   | 100                                                                                    | 99.7                                                                                   | 99.6                                                                                   | 97.9                                                                                   | 99.2                                                                                   | 96.3                                                                                   | 94.5                                                                                   | 99.6                                                                                   | 666                                                                                    | 99.2                                                                                   | 98.7                                                                                   |
| S.areus      | 0.06       | 100 (1/1)                                  | 100 (1/1)    | 94.6                                                                                   | 97.6                                                                                   | 89.1                                                                                   | 84.9                                                                                   | 80.2                                                                                   | 85.1                                                                                   | 65.3                                                                                   | 59.1                                                                                   | 91.1                                                                                   | 95.0                                                                                   | 84.2                                                                                   | 79.7                                                                                   |
| S.areus      | 0.12       | 100 (13/13)                                | 100 (13/13)  | 58.9                                                                                   | 64.4                                                                                   | 33.4                                                                                   | 26.2                                                                                   | 34.2                                                                                   | 35.7                                                                                   | 15.2                                                                                   | 11.6                                                                                   | 55.7                                                                                   | 59.9                                                                                   | 33.2                                                                                   | 26.8                                                                                   |
| S.areus      | 0.25       | 100 (4/4)                                  | 50.0 (2/4)   | 10.1                                                                                   | 7.62                                                                                   | 1.28                                                                                   | 0.80                                                                                   | 4.60                                                                                   | 3.06                                                                                   | 0.34                                                                                   | 0.10                                                                                   | 11.3                                                                                   | 9.72                                                                                   | 2.38                                                                                   | 1.52                                                                                   |
| S.areus      | 0.5        | 0                                          | 0            | 0.32                                                                                   | 0.04                                                                                   | 0                                                                                      | 0                                                                                      | 0.04                                                                                   | 0.02                                                                                   | 0                                                                                      | 0                                                                                      | 0.48                                                                                   | 0.12                                                                                   | 0                                                                                      | 0                                                                                      |
| S.areus      | 1          | 0                                          | 0            | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      | 0                                                                                      |

- a) Based on lefamulin-treated patients in the microITT population from Studies 3101 and 3102. Patients were assessed for early clinical response (ECR) and investigator assessed clinical response (IACR) at 96 ± 24 hours and test of cure (TOC), respectively.
- b) Free-drug plasma AUC:MIC ratio targets were randomly assigned based on an estimated log normal distribution of AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline. The distribution of free-drug plasma AUC:MIC ratio targets was truncated on the log scale such that randomly selected targets were all within 2 standard deviations of the mean value.
- c) The median free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 7.70 and 28.09, respectively.
- d) The second highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 15.12 and 38.8, respectively.
- e) The highest free-drug plasma AUC:MIC ratio targets associated with a 1-log10 CFU reduction from baseline for S. pneumoniae and S. aureus were 17.2 and 42.2, respectively.

The applicant points out that results for the PK-PD target attainment analyses generated using free-drug plasma AUC:MIC ratio targets based on a murine-thigh infection model associated with a 1-log10 CFU reduction from baseline for S. pneumoniae were less favourable among all the PK-PD target assignment methods. The applicant also points to the trend for increasing percentages of patients with clinical success for ECR or IACR as MIC decreased from 0.5 to 0.12 μg/mL. The percent probabilities of PK-PD target attainment analyses based on the neutropenic murine-thigh infection model for IV and fasted PO dosing regimens across all PK-PD target assignment methods were frequently lower than percentages of clinical success at MIC values of 0.25 and 0.5 μg/mL.

Based on plasma targets derived from the lung model, and against the applicant's randomly-assigned PDT, the Day 1 PTA is suboptimal at MIC 0.5 mg/L when dosing in the fed state. PTA at the highest target is suboptimal at 0.5 mg/L in all dosing states. Similar findings apply on Day 3. On both days, PTA at the median was adequate at 0.5 mg/L for IV and oral dosing.

Based on ELF targets derived from the lung model, and against the applicant's favoured randomly-assigned PDT, the Day 1 PTA is suboptimal at MIC 0.5 mg/L with IV dosing and oral dosing in the fasted state and is suboptimal even at 0.25 mg/L when dosing in the fed state. On day 3, target attainment is satisfactory only

<div style=\"page-break-after: always\"></div>

at 0.25 mg/L regardless of dosing conditions. At the highest targets the PTA was poor but PTA at the median was adequate at 0.5 mg/L. Based on plasma targets derived from the thigh model, and against the applicant's favoured randomlyassigned PDT, the Day 1 PTA is suboptimal at MIC &gt;0.12 mg/L with IV dosing and oral dosing in the fasted or fed state. However, PTA at the median PDT is just about satisfactory at 0.25 mg/L for IV and oral dosing in the fasted state. PTA at the highest target is poor. fasted state but it is not satisfactory based on the randomly assigned target. At the highest target, only MICs

On day 3, target attainment at the median PDT is satisfactory at 0.25 mg/L for IV and oral dosing in the up to 0.12 mg/L would be covered by IV and fasted state dosing.

## 2.4.4. Discussion on clinical pharmacology

## Pharmacokinetics

Dose proportionality In the IV SAD study 1001, AUC0-∞ increased dose-proportionally over the 25 to 400 mg range. A subproportional increase in Cmax was seen when single IV doses of 75 mg and 150 mg were each administered over 1 h in study 1002. This sub-proportional increase in Cmax following IV administration was best predicted in the POPPK model after incorporation of the non-linear plasma protein binding (PPB). Although the impact of PPB changes on overall PK was limited, the goodness of fit in the model improved after a non-linear free fraction function was included. In the oral SAD study 1101, AUC0-∞ increases were supra-proportional to the dose from 100 mg to 200 mg but dose-proportional from 200 to 400 mg, whereas increases in Cmax were sub-proportional to the dose. Vss was not estimated after single or multiple oral doses in 1101 or 1102. The supra-proportional increase in AUC from 200 mg upwards is most likely due to saturation of CYP-mediated gut wall metabolism so more lefamulin can enter the blood circulation. Oral absorption With a mean absolute bioavailability from a single 600 mg IR tablet in fasted healthy subjects of 25.8% in 1107 and 27% in the ADME study 1013, the applicant concluded that a 600 mg oral dose is equivalent to an IV dose of 150 mg. This conclusion is based on comparing AUCs when oral dosing is in the fasted state against standard bioequivalence criteria rather than considering the entire plasma concentration curves. The applicant defends this approach based on the proposed PK-PD index (AUC/MIC ratio). pass metabolism in the gut wall, which would be consistent with non-linear PK between 100 mg and 400 mg than was observed for 150 mg BID IV vs. a single dose (1.8-fold vs. 1.4-fold). The applicant has considered

After BID oral dosing in the fasted state, steady state was reached after ~2 days, similar to IV dosing. Following multiple doses of 600 mg q12h in the fed state in study 1105, lefamulin showed an increase in bioavailability at steady state, which the applicant ascribes to lefamulin inhibition of CYP3A affecting firstoral doses. Furthermore, oral dosing with 600 mg BID gave a greater increase in AUC0-12 vs. a single dose the PTA on day 1 of oral dosing in fasted and fed states, from which it has been concluded that this is sufficient without considering a loading dose and regardless of the dosing conditions (see further below).

<div style=\"page-break-after: always\"></div>

## Food effect

Whilst a 600 mg oral dose taken in the fasted state was bioequivalent to a single 150 mg IV dose, the GMR AUC0-∞ for 600 mg taken in the fed state vs. the IV dose was 84.31% (76.94%, 92.37%). The difference was even greater for AUC0-12, with GMR 71.8% (65.4, 78.9). Reflecting these differences, the absolute bioavailability of lefamulin from 600 mg IR tablets was reduced from ~26% in the fasted state to 18-21% (lowest estimate based on AUC0-12) in the fed state. Moreover, in the definitive food effect study (1106) dosing within 1 h before or after a meal reduced plasma exposures and the greatest effect occurred when lefamulin was taken after breakfast.

In both Phase 3 efficacy trials (following a double-blind design vs. moxifloxacin) all oral treatments were to be taken 1h before or 2h after a meal, i.e. lefamulin was to be taken on an empty stomach and the morning dose was taken after an overnight fast. To reflect Phase 3 dosing conditions and the PK-PD analyses (see below), the SmPC for the tablets recommends dosing on an empty stomach.

## Protein binding and estimations of free drug levels in plasma

Lefamulin binding to plasma proteins is concentration-dependent and saturable. Using equilibrium dialysis, lefamulin showed non-linear and saturable plasma protein binding of 73-88% over the range of concentrations observed in humans such that the free fraction increased with increasing concentration of lefamulin. There was low binding affinity to albumin and α1 -acid glycoprotein. At typical plasma concentrations achieved with the proposed IV and oral dosing regimens, the applicant proposed that lefamulin is ~ 87% bound to plasma proteins and this correction factor was applied in the lung and tissue distribution study 1005.

This estimate of 87% conflicted with the mean lefamulin protein binding &gt;94% at 1, 3 and 8 h in the renal impairment study (including the controls) and the values reported in the hepatic impairment study for moderate hepatic impairment (between 89.2% and 92.8%), severe hepatic impairment (between 86.5% and 90.8%) or normal controls (94.8% to 97.1%). The applicant clarified that different methods were applied, including devices from different manufacturers in individual studies, to derive these estimates. However, the exact reasons for the differences is unknown.

## Lung and tissue distribution

In study 1005 there were only 3 subjects at each of the ELF sampling time and the last sampling was at 8 h post-dose whereas the dose interval is 12 h. As expected, the IIV was considerable for ELF concentrations. Overall, this is not considered to be a robust study.

For total drug AUC0-8, based on 3 subjects per sampling, the ELF value was 73% of the plasma value. The applicant calculated that the total drug ELF to free drug plasma AUC0-8 ratio was 5.7 based on an assumption of 13% unbound drug in plasma (see above). It is recognised that if the plasma unbound fraction is even less (i.e. if 87% is an under-estimation of plasma protein binding), this would further increase the ratio. On the other hand, the applicant's calculation has ignored protein binding of lefamulin in ELF, which is not considered appropriate for any drug that is ≥60% bound to plasma proteins. Even if ELF protein were to be 10% of that

<div style=\"page-break-after: always\"></div>

in plasma (e.g. 0.4 g/dL) there might be sufficient impact on free lefamulin, and thus the ELF penetration ratio, to affect the PTA.

The lefamulin Vss is 3- to 5-fold greater than total body water volume in an average adult, indicating distribution into the interstitium.

## Metabolism and excretion

CYP3A4 and 3A5 are the main cytochrome isoenzymes involved in the metabolism of lefamulin.

In the ADME study 1013, the after radiolabelled IV 150 mg (30 min post breakfast) and oral 600 mg (fasted state) doses, the mean recovery in faeces was 77% of the IV radioactivity dose and 88% of the oral radioactivity dose whereas mean recovery in urine was 15% and 5%, respectively. Lefamulin accounted for most (76% after IV and 58% after oral dosing) of the circulating radioactivity in plasma while the inactive mono-hydroxy metabolite BC-8041 accounted for 3% and 12%. No other metabolite accounted for &gt;10% of total radioactivity in plasma after IV or oral dosing. The PK of BC-8041 indicated that some conversion occurs in the gut, with higher plasma levels after oral vs. IV doses.

## Renal impairment

Over 36 h post-dose, mean lefamulin and BC-8041 plasma Cmax concentrations were comparable between the normal and severe groups.

Nevertheless, the 90% CIs were wider than 80, 125% for all parameters (with or without the outlier) and the AUC GMRs were 123% (82, 184) for lefamulin and 148 (94, 232) for the metabolite. These comparisons were based on total drug. Plasma lefamulin AUCs for the 8 subjects on haemodialysis were lower compared to the normal function and severe impairment groups. There was no statistically significant difference in AUC between the Normal and Dialysis groups.

In Normal, Off-dialysis and On-dialysis subjects, the respective free fractions were 5.6%, 5.6%, and 5.4% at 1 h and 3.1%, 3.5%, and 5.0% at 3 h. No correlation between PPB and QTcF could be identified and the larger absolute change in QTcF observed in those on HD was thought to reflect underlying differences between subjects with severe renal impairment requiring HD and healthy subjects. No subjects in any of the renal function status groups had a treatment-emergent QTcF value of &gt;480 msec or a &gt;60 msec increase from baseline.

## Hepatic impairment

The study in hepatic impairment showed relatively modest increases in lefamulin plasma AUCs as hepatic function decreased but the 90% CI were very wide. Increases in BC-8041 were greater than those for lefamulin, suggesting that handling of lefamulin is somewhat different between groups. In this single dose study there was no difference in effect on QTc by hepatic function category. However, a warning appears in section 4.4 of the SmPC to the effect that lefamulin should be used in patients with moderate or severe hepatic impairment only after careful benefit-risk evaluation that takes into account the higher free lefamulin concentrations and potential risk of QT prolongation.

<div style=\"page-break-after: always\"></div>

Age Study 1003 indicated that age per se did not influence lefamulin PK. However, there were only 12 subjects aged &gt; 65 years and none was very elderly (maximum 77 years). The median age of subjects providing samples included in the POPPK analysis was 57 years old with a range from 18 - 97 years but only 57 were aged 75+ years. Taking into account the safety data by age and the warnings that appear in the SmPC, it can be agreed that age per se is not a factor requiring dose adjustment. POPPK analyses In the POPPK analysis 00231-1, a previously developed 3-compartment model with zero-order infusion, firstorder elimination and saturable protein binding provided an adequate fit to the plasma concentrations obtained in the Phase 2 ABSSSI study 2001. No significant covariate relationships were identified. PK parameters and inter-individual variability (IIV) were estimated with reasonably good precision (%SEM values of 30% or less). Overall, the magnitude of the IIV was moderate with the exception of Vcu (CV of 139%). Bayesian shrinkage was not reported. The goodness-of-fit plots showed a good fit to the data for the observed vs individual predicted concentrations. However, for the observed vs population predicted concentrations, some biases in the fit of the data are noted which may indicate some model misspecification. VPCs were not provided. These issues are not further pursued since this model was not used for final PK-PD analyses. In the POPPK analysis FRX-BC3781-PMT-1, the final model showed a good predictive performance of total lefamulin plasma concentrations over time, across doses and different treatments, both for IV and oral dosing. For IV administration, this was supported by the external validation datasets, for which there were satisfactory predictions both for single and steady state doses. The protein binding function included in the final model was based on clinical total plasma concentration samples and in-vitro experimental data on fraction unbound, since only total plasma concentrations were measured in the clinical studies. The ELF distribution model was based on very limited data from one study of 12 healthy subjects with one ELF observation per subject, which represents a significant limitation. In the POPPK analysis 00488-1, the structural model was based on previous modelling efforts, which had revealed a lefamulin disposition characterised by a 3-compartment model with linear clearance, nonlinear protein binding, first-order disposition into and out of the ELF and parallel fast and slow (delayed) first-order absorption following PO dosing. This included fixing PK parameters of CLd2, Vp2, Ka, Ka2, Ftot, FS, ALAG, Fumin, Fumax, Fu50 to those from the previous model (00429-1). There was high shrinkage of all IIV parameters except clearance but further analyses indicated that this did not impact on the results to a substantial extent. Some deficiencies are noted in the pcVPCs for the final POPPK model. In the Phase 2 (ABSSSI patients) VPC, the model tends to over-predict the median of observed concentrations up to around 10 h post-dose and the observed concentrations whilst variability is reasonably well captured. For study 3102, the model appears to variability is over-predicted. In the VPC for study 3101, the model tends to over-predict the median of capture the central tendency but tends to under-predict variability.

<div style=\"page-break-after: always\"></div>

## Drug-drug interactions

## Lefamulin as victim

Oral ketoconazole had a moderate inhibitory effect on lefamulin metabolism (2.65-fold increase in AUC) after oral administration but only a weak effect (1.3-fold increase) after IV administration. The tablet SmPC contraindicates use with strong CYP3A inhibitors. No important effects on lefamulin when given IV or PO were predicted when co-administered with fluconazole (moderate inhibitor of CYP3A) 200 mg QD or fluvoxamine (weak inhibitor of CYP3A4) at 100 mg BID.

Rifampicin had a moderate effect on oral lefamulin (decrease in AUC to 28%) but only a weak effect on IV lefamulin (decrease in AUC to 73%). Using a modified POPPK model to include the effect of rifampicin, concomitant administration with IV lefamulin and oral lefamulin was predicted to result in loss of one or two MIC doubling dilutions, respectively, at which PTA was ≥ 90%. The PBPK model predicted reductions in the lefamulin Cmax and AUC of 8% and 30% (IV lefamulin) and 24% and 43% (oral lefamulin), respectively, when administered with the CYP3A inducer efavirenz. Given that the dose of lefamulin is anyway poorly supported by PK-PD analyses, both SmPCs contraindicate use with strong and moderate inducers of CYP3A.

## Lefamulin as perpetrator

Oral lefamulin had moderate inhibitory effects on the metabolism of oral midazolam (AUC increased 3.2-fold) but IV lefamulin had only a weak effect (upper bound of 90% CI 167%). Co-administration of IV and oral lefamulin with CYP3A substrates that prolong QTc is contraindicated.

Oral lefamulin had an unimportant effect on digoxin. Whilst this is not the most sensitive substrate for detection effects on P-gp the lack of effect could be accepted as evidence that no SmPC statements are needed on use of lefamulin with P-gp substrates.

The PBPK model predicted that oral (but not IV) lefamulin would increase the AUC and Cmax of the CYP3A4/2C8 substrate by 42% and 29%, respectively. Normally if the basic model suggests inhibition, the SmPC should have a contraindication until a clinical study confirms the extent of the inhibition, when appropriate advice on concomitant use should be given as needed. To justify lack of a contraindication for use with CYP2C8 substrates based on the mechanistic static model in lieu of a clinical study, the applicant must address the outstanding question.

Using the PBPK model, Cmax and AUC were predicted to increase by 18% and 24% for ethinyl oestradiol and 14% and 37% for zolpidem, respectively, following oral administration of lefamulin.

Negligible effects were predicted on exposure to the OATP1B1/OATP1B3/BCRP substrate rosuvastatin following either IV or oral administration of lefamulin even after applying a 10-fold correction factor to account for uncertainty. Mean increases in Cmax and AUC to the OCT2/MATEs substrate metformin of &lt;20% were predicted following IV and oral administration of lefamulin. Accounting for potential uncertainty of the in-vitro assays (by applying a 20-fold correction factor), the effects on metformin Cmax and AUC were

<div style=\"page-break-after: always\"></div>

predicted to increase to 27% and 60%, respectively for IV lefamulin and 30% and 65%, respectively for oral lefamulin.

## Pharmacodynamics

## Microbiology

The spectrum of antibacterial activity of lefamulin supports selection of CAP as a target indication. Lefamulin inhibits bacterial protein synthesis by binding to the 50s ribosomal subunit. Several mechanisms of resistance have been found in various species relevant to CAP. Some of these can confer a degree of cross-resistance to other protein synthesis inhibitors, including lincosamides and streptogramins. Also, the G2576T point mutation associated with linezolid resistance in S. aureus can increase lefamulin MIC by 2-16-fold.

Serial passage studies indicated a low rate of selection of resistant mutants. Furthermore, in surveillance studies conducted over several years, low proportions of strains collected have had lefamulin MICs ≥ 1 mg/L. Those that have been characterised have generally been found to have recognised mutations associated with reduced susceptibility.

## PK-PD index

Dose fractionation was conducted using the mouse neutropenic thigh infection model (Wicha WW, Craig WA, Andes D. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. J Antimicrob Chemother . 2019;74(Suppl 3):iii5-iii10.). Serum protein binding values on 3 pooled samples from mice were 79.2% at around 0.120 μg/ml, 77.2% at around 0.530 μg/ml and 75.4% at around 3.250 μg/ml.

Using these estimates, the report and the applicant's summary of microbiology state that Because of the moderate plasma protein binding of lefamulin, free drug concentrations (20.8 to 24.6% of total serum concentrations) were used to calculate the magnitude of the various PK/PD indices . The applicant is unable to clarify exactly how the range was applied to each total drug value to determine the corresponding free drug concentration. For the S. pneumoniae strain the f AUC0-24/MIC ratio gave the best correlation with antibacterial activity whereas for the S. aureus strain the f T&gt;MIC was just as good as a potential PK-PD index.

## Plasma PDTs

Comparison across studies showed that f AUC0-24/MIC ratios associated with stasis and 1-log kill of S. pneumoniae were much lower in the murine lung infection model vs. murine thigh infection model. For example, the plasma f AUC0-24/MIC for 1-log kill of S. pneumoniae was 8.92 in the thigh model vs. 1.51 in the lung model. The 1-log10 and 2-log10 kill plasma PDTs used for estimations of PTA when selecting the IV and oral lefamulin doses for Phase 3 CAP studies were taken from the murine lung infection model data. For 1-log kill of S. pneumoniae , the plasma f AUC0-24/MIC values used for estimating PTA were the median (1.37) and the second highest value (2.73) whereas the highest value in the applicant's experiments was 6.05.

<div style=\"page-break-after: always\"></div>

ELF PDTs The ELF PDTs were derived from the plasma PDTs determined in mice after accounting for the observation that uninfected mouse total lefamulin levels in ELF were ~2x those in plasma. The applicant placed great weight on the PTA in ELF, but this approach has not been accepted previously as the primary method to support dose selection when treating lung infections. Furthermore, the plasma PDTs against which plasma PTA was initially estimated were those documented in the murine lung infection model, which were substantially lower than those derived from the thigh infection model. Therefore, additional analyses were requested using different PDTs, including the plasma PDTs derived from the thigh model (see below). PK-PD analysis of data obtained during IV and PO Phase 3 trials (00488-2) This exercise used the final POPPK model and the applicant's initial analyses reported the day 1 and day 5 PK and PTA for IV and oral administrations using PDTs derived from the murine lung model. The lefamulin oral dosing regimen under fasted conditions gave Day 1 mean and median free-drug plasma AUCs comparable to those achieved after 150 mg BID IV but values after oral dosing in the fed state were 38.2 and 41.0% lower, respectively, than those based on the IV dosing regimen. The effect of dosing conditions was still apparent on Day 3. Using the updated POPPK model, the plasma and ELF PTA was estimated against the median non-clinical PDTs and against randomly assigned AUC/MIC ratio targets based on an estimated log normal distribution of AUC/MIC ratio targets associated with a given endpoint for each pathogen. Again, these were based on the murine lung model. The plasma PTA at the median PDT for S. pneumoniae on Day 1 exceeded 90% at 0.5 mg/L for 150 mg IV q12h and 600 mg PO q12h administered under fed or fasted conditions. Dosing in the fed state was not supported by PTA against randomly assigned targets. The ELF PTA was more sensitive to the effect of dosing in the fed state and overall supported coverage of S. pneumoniae only up to 0.25 mg/L. The PTA for S. aureus PDTs at 0.12 mg/L was &gt;90% regardless of dose route and regimen but only plasma PTA supported sufficiency up to 0.25 mg/L. After submitting additional analyses at D120, it was clear that the Day 1 PTA is suboptimal at MIC 0.5 mg/L for S. pneumoniae based on randomly-assigned plasma targets derived from the lung model when dosing in the fed state. PTA at the highest target was suboptimal at 0.5 mg/L in all dosing states. Similar findings applied on Day 3. On both days, PTA at the median was adequate at 0.5 mg/L for IV and oral dosing. state and was suboptimal even at 0.25 mg/L when dosing in the fed state. On day 3, target attainment was

Based on ELF targets derived from the lung model, and against the randomly-assigned PDT for S. pneumoniae , the Day 1 PTA was suboptimal at MIC 0.5 mg/L with IV dosing and oral dosing in the fasted satisfactory only at 0.25 mg/L regardless of dosing conditions. At the highest targets the PTA was poor but PTA at the median was adequate at 0.5 mg/L.

Based on plasma targets derived from the thigh model, and against the randomly-assigned PDT for S. pneumoniae , the Day 1 PTA was suboptimal at MIC &gt;0.12 mg/L with IV dosing and oral dosing in the fasted or fed state. However, PTA at the median PDT was just about satisfactory at 0.25 mg/L for IV and oral dosing

<div style=\"page-break-after: always\"></div>

in the fasted state. PTA at the highest target was poor. On day 3, target attainment at the median PDT was satisfactory at 0.25 mg/L for IV and oral dosing in the fasted state but it was not satisfactory based on the randomly assigned target. At the highest target, only MICs up to 0.12 mg/L would be covered by IV and fasted state dosing.

In conclusion, the IV and fasted oral doses of lefamulin were predicted to be suboptimal for S. pneumoniae and not adequate to cover organisms with MICs up to 0.5 mg/L. Some analyses indicated that doses were not even adequate for organisms with MICs of 0.25 mg/L. Oral dosing in the fed state could not be supported.

The applicant has presented a rationale for the proposed MIC interpretive breakpoints and has approached EUCAST to set interpretive breakpoints for lefamulin in the EU.

The final susceptibility testing breakpoints established by the EUCAST were:

| Organism                 | MIC breakpoints (mg/L)   | MIC breakpoints (mg/L)   |
|--------------------------|--------------------------|--------------------------|
|                          | Susceptible (≤S)         | Resistant (>R)           |
| Streptococcus pneumoniae | 0.5                      | 0.5                      |
| Staphylococcus aureus    | 0.25                     | 0.25                     |

## QTc prolongation

Using Phase 3 patient data, the effect of lefamulin on QTcF at the recommended clinical dose closely approximated to that of moxifloxacin. For both agents, the magnitude of mean effect was less with oral dosing but was &gt;10 msec for both after IV and 9.5-11.5 msec for oral dosing. In addition to these mean effects, the categorical analysis showed only slightly less issues for lefamulin vs. moxifloxacin.

## 2.4.5. Conclusions on clinical pharmacology

The CHMP concluded that oral lefamulin must be given on an empty stomach. The CHMP also considered that there is a significant risk for loss of efficacy if lefamulin is given with moderate or strong CYP3A inducers and concomitant use is therefore contraindicated in IV and tablet SmPCs. Regarding QTc prolongation, use of lefamulin is associated with a significant risk for QTc prolongation similar to that of moxifloxacin. There are insufficient data to predict whether the risk of arrhythmias may also be similar. The risk of QT prolongation is expected to be enhanced when oral lefamulin is given with strong inhibitors of CYP3A and concomitant use is therefore contraindicated in the tablet SmPC. Finally, the PK-PD analyses do not provide robust support the selected IV and oral dose regimens for treatment of CAP, especially when due to S. pneumoniae with MICs at the upper end of the normal range.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies &amp; main clinical studies

## Main studies - 3101 and 3102

To support the claimed indication for treatment of community-acquired pneumonia (CAP), the applicant conducted two randomised, double-blind and active-controlled Phase 3 trials. There were no dose-finding studies; see the PK-PD analyses for IV and PO dose justification.

Table 30. Description of Clinical Efficacy and Safety Studies (CAP)

| Study Number a StudyStatus Report Location                    | Location of Study Centers (N)                                                                                                                                                                                                                                             | Phase Study Design                                                                               | StudyObjective(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Test Product(s)                                                                                                                                                                                                                                                                         | Dosage Regimen Route of Administration TreatmentDuration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Number of Subjects Population Median Age (Range)                                                                  |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Controlled Clinical StudiesPertinent to theClaimed Indication | Controlled Clinical StudiesPertinent to theClaimed Indication                                                                                                                                                                                                             | Controlled Clinical StudiesPertinent to theClaimed Indication                                    | Controlled Clinical StudiesPertinent to theClaimed Indication                                                                                                                                                                                                                                                                                                                                                                                                                          | Controlled Clinical StudiesPertinent to theClaimed Indication                                                                                                                                                                                                                           | Controlled Clinical StudiesPertinent to theClaimed Indication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Controlled Clinical StudiesPertinent to theClaimed Indication                                                     |
| Study 3101 Completed May 2017 Module 5.3.5.1 (Full CSR)       | Argentina (2); Bosnia and Herzegovina (3); Brazil (1); Bulgaria (10); Georgia (6); Latvia (3); Hungary (4); Netherlands (4); Poland Philippines (1); Penu (2); Federation (4); (4); Russian (2); Romania Serbia (4); South Africa (2); Thailand (1); Ukraine (11); US (2) | Phase 3, multicenter, randomized, double-blind, double-dummy, active- controlled, parallel-group | Primary Demonstrate the NI of lefamulin vs comparator for ECR in the ITT Analysis Set (FDA primary/EMA Demonstrate the NI of secondary); lefamulin vs comparatorforIACR at TOCin the mITT and CE-TOC Analysis FDA secondary) Sets (EMA primary/ Secondary ECR (microITT); ECR plus improvement in vital signs (ITT); IACR at TOC (microITT and ME- TOC); By-pathogen microbiological response at TOC (microITT and ME- TOC); Safety and tolerability; 28-day all-cause mortality (ITT) | Oral/IVlefamulin 150 mg/15 mL concentrate diluted in 250 mL of citrate-buffered saline; 600 mg IR tablet Oral/IV moxifloxacin use infusion bag: 400 mg ready-to- 400 mg over- encapsulated tablet Oral/IV linezolid 600 mg ready-to- use infusion bag: 600 mg over- encapsulated tablet | Lefamulin (n=276) 150mgIVq12hfor5to 10days dependingon the baselinepathogenidentified and the approved protocol version at the time of Screening; subjects could be switched to 600 mg PO q12h at thediscretion ofthe Investigator after 3full days (6 doses) ofIV treatment Moxifloxacin (n=275) 400 mg IV q24h for 7 to 10 days dependingon the baseline pathogen identified and the approved protocol versionatthetime of switched to 400 mg PO q24h Screening; subjects could be at the discretion ofthe Investigator after 3 full days (6 doses)ofIV treatment Note: If theInvestigator determinedthatMRSAwasa probable pathogen at Screening,adjunctive linezolid 600 mg IV q12h was to be added to the moxifloxacin group and linezolid placebo was to be added to the lefamulin group. | 551 adult subjects (330 males, 221 females) with PORTII-V CABP 62.0 (19 to 91) years [Exposed to lefamulin,n=273] |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study Number a Study Status Report Location                | Location of Study Centers (N)                                                                                                                                                                                                                                      | Phase Study Design                                                                              | Study Objective(s)                                                                                                                                                                                                                                                                                                                                                                                                                            | Test Product(s)                                                                    | DosageRegimen RouteofAdministration TreatmentDuration                                   | Number of Subjects Population Median Age (Range)                                                                  |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| ControlledClinicalStudiesPertinent to theClaimedIndication | ControlledClinicalStudiesPertinent to theClaimedIndication                                                                                                                                                                                                         | ControlledClinicalStudiesPertinent to theClaimedIndication                                      | ControlledClinicalStudiesPertinent to theClaimedIndication                                                                                                                                                                                                                                                                                                                                                                                    | ControlledClinicalStudiesPertinent to theClaimedIndication                         | ControlledClinicalStudiesPertinent to theClaimedIndication                              | ControlledClinicalStudiesPertinent to theClaimedIndication                                                        |
| Study 3102 Completed Jan 2018 Module 5.3.5.1 (Full CSR)    | Argentina (5); Bulgaria (12); Chile (1); Georgia (5); Latvia (2); Hungary (3); Mexico (3); Peru (11); Philippines (4); Poland (2); Romania (4); Russian Federation (7); Serbia (4); South Africa (6); South Korea (6); Spain (1); Taiwan (1); Ukraine (13); US (9) | Phase 3, multicenter, randomized, double-blind, double-dummy, active controlled, parallel-group | Primary Demonstrate the NI of lefamulin vs comparator for ECR in the ITT Analysis Set (FDA primary/EMA secondary); Demonstrate the NI of lefamulin vs comparator for IACR at TOC in the mITT and CE-TOC Analysis Sets(EMA primary/ FDA secondary) Secondary ECR (microITT); IACR at TOC (microITT and ME- TOC); By-pathogen microbiological response at TOC (microITT and ME- TOC); Safety and tolerability; 28-day all-cause mortality (ITT) | Oral lefamulin 600 mg IR tablet Oral moxifloxacin encapsulated tablet 400 mg over- | Lefamulin (n=370) 600 mgP0q12h for 5 days Moxifloxacin(n=368) 400 mg P0 q24h for 7 days | 738 adult subjects (387 males, 351 females) with PORTI-IVCABP 59.0 (19 to 97) years [Exposed to lefamulin, n=368] |

## Methods

## Study Participants

In both trials, eligible adults were to have:

- o An acute illness of ≤7 days' duration with at least 3 of new or worsening dyspnoea, cough, purulent sputum or chest pain due to pneumonia

## and

- o At least 2 of: fever (&gt;38°C oral or equivalent) or hypothermia (&lt;35°C oral or equivalent); hypotension (systolic &lt;90 mmHg); tachycardia (&gt;100 beats/min); tachypnoea (&gt;20 breaths/min)

## plus

- o At least one other sign or laboratory finding of CABP including: hypoxaemia (O2 saturation &lt;90% on room air or on baseline supplemental oxygen requirement or PaO2 &lt;60 mmHg); auscultatory and/or percussion findings consistent with pneumonia (e.g. crackles, aegophony, dullness); WBC &gt;10,000 cells/mm 3  or &lt;4500 cells/mm 3  or &gt;15% bands.

plus

<div style=\"page-break-after: always\"></div>

- o Imaging (CXR or CT) documentation indicating pneumonia within 48 h (3102) or 72 h (3101) before enrolment.
-  In 3101 patients were to be in PORT Risk Class ≥III requiring initial IV therapy.
-  In 3102 patients were to be PORT class II-IV and able to initiate oral treatment.

The most important exclusion criteria included:

- o Had received more than one dose of a short-acting oral or IV antibacterial for CAP within 72 h before randomisation except for patients who had clearly failed prior treatment with pathogen resistant to the agent used
- o Had been hospitalised for ≥2 days within 90 days or resided in a nursing home or long -term healthcare facility within 30 days before onset of symptoms
- o Had risk for major cardiac events or QTc prolongation, including concomitant medications that prolong QTc
- o Was receiving a strong P-glycoprotein (P-gp) inhibitor or a strong CYP3A inducer or inhibitor
- o CrCLCG ≤30 mL/min
- o AST or ALT &gt;5xULN or total bilirubin &gt;3xULN or meeting Hy's law
- o Neutropenia &lt;500/mm 3  or thrombocytopenia 50,000/mm 3  or HIV with CD4 count &lt;200/mm 3

## Treatments

In 3101 patients not known or suspected to have MRSA received (as per amendment 3):

- o Lefamulin 150 mg IV q12h for at least 3 days (6 doses) with option to switch to oral lefamulin 600 mg BID from Day 4 onwards; total duration 7 days (5 days prior to amendment); or
- o Moxifloxacin 400 mg IV QD for at least 3 days with option to switch to oral moxifloxacin 400 mg QD from Day 4 onwards; total duration 7 days

All IV doses were administered in 250 mL volumes over 1 h. Subjects in the moxifloxacin group known or suspected to have MRSA could receive linezolid 600 mg q12h from baseline and were to be treated for 10 days. If MRSA was confirmed, moxifloxacin (IV or PO) was to be stopped. If MRSA was not confirmed, linezolid (IV or PO) was to be stopped.

In 3102 patients were randomised to receive 7 days of oral treatment with:

- o Lefamulin 600 mg (using the 600 mg IR tablet) q12h for 5 days and oral moxifloxacin placebo q24h for 7 days (7 doses); or
- o Moxifloxacin 400 mg q24h for 7 days and oral lefamulin placebo q12h for 5 days

<div style=\"page-break-after: always\"></div>

In both trials, oral treatments were to be taken 1h before or 2h after a meal and 2h before or 4 h after any oral cationic substances (e.g. aluminium, zinc, iron).

## Objectives

The primary objective in both trials was to demonstrate the non-inferiority (NI) of lefamulin vs. moxifloxacin for the treatment of CAP. For the EU, NI was based on the Investigator's Assessment of Clinical Response (IACR) at Test of Cure (TOC; on day 5 to 10 post-treatment) in the Modified ITT (mITT) and Clinically Evaluable at TOC (CE-TOC) analysis sets.

## Outcomes/endpoints

The EMA co-primary endpoints were the percentages of subjects with an IACR of success at TOC in the mITT and CE-TOC populations.

Causative pathogens were identified by culture of respiratory or blood samples, polymerase chain reaction (PCR), serology or urine antigen testing. Isolates forwarded to the central laboratory included S. pneumoniae , S. pyogenes , Haemophilus influenzae , S. aureus , Moraxella catarrhalis , L. pneumophila , Mycoplasma pneumoniae and Chlamydophila pneumoniae. Also, all blood culture and any BAL and pleural fluid isolates were forwarded.

Serology was conducted at a central laboratory for evidence of acute infection with L. pneumophila , M. pneumoniae and C. pneumoniae based on a ≥4 -fold increase in IgG antibody titre (acute/convalescent) and reaching ≥1:128 for L. pneumophila or ≥1:160 for M. pneumoniae . Screening urine samples were tested at the study site for S. pneumoniae and L. pneumophila antigen.

A portion of each screening sputum sample was sent to a specialty laboratory for pathogen identification by real-time PCR according to determination criteria as follows:

<div style=\"page-break-after: always\"></div>

Table 31. Amplified Genes and Cut-off Values for Sputum PCR

|                |        | Proposed       | Cut-off Values for Consideration of the Organism as Etiologically Significant for CABP   | Cut-off Values for Consideration of the Organism as Etiologically Significant for CABP   |
|----------------|--------|----------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Organism       | PCR    | Amplified Gene | Cut-off Values                                                                           | Reference                                                                                |
| S. pneumoniae  | RQ-PCR | lytA           | DNA corresponding to ≥104 CFU/mL                                                         | Albrich et al, 2014; Gadsby et al, 2015                                                  |
| H. influenzae  | RQ-PCR | fucK           | DNA corresponding to ≥10° CFU/mL                                                         | Gadsby et al, 2015                                                                       |
| M. catarrhalis | RQ-PCR | copB           | DNA corresponding to ≥10° CFU/mL                                                         | Johansson et al, 2010: Kais et al, 2006; Gadsby et al, 2015                              |
| S. aureus      | RQ-PCR | nuc            | DNA corresponding to ≥6 x 10^ CFU/mL                                                     | Huang et al, 2015; Gadsby et al, 2015                                                    |
| M. pneumoniae  | RT-PCR | CARDS TX gene  | Positive                                                                                 | Thurman et al, 2011; Waites et al, 2012                                                  |
| L. pneumophila | RT-PCR | SSTA           | Positive                                                                                 | Thurman et al, 2011                                                                      |
| C. pneumoniae  | RT-PCR | argR           | Positive                                                                                 | Thurman et al, 2011                                                                      |

CABP = community-acquired bacterial pneumonia; CFU = colony-forming units; DNA = deoxyribonucleic acid; PCR = polymerase chain reaction; RQ-PCR = real-time quantitative polymerase chain reaction; RT-PCR = real-time qualitative polymerase chain reaction

## Randomisation and blinding (masking)

Both studies were of double-blind and double-dummy design.

## Statistical methods

## Analysis populations

- o Intent-to-treat (ITT) = all randomised
- o Modified Intent-to-treat (mITT) = all randomised who received at least one dose
- o Microbiological Intent-to-treat (microITT) = all ITT with at least 1 baseline bacterial pathogen diagnosed by any protocol-listed method known to cause CAP (defined in SAP only)
- o microITT-2 = all ITT with at least 1 baseline bacterial pathogen from a diagnostic method other than PCR. Thus, the following were not considered pathogens in the microITT-2 population:
- S. pneumoniae from RQ-PCR of nasopharyngeal swab
- S. pneumoniae , H. influenzae , S. aureus or M. catarrhalis from RQ-PCR of sputum
- L. pneumophila , M. pneumoniae or C. pneumoniae from RT-PCR of sputum
- M. pneumoniae from RT-PCR of oropharyngeal swab

<div style=\"page-break-after: always\"></div>

- o Clinically Evaluable (CE) = 3 sets were defined according to visits completed (i.e. CE-EOT, CE-TOC and CE-LFU) in protocol-compliant subjects with visits within the protocol defined window for each visit.
- o Microbiologically Evaluable (ME) = corresponding to CE, but excluded if they had CAP caused only by a pathogen resistant to moxifloxacin or non-susceptible to lefamulin (central laboratory); Enterobacteriaceae or a non-fermenting Gram-negative pathogen (except for L. pneumophila and M. catarrhalis ).

## EU primary analysis

- o The co-primary endpoints for the EU were the investigator-assigned clinical response (IACR) (clinical success) rates at TOC in the mITT and CE-TOC populations.
- o The NI test was a 1-sided hypothesis test performed at the 2.5% level of significance, and was based on the lower limit of the 2-sided 95% CI.
- o The primary analysis was adjusted for the randomisation stratification factors except that the number randomised in the US was too small to allow for adjustment for geographic region.
- o If the lower limit of the 95% CI for the difference in IACR success rates in both the mITT and CE-TOC populations was &gt; -10%, then the null hypothesis was rejected and NI was concluded.

## Results

## Results - 3101

The study was conducted between 23-Feb-16 and 12-May-17. The CSR is dated 17-Sep-18.

## · Participant flow

There were 551 subjects randomised (ITT) of which 546 received study drug (mITT; 273 in each group). There were 29 (10.5%) lefamulin and 27 (9.8%) moxifloxacin subjects who discontinued assigned study treatment while 27 (9.8%) and 19 (6.9%) in respective groups discontinued the study but &gt; 95% completed the IACR at TOC assessment. The most common reasons for treatment discontinuation were AEs and subject withdrawal and the most common reason to discontinue study was subject withdrawal.

## · Baseline data

Study subjects were primarily White (86.8%) and male (59.9%) with a mean (SD) age of 60.3 (15.6) years. Overall, 43.6% were ≥65 years of age (25.4% 65 to 74 years and 18.1% ≥75 years) with more subjects ≥65 years in the lefamulin group (47.8% vs. 39.3%). Approximately 76% had normal or mildly impaired renal function and only 3 per group had severe impairment. Based on data entered in the eCRF, 27.8% were PORT Risk Class IV or V (only 7 were V).

<div style=\"page-break-after: always\"></div>

Table 32. Baseline Disease Characteristics (ITT Analysis Set)

| Parameter                          | Lefamulin N=276   | Moxifloxacin N=275   | Total N=551    |
|------------------------------------|-------------------|----------------------|----------------|
| PORT Risk Class from IRT, n (%) a  |                   |                      |                |
| Class III                          | 211 (76.4)        | 211 (76.7)           | 422 (76.6)     |
| Class IV /V                        | 65 (23.6)         | 64 (23.3)            | 129 (23.4)     |
| PORT Risk Class from eCRF, n (%) b |                   |                      |                |
| Class II                           | 0                 | 1 (0.4)              | 1 (0.2)        |
| Class III                          | 196 (71.0)        | 201 (73.1)           | 397 (72.1)     |
| Class IV                           | 76 (27.5)         | 70 (25.5)            | 146 (26.5)     |
| Class V                            | 4 (1.4)           | 3 (1.1)              | 7 (1.3)        |
| PORTscorefrom eCRF                 |                   |                      |                |
| Mean (SD)                          | 87.8 (14.5)       | 86.7 (14.1)          | 87.2 (14.3)    |
| Median (min, max)                  | 84.0 (71, 157)    | 83.0 (62, 145)       | 83.0 (62, 157) |
| CURB-65 score, n (%)               |                   |                      |                |
| 0                                  | 24 (8.7)          | 33 (12.0)            | 57 (10.3)      |
| 1                                  | 130 (47.1)        | 121 (44.0)           | 251 (45.6)     |
| 2                                  | 98 (35.5)         | 97 (35.3)            | 195 (35.4)     |
| 3                                  | 22 (8.0)          | 22 (8.0)             | 44 (8.0)       |
| 4                                  | 2 (0.7)           | 2 (0.7)              | 4 (0.7)        |

There were 25.0% lefamulin and 25.8% moxifloxacin subjects who had received any prior systemic antibacterial medications within 72 h for the current episode of CABP.

In the microITT population (comprising ~58% of the ITT population), 294 (92.5%) had a sputum culture performed but only 55 (18.7%; 36 lefamulin and 19 moxifloxacin) had a pathogen identified of which the most common in those with adequate samples was S. pneumoniae (8.7% lefamulin vs 4.1% moxifloxacin). The microITT-2 population (at least one CAP pathogen from a diagnostic method other than PCR) comprised one third of ITT subjects. While S. pneumoniae was reported for 45.2% lefamulin vs. 51.8% moxifloxacin subjects in this population, many were based on urinary antigen or nasopharyngeal culture.

## · Outcomes and estimation

The mean total duration of treatment (IV and oral combined) was 7.2 days for lefamulin and 7.1 days for moxifloxacin. Mean durations of IV study drug treatment were 5.9 vs. 5.7 days and 104 (38.1%) vs. 121 (44.3%) switched to oral study drug for mean durations of 3.8 vs. 3.5 days.

Lefamulin was non-inferior to moxifloxacin in the EU primary analysis in the mITT and CE populations based on the pre-defined non-inferiority margin. Furthermore, when the unadjusted 95% CIs were computed using a continuity corrected Z-test (designated  b ), the lower limits of the unadjusted 95% CIs were -9.2 and -8.7 in the mITT and CE-TOC populations, respectively.

<div style=\"page-break-after: always\"></div>

Table 33. Investigator ' s Assessment of Clinical Response at TOC (mITT and CE-TOC Analysis Sets)

| IACR Outcome            | Lefamulin n (%)   | Moxifloxacin n (%)   | Treatment Difference (95% CI)   |
|-------------------------|-------------------|----------------------|---------------------------------|
| mITT Analysis Set       | N=273             | N=273                |                                 |
| Success                 | 223 (81.7)        | 230 (84.2)           | -2.6 (-8.9, 3.9) a              |
|                         |                   |                      | -2.6 (-9.2,4.1) b               |
| Failure / indeterminate | 50 (18.3)         | 43 (15.8)            |                                 |
| Failure                 | 43 (15.8)         | 40 (14.7)            |                                 |
| Indeterminate           | 7 (2.6)           | 3 (1.1)              |                                 |
| CE-TOC Analysis Set     | N=236             | N=245                |                                 |
| Success                 | 205 (86.9)        | 219 (89.4)           | -2.5 (-8.4,3.4) a               |
|                         |                   |                      | -2.5 (-8.7, 3.7) b              |
| Failure / indeterminate | 31 (13.1)         | 26 (10.6)            |                                 |
| Failure                 | 31 (13.1)         | 26 (10.6)            |                                 |
| Indeterminate           | NA c              | NA c                 |                                 |

## · Ancillary analyses

There was a larger treatment difference in IACR success rates among subjects enrolled before (5 days lefamulin v. 7 days moxifloxacin) vs. after protocol amendment 2/3 (7 days in both groups).

<div style=\"page-break-after: always\"></div>

Table 34. Investigator ' s Assessment of Clinical Response at TOC by Protocol Version (mITT and CE-TOC Analysis Sets)

| Protocol Version IACR Outcome                                     | Lefamulin n (%)   | Moxifloxacin n (%)   | TreatmentDifference (95% CI) a   |
|-------------------------------------------------------------------|-------------------|----------------------|----------------------------------|
| mITT Analysis Set                                                 | N=273             | N=273                |                                  |
| Subjectsenrolledundertheoriginal protocol or protocol amendment 1 | 67 (24.5)         | 69 (25.3)            |                                  |
| Success                                                           | 52 (77.6)         | 60 (87.0)            | -9.3 (-23.6, 4.9)                |
| Failure /indeterminate                                            | 15 (22.4)         | 9 (13.0)             |                                  |
| Failure                                                           | 12 (17.9)         | 9 (13.0)             |                                  |
| Indeterminate                                                     | 3 (4.5)           | 0                    |                                  |
| Subjectsenrolledunderprotocol amendments3                         | 206 (75.5)        | 204 (74.7)           |                                  |
| Success                                                           | 171 (83.0)        | 170 (83.3)           | -0.3 (-8.1, 7.4)                 |
| Failure/ indeterminate                                            | 35 (17.0)         | 34 (16.7)            |                                  |
| Failure                                                           | 31 (15.0)         | 31 (15.2)            |                                  |
| Indeterminate                                                     | 4 (1.9)           | 3 (1.5)              |                                  |
| CE-TOC Analysis Set                                               | N=236             | N=245                |                                  |
| Subjectsenrolledundertheoriginal protocol or protocol amendment 1 | 55 (23.3)         | 59 (24.1)            |                                  |
| Success                                                           | 46 (83.6)         | 55 (93.2)            | -9.6 (-23.0, 3.9)                |
| Failure                                                           | 9 (16.4)          | 4 (6.8)              |                                  |
| Subjects enrolled under protocol amendments 3                     | 181 (76.7)        | 186 (75.9)           |                                  |
| Success                                                           | 159 (87.8)        | 164 (88.2)           | -0.3 (-7.5, 6.9)                 |
| Failure                                                           | 22 (12.2)         | 22 (11.8)            |                                  |

Results within subgroups were similar to overall results except for those aged &lt;65 years and ATS severity criteria = yes, in which the 95% CIs did not include zero. Subjects who met ATS severity criteria were younger than the overall study population (median age ~52 years vs. ~61-64 years) and had a higher rate of PORT Risk Class IV CAP (26/54 [48.1%] lefamulin and 18/48 [37.5%] moxifloxacin vs. 27.5% and 25.5%, respectively, in the overall study population. Thus findings in the subgroup &lt;65 years are confounded by subjects who met ATS severity c riteria. As a PORT Risk Class ≥III was required for study entry, and age is heavily weighted in the calculation of PORT score, younger subjects needed to meet more age-independent severity criteria to be eligible. When subjects who met ATS severity criteria were removed from the analysis, the difference in IACR success rate between subjects &lt;65 years of age and subjects ≥65 years of age was smaller (see table below).

<div style=\"page-break-after: always\"></div>

Figure 9. Forest Plot of Investigator ' s Assessment of Clinical Response at TOC (Success Rates) (mITT Analysis Set)

<!-- image -->

Table 35. Post-hoc Subgroup Analysis of Investigator ' s Assessment of Clinical Response at TOC by ATS Severity Criteria and Age (mITT Analysis Set)

| ATS Severity Criteria Age Group                 | Lefamulin N=273 n (%)   | Moxifloxacin N=273 (%)   |
|-------------------------------------------------|-------------------------|--------------------------|
| Subjects who met ATS severity criteria          | 53                      | 48                       |
| <65 years                                       | 21/38 (55.3)            | 32/37 (86.5)             |
| ≥65 years                                       | 12/15 (80.0)            | 11/11 (100.0)            |
| Subjects who did not meet ATS severity criteria | 220                     | 225                      |
| <65 years                                       | 86/103 (83.5)           | 114/129 (88.4)           |
| ≥65 years                                       | 104/117 (88.9)          | 73/96 (76.0)             |

While overall study drug discontinuation rates were similar between treatments, among subjects in the ITT population who met ATS severity criteria a greater proportion of subjects in the lefamulin group discontinued study drug than in the moxifloxacin group: 14/54 (25.9%) lefamulin subjects vs. 3/48 (6.3%) moxifloxacin subjects.

<div style=\"page-break-after: always\"></div>

Post hoc analyses were performed using updated ATS severity criteria (confusion, uraemia, RR ≥30 breaths/min, PaO2/FiO2 ≤250 mmHg, multilobar infiltrates and age ≥65 years). A post hoc multivariable analysis in the per-protocol ATS subgroup did not show any differences between treatment groups which could account for the difference in IACR success rates.

Table 36. Investigator ' s Assessment of Clinical Response at TOC by Per Protocol ATS Severity Criteria and Post-hoc Modified ATS Severity Criteria (mITT and CE-TOC Analysis Sets)

| ATS Severity Criteria IACR Outcome                       | Lefamulin n (%)   | Moxifloxacin n (%)   |
|----------------------------------------------------------|-------------------|----------------------|
| mITT Analysis Set                                        | N=273             | N=273                |
| Subjects who met per protocol ATS severity criteria      | 53                | 48                   |
| Success                                                  | 33/53 (62.3)      | 43/48 (89.6)         |
| Subjects who met post-hoc modified ATS severity criteria | 33                | 35                   |
| Success                                                  | 24/33 (72.7)      | 27/35 (77.1)         |
| CE-ToC Analysis Set                                      | N=236             | N=245                |
| Subjects who met per protocol ATS severity criteria      | 45                | 41                   |
| Success                                                  | 31/45 (68.9)      | 39/41 (95.1)         |
| Subjects who met post-hoc modified ATS severity criteria | 28                | 31                   |
| Success                                                  | 22/28 (78.6)      | 26/31 (83.9)         |

ATS = American Thoracic Society; CE-TOC = Clinically Evaluable at Test of Cure;

mITT = Modified Intent-to-treat; TOC = Test of Cure

A total of 9 subjects (5 lefamulin and 4 moxifloxacin) were known to have died by Day 28 but another 15 (10 lefamulin) had unknown status at day 28.

Table 37. 28-day All-cause Mortality (ITT Analysis Set)

|                                      | Lefamulin N=276 n (%)   | Moxifloxacin N=275 n (%)   | Treatment Difference (95% CI)   |
|--------------------------------------|-------------------------|----------------------------|---------------------------------|
| Alive at Day 28 b                    | 261 (94.6)              | 266 (96.7)                 | -2.2 (-5.9, 1.6)                |
| Deceased or status unknown at Day 28 | 15 (5.4)                | 9 (3.3)                    |                                 |
| Deceased at Day 28                   | 5 (1.8) c               | 4 (1.5) d                  |                                 |
| Status unknown at Day 28             | 10 (3.6)                | 5 (1.8)                    |                                 |

The percentage of failures and the distribution of reasons for IACR of failure were generally similar between treatment groups in both analysis sets. The most common reason for IACR of failure in both treatment groups was receipt of non-study antibacterial therapy for CAP signs and symptoms. In the mITT population the number of indeterminate subjects was slightly higher in the lefamulin group (n=7) compared with the moxifloxacin group (n=3).

<div style=\"page-break-after: always\"></div>

## Clinical and microbiological outcomes in those with pathogens

The IACR success rates at TOC in the microITT and ME populations were lower for lefamulin (see below). The IACR success rates at TOC for the microITT-2 population were 82.8% for lefamulin vs. 84.7% for moxifloxacin (95% CI: -13.3, 9.2). IACR success rates at TOC by baseline pathogen were generally comparable between treatments except for penicillin-susceptible S . pneumoniae (see below). The number of pathogens tested was low, but there was no indication that increasing lefamulin MICs resulted in lower IACR success rates at TOC.

Table 38. Investigator ' s Assessment of Clinical Response at TOC (microITT Analysis Set)

| IACR Outcome                                                                   | Lefamulin N=159 n (%)   | Moxifloxacin N=159 (%) u1   | Treatment Difference (95% CI)   |
|--------------------------------------------------------------------------------|-------------------------|-----------------------------|---------------------------------|
| Success                                                                        | 127 (79.9)              | 136 (85.5)                  | -5.7 (-14.1,2.8) a              |
|                                                                                |                         |                             | -5.7 (-14.6, 3.3) b             |
| Failure /indeterminate                                                         | 32 (20.1)               | 23 (14.5)                   |                                 |
| Failure                                                                        | 31 (19.5)               | 19 (11.9)                   |                                 |
| Indeterminate                                                                  | 1 (0.6)                 | 4 (2.5)                     |                                 |
| Reasons for failure                                                            |                         |                             |                                 |
| Failure at previous visit (EOT)                                                | 31 (19.5)               | 19 (11.9)                   |                                 |
| Non-study antibacterial for CABP symptoms                                      | 27 (17.0)               | 13 (8.2)                    |                                 |
| Non-study antibacterial for inflammation                                       | 5 (3.1)                 | 4 (2.5)                     |                                 |
| Non-study antibacterial for bacteremia                                         | 0                       | 0                           |                                 |
| Discontinued study drug due to AE and started non-study antibacterial for CABP | 3 (1.9)                 | 4 (2.5)                     |                                 |
| Died from any cause                                                            | 1 (0.6)                 | 0                           |                                 |
| Reasons for indeterminate                                                      |                         |                             |                                 |
| Lost to follow-up                                                              | 1 (0.6)                 | 1 (0.6)                     |                                 |
| Randomized but not treated                                                     | 0                       | 1 (0.6)                     |                                 |
| Missed visit                                                                   | 0                       | 1 (0.6)                     |                                 |
| Withdrew from study                                                            | 0                       | 1 (0.6)                     |                                 |

Table 39. Investigator's Assessment of Clinical Response at TOC (ME-TOC Analysis Set)

| IACROutcome   | Lefamulin N=137 n (%)   | MIoxifloxacin N=142 (%) uI   | Treatment Difference (95% CI)   |
|---------------|-------------------------|------------------------------|---------------------------------|
| Success       | 115 (83.9)              | 128 (90.1)                   | -6.2 (-14.3, 1.9)               |
|               |                         |                              | -6.2 (-14.8, 2.4)               |
| Failure       | 22 (16.1)               | 14 (9.9)                     |                                 |

<div style=\"page-break-after: always\"></div>

Table 40. By-Pathogen Microbiological Response of Success at TOC (microITT and ME-TOC Analysis Sets)

|                                                  | microITTAnalysisSet      | microITTAnalysisSet         | ME-TOC Analysis Set   | ME-TOC Analysis Set      |
|--------------------------------------------------|--------------------------|-----------------------------|-----------------------|--------------------------|
| BaselinePathogen                                 | Lefamulin N=159 n/N1 (%) | Moxifloxacin N=159 n/N1 (%) | Lefamulin N=137 n (%) | Moxifloxacin N=142 n (%) |
| Gram-positive bacteria (aerobes)                 |                          |                             |                       |                          |
| Streptococcuspneumoniae                          | 79/93 (84.9)             | 85/97 (87.6)                | 74/86 (86.0)          | 82/90 (91.1)             |
| PSSP                                             | 15/21 (71.4)             | 17/18 (94.4)                | 15/21 (71.4)          | 16/16 (100.0)            |
| PISP                                             | 5/5 (100.0)              | 2/2 (100.0)                 | 5/5 (100.0)           | 2/2 (100.0)              |
| PRSP                                             | 2/2 (100.0)              | 1/3 (33.3)                  | 2/2 (100.0)           | 1/3 (33.3)               |
| MDRSP                                            | 6/6 (100.0)              | 4/6 (66.7)                  | 6/6 (100.0)           | 4/6 (66.7)               |
| Macrolide resistant                              | 6/6 (100.0)              | 4/6 (66.7)                  | 6/6 (100.0)           | 4/6 (66.7)               |
| Staphylococcusaureus                             | 8/10 (80.0)              | 4/4 (100.0)                 | 7/9 (77.8)            | 4/4 (100.0)              |
| MSSA                                             | 6/7 (85.7)               | 3/3 (100.0)                 | 6/7 (85.7)            | 3/3 (100.0)              |
| PVL positive                                     | 0/1                      | 0                           | 0/1                   | 0                        |
| PVL negative                                     | 6/6 (100.0)              | 3/3 (100.0)                 | 6/6 (100.0)           | 3/3 (100.0)              |
| β-hemolyticStreptococcus                         | 0                        | 1/1 (100.0)                 | 0                     | 1/1 (100.0)              |
| Streptococcuspyogenes                            | 0                        | 1/1 (100.0)                 | 0                     | 1/1 (100.0)              |
| Gram-negative bacteria (aerobes)                 |                          |                             |                       |                          |
| Haemophilus influenzae                           | 43/51 (84.3)             | 48/57 (84.2)                | 38/43 (88.4)          | 47/52 (90.4)             |
| β-lactamase negative                             | 5/6 (83.3)               | 6/6 (100.0)                 | 5/6 (83.3)            | 6/6 (100.0)              |
| Moraxellacatarrhalis                             | 20/25 (80.0)             | 11/11 (100.0)               | 18/21 (85.7)          | 11/11 (100.0)            |
| Acinetobacterbaumannii                           | 1/1 (100.0)              | 0                           |                       |                          |
| Acinetobactercalcoaceticus- A. baumannii complex | 0                        | 2/2 (100.0)                 | 0                     | 1/1 (100.0)              |
| Acinetobacterjunii                               | 1/1 (100.0)              | 0                           | 1/1 (100.0)           | 0                        |
| Acinetobacterlwoffii                             | 2/2 (100.0)              | 0                           | 1/1 (100.0)           | 0                        |
| Acinetobacter species                            | 0                        | 1/1 (100.0)                 |                       |                          |
| Burkholderia cepacia                             | 0                        | 1/1 (100.0)                 | 0                     | 1/1 (100.0)              |
| Citrobacter koseri                               | 1/1 (100.0)              | 0                           | 1/1 (100.0)           | 0                        |
| Enterobacteraerogenes                            | 1/1 (100.0)              | 1/1 (100.0)                 | 1/1 (100.0)           | 1/1 (100.0)              |
| Enterobactercloacae                              | 2/3 (66.7)               | 0                           | 2/3 (66.7)            | 0                        |
| Escherichia coli                                 | 0                        | 1/2 (50.0)                  | 0                     | 1/2 (50.0)               |
| Haemophilusparainfluenzae                        | 3/3 (100.0)              | 2/2 (100.0)                 | 3/3 (100.0)           | 2/2 (100.0)              |
| Klebsiella pneumoniae                            | 3/3 (100.0)              | 2/2 (100.0)                 | 3/3 (100.0)           | 0                        |
| Pseudomonas aeruginosa                           | 1/1 (100.0)              | 0                           | 1/1 (100.0)           | 0                        |
| Serratiamarcescens                               | 1/1 (100.0)              | 0                           |                       |                          |

<div style=\"page-break-after: always\"></div>

| Atypicalpathogens       |              |              |              |               |
|-------------------------|--------------|--------------|--------------|---------------|
| Mycoplasmapneumoniae    | 16/19 (84.2) | 19/20 (95.0) | 15/17 (88.2) | 18/18 (100.0) |
| Legionellapneumophila   | 14/18 (77.8) | 11/14 (78.6) | 13/14 (92.9) | 10/10 (100.0) |
| Chlamydophilapneumoniae | 8/11 (72.7)  | 13/19 (68.4) | 7/9 (77.8)   | 12/17 (70.6)  |

As for IACR at TOC, microbiological success rates at TOC for penicillin-susceptible S . pneumoniae were 15/21 (71.4%) for lefamulin vs. 17/18 (94.4%) for moxifloxacin. The difference reflected 6 lefamulin subjects with S . pneumoniae bacteraemia, only 1 of whom had an IACR of success at TOC.

By-subject microbiological success rates at TOC in the microITT population were 79.9% for lefamulin and 85.5% for moxifloxacin. Rates in the ME-TOC population were 83.9% for lefamulin vs. 90.1% for moxifloxacin while rates for the microITT-2 population were 82.8% vs. 84.7% (same as IACR at TOC). The treatment difference for by-subject microbiological success rates slightly increased between TOC and LFU, reflecting an increase in the number of indeterminate subjects in the lefamulin group.

Seven lefamulin and 3 moxifloxacin subjects had baseline bacteraemia. In the lefamulin group, 6 had S. pneumoniae and 1 had S. aureus . In the moxifloxacin group, 2 had E. coli and 1 had B. cepacia . The IACR success rate in these subjects was 1/7 (14.3%) for lefamulin vs. 2/3 (66.7%) for moxifloxacin.

The treatment difference between lefamulin and moxifloxacin increased slightly between TOC and LFU. The applicant ascribes this pattern to a higher number of indeterminate subjects in the lefamulin group vs. the moxifloxacin group over time (mITT) or to a lower number of evaluable subjects in the lefamulin group (CE sets). In the mITT population there were no new failures between EOT and TOC but there were 4 new failures (3 lefamulin vs. 1 moxifloxacin) between TOC and LFU. In the CE population there was 1 new failure (moxifloxacin) between EOT and TOC and 3 new failures (2 lefamulin vs. 1 moxifloxacin) between TOC and LFU.

Three lefamulin and 2 moxifloxacin subjects had a superinfection. Those in the lefamulin group were due to pathogens not within its spectrum of activity ( C. koseri , P. aeruginosa and E. cloacae ). No post-baseline pathogens were recovered from lefamulin subjects that showed a ≥4 -fold increase in MIC vs. the baseline isolate.

## Results - 3102

The study was conducted between August 2016 and January 2018. The CSR is dated September 2018.

## · Participant flow

There were 738 subjects randomised (ITT) of which 736 were treated (mITT). There were 25 (6.8%) lefamulin and 28 (7.6%) moxifloxacin subjects who discontinued study drug but only 4.6% and 3.8% discontinued the study and ~96% completed the IACR at TOC visit. Most study drug discontinuations were due to AEs and lack of efficacy.

## · Baseline data

Subjects were primarily white (73.7%) and male (52.4%; 55.9% lefamulin and 48.9% moxifloxacin subjects were male). The mean (SD) age was 57.5 (16.3) years and 37.5% were ≥65 years (21.3% were 65 -74 and 16.3% were ≥75 years).

<div style=\"page-break-after: always\"></div>

Approximately 81% had normal or mildly impaired renal function and 18% had moderate impairment. Based on the eCRFs, 48.8% were PORT Risk Class III or IV and 50.4% were PORT Risk Class II.

Table 41. Baseline Disease Characteristics (ITT Analysis Set)

| Parameter                                 | Lefamulin N=370   | Moxifloxacin N=368   | Total N=738    |
|-------------------------------------------|-------------------|----------------------|----------------|
| PORT Risk Class from IRT, n (%) a         |                   |                      |                |
| Class II                                  | 197 (53.2)        | 197 (53.5)           | 394 (53.4)     |
| Class III/IV                              | 173 (46.8)        | 171 (46.5)           | 344 (46.6)     |
| PORT Risk Class from eCRF, n (%) b        |                   |                      |                |
| Class I                                   | 1 (0.3)           | 2 (0.5)              | 3 (0.4)        |
| Class II                                  | 183 (49.5)        | 189 (51.4)           | 372 (50.4)     |
| Class III                                 | 145 (39.2)        | 133 (36.1)           | 278 (37.7)     |
| Class IV                                  | 40 (10.8)         | 42 (11.4)            | 82 (11.1)      |
| Class V                                   | 1 (0.3)           | 2 (0.5)              | 3 (0.4)        |
| PORT score from eCRF                      |                   |                      |                |
| Mean (SD)                                 | 72.6 (16.10)      | 72.1 (16.05)         | 72.3 (16.07)   |
| Median (min, max)                         | 71.0 (34, 139)    | 69.0 (31, 139)       | 70.0 (31, 139) |
| CURB-65 score, n (%)                      |                   |                      |                |
| 0                                         | 87 (23.5)         | 80 (21.7)            | 167 (22.6)     |
| 1                                         | 197 (53.2)        | 196 (53.3)           | 393 (53.3)     |
| 2                                         | 74 (20.0)         | 77 (20.9)            | 151 (20.5)     |
| 3                                         | 12 (3.2)          | 13 (3.5)             | 25 (3.4)       |
| 4                                         | 0                 | 2 (0.5)              | 2 (0.3)        |
| CURB-65 score                             |                   |                      |                |
| Mean (SD)                                 | 1.0 (0.75)        | 1.1 (0.78)           | 1.1 (0.77)     |
| Median (min, max)                         | 1.0 (0, 3)        | 1.0 (0, 4)           | 1.0 (0, 4)     |
| Met minor ATS severity criteria, n (%)    | 31 (8.4)          | 37 (10.1)            | 68 (9.2)       |
| Met modified ATS severity criteria, n (%) | 20 (5.4)          | 22 (6.0)             | 42 (5.7)       |
| Met SIRS criteria, n (%)                  | 353 (95.4)        | 342 (92.9)           | 695 (94.2)     |
| Subjects with bacteremia, n (%)           | 6 (1.6)           | 9 (2.4)              | 15 (2.0)       |

Within 72 hours before randomisation, 21.1% lefamulin and 20.1% moxifloxacin subjects received systemic antibacterial medications for the current episode of CAP. One lefamulin and 2 moxifloxacin subjects were excluded from the CE population. Most had received amoxicillin-clavulanate.

In microITT population the most frequently identified baseline pathogens were S. pneumoniae (60.0% lefamulin vs. 67.7% moxifloxacin), H. influenzae (27.3% vs. 25.8%), M. pneumoniae (9.8% vs. 7.5%), L. pneumophila (7.8% vs. 9.1%), M. catarrhalis (10.2% vs. 5.9%) and C. pneumoniae (7.8% vs. 6.5%). Staphylococcus aureus was identified in 13 (6.3%) lefamulin and 6 (3.2%) moxifloxacin subjects and 3 had MRSA (2 of which were resistant to moxifloxacin; these were the only cultured CAP pathogens resistant to study drugs). Only 351 of the total subjects had a standard sputum culture and only 76/351 (21.7%) had a

<div style=\"page-break-after: always\"></div>

pathogen isolated. These 76 subjects comprised only 19.4% of the total included in the microITT population. The microITT-2 population comprised 31.4% of the lefamulin ITT and 29.9% of the moxifloxacin ITT subjects. S. pneumoniae occurred in 38.8% lefamulin vs. 50.9% moxifloxacin microITT-2 subjects and most of these came from NP swabs.

## · Outcomes and estimation

The median duration of active treatment was 5 days for lefamulin and 7 days for moxifloxacin. Lefamulin was non-inferior to moxifloxacin in the mITT and CE-TOC populations. When the unadjusted 95% CIs were computed using a continuity corrected Z-test ( b ), the lower limits were -6.5 and -8.4 in the mITT and CE-TOC populations, respectively.

Table 42. Investigator ' s Assessment of Clinical Response at TOC (mITT and CE-TOC Analysis Sets)

| IACR Outcome            | Lefamulin (%) u   | Moxifloxacin n (%)   | Treatment Difference (95% CI)         |
|-------------------------|-------------------|----------------------|---------------------------------------|
| mITT Analysis Set       | N=368             | N=368                |                                       |
| Success                 | 322 (87.5)        | 328 (89.1)           | -1.6 (-6.3, 3.1) a -1.6 (-6.5, 3.3) b |
| Failure / indeterminate | 46 (12.5)         | 40 (10.9)            |                                       |
| Failure                 | 44 (12.0)         | 32 (8.7)             |                                       |
| Indeterminate           | 2 (0.5)           | 8 (2.2)              |                                       |
| CE-TOC Analysis Set     | N=330             | N=326                |                                       |
| Success                 | 296 (89.7)        | 305 (93.6)           | -3.9 (-8.2, 0.5) a -3.9 (-8.4, 0.7) b |
| Failure / indeterminate | 34 (10.3)         | 21 (6.4)             |                                       |
| Failure                 | 34 (10.3)         | 21 (6.4)             |                                       |
| Indeterminate           | NA c              | NA c                 |                                       |

## · Ancillary analyses

Results within the strata defined by prior antibacterial treatment and PORT Risk Class were similar to the overall results for ITT and CE populations. Figure 10 indicates that for most subgroups the rates for IACR at TOC slightly favoured moxifloxacin as in the primary analysis.

<div style=\"page-break-after: always\"></div>

Figure 10. Forest Plot of Investigator ' s Assessment of Clinical Response at TOC (Success Rates) (mITT Analysis Set)

<!-- image -->

A total of 6 subjects (3 lefamulin and 3 moxifloxacin) were known to have died by Day 28 but there were another 4 subjects (3 lefamulin, one moxifloxacin) whose status was unknown at day 28.

The most common reason for IACR of failure at TOC in both treatment groups was receipt of non-study antibacterial therapy for CAP. Most of the failures had already occurred by the time of the EOT visit. Six lefamulin subjects failed between EOT and TOC due to non-study antibacterial therapy for CAP.

## Clinical and microbiological outcomes in those with pathogens

The IACR success rate at TOC in the microITT population was 85.9% for lefamulin and 87.6% for moxifloxacin (treatment difference -1.8%; 95% CI: -8.7, 5.1). Corresponding rates in the ME-TOC population were 88.5% and 91.5%, respectively (treatment difference -3.0%; 95% CI: -9.4, 3.7).

The IACR success rate at TOC in the microITT-2 population was 83.6% for lefamulin and 90.0% for moxifloxacin (treatment difference -6.4%; 95% CI: -15.1, 3.2).

IACR success rates at TOC for S. pneumoniae in the microITT population were 85.4% lefamulin vs. 85.7% moxifloxacin. Among those with PSSP, the IACR success rates were 20/26 (76.9%) for lefamulin vs. 38/38 (100%) for moxifloxacin. Seven of the 26 in the lefamulin group with PSSP were ECR non-responders and/or IACR failures at TOC. Of these 7, 3 received only 1 day of treatment with lefamulin of which one died in the setting of ARDS on Day 2 while 2 received 4 days of treatment with lefamulin and had lack of efficacy and 2 completed 7 days of lefamulin/placebo, one of whom started further CAP treatment on day 8.

<div style=\"page-break-after: always\"></div>

Among lefamulin subjects with PSSP, 69.2% were PORT Risk Class III or IV, 34.6% had a CURB-65 score of 2 or higher, 26.9% met minor ATS severity criteria and 30.8% met modified ATS severity criteria for CABP. By comparison, among moxifloxacin subjects with PSSP, 36.8% had a PORT Risk Class III or IV, 26.3% had a CURB-65 score of 2 or higher, 13.2% met minor ATS severity criteria and 7.9% met modified ATS severity criteria for CABP. There was no difference in the distribution of PSSP serotypes or MLST types between treatment groups and no difference in the distribution of lefamulin MIC among subjects who were IACR failures vs. successes.

The number of pathogens for which MIC data were available was small but there was no indication that increasing lefamulin MICs resulted in lower by-pathogen microbiological response of success at TOC.

<div style=\"page-break-after: always\"></div>

Table 43. By-Pathogen Microbiological Response of Success at TOC (microITT and ME-TOC Analysis Sets)

|                                  | microITT Analysis Set    | microITT Analysis Set       | ME-TOC Analysis Set   | ME-TOC Analysis Set      |
|----------------------------------|--------------------------|-----------------------------|-----------------------|--------------------------|
| Baseline Pathogen                | Lefamulin N=205 n/N1 (%) | Moxifloxacin N=186 n/N1 (%) | Lefamulin N=182 (%) I | Moxifloxacin N=164 n (%) |
| Gram-positive bacteria (aerobes) |                          |                             |                       |                          |
| Streptococcuspneumoniae          | 105/123 (85.4)           | 108/126 (85.7)              | 97/110 (88.2)         | 102/112 (91.1)           |
| PSSP                             | 20/26 (76.9)             | 38/38 (100)                 | 17/21 (81.0)          | 36/36 (100)              |
| PISP                             | 4/4 (100)                | 5/5 (100)                   | 4/4 (100)             | 5/5 (100)                |
| PRSP                             | 5/5 (100)                | 3/4 (75.0)                  | 4/4 (100)             | 3/3 (100)                |
| MDRSP                            | 8/8 (100)                | 11/12 (91.7)                | 7/7 (100)             | 11/11 (100)              |
| Macrolide-resistant              | 7/8 (87.5)               | 10/11 (90.9)                | 6/7 (85.7)            | 10/10 (100)              |
| Staphylococcusaureus             | 12/13 (92.3)             | 5/6 (83.3)                  | 12/13 (92.3)          | 5/6 (83.3)               |
| MSSA                             | 8/9 (88.9)               | 2/2 (100)                   | 8/9 (88.9)            | 2/2 (100)                |
| MRSA                             | 2/2 (100)                | 0/1                         | 2/2 (100)             | 0/1                      |
| PVL positive                     | 0                        | 0/1                         | 0                     | 0/1                      |
| PVL negative                     | 10/11 (90.9)             | 2/2 (100)                   | 10/11 (90.9)          | 2/2 (100)                |
| β-hemolytic Streptococcus        | 2/2 (100)                | 1/1 (100)                   | 2/2 (100)             | 1/1 (100)                |
| Streptococcus pyogenes           | 0                        | 1/1 (100)                   | 0                     | 1/1 (100)                |
| Streptococcus agalactiae         | 2/2 (100)                | 0                           | 2/2 (100)             | 0                        |
| Gram-negative bacteria (aerobes) |                          |                             |                       |                          |
| Haemophilusinfhuenzae            | 52/56 (92.9)             | 40/48 (83.3)                | 46/48 (95.8)          | 38/44 (86.4)             |
| β-lactamase positive             | 2/2 (100)                | 3/3 (100)                   | 2/2 (100)             | 3/3 (100)                |
| β-lactamase negative             | 11/12 (91.7)             | 7/7 (100)                   | 11/12 (91.7)          | 6/6 (100)                |
| Mormxellacatarrhalis             | 17/21 (81.0)             | 11/11 (100)                 | 16/20 (80.0)          | 10/10 (100)              |
| Achromobacterxylosoxidans        | 0                        | 1/1 (100)                   | 0                     | 1/1 (100)                |
| Acinetobactercalcoaceticus       | 0                        | 1/1 (100)                   | 0                     | 1/1 (100)                |
| Acinetobacter ursingii           | 1/1 (100)                | 0                           | 1/1 (100)             | 0                        |
| Aeromonascaviaecomplex           | 1/1 (100)                | 0                           | 1/1 (100)             | 0                        |
| Citrobacter freundii complex     | 0                        | 0/1                         | 0                     | 0/1                      |
| Enterobacter cloacae             | 0                        | 1/1 (100)                   | 0                     | 1/1 (100)                |
| Escherichia coli                 | 1/1 (100)                | 0                           | 1/1 (100)             | 0                        |
| Haemophilhusparainfluenzae       | 6/6 (100)                | 2/2 (100)                   | 6/6 (100)             | 1/1 (100)                |
| Klebsiella oxytoca               | 1/1 (100)                | 0                           | 1/1 (100)             | 0                        |

<div style=\"page-break-after: always\"></div>

| Klebsiellapneumoniae        | 4/5 (80.0)   | 2/2 (100)    | 2/3 (66.7)   | 2/2 (100)    |
|-----------------------------|--------------|--------------|--------------|--------------|
| Klebsiellavariicola         | 0/1          | 0            | 0            | 0            |
| Pasturellapneumotropica     | 0            | 0/1          | 0            | 0/1          |
| Proteusmirabilis            | 1/1 (100)    | 0            | 0            | 0            |
| Pseudomonasaeruginosa       | 2/4 (50.0)   | 2/3 (66.7)   | 2/2 (100)    | 1/1 (100)    |
| Pseudomonasluteola          | 0            | 1/1 (100)    | 0            | 0            |
| Stenotrophomonasmaltophilia | 0/1          | 1/1 (100)    | 0            | 1/1 (100)    |
| Atypical pathogens          |              |              |              |              |
| Mycoplasmapneumoniae        | 19/20 (95.0) | 14/14 (100)  | 18/19 (94.7) | 12/12 (100)  |
| Legionellapneumophila       | 13/16 (81.3) | 15/17 (88.2) | 13/15 (86.7) | 14/16 (87.5) |
| Chlamydophilapneumoniae     | 12/16 (75.0) | 10/12 (83.3) | 12/15 (80.0) | 10/12 (83.3) |

By-subject microbiological response rates at TOC in the microITT population were 85.9% for lefamulin and 87.6% for moxifloxacin group (treatment difference -1.8%; 95% CI: -9.0, 5.5). Rates in the ME-TOC population were 88.5% vs. 91.5% (treatment difference -3.0%; 95% CI: -9.9, 3.9) and rates in the microITT-2 population were 83.6% vs. 90.0% (treatment difference -6.4%; 95% CI: -16.0, 3.3).

Six lefamulin and 9 moxifloxacin subjects had baseline pathogens isolated from blood cultures. In the lefamulin group, 3 had S. pneumoniae and 1 subject each had S. aureus , Acinetobacter ursingii and K. pneumoniae . In the moxifloxacin group, 5 had S. pneumoniae , 2 had S. aureus and 1 subject each had Acinetobacter calcoaceticus and Pasteurella pneumotropica . The IACR success rates were 3/6 (50.0%) for lefamulin and 7/9 (77.8%) for moxifloxacin.

No subjects in the lefamulin group had an IACR of relapse at LFU.

## Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

| Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC-3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia   | Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC-3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia   | Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC-3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                            | NAB-BC-3781-3101                                                                                                                                                                                                                            | NAB-BC-3781-3101                                                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                      | Multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group                                                                                                                                                      | Multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group                                                                                                                                                      |
|                                                                                                                                                                                                                                             | Duration of main phase:                                                                                                                                                                                                                     | Approximately 4 to 5 weeks                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                  | Non-inferiority                                                                                                                                                                                                                             | Non-inferiority                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Treatments groups         | Lefamulin                | Lefamulin                                      | Lefamulin 150 mg IV q12h; after 3 full days (6 doses) lefamulin could be switched to 600 mg orally q12h. The duration of treatment was 5 to 10 days.                      |
|---------------------------|--------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | Moxifloxacin ± linezolid | Moxifloxacin ± linezolid                       | Moxifloxacin 400 mg IV q24h; after 3 full days (6 doses) moxifloxacin could be switched to 400 mg orally q24h. The duration of treatment was 7 to 10 days.                |
| Endpoints and definitions | Co-primary endpoints     | IACR at TOC in the mITT and CE-TOC populations | Success was defined as the subject's clinical signs and symptoms resolved or improved such that no additional antibacterial therapy was administered for treatment of CAP |
| Endpoints and definitions | Secondary endpoint       | ECR in ITT population                          | The percentage of subjects with an Early Clinical Response (ECR) of responder at 96 ±24-hours after the first dose                                                        |
| Endpoints and definitions | Secondary endpoint       | IACR at TOC microITT                           | Success was defined as described for the co-primary endpoints.                                                                                                            |
| Endpoints and definitions | Other endpoint           | IACR at TOC by baseline pathogen               | Success was defined as described for the co-primary endpoints.                                                                                                            |
| Database lock             | 01 Sep 2017              | 01 Sep 2017                                    | 01 Sep 2017                                                                                                                                                               |

## Results and Analysis

| Analysis description                            | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                            | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                            | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                            |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | mITT=all randomized subjects who received any amount of study drug TOC=5 to 10 days after the last dose of study drug | mITT=all randomized subjects who received any amount of study drug TOC=5 to 10 days after the last dose of study drug | mITT=all randomized subjects who received any amount of study drug TOC=5 to 10 days after the last dose of study drug |
| Descriptive statistics and estimate variability | Treatment group                                                                                                       | Lefamulin                                                                                                             | Moxifloxacin ± linezolid                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                    | 273                                                                                                                   | 273                                                                                                                   |
| Descriptive statistics and estimate variability | Success                                                                                                               | 223 (81.7%)                                                                                                           | 230 (84.2%)                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                                 | Failure                                                                                                                                                        | 43 (15.8%)                                                                                                                                                     | 40 (14.7%)                                                                                                                                                     |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Indeterm inate                                                                                                                                                 | 7 (2.6%)                                                                                                                                                       | 3 (1.1%)                                                                                                                                                       |
|                                                 |                                                                                                                                                                | Treatment difference                                                                                                                                           | -2.6                                                                                                                                                           |
|                                                 |                                                                                                                                                                | 95% confidence interval                                                                                                                                        | -8.9, 3.9                                                                                                                                                      |
| Analysis description                            | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                   | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                   | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                   |
| Analysis population and time point description  | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                | Lefamulin                                                                                                                                                      | Moxifloxacin ± linezolid                                                                                                                                       |
| Descriptive statistics and estimate variability | Number                                                                                                                                                         | 236                                                                                                                                                            | 245                                                                                                                                                            |
| Descriptive statistics and estimate variability | Success                                                                                                                                                        | 205 (86.9%)                                                                                                                                                    | 219 (89.4%)                                                                                                                                                    |
| Descriptive statistics and estimate variability | Failure                                                                                                                                                        | 31 (13.1%)                                                                                                                                                     | 26 (10.6%)                                                                                                                                                     |
| Descriptive statistics and estimate variability |                                                                                                                                                                | Treatment difference                                                                                                                                           | -2.5                                                                                                                                                           |
| Descriptive statistics and estimate variability |                                                                                                                                                                | 95% confidence interval                                                                                                                                        | -8.4, 3.4                                                                                                                                                      |
| Analysis description                            | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                 | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                 | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                | Lefamulin                                                                                                                                                      | Moxifloxacin ± linezolid                                                                                                                                       |
| Descriptive statistics and estimate variability | Number                                                                                                                                                         | 159                                                                                                                                                            | 159                                                                                                                                                            |
| Descriptive statistics and estimate variability | Streptococcus pneumoniae                                                                                                                                       | 79/93 (84.9%)                                                                                                                                                  | 85/97 (87.6%)                                                                                                                                                  |
| Descriptive statistics and estimate variability | Staphylococcus aureus                                                                                                                                          | 8/10 (80.0%)                                                                                                                                                   | 4/4 (100.0%)                                                                                                                                                   |
| Descriptive statistics and estimate variability | Haemophilus influenzae                                                                                                                                         | 43/51 (84.3%)                                                                                                                                                  | 48/57 (84.2%)                                                                                                                                                  |
| Descriptive statistics and estimate variability | Haemophilus parainfluenzae                                                                                                                                     | 3/3 (100.0%)                                                                                                                                                   | 2/2 (100.0%)                                                                                                                                                   |
| Descriptive statistics and estimate variability | Moraxella catarrhalis                                                                                                                                          | 20/25 (80.0%)                                                                                                                                                  | 11/11 (100.0%)                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

Mycoplasma pneumoniae

Legionella pneumophila

Chlamydophila pneumoniae

Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia

Study identifier

Design

Hypothesis

Treatment groups

Database lock

## Results and Analysis

| Analysis description                            | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                                             | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                                             | Co-primary analysis - IACR at TOC in the mITT Analysis Set                                                                             |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point              | mITT=all randomised subjects who received any amount of study drug Test of Cure Visit (5 to 10 days after the last dose of study drug) | mITT=all randomised subjects who received any amount of study drug Test of Cure Visit (5 to 10 days after the last dose of study drug) | mITT=all randomised subjects who received any amount of study drug Test of Cure Visit (5 to 10 days after the last dose of study drug) |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                        | Lefamulin                                                                                                                              | Moxifloxacin                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                     | 368                                                                                                                                    | 368                                                                                                                                    |
| Descriptive statistics and estimate variability | Success                                                                                                                                | 322 (87.5%)                                                                                                                            | 328 (89.1%)                                                                                                                            |
| Descriptive statistics and estimate variability | Failure                                                                                                                                | 44 (12.0%)                                                                                                                             | 32 (8.7%)                                                                                                                              |
| Descriptive statistics and estimate variability | Indeterm inate                                                                                                                         | 2 (0.5%)                                                                                                                               | 8 (2.2%)                                                                                                                               |

NAB-BC-3781-3102

Multicenter, randomized, double-blind, double-dummy, active controlled, parallel-group

Duration of main phase:

Non-inferiority

Lefamulin

Moxifloxacin

10 May 2018

16/19 (84.2%)

14/18 (77.8%)

8/11 (72.7%)

19/20 (95.0%)

11/14 (78.6%)

13/19 (68.4%)

Approximately 4 to 5 weeks

Lefamulin 600 mg orally q12h for 5 days

Moxifloxacin 400 mg orally q24h for 7 days

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                                                 | Treatment difference                                                                                                                                            | -1.6                                                                                                                                                            |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                                                                                 | 95% confidence interval                                                                                                                                         | -6.3, 3.1                                                                                                                                                       |
| Analysis description                            | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                    | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                    | Co-primary analysis - IACR at TOC in the CE-TOC Analysis Set                                                                                                    |
| Analysis population and time point description  | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics) | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics) | CE=all randomised subjects who met pre-defined key inclusion/exclusion criteria, minimum dosing criteria, and had no confounding use of prohibited antibiotics) |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                 | Lefamulin                                                                                                                                                       | Moxifloxacin                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                              | 330                                                                                                                                                             | 326                                                                                                                                                             |
| Descriptive statistics and estimate variability | Success                                                                                                                                                         | 296 (89.7%)                                                                                                                                                     | 305 (93.6%)                                                                                                                                                     |
| Descriptive statistics and estimate variability | Failure                                                                                                                                                         | 34 (10.3%)                                                                                                                                                      | 21 (6.4%)                                                                                                                                                       |
| Descriptive statistics and estimate variability |                                                                                                                                                                 | Treatment difference                                                                                                                                            | -3.9                                                                                                                                                            |
| Descriptive statistics and estimate variability |                                                                                                                                                                 | 95% confidence interval                                                                                                                                         | -8.2, 0.5                                                                                                                                                       |
| Analysis description                            | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                  | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                  | Other analysis - IACR at TOC by baseline pathogen in the microITT Analysis Set                                                                                  |
| Analysis population and time point              | microITT=all randomised subjects who had at least 1 baseline bacterial pathogen known to cause CAP                                                              | microITT=all randomised subjects who had at least 1 baseline bacterial pathogen known to cause CAP                                                              | microITT=all randomised subjects who had at least 1 baseline bacterial pathogen known to cause CAP                                                              |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                 | Lefamulin                                                                                                                                                       | Moxifloxacin                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                              | 205                                                                                                                                                             | 186                                                                                                                                                             |
| Descriptive statistics and estimate variability | Streptococcus pneumoniae                                                                                                                                        | 105/123 (85.4%)                                                                                                                                                 | 108/126 (85.7%)                                                                                                                                                 |
| Descriptive statistics and estimate variability | Staphylococcus aureus                                                                                                                                           | 12/13 (92.3%)                                                                                                                                                   | 5/6 (83.3%)                                                                                                                                                     |
| Descriptive statistics and estimate variability | Haemophilus influenzae                                                                                                                                          | 52/56 (92.9%)                                                                                                                                                   | 40/48 (83.3%)                                                                                                                                                   |
| Descriptive statistics and estimate variability | Haemophilus parainfluenzae                                                                                                                                      | 6/6 (100.0%)                                                                                                                                                    | 2/2 (100.0%)                                                                                                                                                    |
| Descriptive statistics and estimate variability | Moraxella catarrhalis                                                                                                                                           | 17/21 (81.0%)                                                                                                                                                   | 11/11 (100.0%)                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Mycoplasma pneumoniae    | 19/20 (95.0%)   | 14/14 (100.0%)   |
|--------------------------|-----------------|------------------|
| Legionella pneumophila   | 13/16 (81.3%)   | 15/17 (88.2%)    |
| Chlamydophila pneumoniae | 12/16 (75.0%)   | 10/12 (83.3%)    |

## Analysis performed across trials (pooled analyses and meta-analysis)

A summary of diagnostic modalities across the two trials is given below. It should be noted that the table shows that many patients were positive (and thus eligible for the microITT and/or microITT-2 populations) by more than one diagnostic test.

Table 44. Baseline pathogens by Diagnostic Modality (microITT and microITT-2 analysis populations)

|                                                | microITT-Pooled310land3102   | microITT-Pooled310land3102   | microITT-Pooled310land3102   | microITT-2-Pooled3101and3102   | microITT-2-Pooled3101and3102   | microITT-2-Pooled3101and3102   |
|------------------------------------------------|------------------------------|------------------------------|------------------------------|--------------------------------|--------------------------------|--------------------------------|
| BaselinePathogen PositiveViaDiagnosticModality | Lefamulin N=364 n (%)        | Moxifloxacin N=345 n (%)     | Overall N=709 n (%)          | Lefamulin N=209 n (%)          | Moxifloxacin N=195 n (%)       | Overall tot=N n (%)            |
| Gram-positive bacteria (aerobes) total         | 229 (62.9)                   | 231 (67.0)                   | 460 (64.9)                   | 104 (49.8)                     | 107 (54.9)                     | 211 (52.2)                     |
| AnyStreptococcuspneumoniae                     | 216 (59.3)                   | 223 (64.6)                   | 439 (61.9)                   | 87 (41.6)                      | 100 (51.3)                     | 187 (46.3)                     |
| Sputum culture                                 | 21 (5.8)                     | 18 (5.2)                     | 39 (5.5)                     | 21 (10.0)                      | 18 (9.2)                       | 39 (9.7)                       |
| Blood culture                                  | 9 (2.5)                      | 5 (1.4)                      | 14 (2.0)                     | 9 (4.3)                        | 5 (2.6)                        | 14 (3.5)                       |
| BAL culhure                                    | 1 (0.3)                      | 1 (0.3)                      | 2 (0.3)                      | 1 (0.5)                        | 1 (0.5)                        | 2 (0.5)                        |
| Plewal fluid culture                           | 0                            | 1 (0.3)                      | 1 (0.1)                      | 0                              | 1 (0.5)                        | 1 (0.2)                        |
| NP culture                                     | 50 (13.7)                    | 60 (17.4)                    | 110 (15.5)                   | 50 (23.9)                      | 60 (30.8)                      | 110 (27.2)                     |
| Urinary antigen test                           | 37 (10.2)                    | 44 (12.8)                    | 81 (11.4)                    | 37 (17.7)                      | 44 (22.6)                      | 81 (20.0)                      |
| RQ-PCR from sputum                             | 171 (47.0)                   | 166 (48.1)                   | 337 (47.5)                   | IN                             | NI                             | IN                             |
| NP RO-PCR                                      | 80 (22.0)                    | 92 (26.7)                    | 172 (24.3)                   | IN                             | NI                             | IN                             |
| AnyStaphylococcusaureus                        | 23 (6.3)                     | 10 (2.9)                     | 33 (4.7)                     | 19 (9.1)                       | 6 (3.1)                        | 25 (6.2)                       |
| Sputum culture                                 | 16 (4.4)                     | 4 (1.2)                      | 20 (2.8)                     | 16 (7.7)                       | 4 (2.1)                        | 20 (5.0)                       |
| Blood culture                                  | 2 (0.5)                      | 2 (0.6)                      | 4 (0.6)                      | 2 (1.0)                        | 2 (1.0)                        | 4 (1.0)                        |
| BAL culhure                                    | 1 (0.3)                      | 0                            | 1 (0.1)                      | 1 (0.5)                        | 0                              | 1 (0.2)                        |
| RQ-PCR from spuum                              | 4 (1.1)                      | 4 (1.2)                      | 8 (1.1)                      | IN                             | NI                             | IN                             |
| Anyβ-hemolytic streptococcis                   | 2 (0.5)                      | 2 (0.6)                      | 4 (0.6)                      | 2 (1.0)                        | 2 (1.0)                        | 4 (1.0)                        |
| Any Streptococcus pyogenes                     | 0                            | 2 (0.6)                      | 2 (0.3)                      | 0                              | 2 (1.0)                        | 2 (0.5)                        |
| Sputum culture                                 | 0                            | 2 (0.6)                      | 2 (0.3)                      | 0                              | 2 (1.0)                        | 2 (0.5)                        |
| Any Streptococcus agalactiae                   | 2 (0.5)                      | 0                            | 2 (0.3)                      | 2 (1.0)                        | 0                              | 2 (0.5)                        |
| Sputum culture                                 | 1 (0.3)                      | 0                            | 1 (0.1)                      | 1 (0.5)                        | 0                              | 1 (0.2)                        |
| BAL culture                                    | 1 (0.3)                      | 0                            | 1 (0.1)                      | 1 (0.5)                        | 0                              | 1 (0.2)                        |

<div style=\"page-break-after: always\"></div>

| Gram-negativeFastidiousBacteria (aerobes)   | 138 (37.9)   | 118 (34.2)   | 256 (36.1)   | 34 (16.3)   | 23 (11.8)   | 57 (14.1)   |
|---------------------------------------------|--------------|--------------|--------------|-------------|-------------|-------------|
| AnyHaemophilusinfuenzae                     | 107 (29.4)   | 105 (30.4)   | 212 (29.9)   | 23 (11.0)   | 18 (9.2)    | 41 (10.1)   |
| Sputum culture                              | 23 (6.3)     | 17 (4.9)     | 40 (5.6)     | 23 (11.0)   | 17 (8.7)    | 40 (9.9)    |
| BAL culture                                 | 0            | 1 (0.3)      | 1 (0.1)      | 0           | 1 (0.5)     | 1(0.2)      |
| RQ-PCR from sputum                          | 98 (26.9)    | 95 (27.5)    | 193 (27.2)   | NA          | NA          | NA          |
| AnyMoraxellacatarrhalis                     | 46 (12.6)    | 22 (6.4)     | 68 (9.6)     | 4 (1.9)     | 3 (1.5)     | 7 (1.7)     |
| Sputum culture                              | 4 (1.1)      | 3 (0.9)      | 7 (1.0)      | 4 (1.9)     | 3 (1.5)     | 7(1.7)      |
| RQ-PCRfromsputum                            | 43 (11.8)    | 19 (5.5)     | 62 (8.7)     | NA          | NA          | NA          |
| AnyHaemophilus parainfluenzae               | 9 (2.5)      | 4 (1.2)      | 13 (1.8)     | 9 (4.3)     | 4 (2.1)     | 13 (3.2)    |
| Spuhum culthure                             | 9 (2.5)      | 4 (1.2)      | 13 (1.8)     | 9 (4.3)     | 4 (2.1)     | 13 (3.2)    |
| Atypicalpathogens                           | 91 (25.0)    | 87 (25.2)    | 178 (25.1)   | 74 (35.4)   | 72 (36.9)   | 146 (36.1)  |
| AnyMycoplasmapneumoniae                     | 39 (10.7)    | 34 (9.9)     | 73 (10.3)    | 29 (13.9)   | 23 (11.8)   | 52 (12.9)   |
| Oropharyngeal swab culture                  | 10 (2.7)     | 7 (2.0)      | 17 (2.4)     | 10 (4.8)    | 7 (3.6)     | 17 (4.2)    |
| Serology                                    | 24 (6.6)     | 20 (5.8)     | 44 (6.2)     | 24 (11.5)   | 20 (10.3)   | 44 (10.9)   |
| RT-PCR from sputum                          | 14 (3.8)     | 16 (4.6)     | 30 (4.2)     | NA          | NA          | NA          |
| Oropharymgeal swabPCR                       | 16 (4.4)     | 12 (3.5)     | 28 (3.9)     | NA          | NA          | NA          |
| AnyLegionellapneumophila                    | 34 (9.3)     | 31 (9.0)     | 65 (9.2)     | 32 (15.3)   | 31 (15.9)   | 63 (15.6)   |
| Legionella sputum culture                   | 2 (0.5)      | 0            | 2 (0.3)      | 2 (1.0)     | 0           | 2 (0.5)     |
| Urinary antigen test                        | 16 (4.4)     | 8 (2.3)      | 24 (3.4)     | 16 (7.7)    | 8 (4.1)     | 24 (5.9)    |
| Serology                                    | 23 (6.3)     | 23 (6.7)     | 46 (6.5)     | 23 (11.0)   | 23 (11.8)   | 46 (11.4)   |
| RT-PCR from sputum                          | 8 (2.2)      | 1 (0.3)      | 9 (1.3)      | NA          | NA          | NA          |
| AnyChlamydophilapneumoniae                  | 27 (7.4)     | 31 (9.0)     | 58 (8.2)     | 22 (10.5)   | 24 (12.3)   | 46 (11.4)   |
| Serology                                    | 22 (6.0)     | 24 (7.0)     | 46 (6.5)     | 22 (10.5)   | 24 (12.3)   | 46 (11.4)   |
| RT-PCRfrom sputum                           | 7 (1.9)      | 7 (2.0)      | 14 (2.0)     | NA          | NA          | NA          |

## Results specific to the microITT-2 population

The microITT-2 population excluded subjects who were positive for a pathogen based only on PCR but did include those with S. pneumoniae obtained from culture of a NP swab. In each of 3101 and in 3102 the microITT-2 population accounted for about one third (30-33%) of the total number randomised. In the summary of efficacy, it is further clarified that in the pooled microITT-2 analysis set:

- S. pneumoniae (46.3% of subjects overall) was most often identified by NP swab culture (58.8%; 110/187 subjects) and UAT (20.0%; 81/187 subjects); after removing those positive by swab culture, the table below from the ISE shows the residual numbers considered to have S. pneumoniae at baseline, most of whom were diagnosed based on urinary antigen detection. Note that these numbers are not identical to those shown in the summary of efficacy table.

<div style=\"page-break-after: always\"></div>

Table 45. Selected Baseline Pathogens by Unique Diagnostic Modality Combinations (Excluding Pathogens from NP and OP Swab Cultures (microITT-2 Analysis Set)

|                                  | Study-3101                     | Study-3101                        | Study-3102                   | Study-3102                      | Pooled                          | Pooled                             | Pooled                        |
|----------------------------------|--------------------------------|-----------------------------------|------------------------------|---------------------------------|---------------------------------|------------------------------------|-------------------------------|
|                                  | Lefamulin IV/0ral (N=93) n (8) | Moxifloxacin IV/0ral (N=85) n (8) | Lefamulin Oral (N=116) n (8) | Moxifloxacin Oral (N=110) n (8) | Lefamulin IV/0ral (N=209) n (8) | Moxifloxacin IV/0ral (N=195) n (8) | Overall IV/0ral (N=404) n (8) |
| Any Streptococcus pneumoniae     | 33( 35.5)                      | 29 ( 34.1)                        | 22 (19.0)                    | 31 (28.2)                       | 55 (26.3)                       | 60(30.8)                           | 115 (28.5)                    |
| Positive Via:                    |                                |                                   |                              |                                 |                                 |                                    |                               |
|                                  | 7 7.5)                         | 4 4.7)                            | 6 （ 5.2)                     | 9 8.2)                          | 13 6.2)                         | 13 6.7)                            | 26 6.4)                       |
| Blood Culture                    | 1 1.1)                         |                                   | 2 1.7)                       | 1 0.9)                          | 3 （ 1.4)                        | 1 0.5)                             | 4 1.0)                        |
| BAL Culture                      |                                |                                   | 1 0.9)                       | 0.9)                            | 1 （ 0.5)                        | 1 0.5)                             | 2 0.5)                        |
| Pleural Fluid Culture            |                                | 1 1.2)                            | 0                            | 0                               | 0                               | 1 0.5)                             | 1 ( 0.2)                      |
| Urine UAT                        | 16 (17.2)                      | 22 ( 25.9)                        | 11 9.5)                      | 13 (11.8)                       | 27 (12.9)                       | 35 (17.9)                          | 62 (15.3)                     |
| Sputum Cultureplus Blood Culture | 1 1.1)                         | 0                                 | 0                            | 0                               | 1 0.5)                          | 0                                  | 1 0.2)                        |
| Sputum Cultureplus Urine UAT     | 4 4.3)                         | 2( 2.4)                           | 1 0.9)                       | 3（ 2.7)                         | 5 （ 2.4)                        | 5 (2.6)                            | 10 （ 2.5)                     |

- S. aureus was identified in 25 (6.2%) subjects overall and was most commonly identified by sputum culture (80.0%; 20/25 subjects);
- H. influenzae and M. catarrhalis were identified in 41 (10.1%) subjects and 7 (1.7%) subjects, respectively, primarily by sputum culture for both H. influenzae (9.9%; 40/41 subjects) and M. catarrhalis (100.0%; 7/7 subjects);
- The most common diagnostic methodology for M. pneumoniae was serology (84.6%; 44/52 subjects), followed by oropharyngeal swab culture (32.7%; 17/52 subjects);
- The most common diagnostic methodology for L. pneumophila was serology (73.0%; 46/63 subjects), followed by UAT (38.1%; 24/63 pathogens);
- For C. pneumoniae , serology was the only diagnostic modality (100.0%; 46/46 subjects).

As discussed by study above, the IACR at TOC (and the by-subject microbiological responses at TOC) in the microITT-2 population were numerically lower for lefamulin vs. moxifloxacin in both trials. Also, in 3101 and 3102 the pneumococcal microbiological response rates at TOC were numerically lower for lefamulin with a larger difference in the oral-only trial 3102. Across the two trials, clinical success rates by S. pneumoniae serotypes (only possible to determine in the microITT-2 subset with a positive culture) were consistently lower for lefamulin vs. moxifloxacin.

On request, the applicant created a Modified microITT-2 Analysis Set that excludes those who were eligible for the microITT-2 Analysis Set only on the basis of a positive culture from an NP swab. This added exclusion impacts the numbers deemed to have S. pneumoniae at baseline, because NP swabs were performed only for the detection of S. pneumoniae . As shown below, 63 subjects were eliminated from the pooled Phase 3 dataset after applying this additional restriction.

<div style=\"page-break-after: always\"></div>

Table 46. Summary of Subjects Included in the Modified microITT-2 Analysis Set

|                      | Study 3101 IV/Oral   | Study 3101 IV/Oral   | Study 3102 Oral   | Study 3102 Oral   | Pooled IV/Oral   | Pooled IV/Oral   |
|----------------------|----------------------|----------------------|-------------------|-------------------|------------------|------------------|
| Population           | LEF                  | MOX                  | LEF               | MOX               | LEF              | MOX              |
| OriginalmicroITT-2   | 93                   | 85                   | 116               | 110               | 209              | 195              |
| Modified microITT-2a | 87                   | 72                   | 96                | 86                | 183              | 158              |
| Subjectsexcludedb    | 6                    | 13                   | 20                | 24                | 26               | 37               |

IV=intravenous; LEF=1efamulin; microITT-2=Microbiological Intent-to-treat-2; MOX=moxifloxacin; NP=nasopharyngeal.

aExcludessubjectswithONLYS.pneumoniaeand ONLY detected byNPswabculture.

b Number of subjects with ONLY S. pneumoniae and ONLY detected by NP swab culture.

Source:ISETable14.1.2andISEPost-hocTable2.1.

As shown below, the exclusion of those who were eligible for the microITT-2 Analysis Set only on the basis of a positive culture from an NP swab did not significantly change the rates for IACR at TOC for the individual studies or the pooled analysis. Furthermore, although more subjects were excluded from the moxifloxacin vs. lefamulin totals, the numerical inferiority for lefamulin vs. moxifloxacin persisted.

Table 47. Investigator's Assessment of Clinical Response at the Test of Cure Visit (microITT-2 and Modified microITT-2 Analysis Sets)

|                               | Study3101 IV/Oral    | Study3101 IV/Oral    | Study 3102 Oral     | Study 3102 Oral     | Pooled IV/Oral      | Pooled IV/Oral      |
|-------------------------------|----------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
| Analysis Set IACR Outcome     | LEF n (%)            | MOX n (%)            | LEF n (%)           | MOX n (%)           | LEF n (%)           | MOX (%) uI          |
| microITT-2                    | (N=93)               | (N=85)               | (N=116)             | (N=110)             | (N=209)             | (N=195)             |
| Success                       | 77 (82.8)            | 72 (84.7)            | 97 (83.6)           | 99 (90.0)           | 174 (83.3)          | 171 (87.7)          |
| Treatment Difference (95% CI) | -1.9 (-13.9, 10.1) a | -1.9 (-13.9, 10.1) a | -6.4 (-16.0, 3.3) a | -6.4 (-16.0, 3.3) a | -4.6 (-11.5, 2.3) b | -4.6 (-11.5, 2.3) b |
| Failure / indeterminate       | 16 (17.2)            | 13 (15.3)            | 19 (16.4)           | 11 (10.0)           | 35 (16.7)           | 24 (12.3)           |
| Failure                       | 16 (17.2)            | 10 (11.8)            | 19 (16.4)           | 11 (10.0)           | 35 (16.7)           | 21 (10.8)           |
| Indeterminate                 | 0                    | 3 (3.5)              | 0                   | 0                   | 0                   | 3 (1.5)             |

|                               | Study 3101 IV/Oral   | Study 3101 IV/Oral   | Study 3102 Oral     | Study 3102 Oral     | Pooled IV/Oral      | Pooled IV/Oral      |
|-------------------------------|----------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
| Analysis Set IACR Outcome     | LEF n (%)            | MOX n (%)            | LEF n (%)           | MOX (%) uI          | LEF n (%)           | MOX n (%)           |
| ModifiedmicroITT-2            | (N=87)               | (N=72)               | (N=96)              | (N=86)              | (N=183)             | (N=158)             |
| Success                       | 71 (81.6)            | 60 (83.3)            | 80 (83.3)           | 76 (88.4)           | 151 (82.5)          | 136 (86.1)          |
| Treatment Difference (95% CI) | -1.7 (-14.8, 11.4) a | -1.7 (-14.8, 11.4) a | -5.0 (-16.2, 6.1) a | -5.0 (-16.2, 6.1) a | -3.6 (-11.4, 4.3) b | -3.6 (-11.4, 4.3) b |
| Failure/indeterminate         | 16 (18.4)            | 12 (16.7)            | 16 (16.7)           | 10 (11.6)           | 32 (17.5)           | 22 (13.9)           |
| Failure                       | 16 (18.4)            | 10 (13.9)            | 16 (16.7)           | 10 (11.6)           | 32 (17.5)           | 20 (12.7)           |
| Indeterminate                 | 0                    | 2 (2.8)              | 0                   | 0                   | 0                   | 2 (1.3)             |

CI=confidence interval; IACR=Investigator's Assessment of Clinical Response; IV=intravenous;LEF=lefamulin; microITT-2=Microbiological Intent-to-treat-2; MOX=moxifloxacin; TOC=Test of Cure.

b Weighted treatment difference. CI computed using the Miettinen and Nurminen method, adjusted for study, with the inverse variance of the effect size as the stratum weights.

a Absolute treatment difference (lefamulin minus moxifloxacin). CI computed using a continuity corrected Z-test.

<div style=\"page-break-after: always\"></div>

The rates for IACR at TOC for S. pneumoniae (including phenotypes) in the Modified microITT-2 Analysis Set were consistent with results in the original microITT-2 Analysis Set. The overall numerical inferiority for lefamulin vs. moxifloxacin for this species persists and, as before, is driven by results in the majority, which comprised PSSP.

Table 48. Investigators Assessment of Clinical Response of Success at the Test of Cure Visit by Baseline Pathogen (Modified microITT-2 Analysis Set)

|                              | Study- 3101              | Study- 3101                  | Study - 3102              | Study - 3102                 | Pooled                    | Pooled                       |
|------------------------------|--------------------------|------------------------------|---------------------------|------------------------------|---------------------------|------------------------------|
| Baxelin                      | Lefamulin (N=87) n/N1(%) | Moxifloxaein (N=72) n/N1 (%) | Lefamulin (N=96) n/N1 (%) | Moxifloxacin (N=86) n/N1 (%) | Lefamulin (N=183) n/N1(%) | Moxifloxnein (N=158) n/N1(%) |
| Gram-Poxitive nria (aerobex) | 33/41(80.5)              | 29/34(85.3)                  | 30/37(81.1)               | 33/36(91.7)                  | 63/78(80.8)               | 62/70(88.6)                  |
| eumon                        | 28/36(77.8)              | 26/31(83.9)                  | 19/25(76.0)               | 30/32(93.8)                  | 47/61(77.0)               | 56/63(88.9)                  |
| PSSP                         | 11/17(64.7)              | 8/8(100.0)                   | 9/12(75.0)                | 18/18(100.0)                 | 20/29(69.0)               | 26/26(100.0)                 |
| PISP                         | 5/5(100.0)               | 0                            | 2/2(100.0)                | 4/4(100.0)                   | 7/7(100.0)                | 4/4(100.0)                   |
| PRSP                         | 1/1(100.0)               | 0                            | 1/1(100.0)                | 1/1(100.0)                   | 2/2(100.0)                | 1/3(33.3)                    |
| MDRSP                        | 5/5(100.0)               | 1/3(33.3)                    | 3/3(100.0)                | 4/4(100.0)                   | 8/8(100.0)                | 5/7(71.4)                    |
| M.                           | 5/5(100.0)               | 1/3(33.3)                    | 3/4(75.0)                 | 2/2(100.0)                   | 8/9(88.9)                 | 3/5(60.0)                    |

Results of IACR at TOC by selected baseline pathogen and unique diagnostic modality combination in the Modified microITT-2 Analysis Set (see below) were consistent with results in the original microITT-2 Analysis Set.

Table 59. Investigators Assessment of Clinical Response of Success at the Test of Cure Visit by Baseline Pathogen and unique diagnostic modality combination (Modified microITT-2 Analysis Set)

|                                              | Seudy 3101              | Seudy 3101             | Study 3102               | Study 3102              | Pooled                   | Pooled         |
|----------------------------------------------|-------------------------|------------------------|--------------------------|-------------------------|--------------------------|----------------|
|                                              | Lefamulin (N=81) /N1(%) | Moxiflox (N=68) /N1(%) | Lefamulin (N=87) n/N1(%) | Moxifloxa (N=80) /N1(%) | Lefamulin (N=168) /N1(%) | (N=148) /N1(%) |
|                                              | 28/36(77.8)             | 26/31(83.9)            | 19/25(76.0)              | 30/32(93.8)             | 47/61(77.0)              | 56/63(88.9)    |
| S                                            | 3/4(75.0)               | 0/1(0.0)               | 3/3(100.0)               | 2/2(100.0)              | 6/7(85.7)                | 2/3(66.7)      |
|                                              | 0/0(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 1/1(100.0)              | 1/1(100.0)               | 1/1(100.0)     |
| BAL                                          | 0/0(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 0/1(0.0)                | 1/1(100.0)               | 0/1(0.0)       |
| Fluid                                        | 0/0(0.0)                | 0/1(0.0)               | 0/0(0.0)                 | 0/0(0.0)                | 0/0(0.0)                 | 0/1(0.0)       |
| NP                                           | 3/3(100.0)              | 2/2(100.0)             | 3/3(100.0)               | 1/1(100.0)              | 6/6(100.0)               | 3/3(100.0)     |
| U,i UAT                                      | 12/14(85.7)             | 18/21(85.7)            | 6/9(66.7)                | 8/9(88.9)               | 18/23(78.3)              | 26/30(86.7)    |
| NPSw                                         | 3/3(100.0)              | 3/3(100.0)             | 2/3(66.7)                | 7/7(100.0)              | 5/6(83.3)                | 10/10(100.0)   |
| plux                                         | 0/1(0.0)                | 0/0(0.0)               | 0/1(0.0)                 | 0/0(0.0)                | 0/2(0.0)                 | 0/0(0.0)       |
| plu Urine UAT                                | 2/2(100.0)              | 1/1(100.0)             | 0/0(0.0)                 | 2/2(100.0)              | 2/2(100.0)               | 3/3(100.0)     |
| Blood plus UrinUAT                           | 0/1(0.0)                | 0/0(0.0)               | 0/0(0.0)                 | 1/1(100.0)              | 0/1(0.0)                 | 1/1(100.0)     |
| NPSwb Culture plux UinUAT                    | 2/2(100.0)              | 1/1(100.0)             | 2/2(100.0)               | 4/4(100.0)              | 4/4(100.0)               | 5/5(100.0)     |
| Blood NPSw                                   | 0/1(0.0)                | 0/0(0.0)               | 0/0(0.0)                 | 0/0(0.0)                | 0/1(0.0)                 | 0/0(0.0)       |
| Sputum Biood UeineUAT                        | 0/1(0.0)                | 0/0(0.0)               | 0/1(0.0)                 | 0/0(0.0)                | 0/2(0.0)                 | 0/0(0.0)       |
| NP Swab Cultur UAT                           | 2/2(100.0)              | 1/1(100.0)             | 1/1(100.0)               | 1/1(100.0)              | 3/3(100.0)               | 2/2(100.0)     |
| Blood Culture NP Swab Culture plux Urine UAT | 1/2(50.0)               | 0/0(0.0)               | 0/0(0.0)                 | 3/3(100.0)              | 1/2(50.0)                | 3/3(100.0)     |
|                                              | 6/7(85.7)               | 3/3(100.0)             | 11/12(91.7)              | 2/3(66.7)               | 17/19(89.5)              | 5/6(83.3)      |
|                                              | 6/6(100.0)              | 3/3(100.0)             | 9/10(90.0)               | 1/1(100.0)              | 15/16(93.8)              | 4/4(100.0)     |
| Blood Cultur                                 | 0/1(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 1/2(50.0)               | 1/2(50.0)                | 1/2(50.0)      |
| BAL Culture                                  | 0/0(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 0/0(0.0)                | 1/1(100.0)               | 0/0(0.0)       |
|                                              | 0/0(0.0)                | 1/1(100.0)             | 0/0(0.0)                 | 1/1(100.0)              | 0/0(0.0)                 | 2/2(100.0)     |
| Cult                                         | 0/0(0.0)                | 1/1(100.0)             | 0/0(0.0)                 | 1/1(100.0)              | 0/0(0.0)                 | 2/2(100.0)     |
|                                              | 0/0(0.0)                | 0/0(0.0)               | 2/2(100.0)               | 0/0(0.0)                | 2/2(100.0)               | 0/0(0.0)       |
| Sputum Cultur                                | 0/0(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 0/0(0.0)                | 1/1(100.0)               | 0/0(0.0)       |
| BAL Culture                                  | 0/0(0.0)                | 0/0(0.0)               | 1/1(100.0)               | 0/0(0.0)                | 1/1(100.0)               | 0/0(0.0)       |

Assessment report EMA/325848/2020

<div style=\"page-break-after: always\"></div>

|                                         | 5/6(83.3)   | 6/6(100.0)   | 15/17(88.2)   | 11/12(91.7)   | 20/23(87.0)   | 17/18(94.4)   |
|-----------------------------------------|-------------|--------------|---------------|---------------|---------------|---------------|
| Sputum Cultur                           | 5/6(83.3)   | 6/6(100.0)   | 15/17(88.2)   | 11/11(100.0)  | 20/23(87.0)   | 17/17(100.0)  |
| BAL Culture                             | 0/0(0.0)    | 0/0(0.0)     | 0/0(0.0)      | 0/1(0.0)      | 0/0(0.0)      | 0/1(0.0)      |
| Mora                                    | 0/1(0.0)    | 1/1(100.0)   | 3/3(100.0)    | 2/2(100.0)    | 3/4(75.0)     | 3/3(100.0)    |
|                                         | 0/1(0.0)    | 1/1(100.0)   | 3/3(100.0)    | 2/2(100.0)    | 3/4(75.0)     | 3/3(100.0)    |
|                                         | 3/3(100.0)  | 2/2(100.0)   | 6/6(100.0)    | 2/2(100.0)    | 9/9(100.0)    | 4/4(100.0)    |
| Sputum Cultur                           | 3/3(100.0)  | 2/2(100.0)   | 6/6(100.0)    | 2/2(100.0)    | 9/9(100.0)    | 4/4(100.0)    |
|                                         | 12/14(85.7) | 11/12(91.7)  | 14/15(93.3)   | 11/11(100.0)  | 26/29(89.7)   | 22/23(95.7)   |
| Serology                                | 7/9(77.8)   | 10/11(90.9)  | 10/10(100.0)  | 5/5(100.0)    | 17/19(89.5)   | 15/16(93.8)   |
| OP Swnb Cul                             | 1/1(100.0)  | 0/0(0.0)     | 3/4(75.0)     | 3/3(100.0)    | 4/5(80.0)     | 3/3(100.0)    |
| Serology plux OP Swnb Culture           | 4/4(100.0)  | 1/1(100.0)   | 1/1(100.0)    | 3/3(100.0)    | 5/5(100.0)    | 4/4(100.0)    |
|                                         | 14/17(82.4) | 11/14(78.6)  | 12/15(80.0)   | 15/17(88.2)   | 26/32(81.3)   | 26/31(83.9)   |
| Urine UAT                               | 6/8(75.0)   | 2/4(50.0)    | 0/1(0.0)      | 3/4(75.0)     | 6/9(66.7)     | 5/8(62.5)     |
| Serelogy                                | 6/6(100.0)  | 9/10(90.0)   | 9/10(90.0)    | 12/13(92.3)   | 15/16(93.8)   | 21/23(91.3)   |
| Urine UAT plux Serology                 | 2/3(66.7)   | 0/0(0.0)     | 2/2(100.0)    | 0/0(0.0)      | 4/5(80.0)     | 0/0(0.0)      |
| Sputum Culture, Urine UAT plux Serology | 0/0(0.0)    | 0/0(0.0)     | 1/2(50.0)     | 0/0(0.0)      | 1/2(50.0)     | 0/0(0.0)      |
|                                         | 7/9(77.8)   | 11/15(73.3)  | 10/13(76.9)   | 7/9(77.8)     | 17/22(77.3)   | 18/24(75.0)   |
|                                         | 7/9(77.8)   | 11/15(73.3)  | 10/13(76.9)   | 7/9(77.8)     | 17/22(77.3)   | 18/24(75.0)   |

## Justification for pathogens listed in section 5.1

The applicant's justification for species claimed to have been successfully treated in trials is based on the microITT and microITT-2 populations.

Table 50. EMA and FDA Primary Efficacy Analyses by Baseline Pathogen (microITT Analysis Population) for Proposed List 1 Organisms

<!-- image -->

|                                            | Study3101 microlTTAnalysisPopulation       | Study3101 microlTTAnalysisPopulation       | Study3102 microlTTAnalysisPopulation       | Study3102 microlTTAnalysisPopulation       | Pooled microITTAnalysisPopulations         | Pooled microITTAnalysisPopulations         |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| BaselinePathogen                           | Lefamulin N=159 (96)IN/u                   | Morifloracin N=159 (96)TN                  | Lefamulin N=205 (46)INu                    | Morifloracin N=186 (96)IN                  | Lefamulin N=364 m/N1 (%6)                  | Morifloracin N=345 (95）TN/                 |
| LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen | LACR at TOC (Success) by Baseline Pathogen |
| OvenallmicrolTT                            | 127 (79.9)                                 | 136 (85.5)                                 | 176 (85.9)                                 | 163 (87.6)                                 | 303 (83.2)                                 | 299 (86.7)                                 |
| Treahment Diff. (95% CT)*                  | -5.7 (-14.6.3.3)                           | -5.7 (-14.6.3.3)                           | -1.8 (-9.0.5.5)                            | -1.8 (-9.0.5.5)                            | -33 (-8.6,2.0)                             | -33 (-8.6,2.0)                             |
| S.poumoviae                                | 79/93 (84.9)                               | 85/97 (87.0)                               | 105/123 (85.4)                             | 108/126 (85.7)                             | 184/216 (85.2)                             | 193/223 (86.5)                             |
| S.mwo5                                     | 8/10 (80.0)                                | 4/4 (100)                                  | 12/13 (92.3)                               | 5/6 (83.3)                                 | 20/23 (87.0)                               | (0'06)01/6                                 |
| H.iduoeao                                  | 43/51 (84.3)                               | 48/57 (84.2)                               | 52/56 (92.9)                               | 40/48 (83.3)                               | 95/107 (88.8)                              | 88/105(83.8)                               |
| H.parainiuonsao                            | 3/3 (100)                                  | 22 (100)                                   | 6/6 (100)                                  | 2/2 (100)                                  | (001)616                                   | 4/4 (100)                                  |
| Mcatarhalis                                | 20/25 (80.0)                               | (OO)1U/!1                                  | 17/21 (81.0)                               | (00D11/11                                  | 37/46 (80.4)                               | 22/22 (100)                                |
| Lomomophila                                | 14/18 (77.8)                               | 11/14 (78.0)                               | 13/16 (81.3)                               | 15/17 (88.2)                               | 27/34 (79.4)                               | 26/31 (83.9)                               |
| Mpgnoniae                                  | 16/19 (84.2)                               | 19/20 (95.0)                               | 19/20 (95.0)                               | 14/14 (100)                                | 35/39 (89.7)                               | 33/34 (97.1)                               |
| C.pomoniae                                 | 8/11 (72.7)                                | 13/19 (68.4)                               | 12/16 (75.0)                               | 10/12 (83.3)                               | 20/27 (74.1)                               | 23/31 (74.2)                               |

<div style=\"page-break-after: always\"></div>

Table 51. EMA and FDA Primary Efficacy Analyses by Baseline Pathogen (microITT-2 Analysis Population) for Proposed List 1 Organisms

<!-- image -->

## Additional sub-group analyses across the Phase 3 trials

The initial analyses indicated that patients in the age group 65-74 years who received lefamulin and did not meet ATS severity criteria achieved a numerically greater probability of IACR success than those receiving moxifloxacin. The opposite was seen in all other subgroups defined by age and ATS severity. Numbers older than age 65 and meeting ATS severity criteria are very small. A numerically better outcome was observed for subjects receiving moxifloxacin except for the subgroup that was aged &gt;65 years and did not meet ATS severity criteria.

<div style=\"page-break-after: always\"></div>

Table 52. Observed Percentage of IACR Failure by ATS Severity Criteria, Age Group, and Randomised Treatment Employing 3 Classifications of Age

<!-- image -->

| ATS Criteria   | Age Group   | Lefamulin   | Moxifloxacin   |
|----------------|-------------|-------------|----------------|
| No             | Age <65     | 14.5%       | 11.0%          |
| No             | Age 65-74   | 10.8%       | 18.5%          |
| No             | Age 75-84   | 10.3%       | 17.9%          |
| No             | Age ≥85     | 14.3%       | 12.5%          |
| Yes            | Age <65     | 32.8%       | 9.1%           |
| Yes            | Age 65-74   | 15.4%       | 0.0%           |
| Yes            | Age 75-84   | 50.0%       | 0.0%           |
| Yes            | Age ≥85     | 0.0%        | 0.0%           |
| No             | Age <65     | 14.5%       | 11.0%          |
| No             | Age 65-74   | 10.8%       | 18.5%          |
| No             | Age ≥75     | 11.1%       | 17.0%          |
| Yes            | Age <65     | 32.8%       | 9.1%           |
| Yes            | Age 65-74   | 15.4%       | 0.0%           |
| Yes            | Age ≥75     | 14.3%       | 0.0%           |
| No             | Age <65     | 14.5%       | 11.0%          |
| No             | Age ≥65     | 10.9%       | 17.9%          |
| Yes            | Age <65     | 32.8%       | 9.1%           |
| Yes            | Age ≥65     | 15.0%       | 0.0%           |

The table below summarises analysis of the full model including the effects of ATS severity, age group, and randomised treatment as well as all 2-way and 3-way interactions.

Table 53. Logistic Regression Analysis of IACR Failure by ATS Severity Criteria, Age Group, and Randomised Treatment

<!-- image -->

| Analysis of Mlaximum Likelihood Estimates   | Analysis of Mlaximum Likelihood Estimates   | Analysis of Mlaximum Likelihood Estimates   | Analysis of Mlaximum Likelihood Estimates   | Analysis of Mlaximum Likelihood Estimates   |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Parameter                                   | Estimate                                    | Standard Error                              | Wald Chi-Square                             | Pr > ChiSq                                  |
| Intercept                                   | -3.5371                                     | 88.0581                                     | 0.0016                                      | 0.9680                                      |
| TRT01PN                                     | -1.9566                                     | 88.0581                                     | 0.0005                                      | 0.9823                                      |
| MATSMETN                                    | -1.6662                                     | 88.0581                                     | 0.0004                                      | 0.9849                                      |
| TRTOIPN*MATSMETN                            | -2.0211                                     | 88.0581                                     | 0.0005                                      | 0.9817                                      |
| ELDERLY                                     | -1.8166                                     | 88.0581                                     | 0.0004                                      | 0.9835                                      |
| TRT01PN*ELDERLY                             | -1.4809                                     | 88.0581                                     | 0.0003                                      | 0.9866                                      |
| MATSMETN*ELDERLY                            | -1.8771                                     | 88.0581                                     | 0.0005                                      | 0.9830                                      |
| TRTO1PN*MIAISMETN* ELDERLY                  | -1.7038                                     | 88.0581                                     | 0.0004                                      | 0.9846                                      |

<div style=\"page-break-after: always\"></div>

None of these terms was deemed significant. An additional model including only 2-way interactions also indicated no significant interaction between ATS severity and age group.

## 2.5.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

To support the claimed indication for treatment of community-acquired pneumonia (CAP), the applicant conducted two randomised, double-blind and active-controlled Phase 3 trials to evaluate use of IV/PO lefamulin in patients with CAP and PORT scores III-V (3101) and PO lefamulin in patients with CAP with PORT scores II-IV (3102). Both trials aimed to demonstrate non-inferiority for lefamulin vs. IV/PO or PO moxifloxacin as the comparative agent based on the clinical outcome at the test of cure (TOC visit) with a 10% non-inferiority margin.

This programme complies with the existing and draft revised CHMP guidance on the development of antibacterial agents. In compliance with existing guidance, the mITT and CE populations were considered coprimary.

## Selection criteria

These were appropriate, including the restriction on pre-study antibacterial treatment for CAP and proportions in each PORT class. It should be noted that patients taking strong P-gp inhibitors or strong CYP3A inducers or inhibitors as well as those at risk for QTc prolongation, including concomitant medications with this risk, were excluded.

## Treatments

## Lefamulin

The IV and oral dose regimens were selected solely from PK-PD considerations (see previous sections) and are the same as those proposed in the SmPCs. However, the SmPC-recommended options for doses and durations are as follows:

- 150 mg of lefamulin by IV infusion every 12 hours (q12h) over 60 minutes for 5 to 7 days
- 150 mg of lefamulin by IV infusion q12h over 60 minutes then switch to a 600 mg lefamulin tablet orally q12h (at the discretion of the physician) for a total of 5 to 7 days
- 600 mg lefamulin tablet orally q12h for 5 days.

In 3101, the initial protocol required that patients with S. pneumoniae bacteraemia, Legionella pneumophila or MRSA were to receive 10 days of active treatment while all other patients were to receive 5 days. After coimplementation of amendments 2 and 3, all patients received 7 days of lefamulin except that patients with MRSA continued to receive up to 10 days. The outcomes for those treated before (25% of total) and after (75% of total) the amendment are therefore very important for considering the IV and IV/PO durations, as discussed below. In 3102 there was a fixed duration of 5 days from the outset so the SmPC recommendation reflects this.

<div style=\"page-break-after: always\"></div>

## Moxifloxacin

This was an acceptable comparator. The doses and durations used in the Phase 3 trials reflected the SmPCs (IV/PO 400 mg QD for 7-10 days in 3101 and 400 mg QD orally for 7 days in 3102).

## Baseline pathogens

The applicant defined a microITT population that included all patients with any positive result (as defined by test) based on cultures (including NP swab cultures), PCR (of sputa or swabs), serology (for pathogens involved in atypical pneumonia) or positive urinary antigen detection test (for S. pneumoniae or L. pneumophila ). Also defined was a microITT-2 population in which all patients with only PCR evidence of a pathogen were excluded.

In prior applications, the CHMP has accepted positive culture of respiratory tract samples, blood, lung abscess material or pleural fluid plus positive urinary antigen tests for the 2 pathogens as above as sufficient to imply possible aetiology for the clinical picture. On the basis of these tests, claims for demonstrating efficacy vs. specific species have been allowed in section 5.1. Nevertheless, it should be understood that sputum culture is not a definitive method to establish causality except for those species causing atypical pneumonia that are not part of the normal flora of the nasopharynx.

For organisms that can be found in the nasopharynx of healthy subjects and so contaminate sputa as it is expectorated, finding colonies on culture plates does not necessarily indicate and cannot confirm the aetiology of pneumonia. It is a rare occurrence that sputum yields a pure growth of a single species that would very strongly suggest causality.

Finding bacterial DNA in specimens (whether applying PCR to sputa or swabs) means only that live or dead bacteria are there. Whilst the applicant provides vast amounts of information on validation (based on sensitivity and specificity), results of these tests (although sensitive at detecting the presence of certain species and able to speciate) does not assist in determining causality.

Therefore, the validity of the microITT population is rejected. Furthermore, since culturing organisms from NP swabs is not helpful, the microITT-2 population (which includes some patients positive only by NP culture) is also not entirely confined to a population that would be considered most likely to have a documented pathogen.

## Efficacy data and additional analyses

## Study populations

The study populations are considered to be adequately representative of the CAP patient population typically encountered in the EU. In both trials Eastern European patients accounted for a considerable proportion of the totals. Treatment and study completion rates were high. Generally, most host and disease factors were well-balanced between treatments in both trials.

## Outcomes in the mITT population

It is acceptable that the primary analysis was conducted in the mITT (all-treated) population since there was very little difference in numbers vs. the ITT population, which is the recommended primary analysis

<div style=\"page-break-after: always\"></div>

population in the revised guidance. The results in the CE population can be viewed as an important secondary analysis.

Both trials demonstrated non-inferiority for lefamulin vs. moxifloxacin in the primary analysis based on clinical outcomes at TOC in the mITT populations. The non-inferiority criterion was also met in the CE population (87% of total) in both trials. Both trials showed that lefamulin was consistently numerically inferior to moxifloxacin for clinical and microbiological success rates at TOC across the pre-defined trial populations.

## Outcomes by duration of IV/PO treatment

In 3101 the mean and median duration of total treatment was 7 days and the duration of IV was near to 6 days in both treatment groups. Whilst 75% of the total was enrolled after the amendment to increase the standard duration of lefamulin from 5 to 7 days, the cure rates at TOC were lower for lefamulin in those enrolled prior (5 days) or after (7 days) the amendment. Although the trial was not designed to assess the effect of duration, there is no reason to accept the applicant's proposal that the treatment duration could be 5-7 days for those who require initial intravenous administration. The SmPC was amended accordingly.

## Outcomes in subgroups

In 3101 and 3102 lefamulin was consistently numerically inferior to moxifloxacin in several large subgroups. In older subjects there did not seem to be lower success rates with lefamulin in either trial. The applicant provided a further breakdown of outcomes in age subsets 75-84 and 84+ years, indicating that success rates in these subsets were comparable between treatment groups as far as can be judged based on relatively small numbers. In light of the discussions over PPB and free lefamulin, it has to be considered that free drug levels may have been higher as age increased. However, this is conjecture.

## Mortality

- o In 3101, all-cause mortality rates to day 28 were 1.8% (5) for lefamulin vs. 1.5% (4) for moxifloxacin but rates including those of unknown status were 5.4% (15) vs. 3.3% (9). Two lefamulin and one moxifloxacin patients considered to have S. pneumoniae died.
- o In 3102 there were 3 patients per treatment group known to have died by day 28 but rates counting those of unknown status were 6 (1.6%) vs. 4 (1.1%). Another 2 deaths occurred in the lefamulin group after day 28 so the final total was 5 vs. 3 known deaths. One per group considered to have S. pneumoniae died.

This applicant provided an explanation of the reasons for unknown status of subjects at day 28 in both studies, indicating no reason to consider that there were important imbalances between treatments.

## Baseline resistance

- o In 3101, 2 (0.7%) lefamulin and 3 (1.1%) moxifloxacin patients were excluded from the ME population due to having only pathogens deemed to be resistant (for lefamulin this was based on the applicant's preliminary criteria) to either study drug; these were all enterobacteria or non-fermenters.

<div style=\"page-break-after: always\"></div>

- o In 3102, 4 (1.1%) lefamulin and 3 (0.8%) moxifloxacin patients were excluded from the ME population due to having only pathogens resistant to either study drug; again, these were all enterobacteria or non-fermenters.

On request, the applicant provided analyses of outcomes at TOC in the mITT, microITT and microITT-2 populations after removing all patients from both treatment groups with any baseline pathogen resistant to moxifloxacin. Across all 3 additional analyses, there was no meaningful change in the rates of IACR success at TOC. In the mITT Analysis Set, specifically, the lower limit of the 95% CI for the difference in IACR success rates was &gt;-10% for the individual studies and the Phase 3 pool.

## Outcomes in patients with a pathogen

In line with the primary analyses, the clinical success rates at TOC in the microITT (58% of total enrolled in 3101 and 53% in 3102) and microITT-2 (32% of total enrolled in 3101 and 31% in 3102) populations were lower for lefamulin vs. moxifloxacin. The trials were not powered for comparisons of clinical outcomes in these sub-populations.

In the microITT-2 populations, clinical success rates at TOC for S. pneumoniae were 81% for lefamulin vs. 86.4% for moxifloxacin (34/42 vs. 38/44) in 3101 and 80% vs. 94.6% (36/45 vs. 53/56) in 3102.

Clinical response rates at TOC by S. pneumoniae serotypes (only possible to determine in the microITT-2 subset with a positive culture) were consistently lower for lefamulin vs. moxifloxacin. Overall, the rates were 50/62 for lefamulin (80.6%) vs. 65/69 (94.2%) for moxifloxacin and the LFU rates were similar at 79% vs. 94.2%.

Nevertheless, the population of major interest consists of those patients with:

- i) acceptable pathogens cultured from any of sputum, BAL, blood or pleuritic fluid or
2. ii) a positive urinary antigen test for S. pneumoniae or L. pneumophila or
3. iii) positive serology for L. pneumophila , M. pneumoniae or C. pneumoniae

This group of major interest did not equate with any of the applicant's pre-defined analysis populations because even the microITT-2 population included those with positive cultures from a nasopharyngeal swab. On request, the applicant created a Modified microITT-2 Analysis Set that excluded those who were eligible for the microITT-2 Analysis Set only on the basis of a positive culture from an NP swab.

After excluding patients included in the microITT-2 population solely on the basis of a NP swab, the cure rates in patients with pneumococcal pneumonia (positive sputum culture or urinary antigen test) were numerically lower for lefamulin vs. moxifloxacin (28/36 [77.8%] vs. 26/31 [83.9%]) when treatment commenced intravenously and 19/25 (76%) vs. 30/32 (93.8%) when treatment commenced orally. Furthermore, among patients with positive cultures and documented lefamulin MICs for S. pneumoniae , the cure rates in patients treated with lefamulin were 9/10 (90%), 34/41 (83%) and 6/9 (67%) when MICs of lefamulin were 0.12, 0.25 and 0.5 mg/L, respectively. Taking into account also the PK-PD analyses, these collective concerns led to a restricted indication that reads as follows:

<div style=\"page-break-after: always\"></div>

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed (see sections 4.4 and 5.1).

## Bacteraemia

In 3101, 7 lefamulin patients had baseline bacteraemia of which 6 had S. pneumoniae and one had S. aureus (but had S. pneumoniae in sputum culture). The success rate was only 1/7 (14.3%). Five of the 6 with S. pneumoniae in blood and one other patient with a positive sputum culture failed. One patient with S. pneumoniae in blood died from uncontrolled infection. In 3102, 6 lefamulin patients had bacteraemia, of which 3 were S. pneumoniae and 2/3 failed although none died. In both trials, success rates in bacteraemic patients treated with moxifloxacin (2/3 in 3101 and 7/9 in 3102) were higher than for lefamulin, although numbers are very small.

## 2.5.3. Conclusions on the clinical efficacy

The applicant conducted two pivotal trials in CAP, both of which showed non-inferiority for lefamulin vs. moxifloxacin. Nevertheless, the most important pathogen to cover is S. pneumoniae . Taking into account the results by pathogen and PK-PD analyses, the final indication was restricted as follows:

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed (see sections 4.4 and 5.1).

## 2.6. Clinical safety

## Patient exposure

The number of subjects exposed to any dose of lefamulin across all completed clinical studies was 1242, including 712 subjects exposed to target doses in Phase 2 or Phase 3 studies.

<div style=\"page-break-after: always\"></div>

Table 54. Number of Subjects Exposed to Lefamulin Across All Clinical Studies

| Clinical Study               | Clinical Study               | Clinical Study               | Clinical Study               | Number of Unique Subjects Exposed to Lefainulin   | Number of Unique Subjects Exposed to Lefainulin   | Number of Unique Subjects Exposed to Lefainulin   | Number of Unique Subjects Exposed to Lefainulin   | Number of Unique Subjects Exposed to Lefainulin   | Number of Unique Subjects Exposed to Lefainulin   |
|------------------------------|------------------------------|------------------------------|------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Phase                        | Population                   | Study Number                 | Exposure Duration (days) a b | Any IV                                            | IV ≥150 mg/ dose                                  | Any PO                                            | PO ≥600 mg/ dose                                  | Any IV or PO                                      | Any IV or PO ≥ target doses                       |
| Phase 1                      | various - single dose        | various - single dose        | 1                            | 190                                               | 181                                               | 119                                               | 79                                                | 289                                               | 240                                               |
| Phase 1                      | various - multiple dose      | various - multiple dose      | 4-15                         | 90                                                | 82                                                | 81                                                | 69                                                | 171                                               | 151                                               |
| Phase 1 Totals d             | Phase 1 Totals d             | Phase 1 Totals d             | Phase 1 Totals d             | 280                                               | 263                                               | 200                                               | 148                                               | 460                                               | 391                                               |
| Phase 2                      | ABSSSI                       | 2001                         | 5-14                         | 141                                               | 71                                                | NA                                                | NA                                                | 141                                               | 71                                                |
| Phase 3                      | CABP                         | 3101                         | 5-10 e                       | 273                                               | 273                                               | 104                                               | 104                                               | 273                                               | 273                                               |
| Phase 3                      | CABP                         | 3102                         | 5                            | NA                                                | NA                                                | 368                                               | 368                                               | 368                                               | 368                                               |
| Phase 2/3 Totals             | Phase 2/3 Totals             | Phase 2/3 Totals             | Phase 2/3 Totals             | 414                                               | 344                                               | 472                                               | 472                                               | 782                                               | 712                                               |
| Total - All Clinical Studies | Total - All Clinical Studies | Total - All Clinical Studies | Total - All Clinical Studies | 694                                               | 607                                               | 672                                               | 620                                               | 1242                                              | 1103                                              |

ABSSSI=acute bacterial skin and skin structure infections; CABP=community-acquired bacterial pneumonia;

IV=intravenous; NA=not applicable; PO=by mouth (oral)

- a In all multiple dose studies, the intended dosing regimen of lefamulin was every 12 hours (q12h).

b Exposure duration as intended per protocol.

- c For Study 1105 (Part A crossover single-dose lefamulin fed/fasted, Part B [same subjects] multiple dose lefamulin vs placebo), all 12 subjects are counted as oral multiple dose.
- d This table summarizes all subjects exposed in Phase 1 studies, whereas Pool 1 (Phase 1 healthy subjects) excludes the 32 subjects in Phase 1 studies who had known hepatic or renal impairment.
- e For Study 3101, the duration of study diug treatment depended on the baseline pathogen identified and the approved protocol version at the time a subject was screened.

In study 3101 the mean IV treatment was for 5.9 vs. 5.7 days and 104 (38.1%) vs. 121 (44.3%) patients switched to oral study drug for mean durations of 3.8 vs. 3.5 days. In 3102 mean oral treatment was 5 days lefamulin vs. 7 days moxifloxacin in accordance with the protocol.

## Adverse events

The first table below provides an overall summary of the safety profiles observed in Phase 3 trials.

The second table shows that the most frequently reported AEs in the lefamulin and moxifloxacin groups, respectively, were gastrointestinal events, including diarrhoea (7.3% vs. 3.9%), nausea (4.2% vs. 2.0%) and vomiting (2.3% vs. 0.6%) driven primarily by AEs occurring during oral administration. In 3102 with oral only dosing the most notable imbalance was for diarrhoea, reported by 12.2% lefamulin and 1.1% moxifloxacin subjects. In contrast, in 3101 overall, rates for diarrhoea were 0.7% vs. 7.7% in respective groups. Infusion site pain in 3101 was reported for 2.9% lefamulin vs. no moxifloxacin subjects.

<div style=\"page-break-after: always\"></div>

Table 55. Summary of Treatment-emergent Adverse Events by Category for Pool 3 (Safety Population)

|                                          | Study 3101                               | Study 3101                               | Study 3102                               | Study 3102                               | Pool3                                    | Pool3                                    |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Adverse event category                   | Lefamulin (N=273)                        | Moxifloxacin (N=273)                     | Lefanulin (N=368)                        | Moxifloxacin (N=368)                     | Lefamulina (N=641)                       | Moxifloxacinb (N=641)                    |
| Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) | Treatment emergent adverse events (TEAE) |
| Any TEAEs                                | 104 (38.1)                               | 103 (37.7)                               | 120 (32.6)                               | 92 (25.0)                                | 224 (34.9)                               | 195 (30.4)                               |
| Related TEAEs                            | 41 (15.0)                                | 39 (14.3)                                | 58 (15.8)                                | 29 (7.9)                                 | 99 (15.4)                                | 68 (10.6)                                |
| Severe TEAE                              | 14 (5.1)                                 | 13 (4.8)                                 | 13 (3.5)                                 | 10 (2.7)                                 | 27 (4.2)                                 | 23 (3.6)                                 |
| TEAEs leading to death c                 | 6 (2.2)                                  | 5 (1.8)                                  | 5 (1.4)                                  | 3 (0.8)                                  | 11 (1.7)                                 | 8 (1.2)                                  |
| Treatment-related TEAEs leading to death | 0                                        | 0                                        | 0                                        | 0                                        | 0                                        | 0                                        |
| Serious adverse events (SAE)             | Serious adverse events (SAE)             | Serious adverse events (SAE)             | Serious adverse events (SAE)             | Serious adverse events (SAE)             | Serious adverse events (SAE)             | Serious adverse events (SAE)             |
| Treatment-emergent SAE                   | 19 (7.0)                                 | 13 (4.8)                                 | 17 (4.6)                                 | 18 (4.9)                                 | 36 (5.6)                                 | 31 (4.8)                                 |
| Related treatment-emergent SAE           | 3 (1.1)                                  | 1 (0.4)                                  | 0                                        | 1 (0.3)                                  | 3 (0.5)                                  | 2 (0.3)                                  |
| Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   | Discontinuation of study drug due toAE   |
| TEAE                                     | 8 (2.9)                                  | 12 (4.4)                                 | 12 (3.3)                                 | 9 (2.4)                                  | 20 (3.1)                                 | 21 (3.3)                                 |
| Related TEAE                             | 3 (1.1)                                  | 5 (1.8)                                  | 4 (1.1)                                  | 3 (0.8)                                  | 7 (1.1)                                  | 8 (1.2)                                  |

AE=adverse event; IV=intravenous; SAE=serious adverse event; TEAE=treatment-emergent adverse event

a Lefamulin 150 mg IV / 600 mg oral

c Three deaths in the lefamulin group and 1 death in the moxifloxacin group occurred after Day 28 (intended Late Follow-up Visit) (Section 2.1.2.1).

b Moxifloxacin 400 mg IV / 400 mg oral

<div style=\"page-break-after: always\"></div>

Table 56. Most Frequently Reported Treatment-Emergent Adverse Events (Preferred Terms Reported for ≥ 1% in Total Lefamulin Group in Pool 3) (Safety Population)

|                      | Study 3101            | Study 3101               | Study 3102            | Study 3102               | Pool3                  | Pool3                     |
|----------------------|-----------------------|--------------------------|-----------------------|--------------------------|------------------------|---------------------------|
| MedDRAPreferred Term | Lefamulin N=273 n (%) | Moxifloxacin N=273 n (%) | Lefamulin N=368 n (%) | Moxifloxacin N=368 n (%) | Lefamulina N=641 n (%) | Moxifloxacinb N=641 n (%) |
| Any TEAE             | 104 (38.1)            | 103 (37.7)               | 120 (32.6)            | 92 (25.0)                | 224 (34.9)             | 195 (30.4)                |
| Diarrhoea            | 2 (0.7)               | 21 (7.7)                 | 45 (12.2)             | 4 (1.1)                  | 47 (7.3)               | 25 (3.9)                  |
| Nausea               | 8 (2.9)               | 6 (2.2)                  | 19 (5.2)              | 7 (1.9)                  | 27 (4.2)               | 13 (2.0)                  |
| Vomiting             | 3 (1.1)               | 1 (0.4)                  | 12 (3.3)              | 3 (0.8)                  | 15 (2.3)               | 4 (0.6)                   |
| Headache             | 5 (1.8)               | 5 (1.8)                  | 4 (1.1)               | 6 (1.6)                  | 9 (1.4)                | 11 (1.7)                  |
| Pneumonia            | 5 (1.8)               | 1 (0.4)                  | 4 (1.1)               | 1 (0.3)                  | 9 (1.4)                | 2 (0.3)                   |
| ALT increased        | 5 (1.8)               | 6 (2.2)                  | 3 (0.8)               | 4 (1.1)                  | 8 (1.2)                | 10 (1.6)                  |
| COPD                 | 4 (1.5)               | 3 (1.1)                  | 4 (1.1)               | 0                        | 8 (1.2)                | 3 (0.5)                   |
| Infusion site pain c | 8 (2.9)               | 0                        | 0                     | 0                        | 8 (1.2)                | 0                         |
| Hypokalaemia         | 8 (2.9)               | 6 (2.2)                  | 0                     | 1 (0.3)                  | 8 (1.2)                | 7 (1.1)                   |
| Insomnia             | 8 (2.9)               | 5 (1.8)                  | 0                     | 4 (1.1)                  | 8 (1.2)                | 9 (1.4)                   |
| Hypertension         | 2 (0.7)               | 6 (2.2)                  | 5 (1.4)               | 5 (1.4)                  | 7 (1.1)                | 11 (1.7)                  |

ALT=alanine aminotransferase; COPD=chronic obstructive pulmonary disease; MedDRA=Medical Dictionary for Regulatory Activities; SOC=system organ class; TEAE=treatment-emergent adverse event

a Lefamulin 150 mg IV / 600 mg oral

C All infusion site pain occurred in Study 3101.

b Moxifloxacin 400 mg / 400 mg oral

When examined by SOC, the incidence of AEs in the SOC of Gastrointestinal Disorders was 13.1% in the lefamulin group and 10.1% in the moxifloxacin group, mainly reflecting 3102. In the SOC of General Disorders and Administration Site Conditions, the incidence of TEAEs was 4.4% in the lefamulin group and 2.7% in the moxifloxacin group, mainly due to infusion site reactions in 3101. Most AEs were mild (18.6% vs. 18.3%) or moderate (12.2% vs. 8.6%) in severity. The incidence of severe AEs was similar between groups (4.2% and 3.6%, respectively). The most frequently reported treatment-related TEAEs are shown below.

<div style=\"page-break-after: always\"></div>

Table 57. Most Frequently Reported Treatment-related Adverse Events (Preferred Terms Reported for ≥ 1% in Total Lefamulin Group in Pool 3) (Safety Population)

|                            | Study 3101            | Study 3101               | Study 3102            | Study 3102               | Pool3                   | Pool3                      |
|----------------------------|-----------------------|--------------------------|-----------------------|--------------------------|-------------------------|----------------------------|
| MedDRAPreferred Term       | Lefamulin N=273 n (%) | Moxifloxacin N=273 n (%) | Lefamulin N=368 n (%) | Moxifloxacin N=368 n (%) | Lefamulina N=641 (%) uI | Moxifloxacinb N=641 (%) uI |
| Any treatment-related TEAE | 41 (15.0)             | 39 (14.3)                | 58 (15.8)             | 29 (7.9)                 | 99 (15.4)               | 68 (10.6)                  |
| Diarrhoea                  | 2 (0.7)               | 17 (6.2)                 | 34 (9.2)              | 3 (0.8)                  | 36 (5.6)                | 20 (3.1)                   |
| Nausea                     | 6 (2.2)               | 5 (1.8)                  | 15 (4.1)              | 6 (1.6)                  | 21 (3.3)                | 11 (1.7)                   |
| Vomiting                   | 3 (1.1)               | 0                        | 8 (2.2)               | 0                        | 11 (1.7)                | 0                          |
| Infusion site painc        | 7 (2.6)               | 0                        | NA                    | NA                       | NA                      | NA                         |

MedDRA=Medical Dictionary for Regulatory Activities; NA=not applicable; SOC=System Organ Class; TEAE=treatmentemergent adverse event

- a Lefamulin 150 mg IV / 600 mg oral
- b Moxifloxacin 400 mg IV / 400 mg oral
- c Infusion site reactions are only applicable to IV dosing in Study 3101.

Although the lefamulin infusion conditions were modified before commencing efficacy trials, there was a higher rate of TEAEs associated with the infusion in the lefamulin group vs. the moxifloxacin group.

<div style=\"page-break-after: always\"></div>

Table 58. Administration Site Reaction TEAEs for Pool 3 during the IV Dosing Period (Safety Population)

| Adverse Event Preferred Term                               | Lefamulin 150 mg IV (N=273) (%) 1   | Moxifloxacin 400 mg IV (N=273) n (%)   |
|------------------------------------------------------------|-------------------------------------|----------------------------------------|
| Administration site reactions                              | 21 (7.7)                            | 10 (3.7)                               |
| Infusion site reactions                                    | 14 (5.1)                            | 6 (2.2)                                |
| Infusion site pain                                         | 8 (2.9)                             | 0                                      |
| Infusion site phlebitis                                    | 6 (2.2)                             | 3 (1.1)                                |
| Infusion site erythema                                     | 2 (0.7)                             | 2 (0.7)                                |
| Infusion site reaction                                     | 2 (0.7)                             | 1 (0.4)                                |
| Infusion site coldness                                     | 1 (0.4)                             | 0                                      |
| Injection site reactions                                   | 5 (1.8)                             | 1 (0.4)                                |
| Injection site pain                                        | 2 (0.7)                             | 0                                      |
| Injection site reaction                                    | 2 (0.7)                             | 0                                      |
| Injection site bruising                                    | 1 (0.4)                             | 0                                      |
| Injection site erythema                                    | 1 (0.4)                             | 1 (0.4)                                |
| Administration site reactions NEC                          | 1 (0.4)                             | 3 (1.1)                                |
| Vessel puncture site erythema                              | 1 (0.4)                             | 1 (0.4)                                |
| Vessel puncture site haematoma                             | 0                                   | 1 (0.4)                                |
| Vessel puncture site pain                                  | 0                                   | 1 (0.4)                                |
| Vessel puncture site reaction                              | 0                                   | 1 (0.4)                                |
| Implant and catheter site reactions                        | 1 (0.4)                             | 0                                      |
| Catheter site inflammation                                 | 1 (0.4)                             | 0                                      |
| Total Infusion Site Reactions and Injection Site Reactions | 19 (7.0)                            | 7 (2.6)                                |

During oral treatment (see below), the overall differences in AEs were driven by rates of diarrhoea (12.2% vs. 1.1%), nausea (5.2% vs. 1.9%) and vomiting (3.3% vs. 0.8%).

<div style=\"page-break-after: always\"></div>

Table 59. Overall Summary of Adverse Events (Safety Analysis Set)

| Subjects with at least l:                         | Lefamulin N=368 (%)   | Moxifloxacin N=368 n (%)   |
|---------------------------------------------------|-----------------------|----------------------------|
| Adverse event                                     | 122 (33.2)            | 100 (27.2)                 |
| Treatment-emergent AE                             | 120 (32.6)            | 92 (25.0)                  |
| Related TEAE                                      | 58 (15.8)             | 29 (7.9)                   |
| Serious TEAE                                      | 17 (4.6)              | 18 (4.9)                   |
| Related serious TEAE                              | 0                     | 1 (0.3)                    |
| Treatment-emergent AE leading to DC of study drug | 12 (3.3)              | 9 (2.4)                    |
| Treatment-emergent AE leading to DC of study      | 5 (1.4)               | 5 (1.4)                    |
| Treatment-emergent AE leading to death            | 5 (1.4)               | 3 (0.8)                    |

## Cardiac events and QTc data

In Phase 3 trials, AEs mapping to the SOC Cardiac Disorders were reported for 2.5% lefamulin and 3.1% moxifloxacin subjects, mainly due to a difference with IV in 3101 (2.9% vs. 4%) rather than oral in 3102 (2.2% vs. 2.4%). An analysis using the MedDRA SMQ of Torsade de pointes/QT prolongation (broad) showed that 5 subjects (0.8%) in the lefamulin group and 6 subjects (0.9%) in the moxifloxacin group had TEAEs within this SMQ.

Table 60. Treatment-Emergent QT/QTc Prolongation Adverse Events for Pool 3 (Safety Population)

| Adverse Event Preferred Term   | Lefamulin (150 mg IV/600 mg oral) (N=641) n (%)   | Moxifloxacin (400 mg IV/400 mg (7e.0 (N=641) n (%)   |
|--------------------------------|---------------------------------------------------|------------------------------------------------------|
| QT Prolongation²               | 5 (0.8)                                           | 6 (0.9)                                              |
| Electrocardiogram QT prolonged | 4 (0.6)                                           | 5 (0.8)                                              |
| Ventricular arrhythmia         | 1 (0.2)                                           | 0                                                    |
| Cardiac arrest                 | 0                                                 | 1 (0.2)                                              |

TEAE=treatment-emergent adverse event

AE=adverse event; IV=intravenous; MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standard MedDRA query.

a QT prolongation includes the MedDRA SMQ \"Torsade de pointes/QT prolongation\" (broad).

In the lefamulin group two cardiac AEs resulted in discontinuation of study drug. A fatal event of ventricular arrhythmia (no ECG confirmation) on Day 20, considered not related to lefamulin, occurred in 3101 in a 72year-old male enrolled with PORT Risk Class IV CABP. Due to his history of heavy smoking, pulmonary tuberculosis, COPD and coronary artery disease, and baseline ECGs that showed incomplete right bundle

<div style=\"page-break-after: always\"></div>

branch block and ST/T wave changes (mean QTcF was 441 msec) he was considered inappropriate for the trial and was discontinued after dosing on Day 2.

ECGs were recorded before the first IV infusion and within 15 minutes after the end of the first infusion of study drug on Day 1 and Day 3 in 3101. ECGs were recorded before the first dose of study drug and 1 to 3 h after dosing on Day 1 and Day 4 in 3102. The only ECG findings reported as TEAES for &gt;1 subject per treatment group were electrocardiogram QT prolonged (0.6% lefamulin, 0.8% moxifloxacin) and atrial fibrillation (0.5% lefamulin, 0.6% moxifloxacin).

At the Day 3/4 post-dose evaluation the mean change from baseline in QTcF was 11.4 ms for lefamulin vs. 13.6 msec for moxifloxacin group. The mean maximum change in QTcF interval at any time was 16.8 msec for lefamulin and 19.3 msec for moxifloxacin and maximum changes in QTcF for individual subjects were 87.7 msec vs. 98.7 msec. With IV dosing the mean change from baseline in QTcF was 13.8 msec for lefamulin and 16.4 msec for moxifloxacin while oral dosing gave changes of 9.5 msec for lefamulin and 11.6 msec for moxifloxacin.

Post-baseline QTcF increases &gt;30 msec were seen in 17.9% and 22.3% of subjects in the lefamulin and moxifloxacin groups, respectively, while increases &gt;60 msec occurred in 1.7% and 2.5%. One (0.2%) lefamulin and 4 (0.6%) moxifloxacin subjects had QTcF increases &gt;60 msec that resulted in a value of &gt;480 msec. ECGs following IV dosing showed that 2.6% of lefamulin subjects had a post-baseline QTcF increase of &gt;60 msec compared to 1.1% with oral dosing.

Table 61. Post-Baseline QTcF Values and Increases for Pool 3 (Safety Population)

|                                            | Study3101                                  | Study3101                                  | Study 3102                                 | Study 3102                                 | Pool3                                      | Pool3                                      |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Parameter                                  | Lefamulin (N=273) n (%)                    | Moxifloxacin (N=273) n (%)                 | Lefamulin (N=368) n (%)                    | Moxifloxacin (N=368) n (%)                 | Lefamulina (N=641) n (%)                   | Moxifloxacinb (N=641) n (%)                |
| Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) | Change from Baseline in QTcF Values (msec) |
| N                                          | 273                                        | 271                                        | 363                                        | 367                                        | 636                                        | 638                                        |
| Value >480                                 | 13 (4.8)                                   | 12 (4.4)                                   | 7 (1.9)                                    | 9 (2.5)                                    | 20 (3.1)                                   | 21 (3.3)                                   |
| Value >500                                 | 1 (0.4)                                    | 4 (1.5)                                    | 1 (0.3)                                    | 2 (0.5)                                    | 2 (0.3)                                    | 6 (0.9)                                    |
| Increaseof>30                              | 58 (21.2)                                  | 74 (27.3)                                  | 56 (15.4)                                  | 68 (18.5)                                  | 114 (17.9)                                 | 142 (22.3)                                 |
| Increase of >60                            | 7 (2.6)                                    | 9 (3.3)                                    | 4 (1.1)                                    | 7 (1.9)                                    | 11 (1.7)                                   | 16 (2.5)                                   |
| Increase>30&value>480                      | 3 (1.1)                                    | 8 (3.0)                                    | 6 (1.7)                                    | 3 (0.8)                                    | 9 (1.4)                                    | 11 (1.7)                                   |
| Increase >30&value >500                    | 1 (0.4)                                    | 2 (0.7)                                    | 1 (0.3)                                    | 1 (0.3)                                    | 2 (0.3)                                    | 3 (0.5)                                    |
| Increase >60& value >480                   | 0                                          | 2 (0.7)                                    | 1 (0.3)                                    | 2 (0.5)                                    | 1 (0.2)                                    | 4 (0.6)                                    |
| Increase >60 & value >500                  | 0                                          | 0                                          | 0                                          | 1 (0.3)                                    | 0                                          | 1 (0.2)                                    |

QTcF=QTintervalcorrected by theFredericaformula

α Lefamulin 150 mg IV / 600 mg oral

b Moxifloxacin 400 mg IV / 400 mg oral

of subjects having values at baseline and at the visit (N).

The Cardiac Expert Evaluation report concluded that ' The QT effect after an IV infusion of 150 mg is not larger than that of 400 mg IV moxifloxacin, the standard-of-care. While this effect levels seems small, it is prudent to recommend caution when lefamulin is given to patients on other drugs with known effect on the QT interval .' The applicant's conclusion appears to be that ' a small effect on QTc prolongation by lefamulin

<div style=\"page-break-after: always\"></div>

was demonstrated but does not pose a clinically significant risk of ventricular pro-arrhythmia with appropriate precautions and use.'

Hepatic effects (see also under laboratory findings)

The incidence of liver AEs was 2.5% in the lefamulin group vs. 3% in the moxifloxacin group.

Table 62. Liver Safety Treatment-Emergent Adverse Events for Pool 3 (Safety Population)

| Adverse Event Preferred Term          | Lefamulin 150 mg IV/600 mg oral (N=641) (%)   | Moxifloxacin 400 mg IV/400 mg oral (N=641) n (%)   |
|---------------------------------------|-----------------------------------------------|----------------------------------------------------|
| Liver Safety a                        | 16 (2.5)                                      | 19 (3.0)                                           |
| Alanine aminotransferase increased    | 8 (1.2)                                       | 10 (1.6)                                           |
| Aspartate aminotransferase increased  | 6 (0.9)                                       | 6 (0.9)                                            |
| Gamma-glutamyltransferase increased   | 6 (0.9)                                       | 2 (0.3)                                            |
| Blood allkaline phosphatase increased | 4 (0.6)                                       | 0                                                  |
| Liver function test increased         | 2 (0.3)                                       | 0                                                  |
| Transaminases increased               | 2 (0.3)                                       | 1 (0.2)                                            |
| Blood bilinubin increased             | 0                                             | 1 (0.2)                                            |
| Hepatic enzyme increased              | 0                                             | 3 (0.5)                                            |
| Hypertransaminasaemia                 | 0                                             | 1 (0.2)                                            |
| Hypoalbuminaemia                      | 0                                             | 3 (0.5)                                            |

AE=adverse event; IV=intravenous; MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standard MedDRA query. TEAE=treatment-emergent adverse event

Liver Safety includes the 2 SMQs \"Liver related investigations, signs and symptoms\" (broad) and \"Biliary system related investigations, signs and symptoms\" (broad).

Two lefamulin and one moxifloxacin subject discontinued study drug due to hepatobiliary AEs. In the lefamulin group:

- One had non-serious hepatitis toxic on Day 4, which was moderate in severity and considered to be possibly related to study treatment. The event resolved with treatment in 19 days.
- One had AEs of increased ALT, AST, ALP and GGT, which were non-serious, moderate in severity and considered unrelated to study drug. All events began on Day 5 and resolved without treatment.

## C. difficile

One lefamulin subject in 3102 had a mild, non-serious AE of C. difficile colitis on Day 12, 1 week after completing 5 days of lefamulin. The event resolved on Day 24 after a course of oral vancomycin and was considered by the Investigator to be unrelated to lefamulin. Two other lefamulin-treated subjects in 3102 received metronidazole for diarrhoea beginning on Day 30 and Day 34, respectively. One had a negative test for C. difficile and the other was not tested.

<div style=\"page-break-after: always\"></div>

## Serious adverse event and deaths

There were no SAEs or deaths in Phase 1 studies. In the Phase 2 study no deaths occurred but 3 lefamulin patients had SAEs, none of which was considered treatment-related.

In Phase 3 trials the numbers confirmed deceased by Day 28 are shown below. Whilst the numbers of confirmed deaths were similar in both trials, there were more subjects of unknown status in the lefamulin groups such that the known alive rates at day 28 were slightly lower vs. moxifloxacin.

Table 63. 28-Day All-cause Mortality in Pool 3 (Intent-to-Treat Population)

|                                      | Study 3101            | Study 3101               | Study 3102            | Study 3102               |
|--------------------------------------|-----------------------|--------------------------|-----------------------|--------------------------|
|                                      | Lefamulin N=276 n (%) | Moxifloxacin N=275 n (%) | Lefamulin N=370 n (%) | Moxifloxacin N=368 n (%) |
| Alive at Day 28a                     | 261 (94.6)            | 266 (96.7)               | 364 (98.4)            | 364 (98.9)               |
| Deceased or status unknown at Day 28 | 15 (5.4)              | 9 (3.3)                  | 6 (1.6)               | 4 (1.1)                  |
| Deceased at Day 28                   | 5 (1.8)               | 4 (1.5)                  | 3 (0.8)               | 3 (0.8)                  |
| Status unkmown at Day 28             | 10 (3.6)              | 5 (1.8)                  | 3 (0.8)               | 1 (0.3)                  |

LFU=Latefollow-up

Alive as of the LFU Visit, or on Day 28 for subjects without an LFU Visit.

Another 4 deaths not shown above were reported after Day 28 (intended LFU Visit), giving totals of 1.7% (11) in the lefamulin group and 1.2% (8) in the moxifloxacin group. The 3 additional deaths in the lefamulin group were due to sepsis leading to death on Day 32, endocarditis leading to death on Day 57 and acute myeloid leukaemia leading to death on Day 271. No deaths in either group were considered treatmentrelated. Deaths occurred within 5 days of the first dose in 5/11 (45%) lefamulin-treated and 3/8 (38%) moxifloxacin-treated subjects and 11/19 were in PORT Risk Class IV or V.

Rates for SAEs were 5.6% in the lefamulin group and 4.8% in the moxifloxacin group. SAEs were most commonly reported in the SOC of Infections and Infestations and account for the treatment difference in 3101 as well as the overall difference. Most of these SAEs represented worsening or complications of CAP and none of these events was considered related to study drug. Of the 12 lefamulin-treated subjects with SAEs of pneumonia or acute respiratory decline, 6 were non-responders at ECR while 5 were ECR responders but failed at TOC. The remaining subject was an ECR responder and a success at TOC, but had an SAE of pneumonia starting on day 17 and was considered a relapse at LFU.

In the lefamulin group, SAEs considered by the investigator to be related to study treatment included events of liver function test increased, ALT increased and injection site reaction. In the moxifloxacin group, treatment-related SAEs were angioedema and acute myocardial infarction.

<div style=\"page-break-after: always\"></div>

Table 64. Most Common Serious (Fatal and Non-fatal) Treatment-emergent Adverse Events ( ≥ 2 Subjects in Total Lefamulin or Moxifloxacin Groups) by System Organ Class and Preferred Term for Pool 3 (Safety Population)

|                                                      | Study 3101      | Study 3101       | Study 3102      | Study 3102      | Pool3           | Pool3            |
|------------------------------------------------------|-----------------|------------------|-----------------|-----------------|-----------------|------------------|
| System Organ Class/ MedDRA Preferred Term            | Lef N=273 n (%) | Mox N=273 (%) uI | Lef N=368 n (%) | Mox N=368 n (%) | Lef N=641 n (%) | Morb N=641 n (%) |
| Any Serious TEAE                                     | 19 (7.0)        | 13 (4.8)         | 17 (4.0)        | 18 (4.9)        | 36 (5.0)        | 31 (4.8)         |
| Infections and infestations                          | 8 (2.9)         | 4 (1.5)          | 9 (2.4)         | 5 (1.4)         | 17 (2.7)        | 9 (1.4)          |
| Pneumonia                                            | 4 (1.5)         | 1 (0.4)          | 4 (1.1)         | 1 (0.3)         | 8 (1.2)         | 2 (0.3)          |
| Urinary tract infection                              | 1 (0.4)         | 0                | 1 (0.3)         | 1 (0.3)         | 2 (0.3)         | 1 (0.2)          |
| Lung abscess                                         | 0               | 1 (0.4)          | 1 (0.3)         | 2 (0.5)         | 1 (0.2)         | 3 (0.5)          |
| Respiratory,thoracic, and mediastinal disorder's     | 4 (1.5)         | 3 (1.1)          | 4 (1.1)         | 1 (0.3)         | 8 (1.2)         | 4 (0.6)c         |
| Acute respiratory distress syndrome                  | 0               | 0                | 2 (0.5)         | 0               | 2 (0.3)         | 0                |
| Cardiac disorder's                                   | 3 (1.1)         | 3 (1.1)          | 3 (0.8)         | 2 (0.5)         | 6 (0.9)         | 5 (0.8)          |
| Atrial fibrillation                                  | 1 (0.4)         | 0                | 1 (0.3)         | 0               | 2 (0.3)         | 0                |
| Myocardial infarction                                | 1 (0.4)         | 0                | 1 (0.3)         | 0               | 2 (0.3)         | 0                |
| Acute myocardial infarction                          | 0               | 1 (0.4)          | 1 (0.3)         | 2 (0.5)         | 1 (0.2)         | 3 (0.5)          |
| General disorders and administration site conditions | 1 (0.4)         | 1 (0.4)          | 0               | 1 (0.3)         | 1 (0.2)         | 2 (0.3)          |
| Death                                                | 0               | 1 (0.4)          | 0               | 1 (0.3)         | 0               | 2 (0.3)          |
| Nervous system disorder's                            | 0               | 1 (0.4)          | 0               | 3 (0.8)         | 0               | 4 (0.0)          |
| Cerebrovascular accident                             | 0               | 1 (0.4)          | 0               | 1 (0.3)         | 0               | 2 (0.3)          |
| Skin and subcutaneous tissue                         | 0               | 1 (0.4)          | 0               | 1 (0.3)         | 0               | 2 (0.3)          |
| Angioedema                                           | 0               | 1 (0.4)          | 0               | 1 (0.3)         | 0               | 2 (0.3)          |

Mox=moxifloxacin; SAE=serious adverse event; SOC=system organ class; TEAE=treatment-emergent adverse event

AE=adverse event; ALT=alanine aminotransferase; Lef=lefamulin; MedDRA=Medical Dictionary for Regulatory Activities;

Lefamulin 150 mg IV / 600 mg oral

One subject (moxifloxacin group) had a non-treatment emergent SAE of asthma (ISS Table P3.14.3.1.9).

b Moxifloxacin 400 mg IV / 400 mg oral

## Laboratory findings

In Phase 3 trials the most frequently reported haematology laboratory AEs were anaemia (0.5% vs. 0.6%) and WBC increased (0.2% vs. 0.5%), none of which led to discontinuation of treatment. The most frequently reported chemistry laboratory AEs other than those relating to liver function were hypokalaemia (1.2% lefamulin vs. 1.1% moxifloxacin), CK increased (0.5% vs. 0.2%), hyperglycaemia (0.2% vs. 0.5%) and

<div style=\"page-break-after: always\"></div>

hypoalbuminaemia (0% vs. 0.5%). In addition to the two lefamulin subjects who discontinued study drug due to hepatic AEs, one subject in 3102 discontinued due to an AE of non-serious creatinine clearance decreased, which was mild and unrelated.

The percentages of subjects with PCS haematology and clinical chemistry parameters at any time postbaseline were slightly higher for lefamulin vs. moxifloxacin. The overall differences shown below seem to mainly reflect higher rates of PCS values in the lefamulin group for increased platelets (3.8% vs. 2.2%), increased neutrophils (3.7% vs. 1.8%) and leucocytes (1.6% vs. 1.1%), decreased haemoglobin (1.3% vs. 0.7%) and increases in potassium (1.2% vs. 0.5%), AST (2.0% vs. 1.2%), ALT (3.5% vs. 3.1%), GGT (3.0% vs. 1.3%) and ALP 1.2% vs. 0.5%).

Table 65. Subjects with any Post-Baseline Treatment-emergent Potentially Clinically Significant Laboratory Parameters for Pool 3 (Safety Population)

| LaboratoryParameter                                                | Lefamulina (N=641) n/N (%)   | Moxifloxacinb (N=641) n/N (%)   |
|--------------------------------------------------------------------|------------------------------|---------------------------------|
| Any Potentially Clinically Significant Value                       | 94/620 (15.2)                | 64/628 (10.2)                   |
| Any Hematology Potentially Clinically Significant Value            | 56/548 (10.2)                | 33/559 (5.9)                    |
| Hemoglobin (High: >1.3 x ULN and increase of >30% from baseline)   | 0/548                        | 0/559                           |
| Hemoglobin (Low: <0.8 x LLN and decrease >20% from baseline)       | 7/548 (1.3)                  | 4/559 (0.7)                     |
| Platelets (High: >1.5 x ULN and increase of >100% from baseline)   | 20/529 (3.8)                 | 12/540 (2.2)                    |
| Platelets (Low: <0.65 x LLN and decrease >50% from baseline)       | 2/529 (0.4)                  | 3/540 (0.6)                     |
| Leukocytes (High: >1.6 x ULN and increase of >100% ffom baseline)  | 9/548 (1.6)                  | 6/559 (1.1)                     |
| Leukocytes (Low: <0.65 x LLN and decrease >60% from baseline)      | 3/548 (0.5)                  | 2/559 (0.4)                     |
| Neutrophils (High: >1.6 x ULN and increase of >100% from baseline) | 20/547 (3.7)                 | 10/558 (1.8)                    |
| Neutrophils (Low: <0.65 x LLN and decrease >75% from baseline)     | 9/547 (1.6)                  | 4/558 (0.7)                     |
| Lymphocytes (High: >1.6 x ULN and increase of >100% from baseline) | 3/547 (0.5)                  | 3/558 (0.5)                     |
| Lymphocytes (Low: <0.65 x LLN and decrease >75% from baseline)     | 2/547 (0.4)                  | 1/558 (0.2)                     |

<div style=\"page-break-after: always\"></div>

| Any Chemistry Potentially Clinically Significant Value                     | 52/610 (8.5)   | 36/618 (5.8)   |
|----------------------------------------------------------------------------|----------------|----------------|
| Blood Urea Nitrogen (High: >3.0 x ULN and increase of >200% from baseline) | 0/607          | 0/615          |
| Creatinine (High: >2.0 x ULN and increase >100% from baseline)             | 5/606 (0.8)    | 0/615          |
| Glucose (High: >3.0 x ULN and increase >200% from baseline)                | 0/573          | 4/581 (0.7)    |
| Glucose (Low: <0.6 x LLN and decrease of>40% from baseline)                | 0/573          | 0/581          |
| Sodium (High: >1.1 x ULN and increase of >10% from baseline)               | 0/608          | 0/613          |
| Sodium (Low: <0.85 x LLN and decrease of >10% from baseline)               | 0/608          | 0/613          |
| Potassium (High: >1.2 x ULN and increase >20% from baseline)               | 7/605 (1.2)    | 3/604 (0.5)    |
| Potassium (Low: <0.8 x LLN and decrease >20% from baseline)                | 4/605 (0.7)    | 5/604 (0.8)    |
| Calcium (High: >1.3 x ULN and increase >30% from baseline)                 | 0/607          | 1/615 (0.2)    |
| Calcium (Low: <0.7 x LLN and decrease >30% from baseline)                  | 4/607 (0.7)    | 1/615 (0.2)    |
| Magnesium (Low: <0.5 x LLN and decrease >50% from baseline)                | 2/607 (0.3)    | 1/615 (0.2)    |
| Phosphate (High: >3.0 x ULN and increase of >200% from baseline)           | 0/609          | 0/613          |
| Phosphate (Low: <0.5 x LLN and decrease of >50% from baseline)             | 0/609          | 0/613          |
| AST (High:>3.0 x ULN and increase >200% from baseline)                     | 11/553 (2.0)   | 7/572 (1.2)    |
| ALT (High: >3.0 x ULN and increase >200% from baseline)                    | 20/573 (3.5)   | 18/583 (3.1)   |
| GGT (High: >3.0 x ULN and increase >200% from baseline)                    | 18/606 (3.0)   | 8/613 (1.3)    |
| ALP (High: >2.0 x ULN and increase >100% from baseline)                    | 7/607 (1.2)    | 3/613 (0.5)    |
| ALP (Low: <0.5 x LLN and decrease of >80% from baseline)                   | 0/607          | 0/613          |
| Bilirubin (High: ≥2.0 x ULN and increase >150% from baseline)              | 1/574 (0.2)    | 1/585 (0.2)    |
| Albumin (High: >1.5 x ULN and increase of >50% from baseline)              | 0/610          | 0/618          |
| Albumin (Low: <0.5 x LLN and decrease of >50% fom baseline)                | 0/610          | 0/618          |

For all subjects in Phase 3 trials with available data, the mean maximum increases from baseline in ALT were greater in the lefamulin group (ALT 19.0 U/L vs. 10.8 U/L; AST 10.6 U/L vs. 5.9 U/L; ALP 13.2 U/L vs. 8.5 U/L). The mean maximum increases from baseline in bilirubin were 1.6 U/L vs. 1.0 U/L. The maximum postbaseline ALT, AST, ALP and total bilirubin values relative to the ULN are shown below. In 3101, there was a higher percentage in the lefamulin group with ALT &gt;3 x ULN. In 3101 and in 3102, there was a higher percentage in the lefamulin group with AST &gt;3 x ULN. Whilst numbers with ALT or AST increases to &gt;5 x or 10 x ULN were small in both groups, there were slightly more such subjects in the lefamulin group. However, elevations in total bilirubin &gt;2 x ULN were the same for the two treatment groups. Across Phase 2 and 3 no subjects in the lefamulin group and 1 subject in the moxifloxacin group met the laboratory criteria for potential Hy's Law (see the eDISH plot below).

<div style=\"page-break-after: always\"></div>

Table 66. Maximum Post-Baseline Increase in Liver Safety Laboratory Parameters for Pool 3 (Safety Population)

<!-- image -->

|                                                                                | Study 3101                                                                     | Study 3101                                                                     | Study 3102                                                                     | Study 3102                                                                     | Pool3                                                                          | Pool3                                                                          |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Parameter ULN category                                                         | Lefamulin N=273 n/N (%)                                                        | Moxifloxacin N=273 n/N (%)                                                     | Lefamulin N=368 n/N (%)                                                        | Moxifloxacin N=368 n/N (%)                                                     | Lefamulina N=641 n/N (%)                                                       | Moxifloxacinb N=641 n/N (%)                                                    |
| ALT                                                                            |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| >3x                                                                            | 19/268 (7.1)                                                                   | 17/267 (6.4)                                                                   | 15/355 (4.2)                                                                   | 17/361 (4.7)                                                                   | 34/623 (5.5)                                                                   | 34/628 (5.4)                                                                   |
| >5x                                                                            | 6/268 (2.2)                                                                    | 5/267 (1.9)                                                                    | 7/355 (2.0)                                                                    | 3/361 (0.8)                                                                    | 13/623 (2.1)                                                                   | 8/628 (1.3)                                                                    |
| >10x                                                                           | 1/268 (0.4)                                                                    | 0/267                                                                          | 1/355 (0.3)                                                                    | 0/361                                                                          | 2/623 (0.3)                                                                    | 0/628                                                                          |
| AST                                                                            |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| >3x                                                                            | 11/268 (4.1)                                                                   | 7/267 (2.6)                                                                    | 12/355 (3.4)                                                                   | 8/361 (2.2)                                                                    | 23/623 (3.7)                                                                   | 15/628 (2.4)                                                                   |
| >5x                                                                            | 2/268 (0.7)                                                                    | 2/267 (0.7)                                                                    | 6/355 (1.7)                                                                    | 5/361 (1.4)                                                                    | 8/623 (1.3)                                                                    | 7/628 (1.1)                                                                    |
| >10x                                                                           | 1/268 (0.4)                                                                    | 0/267                                                                          | 1/355 (0.3)                                                                    | 0/361                                                                          | 2/623 (0.3)                                                                    | 0/628                                                                          |
| ALP                                                                            |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| >2x                                                                            | 5/268 (1.9)                                                                    | 5/267 (1.9)                                                                    | 14/357 (3.9)                                                                   | 6/362 (1.7)                                                                    | 19/625 (3.0)                                                                   | 11/629 (1.7)                                                                   |
| Total bilinubin                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |                                                                                |
| >1.5 x                                                                         | 3/268 (1.1)                                                                    | 3/267 (1.1)                                                                    | 3/355 (0.8)                                                                    | 3/361 (0.8)                                                                    | 6/623 (1.0)                                                                    | 6/628 (1.0)                                                                    |
| >2x                                                                            | 0/268                                                                          | 2/267 (0.7)                                                                    | 2/355 (0.6)                                                                    | 0/361                                                                          | 2/623 (0.3)                                                                    | 2/628 (0.3)                                                                    |
| ALTorAST>3xULNandTBL>2xULN                                                     |                                                                                | ***                                                                            | ***                                                                            | **.                                                                            | 0/623                                                                          | 1/628 (0.2)                                                                    |
| ALTorAST>5xULNandTBL>2xULN                                                     |                                                                                |                                                                                |                                                                                |                                                                                | 0/623                                                                          | 1/628 (0.2)                                                                    |
| ALTorAST>10xULNandTBL>2xULN                                                    |                                                                                |                                                                                |                                                                                |                                                                                | 0/623                                                                          | 0/628                                                                          |
| ALP>2xULNandTBL>2xULN                                                          |                                                                                |                                                                                |                                                                                |                                                                                | 1/623 (0.2)                                                                    | 0/628                                                                          |
| ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN | ALT or AST value >3 x ULN and any post-baseline total bilirubin value >2 x ULN |
| with ALP ≤2 x ULN                                                              | 0/0                                                                            | 1/1 (100.0)                                                                    | 0/0                                                                            | 0/0                                                                            | 0/0                                                                            | 1/1 (100.0)                                                                    |
| withALP>2xULN                                                                  | 0/0                                                                            | 0/1                                                                            | 0/0                                                                            | 0/0                                                                            | 0/0                                                                            | 0/1                                                                            |

a Lefamulin 150 mg IV / 600 mg oral

ALP=alkalinephosphatase;ALT=alanineaminotransferase;AST=aspartate aminotransferase;n=number of subjectsmeeting the specified laboratory criteria ineach treatment group; N= number of subjects with both a baseline and post-baseline value; TBL=total bilirubin; ULN=upper limit of normal

b Moxifloxacin 400 mg IV / 400 mg oral

<div style=\"page-break-after: always\"></div>

Figure 11. eDISH Analysis of Safety Pool 2-3 -Maximum Post-baseline ALT or AST vs Maximum Post-baseline Total Bilirubin, Expressed as Multiples of ULN

<!-- image -->

For changes in ALT over time for Phase 3 lefamulin subjects with increases to ALT &gt;5 x ULN, peak ALT typically occurred within the first week after the first dose and declined to within or near normal levels by the LFU Visit. This pattern contrasted with that for moxifloxacin subjects with values &gt;5xULN, where the timing of the peak value was much more variable.

<div style=\"page-break-after: always\"></div>

Figure 12. ALT Values Over Time for Subjects with Values &gt;5 x ULN in Pool 3 (Safety Analysis Set)

## Lefamulin

<!-- image -->

The dossier included a Liver Safety Analysis Report prepared by an external expert in which 3 cases are discussed. One lefamulin patient was reported to have drug-related chronic hepatitis but this does not seem to have actually been the case. One was reported to have toxic hepatitis with onset on day 4 of increased ALT (max 4.9xULN) and AST (max 6.3xULN) considered to be drug-related leading to discontinuation of treatment. The abnormalities had resolved by day 22. A third lefamulin subject was reported to have hypoxic hepatopathy starting on treatment with day 4 values of ALT 9xULN and AST &gt;10xULN, at which time he was not hypoxic. He remained on treatment and next day the values had fallen to below 5xULN with resolution documented on day 27. He was considered a treatment success on day 5. The report investigated laboratory abnormalities by demographics but no firm conclusions could be drawn. However, subjects with baseline AST or ALT &gt; ULN were more likely to have on-treatment increases regardless of treatment group. The shift analysis reached a similar conclusion.

<div style=\"page-break-after: always\"></div>

Table 67. Post-baseline ALT and AST Values Relative to ULN in Phase 3 Studies by Baseline Liver Enzymes

|                        | Post-baseline ALT   | Post-baseline ALT   | Post-baseline AST   | Post-baseline AST   |
|------------------------|---------------------|---------------------|---------------------|---------------------|
| Baseline Liver Enzymes | Lefamulin           | Comparator a        | Lefamulin           | Comparator a        |
|                        | >3 x ULN            | >3 x ULN            | >3 x ULN            | >3 x ULN            |
| Normal ALT and AST     | 15/457 3.3%         | 9/437 2.1%          | 8/435 1.8%          | 3/432 0.7%          |
| ALT or AST >ULN        | 15/114 13.2%        | 23/142 16.2%        | 12/114 10.5%        | 10/142 7.0%         |
|                        | >5 x ULN            | >5 x ULN            | >5 x ULN            | >5 x ULN            |
| Normal ALT and AST     | 7/457 1.5%          | 1/437 0.2%          | 5/435 1.1%          | 1/432 0.2%          |
| ALT or AST >ULN        | 4/114 3.5%          | 7/142 4.9%          | 2/114 1.8%          | 5/142 3.5%          |
|                        | >10 x ULN           | >10 x ULN           | >10 x ULN           | >10 x ULN           |
| Normal ALT and AST     | 1/457 0.2%          | 0/437 0             | 0/435 0             | 0/432 0             |
| ALT or AST >ULN        | 0/114 0             | 0/142 0             | 1/114 0.9%          | 0/142 0             |

ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal

a Comparator for CABP studies was moxifloxacin.

The report also discusses individual cases with outlying post-baseline ALT values:

- In Phase 2 there were two such lefamulin subjects. One had an increase to ALT 7.2xULN and AST 8.6xULN plus an elevated GGT on the last day of treatment (day 6) and normal values on day 9. The other had slight baseline abnormalities and on day 15 (1-day post-treatment) had ALT 6.4xULN and AST 3.7xULN that substantially decreased by day 22.
- In Phase 3 there was one subject in 3101 with ALT&gt;10xULN on day 8 (1-day post-treatment) but AST was only 1.5xULN and there were substantial decreases by day 13. Subjects with such values in 3102 included the case described above with hypoxic hepatopathy, a case with day 5 (EOT) ALT 9.3xULN and AST 6.6xULN as well as raised GGT and ALP, all of which decreased thereafter, and a case with day 5 (EOT) ALT&gt;10xULN and AST 5.6xULN as well as raised GGT and ALP, all of which decreased thereafter.

From the R-value analysis of cases of ALT elevation, the following patterns were observed for lefamulin.

<div style=\"page-break-after: always\"></div>

Table 68. Hepatotoxicity Injury Patterns (Categorised by R-values) for Lefamulin-treated Subjects with CTCAE Grade 2 or Higher ALT in Phase 3 Studies

|                               | Lefamulin             | Lefamulin            | Lefamulin                    |
|-------------------------------|-----------------------|----------------------|------------------------------|
| Hepatotoxicity Injury Pattern | Study 3101 N=12 n (%) | Study 3102 N=8 n (%) | Pooled3101and3102 N=20 n (%) |
| Hepatocellular (R≥5)          | 5 (41.7)              | 5 (62.5)             | 10 (50.0)                    |
| Mixed (2<R<5)                 | 6 (50.0)              | 2 (25.0)             | 8 (40.0)                     |
| Cholestatic (R≤2)             | 1 (8.3)               | 1 (12.5)             | 2 (10.0)                     |

CTCAE=Common Terminology Criteria for Adverse Events (version 5.0)

Note: CTCAE Grade 2 is defined as an ALT &gt;3x ULN ifnormal at baseline or an ALT &gt;3 x baseline if abnormal at baseline. The R-value is defined as the ratio of the (maximum post-baseline ALT value divided by ULN), divided by the (ALP value divided by ULN). The ALP value was taken from the same day as the maximum ALT value. If ALP was not available, then the ALP assessment closest to the day of the maximum ALT value was used.

The report summarises the overall picture for lefamulin as follows:

- Rapid onset (within 4-5 days) after oral or IV dosing with lefamulin
- Peak values around Day 5-8 (at completion of dosing) or by Day 15
- Predominantly hepatocellular (50.0%) or mixed injury (40.0%) pattern
- ALT/AST usually &lt;10 x ULN; ALP &lt;5 x ULN
- ALT generally higher than AST (in the absence of muscle injury or alcohol use)
- Bilirubin remained normal (or &lt;2 x ULN)
- The mechanism for potential hepatotoxicity is undefined but the very short latency (days) suggests a form of direct hepatotoxicity in a susceptible patient
- The low incidence argues against intrinsic (predictable) hepatotoxicity
- Subjects were asymptomatic, with no hypersensitivity features
- The aminotransferase time course indicated reversible injury (within 2-4 weeks) with no development of chronic injury
- There was no major difference in ALT &gt;3 x ULN and &gt;200% increase from baseline vs. comparator in the Phase 3 studies (3101: 5.0% lefamulin vs. 3.7% moxifloxacin; 3102: 2.4% vs. 2.7%; pooled: 3.5% vs.3.1%
- There were no Hy's Law cases for lefamulin and no cases of acute liver failure

Additional analyses were requested. The table below shows baseline characteristics, medication use and safety data for Phase 3 patient subgroups with and without elevated baseline liver enzymes. Medication use revealed that the rate of systemic antibacterial use within 72 hours before randomisation was higher in lefamulin patients with elevated ALT or AST at baseline (29.4%) compared to those with normal ALT and AST

<div style=\"page-break-after: always\"></div>

at baseline (21.3%). During the study, concomitant systemic antibacterial use was approximately twice as high in those with elevated ALT or AST at baseline compared to those without such elevation (23.5% vs. 12.8%, respectively). A similar pattern was observed in the moxifloxacin group.

<div style=\"page-break-after: always\"></div>

Table 69. Analysis of Subjects in Phase 3 Studies by Baseline Liver Enzymes

|                                                             | ALT and AST ≤ULN at Baseline                               | ALT and AST ≤ULN at Baseline   | ALT or AST >ULN at Baseline   | ALT or AST >ULN at Baseline   |
|-------------------------------------------------------------|------------------------------------------------------------|--------------------------------|-------------------------------|-------------------------------|
|                                                             | LEF (N=522)                                                | MOX (N=497)                    | LEF (N=119)                   | MOX (N=144)                   |
| Baseline characteristics                                    |                                                            |                                |                               |                               |
| Age, years, mean (SD)                                       | 59.5 (16.3)                                                | 58.6 (15.8)                    | 56.4 (17.2)                   | 58.0 (15.2)                   |
| BMI, kg/m², mean (SD)                                       | 26.5 (6.0)                                                 | 26.6 (6.3)                     | 26.4 (5.1)                    | 26.0 (5.2)                    |
| PORT Risk Class, n (%)                                      |                                                            |                                |                               |                               |
| Class I                                                     | 1 (0.2)                                                    | 1 (0.2)                        | 0                             | 1 (0.7)                       |
| Class II                                                    | 154 (29.5)                                                 | 148 (29.8)                     | 29 (24.4)                     | 42 (29.2)                     |
| Class III                                                   | 271 (51.9)                                                 | 262 (52.7)                     | 66 (55.5)                     | 71 (49.3)                     |
| Class IV                                                    | 94 (18.0)                                                  | 82 (16.5)                      | 21 (17.6)                     | 29 (20.1)                     |
| Class V                                                     | 2 (0.4)                                                    | 4 (0.8)                        | 3 (2.5)                       | 1 (0.7)                       |
| Medication use, n (%)                                       |                                                            |                                |                               |                               |
| Systemic antibacterial use within 72 h before randomization | 111 (21.3)                                                 | 107 (21.5)                     | 35 (29.4)                     | 36 (25.0)                     |
| Concomitant systemic antibacterial use                      | 67 (12.8)                                                  | 49 (9.9)                       | 28 (23.5)                     | 27 (18.8)                     |
| Subjects with adverse events, n (%)                         |                                                            |                                |                               |                               |
| TEAE                                                        | 174 (33.3)                                                 | 140 (28.2)                     | 50 (42.0)                     | 55 (38.2)                     |
| Related TEAE                                                | 82 (15.7)                                                  | 49 (9.9)                       | 17 (14.3)                     | 19 (13.2)                     |
| Serious TEAE                                                | 27 (5.2)                                                   | 19 (3.8)                       | 9 (7.6)                       | 12 (8.3)                      |
| Related Serious TEAE                                        | 3 (0.6)                                                    | 1 (0.2)                        | 0                             | 1 (0.7)                       |
| TEAEs by SOC reported in≥5% of any subgroup                 | TEAEs by SOC reported in≥5% of any subgroup                |                                |                               |                               |
| Gastrointestinal disorders                                  | 69 (13.2)                                                  | 51 (10.3)                      | 15 (12.6)                     | 14 (9.7)                      |
| Related                                                     | 51 (9.8)                                                   | 26 (5.2)                       | 8 (6.7)                       | 9 (6.3)                       |
| Infections and infestations                                 | 34 (6.5)                                                   | 29 (5.8)                       | 13 (10.9)                     | 11 (7.6)                      |
| Related                                                     | 6 (1.1)                                                    | 1 (0.2)                        | 0                             | 2 (1.4)                       |
| General disorders and administration site conditions        | 20 (3.8)                                                   | 13 (2.6)                       | 8 (6.7)                       | 4 (2.8)                       |
| Related                                                     | 13 (2.5)                                                   | 6 (1.2)                        | 5 (4.2)                       | 1 (0.7)                       |
| Cardiac disorders                                           | 10 (1.9)                                                   | 13 (2.6)                       | 6 (5.0)                       | 7 (4.9)                       |
| Related                                                     | 3 (0.6)                                                    | 4 (0.8)                        | 1 (0.8)                       | 0                             |
| Investigations                                              | 26 (5.0)                                                   | 13 (2.6)                       | 5 (4.2)                       | 13 (9.0)                      |
| Related                                                     | 14 (2.7)                                                   | 8 (1.6)                        | 3 (2.5)                       | 4 (2.8)                       |
| Subjects with post-baseline transaminase values*, n/N (%o)  | Subjects with post-baseline transaminase values*, n/N (%o) |                                |                               |                               |
| ALT >3xULN                                                  | 15/457 (3.3)                                               | 9/437 (2.1)                    | 15/114 (13.2)                 | 23/142 (16.2)                 |
| ALT >5xULN                                                  | 7/457 (1.5)                                                | 1/437 (0.2)                    | 4/114 (3.5)                   | 7/142 (4.9)                   |
| ALT >10xULN                                                 | 1/457 (0.2)                                                | 0                              | 0                             | 0                             |
| AST>3 xULN                                                  | 8/435 (1.8)                                                | 3/432 (0.7)                    | 12/114 (10.5)                 | 10/142 (7.0)                  |
| AST >5x ULN                                                 | 5/435 (1.1)                                                | 1/432 (0.2)                    | 2/114 (1.8)                   | 5/142 (3.5)                   |
| AST >10xULN                                                 | 0                                                          | 0                              | 1/114 (0.9)                   | 0                             |

ALT=alanine aminotransferase; AST=aspartate aminotransferase; BMI=body mass index; LEF=lefamulin; MOX=moxifloxacin;

PORT=Pneumonia Outcomes Research Team; SOC=system organ class; TEAE=treatment-emergent adverse event;

ULN=upper limit of normal.

a Numerators are the numbers of subjects whose highest post-baseline value met the criterion at any time post-baseline. Denominators are the numbers of subjects with both a baseline value and at least 1 post-baseline value for the specified parameter.

<div style=\"page-break-after: always\"></div>

## The data suggested that:

- o Patients with elevated baseline liver enzymes had more severe underlying disease (in aspects not captured by PORT Risk Class alone) so were more likely to experience TEAEs that were not related to study drug but due to underlying conditions.
- o The greater extent of on-study liver enzyme elevations in this subgroup may have been related to underlying disease complications and/or the greater use of non-study antibacterial medications that carry their own risk of transaminitis.

While the overall incidence of TEAEs was higher in those with vs. without elevated baseline liver enzymes (42.0% vs. 33.3% for lefamulin and 38.2% vs. 28.2% for moxifloxacin), the incidence of TEAEs considered related to study drug was essentially the same for lefamulin (14.3% vs.15.7%) and only slightly higher for moxifloxacin (13.2% vs. 9.9%).

For lefamulin, half of the increase in the overall incidence of TEAEs in the subgroup with elevated baseline liver enzymes was caused by events in the SOC of Infections and infestations (e.g. HIV infection, pneumonia, sinusitis and hepatitis C), all of which were considered not related to study drug.

Among the most frequently reported TEAEs by SOC, only in the SOC of General disorders and administration site conditions were the related TEAEs notably more frequent in the subgroup with elevated baseline liver enzymes (4.2% vs. 2.5%) and most were administration site reactions. The overall incidence of serious TEAEs was slightly higher in those with elevated baseline liver enzymes compared to those without such elevation (7.6% vs 5.2% for lefamulin) but this was also the case for the moxifloxacin group.

Patients in both treatment groups with elevated ALT or AST at baseline were much more likely to have postbaseline elevations &gt;3 x ULN as compared to those with normal ALT and AST at baseline. The distribution of baseline values and the highest ('worst') post-baseline values for ALT and AST are shown in the figures below by subgroup.

<div style=\"page-break-after: always\"></div>

Figure 13. Distribution of ALT Values (in Multiples of ULN) by Baseline Liver Enzyme Elevation

<!-- image -->

Figure 14. Distribution of AST Values (in Multiples of ULN) by Baseline Liver Enzyme Elevation

<!-- image -->

Since the group with elevated baseline liver enzymes was defined by having either an elevated ALT or AST at baseline, the figures show a broad distribution of values for each parameter at baseline. The figures show that while more patients with pre-existing elevations shifted into the &gt;3 x ULN stratum, few values were &gt;5 x ULN, with a comparable pattern observed for the moxifloxacin group.

<div style=\"page-break-after: always\"></div>

## Immunological events

In Phase 3 trials, AEs of rashes, pruritus and other potential manifestations of hypersensitivity were reported for 3 (0.5%) in the lefamulin group vs. 14 (2.2%) in the moxifloxacin group. One lefamulin subject (0.2%) experienced a non-serious rash of mild severity, which was considered by the investigator to be unrelated to study drug. The rash resolved the same day with treatment, and no action was taken.

Two other lefamulin subjects (0.3%) experienced non-serious AEs of bronchospasm, one of which was severe starting on day 2 while the other was of moderate severity starting on day 7 and was considered by the Investigator to be possibly related to study drug. Neither subject had a medical history of COPD or asthma. Both events resolved with treatment and no action was taken with study drug in either case.

## Safety related to drug-drug interactions and other interactions

There is a potential for a pharmacodynamic (additive) effect to occur if lefamulin is given with other agents that can affect cardiac conduction. In Phase 3 trials patients were excluded if they had received within 7 days before enrolment any Class Ia or Class III anti-arrhythmic agent (Class Ia: quinidine, procainamide, disopyramide; Class III: amiodarone, dofetilide, ibutilide, sotalol) or any other medication with potential to prolong the QT interval. There is also a PK interaction risk, that could lead to increased or decreased lefamulin concentrations, affecting safety or efficacy, respectively. In Phase 3 trials patients taking a strong P-gp inhibitor or a strong CYP3A inducer or inhibitor were excluded.

<div style=\"page-break-after: always\"></div>

## Safety related to age

Table 70. Overall Summary of Adverse Events by Age Group for Pool 3 (Safety Analysis Set)

|                                          | 18-64 year's                             | 18-64 year's   | 65-74 yeal's   | 65-74 yeal's   | 75-84 yeal's   | 75-84 yeal's   | ≥85 year's   | ≥85 year's   |
|------------------------------------------|------------------------------------------|----------------|----------------|----------------|----------------|----------------|--------------|--------------|
| Adverse event category                   | LEF (N=374)                              | MOX (N=393)    | LEF (N=152)    | MOX (N=145)    | LEF (N=89)     | MOX (N=80)     | LEF (N=20)   | MOX (N=17)   |
| TEAEs, n (%)                             |                                          |                |                |                |                |                |              |              |
| Al1                                      | 143 (38.2)                               | 115 (29.3)     | 34 (22.4)      | 46 (31.7)      | 36 (40.4)      | 30 (34.9)      | 11 (42.3)    | 4 (23.5)     |
| Related                                  | 63 (16.8)                                | 39 (9.9)       | 17 (11.2)      | 18 (12.4)      | 17 (19.1)      | 9 (10.5)       | 2 (7.7)      | 2 (11.8)     |
| Severe TEAEs, n (%)                      |                                          |                |                |                |                |                |              |              |
| Al1                                      | 11 (2.9)                                 | 10 (2.5)       | 6 (3.9)        | 4 (2.8)        | 8 (9.0)        | 7 (8.1)        | 2 (7.7)      | 2 (11.8)     |
| Related                                  | 3 (0.8)                                  | 2 (0.5)        | 1 (0.7)        | 0              | 0              | 1 (1.2)        | 0            | 1 (5.9)      |
| Serious TEAEs, n (%)                     |                                          |                |                |                |                |                |              |              |
| Al1                                      | 15 (4.0)                                 | 16 (4.1)       | 8 (5.3)        | 5 (3.4)        | 11 (12.4)      | 9 (10.5)       | 2 (7.7)      | 1 (5.9)      |
| Related                                  | 1 (0.3)                                  | 1 (0.3)        | 1 (0.7)        | 0              | 1 (1.1)        | 1 (1.2)        | 0            | 0            |
| TEAEs leading to DC of study drug, n (%) | TEAEs leading to DC of study drug, n (%) |                |                |                |                |                |              |              |
| All                                      | 12 (3.2)                                 | 8 (2.0)        | 4 (2.6)        | 5 (3.4)        | 4 (4.5)        | 6 (7.0)        | 0            | 2 (11.8)     |
| Related                                  | 5 (1.3)                                  | 6 (1.5)        | 0              | 0              | 2 (2.2)        | 0              | 0            | 2 (11.8)     |
| TEAEs leading to death, n (%)            | TEAEs leading to death, n (%)            |                |                |                |                |                |              |              |
| Al1                                      | 2 (0.5)                                  | 3 (0.8)        | 4 (2.6)        | 2 (1.4)        | 4 (4.5)        | 3 (3.5)        | 1 (3.8)      | 0            |
| Related                                  | 0                                        | 0              | 0              | 0              | 0              | 0              | 0            | 0            |

a 3 deaths in the lefamulin group (1 each in the 65-74, 75-84, and ≥85 years age groups) and 1 death in the moxifloxacin group (18-64 years age group) occurred after Day 28 (the intended Late Follow-up Visit) (Module 2.7.4.2.1.2)

DC=discontinuation; LEF=lefamulin; MOX=moxifloxacin; TEAE=treatment-emergent adverse event.

In Pool 3, 59.8% of subjects were 18-64 years old, 23.2% were 65-74 years old, 13.7% were 75-84 years old, and 3.4% of subjects were ≥85 years old. The rates of severe TEAEs, serious TEAEs, and TEAEs leading to death were higher among older subjects (75-84 years and ≥85 years) compared with younger subjects (18-64 years and 65-74 years) in both treatment groups. The rates of TEAEs leading to discontinuation of study drug were similar among older and younger subjects in the lefamulin group, and were higher among older subjects compared with younger subjects in the moxifloxacin group. The most frequently reported TEAEs (≥2% in either treatment group) in subjects 65 -74 years old were diarrhoea (5.9% lefamulin and 2.1% moxifloxacin) and nausea (2.0% and 3.4%). T he most frequently reported TEAEs (≥2% in either treatment group) in subjects 75-84 years old were atrial fibrillation (2.2% lefamulin and 2.3% moxifloxacin), diarrhoea (5.6% and 4.7%), nausea (2.2% and 1.2%) and vomiting (4.5% and 0). The most frequently reported TEAEs (≥2 subjects in either treatment group) in subjects ≥85 years old were nausea (2 lefamulin subjects and 0 moxifloxacin subjects) and urinary tract infection (1 lefamulin subject and 2 moxifloxacin subjects).

## Discontinuation due to adverse events

In Phase 3 trials AEs leading to discontinuation of treatment occurred in 3.1% lefamulin and 3.3% moxifloxacin subjects. Most frequent were AEs in the SOC of Infections and Infestations (0.6% and 0.9% in

<div style=\"page-break-after: always\"></div>

respective groups). AEs by PTs reported for more than 1 lefamulin subject were ECG QT prolonged (2 [0.3%] lefamulin and 3 [0.5%] moxifloxacin-treated subjects) and vomiting (2 vs. 1 subjects). AEs in the SOC of Gastrointestinal Disorders led to study drug discontinuation in 3 lefamulin (2 with vomiting and 1 with abdominal pain upper) and 1 moxifloxacin-treated subject (vomiting). One subject in the lefamulin group discontinued due to infusion site phlebitis, and 1 subject in the moxifloxacin group discontinued due to infusion site erythema.

Seven lefamulin and 8 moxifloxacin subjects had TEAEs leading to discontinuation that were considered by moxifloxacin group, these included: urticaria and ECG QT prolonged (each reported in 2 subjects); infusion the investigator to be related to study drug. In the lefamulin group, these included: vomiting and ECG QT prolonged (each reported in 2 subjects), hepatitis toxic, infusion site phlebitis and bradycardia. In the site erythema, confusional state, and angioedema (each reported in 1 subject); and dizziness and palpitations (reported in 1 subject).

## Post-marketing experience

None.

## 2.6.1. Discussion on clinical safety

Adverse events With two pivotal studies completed plus a comprehensive Phase 1 programme and a Phase 2 trial in ABSSSI, the safety database is larger than is often seen with new antibacterial agents. In Phase 3 trials the proportions reporting AEs (about one third) was lower than is often observed. In 3101 the total rates were very comparable between treatments. The mode of intravenous administration was amended during development to reflect the finding that dilution in citrate buffered saline reduced local pain. In addition, a 1-h infusion time was adopted. In 3101 IV, using these recommended infusion conditions, lefamulin was more likely to be associated with local intolerance than IV moxifloxacin but the rates were acceptably low and few cases were severe. In 3102, lefamulin was associated with higher AE (all and related) rates and very slightly higher rates for severe AEs and AEs leading to discontinuation. It seems that this difference reflects poor gastrointestinal tolerance of oral lefamulin compared to oral moxifloxacin. The between-treatment differences in rates of nausea, vomiting and diarrhoea also drove the observed higher rates of drug-related AEs with lefamulin in 3102. Despite the relatively modest spectrum of activity of lefamulin, a risk for C. difficile enterocolitis exists. The rates for hypersensitivity reactions to lefamulin have been low. Thus far, it does not appear that lefamulin has a particular propensity for toxic effects on the bone marrow. Effect on QTc interval

In Phase 3 trials, in which other drugs known to prolong QTc were not to be co-administered, AEs mapping to the SOC Cardiac Disorders were reported with IV (2.9% lefamulin vs. 4% moxifloxacin) and oral treatments

<div style=\"page-break-after: always\"></div>

(2.2% vs. 2.4%). AEs of QT prolongation were reported for 4 (0.6%) in the lefamulin group (2 discontinued) and 5 (0.8%) in the moxifloxacin group (3 discontinued). The maximum changes at any time post-baseline were 16.8 msec for lefamulin vs. 19.3 msec for moxifloxacin and maximum individual changes were 87.7 msec vs. 98.7 msec. With IV dosing the mean change from baseline in QTcF was 13.8 msec vs. 16.4 msec and oral dosing gave changes of 9.5 msec vs. 11.6 msec. Post-baseline QTcF increases &gt;30 msec (17.9% vs. 22.3%) and &gt;60 msec (1.7% vs. 2.5%) were observed. ECGs following IV dosing showed that QT outliers occurred at rates of 4.8% vs. 4.4% for QTcF &gt; 480 msec and 2.6% vs. 3.3% for change in QTcF &gt; 60 msec. In comparison 1.1% of lefamulin subjects had a post-baseline QTcF increase of &gt;60 msec with oral dosing.

In conclusion, the effect of lefamulin on the QTc interval is very similar to that of moxifloxacin. Although the risk of arrhythmias cannot be deduced from this comparison, the contraindications in the moxifloxacin SmPC have been applied to lefamulin.

## Hepatic effects

In pooled Phase 3 trials, the rates for hepatic AEs were very similar between the two treatment groups. Potentially clinically significant increases in AST, ALT, GGT and ALP occurred more often in the lefamulin group and the mean maximum increases in these parameters, as well as bilirubin, were all greater for lefamulin vs. moxifloxacin. Numbers with increases to &gt;5x or 10x ULN were small in both groups but there were slightly more such subjects in the lefamulin group. However, elevations in total bilirubin &gt;2 x ULN were the same for the two treatment groups.

Despite these differences, across Phase 2 and 3 no subjects in the lefamulin group and 1 subject in the moxifloxacin group met the laboratory criteria for potential Hy's Law. Changes over time indicated that the peak ALT in lefamulin subjects tended to occur within 7 days of starting treatment and declined posttreatment. There was some indication that those with baseline elevated transaminases were more at risk of additional on-treatment increases.

In addition, differences in the incidences of all AEs were observed for subjects with elevated baseline liver enzymes compared with subjects with normal baseline liver enzymes (lefamulin: 42.0% vs. 33.3%, moxifloxacin: 38.2% vs. 28.2%). Similarly, incidences of severe AEs were lefamulin 5.9% vs. 3.8% and moxifloxacin 5.6% vs. vs 3.0% and rates for SAEs were lefamulin 7.6% vs. 5.2% and moxifloxacin 8.3% vs. 3.8%.

Since there is no human experience with administration of systemic pleuromutilins, there are no potentially relevant data that might assist in assessing the risk that the hepatic enzyme abnormalities may translate into serious hepatotoxicity. The actual risk of serious hepatotoxicity occurring cannot be predicted solely by comparing the rates for hepatic enzyme abnormalities.

## SAEs and deaths

Although none of the deaths was considered treatment-related, several of the deaths as well as non-fatal SAEs were apparently related to failure of treatment and it appears that worsening of CAP accounted for the higher rate of SAEs in the lefamulin group in 3101.

<div style=\"page-break-after: always\"></div>

## 2.6.2. Conclusions on the clinical safety

It is concluded that the effects of lefamulin on QTc and on transaminases are not distinguishable from those of moxifloxacin. However, that does not mean that the risk of severe hepatic toxicity and life-threatening arrhythmias will be the same. Post-marketing data will have to address these questions.

The other features of the lefamulin safety profile do not raise issues that would preclude authorisation.

## 2.7. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                         |
|------------------------------|------------------------------------------------------------------------------------|
| Important identified risks   | none                                                                               |
| Important potential risks    | Severe Hepatotoxicity                                                              |
| Missing information          | Use in Patients with Severe Hepatic Impairment Use in Pregnant and Lactating Women |

## Pharmacovigilance plan

Routine pharmacovigilance is considered sufficient to monitor the risks of the product and to measure the effectiveness of the risk minimisation measures.

## Risk minimisation measures

| Safety Concern                                 | Routine Risk Minimisation Activities                                 |
|------------------------------------------------|----------------------------------------------------------------------|
| Severe Hepatotoxicity                          | SmPC Section 4.4 Special warning and Precautions: Hepatic Impairment |
| Use in Patients with Severe Hepatic Impairment | SmPC Section 4.4 Special warning and Precautions: Hepatic Impairment |
| Use in Pregnancy or Lactating Women            | SmPC Section 4.6 Fertility, pregnancy and lactation                  |

Routine minimisation activities are considered sufficient to minimise the risks of the product.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 1.0 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 19.08.2019. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. New Active Substance

The applicant compared the structure of lefamulin with active substances contained in authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer, mixture of isomers, complex or derivative of any of them.

The CHMP, based on the available data, considers lefamulin to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Xenleta (lefamulin) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Xenleta is intended for the treatment of community-acquired pneumonia (CAP) in adults.

Populations at risk for CAP include the elderly, patients who smoke, suffer from alcoholism, patients with underlying comorbidities (such as COPD, chronic heart failure, cardiovascular disease, and having a history of cerebrovascular disease/stroke) and those with recent hospital, healthcare or nursing home exposure. Given the increasing numbers of older patients hospitalised in the EU with CAP, it is expected that the burden of CAP will increase.

Approximately 3,370,000 cases of pneumonia occur annually in the EU. The incidence of all-cause pneumonia in the EU ranged from 68-7000 per 100,000 persons but this varied by country, age, group, study and timeperiod. The incidence in hospitalised CAP of all causes ranged from 16-3581 per 100,000 persons and the incidence increased consistently with age within the EU. In Finland, the incidence of CAP increased six-fold when comparing patients aged 30-44 years and those aged &gt;75 years. The mortality rate for CAP was 9.1%, with ranges varying widely from &lt;1% to as high as 48%, especially when patients with CAP are treated in the intensive care unit. A long-term follow-up study found that elderly patients treated for CAP in both ambulatory and hospital settings had significantly higher risks of death and death related to pneumonia and cardiovascular conditions for several years following a diagnosis of pneumonia than the elderly without pneumonia.

## 3.1.2. Available therapies and unmet medical need

In 2011, a collaboration between the European Respiratory Society (ERS) and The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) published updated European guidelines for the treatment of CAP. The recommendation for outpatients was use of either amoxicillin or tetracycline as monotherapy, and for patients with hypersensitivity to amoxicillin, a tetracycline or macrolide should be prescribed; however, regional, macrolide resistance rates to S. pneumoniae need to be considered. When resistance rates are clinically relevant, a respiratory fluoroquinolone (levofloxacin or moxifloxacin) can be used.

For hospitalised patients not considered severe, penicillin G ± macrolide, an aminopenicillin (amoxicillin) ± macrolide, an aminopenicillin/beta-lactamase inhibitor (amoxicillin/clavulanic acid ± macrolide), a nonantipseudomonal, third-generation cephalosporin, such as cefotaxime or ceftriaxone ± macrolide or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) can be given. The ERS/ESCMID guidelines suggest that combination therapy should be restricted to patients with severe presentation of CAP, with combination therapy being the treatment of choice for patients with severe CAP being treated in the intensive care unit (ICU).

<div style=\"page-break-after: always\"></div>

Macrolide resistance in M. pneumoniae is at least 15% in the European Union (EU) and the US and is approaching 100% in Asia. Increased rates of resistance have also been reported for fluoroquinolones, another commonly prescribed antibiotic therapy for CAP. Although the IDSA/ATS guidelines recommend initiating treatment of CAP with macrolides, if local pneumococcal resistance is less than 25%, resistance among S. pneumoniae and M. pneumoniae isolates to this class has been increasingly reported worldwide. Approximately 50% of S. pneumoniae strains are resistant to macrolides in the US with rates varying significantly by geographic region.

Although there is increasing resistance in common CAP pathogens, at the present time there remain several options available such that it is very rare, especially in the EU, that patients are left with only one or two predicted active agents. Thus, although new agents to treat CAP, including strains resistant to commonly used antibacterial agents, would be welcomed, it is not perceived that there is a major unmet need in this regard.

## 3.1.3. Main clinical studies

To support the claimed indication for treatment of CAP, the applicant conducted two randomised, doubleblind and active-controlled Phase 3 trials to evaluate use of IV/PO lefamulin in patients with CAP and PORT scores III-V (3101) and PO lefamulin in patients with CAP with PORT scores II-IV (3102). Both trials aimed to demonstrate non-inferiority for lefamulin vs. IV/PO or PO moxifloxacin as the comparative agent based on the clinical outcome at the test of cure (TOC visit) with a 10% non-inferiority margin. This programme complies with the existing and draft revised CHMP guidance on the development of antibacterial agents. In compliance with existing guidance, the mITT and CE populations were considered co-primary. Moxifloxacin (IV and PO) was a suitable comparator and allowed a double-blind design for both trials as well as permitting a switch from IV to PO in 3101.

## 3.2. Favourable effects

Both trials demonstrated non-inferiority for lefamulin vs. moxifloxacin in the primary analyses based on clinical outcomes at TOC in the mITT populations. It is acceptable that the primary analyses were conducted in the mITT (all-treated) population since there was very little difference in numbers vs. the ITT population, which is the recommended primary analysis population in the revised guidance. The non-inferiority criterion was also met in the CE population (87% of total) in both trials.

## 3.3. Uncertainties and limitations about favourable effects

Both trials showed that lefamulin was consistently numerically inferior to moxifloxacin for clinical and microbiological success rates at TOC across the pre-defined trial populations.

Lefamulin was numerically inferior to moxifloxacin in several large subgroups, including age &lt; 65 years and ATS severe category patients, and this consistently across trials. After further investigations, no clear explanation could be found for the observed imbalances.

<div style=\"page-break-after: always\"></div>

In line with the primary analyses, the clinical success rates at TOC in the microITT (58% of total enrolled in 3101 and 53% in 3102) and microITT2 (32% of total enrolled in 3101 and 31% in 3102) populations were consistently numerically lower for lefamulin vs. moxifloxacin. Furthermore, in the microITT-2 populations, clinical success rates at TOC for S. pneumoniae were 81% for lefamulin vs. 86.4% for moxifloxacin (34/42 vs. 38/44) in 3101 and 80% vs. 94.6% (36/45 vs. 53/56) in 3102.

In addition, the clinical success rates for PSSP were lower for lefamulin vs. moxifloxacin (in 3101 71.4% vs. 94.4% [n = 15/21, of which 5/6 failures had PSSP in blood, and 17/18]; in 3102 76.9% vs. 100% [n=20/26 and 38/38]). In 3102, 3 of the 6 PSSP failures in the lefamulin group received only one day of treatment but the other three were clearly all treatment failures.

Moreover, clinical response rates at TOC by S. pneumoniae serotypes (only possible to determine in the microITT-2 subset with a positive culture) were consistently lower for lefamulin vs. moxifloxacin. Across the two trials the rates were 50/62 for lefamulin (80.6%) vs. 65/69 (94.2%) for moxifloxacin and the LFU rates were 79% vs. 94.2%.

Underlining the concerns, 7 lefamulin patients in 3101 had baseline bacteraemia of which 6 had S. pneumoniae and one had S. aureus (but had S. pneumoniae in sputum culture). The success rate was only 1/7 (14.3%), with 5/6 with S. pneumoniae in blood and the other patient with a positive sputum culture failing. One patient with S. pneumoniae in blood died from uncontrolled infection. In 3102, 6 lefamulin patients had bacteraemia, of which 3 were S. pneumoniae and 2/3 failed although none died. In both trials, success rates in bacteraemic patients treated with moxifloxacin (2/3 in 3101 and 7/9 in 3102) were higher than for lefamulin although numbers are very small.

To investigate further, the applicant provided analyses of efficacy confined to patients with evidence of a pathogen based solely on positive sputum or blood culture, positive urinary antigen for S. pneumoniae or L. pneumophila or positive serology for pathogens associated with atypical pneumonia.

After excluding all other patients, the cure rates in patients with pneumococcal pneumonia were numerically lower for lefamulin vs. moxifloxacin (28/36 [77.8%] vs. 26/31 [83.9%] when treatment commenced intravenously and 19/25 (76%) vs. 30/32 (93.8%) when treatment commenced orally. Furthermore, among patients with positive cultures and lefamulin MICs for S. pneumoniae , the cure rates in patients treated with lefamulin were 9/10 (90%), 34/41 (83%) and 6/9 (67%) when MICs of lefamulin were 0.12, 0.25 and 0.5 mg/L, respectively.

Concerns over the observed efficacy of lefamulin against S. pneumoniae are not helped by the PK-PD analyses. When the POPPK model was updated using Phase 3 PK data, PTA was re-estimated against the PDTs derived from murine lung and thigh models. Results suggested that the IV and oral (when taken on an empty stomach) regimens were not sufficient to cover pneumococci with MICs at the upper end of the distribution curve.

In 3101 the mean and median duration of total treatment was 7 days and the duration of IV was near to 6 days in both treatment groups. Whilst 75% of the total was enrolled after the amendment to increase the standard duration of lefamulin from 5 to 7 days, the cure rates at TOC were lower for lefamulin in those enrolled prior (5 days) or after (7 days) the amendment. Therefore, for patients who need to start with IV treatment, a total duration of 7 days is recommended.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

With two pivotal studies completed plus a comprehensive Phase 1 programme and a Phase 2 trial in ABSSSI, the safety database is larger than is often seen with new antibacterial agents. It is notable that in Phase 3 trials the proportions reporting AEs (about one third) was lower than is often observed. Nevertheless, the sponsor conducted several audits and there have site inspections by FDA and there is no clear reason to be concerned about adequacy of reporting.

In 3101 the total rates for AEs were very comparable between treatments. The mode of intravenous administration was amended during development when it was found that dilution in citrate buffered saline reduced local pain. In addition, a 1-h infusion time was adopted. In 3101, using these recommended infusion conditions, IV lefamulin was more likely to be associated with local intolerance than IV moxifloxacin but the rates were acceptably low and few cases were severe.

In 3102, lefamulin was associated with higher AE (all and related) rates and very slightly higher rates for severe AEs and AEs leading to discontinuation. It seems that this difference reflects poor gastrointestinal tolerance of oral lefamulin compared to oral moxifloxacin. The between-treatment differences in rates of nausea, vomiting and diarrhoea also drove the observed higher rates of drug-related AEs with lefamulin in 3102.

The rates for hypersensitivity reactions to lefamulin have been low. Despite the relatively modest spectrum of activity of lefamulin, a risk for C. difficile enterocolitis exists. Thus far, it does not appear that lefamulin has a particular propensity for toxic effects on the bone marrow.

The clinical effect of lefamulin on the QTc interval was apparent in the first Phase 1 studies.

In Phase 3 trials, in which other drugs known to prolong QTc were not to be co-administered, AEs mapping to the SOC Cardiac Disorders were reported with IV (2.9% lefamulin vs. 4% moxifloxacin) and oral treatments (2.2% vs. 2.4%). AEs of QT prolongation were reported for 4 (0.6%) in the lefamulin group (2 discontinued) and 5 (0.8%) in the moxifloxacin group.

The maximum changes at any time post-baseline were 16.8 msec for lefamulin vs. 19.3 msec for moxifloxacin and maximum individual changes were 87.7 msec vs. 98.7 msec. With IV dosing the mean change from baseline in QTcF was 13.8 msec vs. 16.4 msec and oral dosing gave changes of 9.5 msec vs. 11.6 msec. Post-baseline QTcF increases &gt;30 msec (17.9% vs. 22.3%) and &gt;60 msec (1.7% vs. 2.5%) were observed. ECGs following IV dosing showed that QT outliers occurred at rates of 4.4% vs. 2.9% for QTcF &gt; 480 msec and 2.6% vs. 3.3% for change in QTcF &gt; 60 msec. In comparison 1.1% of lefamulin subjects had a post-baseline QTcF increase of &gt;60 msec with oral dosing.

In pooled Phase 3 trials, the rates for hepatic AEs were very similar between the two treatment groups. Potentially clinically significant increases in AST, ALT, GGT and ALP occurred more often in the lefamulin group and the mean maximum increases in these parameters, as well as bilirubin, were all greater for lefamulin vs. moxifloxacin. Numbers with increases to &gt;5x or 10x ULN were small in both groups but there were slightly more such subjects in the lefamulin group. However, elevations in total bilirubin &gt;2 x ULN were the same for the two treatment groups and no subjects in the lefamulin group vs. 1 subject in the moxifloxacin group met the laboratory criteria for potential Hy's Law. Changes over time indicated that the peak ALT in lefamulin subjects tended to occur within 7 days of starting treatment and declined post-

<div style=\"page-break-after: always\"></div>

treatment. There was some indication that those with baseline elevated transaminases were more at risk of additional on-treatment increases and had higher AE reporting rates vs. those with normal levels at baseline.

## 3.5. Uncertainties and limitations about unfavourable effects

Whilst lefamulin is associated with rates for QTc prolongation and elevated transaminases that are very similar to those for moxifloxacin, it cannot be predicted from such data whether lefamulin will also have similar risks for serious arrhythmias or hepatotoxicity. Furthermore, since there is no other pleuromutilin licensed for systemic administration to man, there are no relevant class effect data available to take into account.

## 3.6. Effects Table

Table 71. Effects Table for Xenleta (lefamulin) in treatment of CAP

| Effect                                                | Short Description                        | Unit               | Treatment                 | Control                       | Uncertainties/ Strength of evidence            | Refere nces        |
|-------------------------------------------------------|------------------------------------------|--------------------|---------------------------|-------------------------------|------------------------------------------------|--------------------|
| Favourable Effects                                    | Favourable Effects                       | Favourable Effects | Favourable Effects        | Favourable Effects            | Favourable Effects                             | Favourable Effects |
| Clinical success at TOC mITT CE                       | Resolution of CAP at post- therapy visit | n/N %              | Lefamulin IV/PO 81.7 86.9 | Moxifloxa cin IV/PO 84.2 89.4 | 95% CI -8.9, 3.9 95% CI -8.4, 3.4              | 3101               |
| Clinical success at TOC mITT CE                       | Resolution of CAP at post- therapy visit | n/N %              | Lefamulin PO 87.5 89.7    | Moxifloxa cin PO 89.1 93.6    | 95% CI -6.3, 3.1 95% CI -8.2, 0.5              | 3102               |
| microITT- 2 with S. pneumoni ae microITT- 2 with PSSP |                                          |                    | 34/42 (81%) 15/21 (71.4%) | 38/44 (86.4%) 17/18 (94.4%)   | microITT-2 still includes NP culture positives | 3101 and 3102      |

| Effect               | Short Description    | Unit                 | Treatment            | Control              | Uncertainties/ Strength of evidence   | Refere nces          |
|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------------------------|----------------------|
| Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                  | Unfavourable Effects |

<div style=\"page-break-after: always\"></div>

| Effect                     | Short Description                               | Unit   | Treatment                          | Control                                | Uncertainties/ Strength of evidence                                                                              | Refere nces   |
|----------------------------|-------------------------------------------------|--------|------------------------------------|----------------------------------------|------------------------------------------------------------------------------------------------------------------|---------------|
| QTcF                       | Day 3 or 4 mean change from baseline            | msec   | Lefamulin IV or PO                 | Moxifloxa cin IV or PO                 | 11.4 vs. 13.6 pooled 13.8 vs. 16.4 for IV 9.5 vs. 11.6 for oral                                                  | 3101 and 3102 |
|                            | Mean maximum change from baseline               |        |                                    |                                        | 87.7 vs. 98.7                                                                                                    |               |
|                            | Increase > 30 Increase > 60                     | %      |                                    |                                        | 17.9% vs. 22.3% 1.7% vs. 2.5%                                                                                    |               |
| Hepatic effects            | ALT >3xULN ALT > 5xULN                          | %      | Lefamulin IV or PO 5.5 2.1 3.7 1.3 | Moxifloxa cin IV or PO 5.4 1.3 2.4 1.1 | N=641 patients per group; onset with lefamulin mostly early on treatment; no Hy's Law cases for lefamulin (1 for | 3101 and 3102 |
|                            | AST > 3xULN AST > 5x ULN ALP >2xULN             |        | 3.0                                | 1.7                                    | moxifloxacin)                                                                                                    | 3101          |
| IV infusion site AEs       |                                                 | %      | 7.7                                | 3.7                                    |                                                                                                                  |               |
| Oral gastrointe stinal AEs | All Diarrhoea Nausea Vomiting                   | %      | 17.9% 12.2% 5.2% 3.3%              | 7.6% 1.1% 1.9% 0.8%                    | In the IV study (mean durations IV > 5 days) rates were similar or lower for lefamulin vs. moxifloxacin          | 3102          |
| Day 28 mortality           | Known deaths 3101 3102 Deaths plus unknown 3101 | %      | 5 (1.8%) 3 (0.8%)                  | 4 (1.5%) 3 (0.8%)                      | Higher numbers in lefamulin groups with unknown vital status at day 28                                           | 3101 and 3102 |
|                            | 3102                                            |        | 15 (5.4%) 6 (1.6%)                 | 9 (3.3%) 4 (1.1%)                      |                                                                                                                  |               |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The applicant conducted two pivotal trials in CAP, both of which showed non-inferiority for lefamulin vs. moxifloxacin. Nevertheless, the most important pathogen to cover is S. pneumoniae . Taking into account also the concerns regarding the PK-PD analyses, there is concern regarding the ability of lefamulin when used at the recommended doses to treat S. pneumoniae and the indication has been restricted.

## 3.7.2. Balance of benefits and risks

The benefit-risk balance is considered to be favourable.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall benefit-risk of Xenleta is considered positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Xenleta is favourable in the following indication:

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed (see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

<div style=\"page-break-after: always\"></div>

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that lefamulin is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.